DEVELOPMENT OF A HEPATITIS C VIRUS KNOWLEDGEBASE WITH COMPUTATIONAL PREDICTION OF FUNCTIONAL HYPOTHESIS OF THERAPEUTIC RELEVANCE

KOJO KWOFIE SAMUEL

Thesis presented in fulfillment of the requirements for the Degree of *Doctor Philosophiae* at the South African National Bioinformatics Institute, Faculty of Natural Sciences, University of the Western Cape



May 2011

WESTERN CAPE

Supervisor: Prof. Vladimir Bajic

Co-supervisor: Prof. Alan Christoffels

Keywords

Abstract

Association

Biomedical concepts

Database

Dictionaries

Hepatitis C Virus

Hepatocellular carcinoma

Hypothesis generation

Protein-protein interactions

Text mining



UNIVERSITY of the WESTERN CAPE

Abstract

To ameliorate Hepatitis C Virus (HCV) therapeutic and diagnostic challenges requires robust intervention strategies, including approaches that leverage the plethora of rich data published in biomedical literature to gain greater understanding of HCV pathobiological mechanisms. The multitudes of metadata originating from HCV clinical trials as well as low and high-throughput experiments embedded in text corpora can be mined as data sources for the implementation of HCV-specific resources. HCV-customized resources may support the generation of worthy and testable hypothesis and reveal potential research clues to augment the pursuit of efficient diagnostic biomarkers and therapeutic targets. This research thesis report the development of two freely available HCV-specific web-based resources: (i) Dragon Exploratory System on Hepatitis C Virus (DESHCV) accessible via http://cbrc.kaust.edu.sa/deshcv/ and (ii) Hepatitis C Virus Protein Interaction Database (HCVpro) accessible via http://cbrc.kaust.edu.sa/hcvpro/.

DESHCV is a text mining system implemented using named concept recognition and cooccurrence based approaches to computationally analyze about 32, 000 HCV related abstracts obtained from PubMed. As part of DESHCV development, the pre-constructed dictionaries of the Dragon Exploratory System (DES) were enriched with HCV biomedical concepts, including HCV proteins, name variants and symbols to enable HCV knowledge specific exploration. The DESHCV query inputs consist of user-defined keywords, phrases and concepts. DESHCV is therefore an information extraction tool that enables users to computationally generate association between concepts and support the prediction of potential hypothesis with diagnostic and therapeutic relevance. Additionally, users can retrieve a list of abstracts containing tagged concepts that can be used to overcome the herculean task of manual biocuration. DESHCV has been used to simulate previously reported thalidomide-chronic hepatitis C hypothesis and also to model a potentially novel thalidomide-amantadine hypothesis.

HCVpro is a relational knowledgebase dedicated to housing experimentally detected

HCV-HCV and HCV-human protein interaction information obtained from other databases and curated from biomedical journal articles. Additionally, the database contains consolidated biological information consisting of hepatocellular carcinoma (HCC) related genes, comprehensive reviews on HCV biology and drug development, functional genomics and molecular biology data, and cross-referenced links to canonical pathways and other essential biomedical databases. Users can retrieve enriched information including interaction metadata from HCVpro by using protein identifiers, gene chromosomal locations, experiment types used in detecting the interactions, PubMed IDs of journal articles reporting the interactions, annotated protein interaction IDs from external databases, and via "string searches". The utility of HCVpro has been demonstrated by harnessing integrated data to suggest putative baseline clues that seem to support current diagnostic exploratory efforts directed towards vimentin. Furthermore, eight genes comprising of ACLY, AZGP1, DDX3X, FGG, H19, SIAH1, SERPING1 and THBS1 have been recommended for possible investigation to evaluate their diagnostic potential. The data archived in HCVpro can be utilized to support protein-protein interaction network-based candidate HCC gene prioritization for possible validation by experimental biologists.

WESTERN CAPE

Declaration

I declare that "Development of a Hepatitis C Virus knowledgebase with computational prediction of functional hypothesis of therapeutic relevance" is my own work, that it has not been submitted for degree or examination at any other university, and that all the resources I have used or quoted, and all work which was the result of joint effort, have been indicated and acknowledged by complete references.

Samuel Kojo Kwofie



UNIVERSITY of the WESTERN CAPE

Acknowledgement

I would like to thank my supervisors and mentors, Professors Alan Christoffels and Vladimir Bajic for their guidance, support, tutorship and opportunity given to me throughout this PhD journey. My gratitude to them is immeasurable and I will walk the path of hard work that they taught me. My mentors allowed me to present my work at international conferences and made me to meet potential collaborators and other pioneers in the field of bioinformatics. Vlad and Alan, through their publications and track records are amongst the finest computational biologists in the world today and they constitute the few pioneers of this research domain in Africa. My big thanks go to Dr. Junaid Gamieldien (Principal Investigator at SANBI) for reading part of the manuscript and the continuous advice given to me over the years. Indeed, Junaid accepted me into the bioinformatics community as an intern at the National Bioinformatics Network in Cape Town. The skills and discipline imbibed in me will surely blossom and bear fruits. I Thank the National Bioinformatics Network (NBN), South African National Bioinformatics Institute (SANBI) and National Research Foundation (NRF) of South Africa for generously funding my studies. WESTERN CAPE

I would also like to thank my collaborators for their immense contribution towards my research: Ulf Schaefer PhD, Vijayaraghava S. Sundararajan PhD, Aleksandar Radovanovic PhD, and Monique Maqungo MSc. These wonderful people contributed towards the development and implementation of the two Hepatitis C Virus resources: Dragon Exploratory System on Hepatitis C Virus (DESHCV) and Hepatitis C Virus Protein Interaction Database (HCVpro). They freely worked with me with absolutely no hesitation and I learnt immensely from all of them. Also my thanks go to Dale and Peter for equipping me with computers and resources for my project. They were there when I called on them. To Dr. Samson Muyanga, I appreciate all the guidance you gave me. To the other academic staff at SANBI, I appreciate all the valuable comments you gave me whenever I presented my work. To Prof. Simon Travers, Dr. Nicki Tiffin, Dr. Gordon Harkins and Mario Jonas, I say ayeekoo. To Ferial Mullins and Maryam Salie, I say

thank you for the administrative support. To my fellow students and other Staff not mentioned here, I greatly appreciate your role as part of my family in South Africa.

This work would not have been possible without the support of my family and friends and will like to give special thanks to all of them. To the following crew I love you all: Samuelle Marie Ama Kwofie (daughter), Agnes Aba Quarshie (mum), Mary Amoah (grandma), Therasa Nana Quartey (Aunt), Mabel Asibon (Aunt), Faustina Amoakwa (Aunt), Samuel Kwofie (Dad), Mr. Mensah (Dad), Margin-Enimil (Mentor Dad), Jeffery Mensah (bro), and Samuel Quartey (bro). To my uncles (Emmanuel and Anthony) and sisters (Mabel and Lorna), you are all remembered. And I also thank my dearest friends Felix Adusei-Danso (USA Navy and UCT/UWC Alumnus) and Chantyclaire Tiba (CPUT).

Finally, I thank the Almighty God for the gift of wisdom, life and perseverance. May the Good Lord bless my supervisors (Vlad and Alan), Rev. Fr. Mike Hagan (UWC Chaplain), family and friends in all their future endeavors.

UNIVERSITY of the WESTERN CAPE

Journal articles arising out of this thesis

- Kwofie, S. K., Radovanovic, A., Sundararajan, V. S., Maqungo, M., Christoffels, A., & Bajic, V. B. (2011). Dragon exploratory system on hepatitis C virus (DESHCV). *Infect Genet Evol*, 11(4), 734-739.
- Maqungo, M., Kaur, M., Kwofie, S. K., Radovanovic, A., Schaefer, U., Schmeier, S., et al. (2011). DDPC: Dragon Database of Genes associated with Prostate Cancer. *Nucleic Acids Res*, 39(Database issue), D980-985.
- Kwofie, S. K., Schaefer, U., Sundararajan, V. S., Bajic, V. B., & Christoffels, A., (2011). Hepatitis C Virus Protein Interaction Database (HCVpro). *Infect Genet Evol.* Submitted.



WESTERN CAPE

Conference proceedings arising out of this thesis

- Kwofie, S. K., Radovanovic, A., Maqungo, M., Bajic, V.B., Christoffels, A. (2009, December 01–03, 2009). *Hepatitis C Virus discovery database (HCVdd): a biomedical text mining and relationship exploring knowledgebase*. Abstract presented at the ISCB Africa ASBCB Joint Conference on Bioinformatics of Infectious Diseases. Bamako, Mali.
- Kwofie, S. K., Radovanovic, A., Maqungo, M., Bajic, V.B., Christoffels, A. (2010, December 01–03, 2010). DESHCV: Hepatitis C Virus web-based software for biomedical text mining. Abstract presented at the 22nd International CODATA Conference on CODATA on Scientific Data and Sustainable Development. Cape Town, South Africa.
- Maqungo, M., Kaur, M., **Kwofie, S. K.**, Radovanovic, A., Schaefer, U., Schmeier, S., et al. (2010, December 01–13, 2010). *Dragon database of genes associated with prostate cancer (ddpc)*. Abstract presented at the 22nd International CODATA Conference on CODATA on Scientific Data and Sustainable Development. Cape Town, South Africa.
- Kwofie, S. K., Radovanovic, A., Bajic, V.B., Christoffels, A. (2011, March 09–11, 2011). Inferring enriched biological information from graphs composed of textderived biomedical concepts of ontologies related to Hepatitis C Virus. Abstract presented at the ISCB Africa ASBCB Joint Conference on Bioinformatics of Infectious Diseases. Cape Town, South Africa.

Table of Contents

KEYWORDS	II
ABSTRACT	III
DECLARATION	V
ACKNOWLEDGEMENT	VI
JOURNAL ARTICLES ARISING OUT OF THIS THESIS	VIII
CONFERENCE PROCEEDING ARISING OUT OF THIS THESIS	IX
TABLE OF CONTENTS	X
LIST OF TABLES	XIII
LIST OF FIGURES	
LIST OF APPENDIX	
ABBREVIATIONS	XV
CHAPTER 1: GENERAL INTRODUCTION	1
1.1 Overview	
1.2 Hepatitis C Virus Pathobiology	
1.2.1 Molecular Biology of HCV	
1.2.2 HCV LIFE CYCLE	
1.2.3 HCV nomenclature and classification	
1.2.4 HCV epidemiology and therapeutic challenges	
1.3 Text mining	16
1.3.1 Analysis of text-image data	
1.3.2 Information retrieval (IR)	20
1.3.2.1 Ad hoc information retrieval systems	
1.3.2.2 Text categorization system	
1.3.4 Named Entity Recognition (NER)	24
1.3.5 Information extraction (IE)	26
1.3.5.1 Co-occurrence methods	
1.3.5.2 Natural language processing	
1.3.5.3 Pattern-matching	
1.3.5.4 Hypothesis generation and Literature-based discovery (LBD)	
1.4 PROTEIN-PROTEIN INTERACTIONS	
1.4.1 Efforts towards harnessing predicted protein-protein interactions	

1.4.2 Towards the storage and utilizat	tion of curated protein-protein interactions	41
1.4.3 Available resources and tools fo	r exploring PPI data	46
1.5 THESIS RATIONAL		48
1.5.1 Aims and Objectives		50
1.5.2 Thesis outline		50
1.6 References		51
CHAPTER 2: DRAGON EXPLORATOR	RY SYSTEM ON HEPATITIS C VIRUS (DESHCV	[^])66
2.1 Abstract		67
2.2 INTRODUCTION		67
2.3 CONSTRUCTION AND CONTENT		71
2.3.1 Implementation		71
2.3.2 Database architecture		73
2.3.3 The database interfaces		75
2.4 Results and discussions		77
2.4.1 Concepts queries		77
2.4.2 Abstract queries		80
2.4.3 Evaluation of DES by reproduci.	ng a known hypothesis	80
2.4.4 Generation of thalidomide-amar	ntadine association	83
2.4.5 Systems reports		86
2.5 LIMITATIONS	IVERSITY of the	86
2.6 FUTURE DIRECTIONS	STERN CAPE	86
2.7 Conclusions		87
2.8 References		87
CHAPTER 3: HEPATITIS C VIRUS PR	OTEIN INTERACTION DATABASE (HCVPRO) .	90
3.1 ABSTRACT		91
3.2 INTRODUCTION		91
3.3 CONSTRUCTION AND CONTENT		94
3.3.1 Protein interaction data curation	n and integration	94
3.3.2 HCV and human protein context	tual data sources	97
3.3.3 Database architecture		100
3.4 UTILITY AND DISCUSSION		100
3.4.1 Database usage		100
3.4.1.1 Protein Select		102
3.4.1.2 Evidence Search		102
3.4.2 Value of the database to predict	ion of diagnostic biomarkers	103

3.4.3 Additional system features	
3.5 FUTURE PROSPECTS	
3.6 Conclusions	
3.7 References	
CHAPTER 4: CONCLUSION	
4.1 Research aims revisited	
4.1.1 Aim 1	
4.1.2 Research aim 2	
4.1.3 Research aim 3	
4.2 Research contribution	
4.3 Limitations and future work	
4.3.1 Limitations and future work on DESHCV	
4.3.2 Limitations and future work on HCVpro	
4.4 References	



UNIVERSITY of the WESTERN CAPE

List of Tables

TABLE 1.1. HCV PROTEINS, THEIR MOLECULAR WEIGHTS AND FUNCTIONS	4
--	---

List of Figures

FIGURE 1.1. A MODEL OF HCV PARTICLE
FIGURE 1.2. HCV GENOME ORGANIZATION
FIGURE 1.3. POST TRANSLATIONALLY PROCESSED HCV POLYPROTEIN
FIGURE 1.4. DETAILS OF HCV LIFECYCLE
FIGURE 1.5. AN EVOLUTIONARY TREE DEPICTING THE MAJOR HCV GENOTYPES11
FIGURE 1.6. VARIOUS DISEASE STAGES FOLLOWING HCV INFECTIONS
FIGURE 1.7. A GRAPH SHOWING THE TOTAL GROWTH OF PUBMED CITATIONS
FIGURE 1.8. INFORMATION RETRIEVAL AND EXTRACTION SYSTEMS
FIGURE 1.9. THE SWANSON'S ABC DISCOVERY MODEL
FIGURE 1.10. OPEN DISCOVERY SYSTEM. E.R.S.L.T.Y. of the
FIGURE 1.11. CLOSED DISCOVERY SYSTEM. CAPE
FIGURE 1.12. A SIMPLIFIED VERSION OF THE OPEN AND CLOSED DISCOVERY SYSTEMS 36
FIGURE 1.13. A DRUG DISCOVERY WORKFLOW
FIGURE 2.1. SCHEMATIC DIAGRAM OF THE INTEGRATED DATABASE OF DESHCV
FIGURE 2.2. DESHCV DATA FLOW SCHEMA DIAGRAM
FIGURE 2.3. A DIAGRAM DISPLAYING THALIDOMIDE CONCEPT QUERY OUTPUT
FIGURE 2.4. A DIAGRAM DISPLAYING THALIDOMIDE-CHRONIC HEPATITIS C HYPOTHESIS. 82
FIGURE 2.5. A DIAGRAM DISPLAYING THALIDOMIDE-AMANTADINE HYPOTHESIS
FIGURE 3.1. DISTRIBUTION OF EXPERIMENTAL METHODS TO VERIFY PPIS
FIGURE 3.2. PROTEIN-PROTEIN INTERACTION VERIFICATION METHOD DISTRIBUTION 99
FIGURE 3.3. A DIAGRAM DISPLAYING THE HCVPRO USER QUERY INTERFACE
FIGURE 3.4. A SCREENSHOT OUTPUT AFTER DATABASE SEARCH WITH VIMENTIN

List of Appendix

APPENDIX	
APPENDIX I (CHAPTER 2)	
APPENDIX II (CHAPTER 2)	
APPENDIX III (CHAPTER 3)	
APPENDIX IV (CHAPTER 3)	
APPENDIX V (CHAPTER 3)	
Appendix Va	
APPENDIX VB	
APPENDIX VI (CHAPTER 3)	
Appendix VA	
APPENDIX VC	
APPENDIX VII (CHAPTER 3)	
APPENDIX VIII (CHAPTER 3)	UNIVERSITY of the
	WESTERN CAPE

Abbreviations

DES: Dragon Exploratory System DESHCV: Dragon Exploratory System on Hepatitis C Virus GO: Gene Ontology HCV: Hepatitis C Virus HCC: Hepatocellular carcinoma HCVpro: Hepatitis C Virus Protein Interaction Database **ID:** Identification IE: Information extraction **IR:** Information retrieval LBD: Literature-Based Discovery NER: Named Entity Recognition NLP: Natural language processing **PPI:** Protein-Protein Interaction PPIN: Protein-Protein Interaction Network **UNIVERSITY** of the WESTERN CAPE



1.1 Overview

This chapter provides a brief overview on Hepatitis C Virus biology as well as therapeutic challenges. It also elaborates on the basic principles underlying text mining and provides a brief discussion on concerted efforts directed toward harvesting and harnessing protein-protein interactions. Furthermore, it provides the rationale underpinning the research thesis reported here.

1.2 Hepatitis C Virus Pathobiology

The identification and characterization of Hepatitis C Virus (HCV) had proved elusive in the 1970s and early 1980s, and HCV was inadvertently referred to as non-A, non-B associated hepatitis. However, with the advent of sophisticated molecular cloning techniques, HCV cDNA was finally isolated and characterized in 1988 (Choo et al., 1998). Although this significant discovery has proved useful, thorough understanding of HCV infection, replication and propagation in cellular hosts remains elusive. Furthermore, elucidation of the molecular pathogenesis and design of appropriate therapeutic interventions are hindered by lack of suitable animal models for HCV infection and appropriate medium for *in vitro* cultivation or propagation of HCV. Even though certain small animal models are permissive to HCV infection or allow protein expression, there is no single suitable small animal model that supports appropriately the full replication cycle of HCV. Nevertheless, rodent models obtained from rat and mice appear to have enhanced our current understanding of some aspects of the molecular etiology underlying HCV infection. Indeed significant progress could be made by developing rodent models which are capable of harboring both human immune system and human liver cells that are susceptible to HCV infection (Kremsdorf and Brezillon, 2007). The chimpanzee offers a suitable animal model susceptible to HCV infections (Lanford et al., 2001) but its usage is expensive, laborious and besieged with ethical furore. Recent development of cell cultures that support HCV infection (Wakita et al., 2005) and replication of subgenomic HCV RNAs in hepatoma cell lines (Lohmann et al.,

1999; Long et al., 2011) may contribute to understanding of HCV pathophysiological mechanisms.

1.2.1 Molecular Biology of HCV

Hepatitis C Virus (HCV) is a small, spherical, enveloped, hepatotropic RNA virus, belonging to the family *Flaviviridae*, in the genus of hepacivirus (Figure 1.1). The HCV genome is a single-stranded positive sense RNA of about 9600 bases, flanked by 5' and 3' non-coding regions (Figure 1.2). The genome is made up of a single, large open reading frame encoding a single polyprotein consisting of about 3000 amino acid residues. The polyprotein is cleaved by both viral proteases and host cellular signalases into 10 distinct proteins in the order as follows: NH2-Core-E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B-COOH (Suzuki et al., 1999; Figure 1.3). The 5' non-coding region contains the internal ribosomal entry site (IRES), which is implicated in translation initiation. An additional HCV protein, alternative reading frame protein (ARFP) or otherwise known as F protein produced by ribosomal frameshift within the capsid-encoding region has been described (Xu et al., 2001). The HCV proteins Core, E1 and E2 constitute the structural proteins whilst NS2, NS3, NS4A, NS4B, NS5A and NS5B are nonstructural proteins. The structural and nonstructural proteins are cleaved by host and viral proteinases respectively. The p7 protein, a member of the viroporin family forms a bridge connecting the structural and nonstructural proteins and is cleaved by host proteinases. As pestivirus p7 was suggested not to be a major structural constituent, it can be presumed that HCV p7 protein is not a structural protein (Elbers, 1996). The major roles played by the various HCV proteins have been summarized in Table 1.1 and detailed reviews on the biochemical and functional proteins can be found elsewhere (Bartenschlager, 2004; Penin et al., 2004; Chevaliez and Pawlotsky, 2006; Dubuisson, 2007; Vassilaki and Mavromara, 2009).

TABLE 1.1. HCV PROTEINS, THEIR MOLECULAR WEIGHTS AND FUNCTIONS.

(Table adapted from Penin et al., 2004; Chaveliez and Pawlotsky, 2006; Dubuisson 2007)

HCV		Molecular mass by	Apparent molecular
Protein	Function	SDS page (kDa)	weight (kDa)
	RNA binding;		23 (precursor); 21
Core	nucleocapsid	21	(mature)
	Envelope glycoprotein;		
E1	associate with E2	31-35	33-35
	Envelope glycoprotein;		
	receptor binding; associate		
E2	with E1	70	70-72
P7	Ion channel	7	7
	Component of NS2-3		
NS2	proteinase	21	21-23
	NS2/3 proteinase; NS3/4		
	proteinase; NTPase; RNA		
NS3	helicase; RNA binding	69	69
	NS3-4A proteinase		
NS4A	cofactor	6	6
	NS5A phosphorylation; N1	VERSITY of the	
	membranous web WES	TERN CAPE	
NS4B	induction	27	27
	Phosphoprotein; RNA		
	replication by formation of		
	replication complexes;		
	possibly involved in		
	inhibition of INF-alpha;		56 (basal form); 58
NS5A	inhibition of apoptosis	56-58	(hyperphosphorylated)
	RNA-dependent RNA		
NS5B	polymerase	68	68
	Possibly involved in HCV		
F/ARF-	core protein RNA binding	1.5	
protein	activities	17	16-17

2007).




FIGURE 1.1. A MODEL OF HCV PARTICLE.

A diagram showing the molecular organization involving viral proteins and RNA (Krekulová et al., 2006).



FIGURE 1.2. HCV GENOME ORGANIZATION.

The blue and red coloured segments of the genome encode structural and nonstructural proteins respectively (Dubuisson, 2007).




FIGURE 1.3. POST TRANSLATIONALLY PROCESSED HCV POLYPROTEIN

Diagram shows the 10 distinct structural and nonstructural proteins as well as junction protein p7. The scissors represent proteolytic cleavages by host peptidases, arrows indicate NS2-3 and NS3-4A cleavages. The transmembrane arrows show cleavage by host signal peptidases (Dubuisson, 2007).

1.2.2 HCV LIFE CYCLE

HCV host cell entry and tissue tropism seems poorly understood even though significant advances have been made by elucidating viral-cellular protein interactions as well as associated essential pathways. HCV glycoproteins E1 and E2 binds host cellular membranous constituents enabling viral interaction with a complex set of cell-surface molecules or cellular co-receptors, including tetraspanin (CD81) (Pileri et al., 1998; Flint et al., 1999; Petracca et al., 2000), human scavenger receptor class B type I (SR-BI) (Scarselli et al., 2002; Bartosch et al., 2003), dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) (Gardner et al., 2003; Lozach et al., 2004), liver/lymph node-specific intracellular adhesion molecule-3 (ICAM-3)-grabbing integrin (L-SIGN) (Gardner et al., 2003; Lozach et al., 2004), low-density lipoprotein receptor (LDL-R) (Agnello et al., 1999; Monazahian et al., 1999), asialoglycoprotein receptor (ASGP-R) (Saunier et al., 2003), glycosaminoglycans (HSPG) (Barth et al., 2003), claudin-1 and occludin (Figure 1.4). Tight junction proteins claudin-1 and occludin are thought to control hepatitis C virus entry by mediating virion internalization processes in host cells (Yang et al., 2008; Liu et al., 2009; Ploss et al., 2009). Viral-cell entry also depends on clathrin-mediated endocytic pathway mechanisms, accompanied by a fusion process that appears to require an acidic endosomal environment (Codran et al., 2006). The fusion arises from conformational changes in the glycoproteins triggering decapsidation of viral nulceocapsids to release free positive-strand RNA into the cytoplasm. The liberated RNAs undergoes translation to produce a large HCV polyprotein precursor via the internal ribosome entry site located in the 5' untranslated region of the HCV genome, after which viral proteases and host signalases process the obtained polyprotein into distinct structural and nonstructural proteins through cotranslation and post-translation mechanisms. Thereafter, a NS4B-induced membranous web, consisting of a membrane-associated multiprotein complex constitutes the viral replication complex (Egger et al., 2002; Elazar et al., 2004). HCV replication then proceeds via two stages catalyzed by NS5B (Chevaliez and Pawlotsky, 2006): (1) synthesis of a negative-strand RNA intermediate from a template composed of the positive-strand genome RNA and (2) negative-strand RNA intermediate then serves as template for synthesis of several progeny positive-strand RNA, which are then packaged into new virions (Bartenschlager et al, 2004) assembled on lipid droplets (Gouttenoire et al., 2010). The matured viral particles are then released. However, the mechanisms underlying the maturation and release are still unclear. Comprehensive reviews on the HCV life and intricacies have been discussed elsewhere (Rychłowska and Bieńkowska-Szewczyk, 2007; Dubuisson et al., 2008).



WESTERN CAPE




FIGURE 1.4. DETAILS OF HCV LIFECYCLE.

(1) Binding of HCV to cell surface receptors; (2) entry of HCV into the cell via endocytosis; (3) viral genome is released into cytoplasm; (4) internal ribosomal entry site-mediated polyprotein translation; (5) polyprotein processing; (6) formation of membranous web as part of replication complexes); (7) viral RNA replication; (8) packaging and assembly of progeny virions; and (9) matured virions are released via the host cellular secretory system (Tencate et al., 2010).

1.2.3 HCV nomenclature and classification

Ever since the HCV genome sequence was elucidated and vast amount of sequenced nucleotide, proteins and epitope data became available, several recommendations have emanated from various fora with the sole aim of unifying the nomenclature and classification of HCV isolates to conform to the guidelines stipulated by the International Committee on Virus Taxonomy (ICVT) (Simmonds et al., 1993; Simmonds et al., 1994; Robertson et al., 1998; Simmonds et al., 2005; Kuiken and Simmonds, 2009). This taxonomic framework guides the deposition of HCV sequences in online databases for further exploration by researchers. Furthermore, it allows the resolution of conflict pertaining to assignment of genotypes and any novel isolate that may be discovered in the future. As a result of HCV sequence variability and genetic heterogeneity, the standardization is relevant to research relating to the epidemiology, evolution and pathobiology of HCV associated infections (Kuiken and Simmonds, 2009).

By using comparative techniques including phylogenetic analysis, numerous distinct relationships have been established between HCV isolates thereby leading to the identification of six major genotypes (Simmonds et al., 1993; Simmonds et al., 1994). These divisions are further elaborated using phylogenetic trees (Figures 1.5). Additionally, the system of nomenclature has adopted the full-length genome sequence of isolate H77 (accession number AF009606) as a reference strain for annotation of other variants. The quasispecies nature of HCV allows the coexistence of multiple genetically different but closely related variants in infected individuals (Martell et al., 1992). The genotypes differ in their nucleotide sequence by 31-33% whilst the subtypes differ by 20-25%. The proteins are also known to differ by about 30% in amino acid sequences (Suzuki et al., 2007). The high degree of genetic variability exhibited by HCV could be attributed to the inability of the error-prone RNA-dependent RNA polymerase to proofread, high rate of viral replication and typical larger population size.




FIGURE 1.5. AN EVOLUTIONARY TREE DEPICTING THE MAJOR HCV GENOTYPES. It shows prevalence according to different geographic regions or countries. (Kuiken and Simmonds, 2009).

1.2.4 HCV epidemiology and therapeutic challenges

Currently, about 3% of the global population is infected with HCV, a foremost risk factor and major causative agent for development of acute and chronic hepatic infections. The chronification rate is about 70-80% (Krekulová et al., 2006). HCV infected individuals can develop chronic hepatitis, which may progress from fibrosis to HCV-induced cirrhosis with some subsequently developing hepatocellular carcinoma (HCC) (Figure 1.6). HCC is the 3rd most deadly and 5th most frequent cancer globally (Zender and Kubicka, 2008) and the epidemiology is further exacerbated by the asymptomatic as well as occasionally undetectable nature of HCV infections. HCV infected individuals in the long term may ultimately require liver transplant to abort death from liver impairment. As reported by the Eurasian Harm Reduction Network (EHRN), the World Health Organization (WHO) in 2002 estimated 53,700 annual global deaths could be directly associated with HCV infection. The scale of the infection is further exacerbated by the revelation that liver cancer caused by HCV may be likely linked to 308,000 deaths annually. In total, HCV could be implicated in about 500,000 global deaths annually (EHRN, 2007) and the potential exists for these mortality and morbidity rates to increase in the near future.

WESTERN CAPE

The HCV prevalence have been shown to differ amongst various geographic regions in the world (Sy and Jamal, 2006; Baldo et al., 2008). Infection figures from the World Health Organization (2009) are reported here. HCV prevalence was less than 1% in Australia, Canada and Northern Europe; about 1% in USA and most of Europe; and more than 2% in most countries found in Africa, Latin America and Central and South-Eastern Asia. Furthermore, HCV prevalence figures between 5 and 10% are usually reported in certain countries in the aforementioned regions. Countries with relatively high prevalence rates include Egypt (15%), Pakistan (4.7%) and Taiwan (4.4%) (Sievert et al., 2011). Particularly, the Nile delta region of Egypt has significantly higher seroprevalence of HCV, which was revealed to increase with age from 19% in persons of 10-19 years old to approximately 60% in persons of 30 years of age. The Egyptian HCV crisis could be attributed to the earlier lapses that existed during the nationwide campaign to help reduce the prevalence of schistosomiasis (Yahia, 2011). Intravenous drug use and blood

transfusion-related infections appear as the emerging risk factors in both developed and developing countries, respectively (Sy and Jamal, 2006).

Diagnostically, histologic liver biopsy, ultrasound, and biomarkers are among the variety of techniques employed to evaluate progression of chronic infections to HCC and hepatic steatosis (Kim et al., 2002; Mas et al. 2009; Yu et al., 2010). Unfortunately, liver biopsy is invasive with possible complications (Caillot et al., 2009) whilst reduced sensitivity and specificity can hamper the effectiveness of diagnostic techniques (Outwater et al., 2010). The need for diagnoses or evaluation of liver disease progression with a combination of biomarkers has been proposed (Gangadharan et al., 2007).

The most effective treatment for HCV infection is a combination therapy of pharmacokinetically enhanced pegylated interferon alpha (peginterferon alpha) and nucleoside analogue ribavirin (Fried et al., 2002; Krekulová et al., 2006), but it is sometimes accompanied by undesirable side effects and reduced quality of life during medication. Under standard care medication, this combination treatment cures about 80% of individuals infected with genotype 2 or 3, and 40% of genotype 1 (Strader et al., 2004; Suzuki et al., 2007; Gambarin-Gelwan and Jacobson, 2008; WHO, 2010). It is perceived that about half of infected individuals do not derive significant long term benefit from the combination therapy. It is proposed that the current treatment options can be augmented with an immunotherapeutic vaccine which may be beneficial in immunocompromised individuals (Sharma, 2010). Recently, the search for HCV therapy was vigorously focused on the development of anti-viral drugs targeting host cellular proteins and also protease/polymerase inhibitors specifically designed to disrupt the role of the HCV proteins during viral propagation and replication (Tencate et al., 2010). Some of the HCV or host protein-specific drugs under considerations include lectin cyanovirin-N (CV-N) (Helle et al., 2006), alpha-glucosidase I inhibitor (Celgosivir) (Durantel, 2009), n-butyl deoxynojirimycin (nB-DNJ) (Ouzounov et al., 2002), class of compounds with a thiazolidinone core structure (BMS-824) (Lemm et al., 2010), zinc mesoporphyrin (ZnMP) (Hou et al., 2010) and valyl ester prodrug (NM283) (Gardelli et al, 2009) whilst non HCV-specific anti-viral drugs comprises of nitazoxanide (Rossignol et al., 2010),

cyclophilin inhibitors (NIM811) (Ma et al., 2006; Lawitz et al, 2011) and silibinin (Payer et al., 2010).



UNIVERSITY of the WESTERN CAPE




FIGURE 1.6. VARIOUS DISEASE STAGES FOLLOWING HCV INFECTIONS (This diagram was modified from Sharma, 2010)

1.3 Text mining

Nowadays, most biomedical research institutions around the world have been expending significant proportions of their budgetary allocations in both material and human resource capacity development, thereby making it easier for them to generate large amount of potentially meaningful results for exploration in a short span of time through the usage of high throughput techniques such as genomics, proteomics, and microarray. The myriad of information derived from both low and high-throughput experiments published in journals can be located in the main body text or as supplementary information for easy electronic accessibility. As a result, biomedical researchers have adopted integrated natural language processing approaches to harness the available information in the published text as part of the strategies used in answering relevant biological questions. This is due to the fact that it is practically impossible to manually sift through the huge volumes of biomedical literature in order to unravel any meaningful latent semantic connections between different parts of the text due to potential human curation errors. The advent of online manuscript submission for journal publications may have contributed in the reported exponential growth in the amount of published biomedical literature recently (Hunter and Cohen, 2006). Currently, PubMed database (Sayers et al., 2011) has grown rapidly to over 20 million indexed citations (Figure 1.7) and houses abstracts from over 5000 life science journals from biomedical articles dating back to 1948 (Lu, 2011). Similarly, the National Library of Medicine expects 1 million journal articles to be indexed annually by 2015, indicating a 50% potential rise in number of processed articles when compared to 2004 (Neveol et al., 2006). By searching for global trends, the number of new journal articles reporting results on certain research topics such as "cell cycle" has also increased appreciably over the years (Jensen et al., 2006). Interestingly, new articles reporting previous popular topics, notable "protein Cdc28" seems to have declined. The rise in scientific review articles and concomitant explosion of scientific publications require the use of automated strategies such as text mining to computationally harvest the vast quantities of knowledge or otherwise may be referred to as knowledge about knowledge (metaknowledge) embedded in the text (Evans and Foster, 2011). Although biomedical text mining techniques and related application tools are increasingly becoming popular with bench biologists, they still face significant challenges in extracting relevant information from texts. Nevertheless, significant improvement has been achieved through the incorporation of computational linguistics techniques. Text mining has been defined in a broader sense as any system capable of retrieving knowledge from text; and in strictest sense as a system that extracts implicit knowledge not obviously stated in the text (Zweigenbaum et al., 2007). The field of text mining can be divided into the following domains: (1) information retrieval, (2) information extraction, (3) entity recognition, and (4) analysis of text-image data.






FIGURE 1.7. A GRAPH SHOWING THE TOTAL GROWTH OF PUBMED CITATIONS. The graph was generated with citations from 1986 to 2010. PubMed currently houses over 20-million citations and grows at an annual rate of about 4% (Lu, 2011).

1.3.1 Analysis of text-image data

Most non-textual data such as figures and tables in published full-text articles convey varying degrees of experimental outcomes which aid in the interpretation of research findings. Figure legends comprising of text of sentences are used to describe or annotate non-textual data. With the increase in amount of published articles and associated textimage datasets, natural language processing and image processing techniques are employed in concert to automatically extract structured information from text. This approach has been implemented in the development of the Structured Literature Image Finder (SLIF) project, a pipeline that enables the extraction of structured information from full-text articles and also provides a user-friendly web-based tool for accessing information about subcellular location from fluorescence microscopy images (Coelho et al., 2010). The pipeline consists of three main stages, namely caption processing, image processing and latent topic discovery. During the first two stages, figures and their respective captions are extracted from a collection of papers and are used as entries to create a database. The captions are further analysed to obtain biological entities such as proteins, cell types or lines and are then mapped onto external databases. Next, the figures are panel-segmented and fluorescence microscopy images are then classified according to depicted subcellular location. The final stage is to uncover a core set of themes known as latent topics from the processed full-text papers which then form the basis for visualization and semantic interpretation that aid in new knowledge discovery. Another usefulness of a text-image mining system such as SLIF is illustrated by the fact that users can retrieve articles with images for which a topic, for instance "tumorigenesis" is overly represented for future exploration. Other publicly available online resources for retrieving images and associated papers from image caption text are Yale Image Finder (Xu et al., 2008) and GoldMiner (Kahn and Thao, 2007). Comprehensive reviews and research involving text-image dataset processing have been reported elsewhere (Müller et al., 2004a; Shatkay et al., 2006; Uwimana and Ruiz, 2008; Qian and Murphy, 2008).

1.3.2 Information retrieval (IR)

IR entails using automated systems, particularly a search engine to identify and rank any list of documents or portion of text relevant to user interest or based on the user's query. Simplistically, IR filters the relevant documents from a large pool of documents. The retrieved text corpora can consist of any documents comprising of full-text articles, abstracts or phrases. IR can be separated into two distinct domains consisting of *ad hoc* and text categorization systems.

1.3.2.1 Ad hoc information retrieval systems

Ad hoc information retrieval involves the use of user-supplied keyword queries to return subset of documents containing the queried keywords (Figure 1.8). A popular ad hoc IR system is PubMed, which take as input natural language in the form of free-text keywords to recover a list of citations that match the queried text (Lu, 2011). PubMed search strategy is based on both Boolean model and automatic term mapping (ATM) techniques. For a typical Boolean query, the Boolean operator "AND" is inserted between multi-term user defined query such as 'vulval cell' to retrieve a list of documents containing the search string 'vulva AND cell'. Additionally, stop words such as "the" and "it" are removed while common words ending with "-ing" and "-s" are truncated to enable name variants of the queried word to match documents (Jensen et al., 2006). The ATM system compares and maps the user-constructed keywords to a set of pre-indexed terms, for example the Medical Subject Headings (MeSH). Documents containing the user keywords as well as the mapped MeSH pre-indexed terms are retrieved as the query output (Lu, 2011). Additionally, Current IR systems being developed have been enhanced by their ability to allow flexible ranking of articles (MedlineRanker, Fontaine et al., 2009), prioritize (Pubfocus, Plikus et al., 2006) or generate multi-level relevance feedback upon querying without expert knowledge (RefMed, Yu et al., 2011). Similarly, design of a dynamic user query interface for MEDLINE database is actively being pursued with a notable example being iPubMed (Wang et al., 2010), a system that enables interactive queries with on the spot feedback to users' searches letter by letter as

well as an extra feature for fuzzy search. Also since some users of IR systems possess different language backgrounds, BabelMeSH has been designed as a platform to allow cross-language querying via MEDLINE/PubMed (Liu et al., 2006).



UNIVERSITY of the WESTERN CAPE




FIGURE 1.8. INFORMATION RETRIEVAL AND EXTRACTION SYSTEMS. Diagram depicting the variety of results obtained by querying both information retrieval and extraction systems (modified from Lu, 2011).

1.3.2.2 Text categorization system

It is often not possible to use keyword queries to retrieve a subset of published biomedical documents sharing common topical characteristics among a large set of documents. Biologists confronted with large numbers of routinely published articles may require classifying these papers into smaller topic-specific groups or subgroups to enhance knowledge retrieval (Shatkay et al., 2006). For instance, a researcher may like to retrieve a set of documents pertaining to current or future research interest with ease. Text categorization therefore provides efficient approach to cluster documents into various taxonomies based on pre-defined set of categories. In this way papers reporting research in a similar domain can belong to the same category. The cluster labels assigned to taxonomies aid new researchers to locate new concepts among the pool of papers, whilst allowing experts to explore hierarchically clustered documents to effectively identify papers reporting specific concepts (Chen et al., 2006).

The categories used for clustering could be Gene Ontologies, genomic features or any shared biomedical concepts. Notable projects such as BioCreAtIvE challenge (Critical Assessment of Information Extraction in Biology) and Knowledge Discovery and Data Mining (KDD) Challenge Cup (Yeh et al., 2003) developed systems to locate short text passages that shared similar Gene Ontology annotations for specific proteins found in full-text articles. Text categorization concept has been implemented in the development of the automatic classification software, a document classification engine capable of classifying papers into topic-based hierarchy (Chen et al., 2006). The engine classifies over 7000 papers housed in Textpresso (Müller et al., 2004b) by using two-stage technique composed of a support vector machine-based classifier and a newly developed phrase-based clustering algorithm. Although the text classification has been optimized for *Caenorhabditis elegans* related papers by using human-created rules composed of an inventory of terms associated with each topic, it is amenable to any types of document sources. The usefulness of this system is illustrated as follows: classification of papers based on "Sex Determination category" returned the following top ranked clustered output: "hermaphrodite male", "sex determination", "development gene", "development cells", "cells fate", 'vulval cells", "cell signaling", "fate signaling", "precursor cell" and "signaling induction". These results allow the user to analyze the papers according to sex determination sub-categories making it easier to avoid the herculean task of manual sorting. Another popular text categorization software platform developed by Vivisimo (Taylor, 2007) uses a different approach by allowing documents to be categorized into descriptive folders without classifying into taxonomies. Elsewhere (Aphinyanaphongs and Aliferis 2003; 2005), text categorization models were built to successfully categorize content-specific and high-quality PubMed articles to aid in Evidence Based Medicine (EBM) and were reported to outperform text mining systems employing preconstructed Boolean-based queries such as PubMed clinical query filters. On the contrary, caution must be exercised when comparing the performances of two different text mining systems since it is very tempting to make conclusive inferences based on recall, precision and F-score values without considering the fact that each system operates under characteristically different environment with unique merit.



1.3.4 Named Entity Recognition (NER)

This process identifies and extracts biomedical entity names from published text and assigns them to predefined semantic categories with similar topical characteristics. In certain instances, the terms "entity" and "concept" are interchangeable leading to the analogy "named concept recognition". Therefore concepts or entities can be names of genes, proteins, diseases, pathways, drugs or pharmacological substances and may belong to different categories which can be referred to as dictionaries (Kwofie et al., 2011). There are instances where categories consisting of biomedical entities are organized into ontologies, a catalogue of concepts, objects and their relationship (Müller et al., 2004b). Some of the relations generally present in almost any domains are "-is a" and "part-of", whiles model domain-specific relations are exemplified by "has-location" and "clinically-associated-with" (Spasic et al., 2005). NER is particularly useful since it circumvents the difficult process of biologists having to manually scan through a large amount of published articles to locate biomedical entities. Accurately predicted terms (entities) can be used to augment existing biological database entries or used to infer relationships for

hypothesis generation. Additionally, the terms may provide indices into literature to aid in research result communication (Hirschman et al., 2002). The earlier NER tools were designed based on variety of techniques that sought to tackle some of the major difficulties usually encountered in developing automated text recognition systems, including named entity variant structural characteristics, name ambiguities, the unavailability of common standards and fixed nomenclatures, and different morphological description of entities in the biomedical text (Franzén et al., 2002). Furthermore, systems developed from precompiled dictionaries may not be able to recognize new entities present in recently published text.

Approaches used in developing NER systems have been categorized into 3 broad techniques (Cohen and Hunter, 2008; Torii et al., 2009) consisting of (i) rule/patternbased systems characterized by hand-written rules, (ii) statistics or machine-learningbased systems and (iii) entity lookup system via pre-compiled dictionary. Some of the systems employing the handcrafted rule-based techniques are PROSPER (Fukuda et al., 1998), Yapex (Franzén et al., 2002), ProMiner (Hanisch et al., 2003; 2005), GAPSCORE (Chang et al., 2004), Text Detective (Tamames, 2005) and another described elsewhere (Narayanaswamy et al., 2003). The dictionary lookup systems are ProtScan (Egorov et al., 2004), HMMs (Kou et al., 2005), NLProt (Mika et al., 2004) and others (Tsuruoka and Tsujii, 2004; Koike et al., 2005; Tsuruoka et al., 2007; Sasak et al., 2008). Examples of machine learning-based systems are BANNER (Leaman and Gonzalez, 2008), PowerBioNE (Zhou et al., 2004), BioCreAtIvE task 1A/II (Yeh et al., 2005; Smith et al., 2008), POSBIOTM-NER (Song et al., 2005) and others (Proux et al., 1998; Lee et al., 2004; Li et al., 2011). Ideally, NER systems are developed by combining all or some of the above-mentioned approaches (BioTagger-GM, Torii et al., 2009).

Additionally, each text mining implementation approach has peculiar advantages or disadvantages over others. For instance, dictionary-based systems intrinsically provide ID information for recognized terms by matching them to identical terms in the preconstructed dictionary, thereby making this approach the preferable choice within the earlier stages of the named entity extraction pipelines (Tsuruoka and Tsujii, 2004). Unfortunately, dictionary-based approach is besieged with poor recognition of short names resulting in high rate of false positives with concomitant decrease in overall precision during evaluation, and this hurdle is remedied by using machine learning approaches to heuristically filter out the false positives (Tsuruoka and Tsujii, 2004). Concerning fine-tuning of systems, machine learning techniques are easy to tune to new domains once the tagged training dataset is available but the rule-based system requires laborious human analysis to obtain a transparent system easier to fine-tune, expand and support (Franzén et al., 2002). Interestingly, the supervised machine learning approach has a disadvantage since it sometimes requires a large amount of error-free annotated corpus that needs a lot of time and extensive energy to create (Narayanaswamy et al., 2003). This deficiency has been circumvented by using rule-based approaches which exploits surface clues and simple linguistic as well as domain knowledge to locate relevant named entities in biomedical text (Narayanaswamy et al., 2003).



1.3.5 Information extraction (IE)

IE is the automated extraction of structured information from bibliome to generate relationships between biomedical concepts and hypothesis (Figure 1.8). The notable approaches for relation extraction are co-occurrence-based, pattern-matching, and natural language processing systems.

1.3.5.1 Co-occurrence methods

The simplest IE approach used to infer relationship between entities is the detection of co-occurring entities within an abstract, sentence or a phrase (Ding et al., 2002; Wren and Garner, 2004). If two biomedical concepts such as proteins appear together frequently in separate abstracts, the likelihood that a functionally relevant relationship exist between these proteins is high. Ideally, relationships suggested from co-occurrences are usually vague and it is impossible to infer the type or direction of the relationships (Fundel et al.,

2007). Furthermore, it is not easy to differentiate between either direct or indirect relationships amongst entities (Jensen, 2006).

Generally, co-occurrence-based methods are combined with other machine learning or natural language processing techniques to detect relationships between entities. For instance, a Hebbbian-type of learning algorithm, known as associative concept space (ACS) has been employed in combination with co-occurrence method to extract biological relationships between genes using meta-analysis of scientific texts (Jelier et al., 2005). Two genes co-occur if they are co-mentioned in the abstract, title or medical subject headings (MeSH) index of the text document. Co-occurrences between genes are weighted by using a co-occurrence matrix containing the number of times genes from a given set co-occur. For integration with ACS, only co-occurrences weighted above a specified minimum threshold are included for further analysis. ACS is a multidimensional Euclidean space composed of thesaurus concepts which are positioned in space and the computed distance existing between concepts is an indication of their supposed relatedness. ACS is ideal for relationship extraction when compared to a simple co-occurrence method because ACS has the potential to identify more detailed functional biological relationships and can also achieve better results with less literature per gene (Jelier et al., 2005). Similarly, co-occurrence method was integrated into the implementation of PubGene, an online database with variety of tools for gene-expression analysis (Jenssen et al., 2001). Pre-constructed gene-article index was used to generate a network composed of nodes denoting genes and edges representing co-occurrence of genes symbols or short gene names in the title or abstract of the same MEDLINE article. The detected associations between genes were mapped onto Gene Ontologies and MeSH index annotations. As usual, co-occurrence support the premise of meaningful biological relatedness and this assertion was validated to a reasonable extent by analyzing data from three large-scale experiments. Other works describing the use of co-occurrence methods for elucidating biological relationships between entities are reported elsewhere (Stapley and Benoit, 2000; Chaussabel and Sher, 2002; Alako et al., 2005; Chun et al., 2006; Gabow et al., 2008). Under certain circumstances, co-occurrence based IE methods can provide high recall but may possess poor precision than natural language processing, and

are employed preferable as baseline method for comparing other techniques (Zweigenbaum et al., 2007). Additionally, co-occurrence method is employed suitably as a component of exploratory tools such as STRING (von Mering et al., 2005) and Prolinks (Bowers et al., 2004) because of their potential to identify almost any kind of relationships (Jensen, 2006).

1.3.5.2 Natural language processing

Natural language processing (NLP) employs parser-based techniques that involve automated analysis of sentence syntax and semantic structures to recognize meaningful relationships between concepts or entities found in biomedical text corpus. NLP relationship extraction techniques can be loosely categorized into full parser-based and shallow parser-based systems. Shallow parsers partially reconstruct the structure of an entire sentence and are based on extraction of local dependencies between phrasal components. Shallow parsers are very simple to implement, much more efficient and robust. On the contrary, full parsers consider the structure of an entire sentence and though they appear inherently complex, domain sensitive and time consuming, they can be fine-tuned to provide more accurate results (Daraselia et al., 2004; Huang et al., 2006).

A full parser-based approach was implemented in MedScan, an automated system for extracting interactions between proteins from MEDLINE abstracts (Daraselia et al., 2004). Additionally, the system is capable of extracting different types of protein function information encoded as extendable ontology with high precision. MedScan is implemented in three steps: (i) preprocessor module for tagging protein names, (ii) NLP engine composed of syntactic parser and semantic processors, and (iii) information extraction module which function as a domain-specific filter for sentence structures and present extracted information as concept graph. A total of 2976 human protein interactions have been extracted from MEDLINE abstracts published after 1988 and it achieved precision of 91%. When MedScan interactions were compared with key databases (BIND and DIP), about 96% of extracted information were novel. Interestingly,

the system achieved a recall rate of 21%. Other systems incorporating full parsing techniques are described elsewhere (Park et al., 2001; Leroy and Chen, 2002).

A foremost example of NLP shallow parser-based system was implemented in Genescence, a database housing relations extracted from MEDLINE abstracts pertaining to essential topics such as p53, AP-1 and yeast (Leroy et al., 2003). This parser is composed of semantic module for capturing abstract contents and structure module composed of cascaded finite state automata (FSA) for capturing sentence structure as well as modeling relations. Sentence structure capture involves shallow parsing closed class English words for effective detection of relations between noun phrases in biomedical text. Three cancer researchers from the Arizona Cancer Center evaluated 330 relations extracted from 26 abstracts in their area of expertise. A total of 296 relations were rightly extracted from the abstracts resulting in precision of 90% and overall average of 11 rightly extracted relations per abstract. The system is able to extract variety of relations using small number of rules and also mines more relations per abstract since relations are not restricted to specific verbs or unique entities (Leroy et al., 2003). Relationship extraction has been employed as part of the techniques to successful mine gene/protein biological functions from biomedical literature (Koike et al., 2005). In this system, a text sentence is shallowly parsed after which an adopted rule-based sentence structure analysis approach is used to extract the ACTOR (doer of action) and OBJECT (receiver of action) relationships. This system extracted from PubMed more than 190 000 gene-gene ontology (GO) relationships and 150 000 family-GO relationships for major eukaryotes. Additionally, it achieved recall and precision ranges of 54-64% and 91-94% respectively for actual functions described in abstracts. An earlier system developed based on a shallow parser (EngCG) was able to retrieve interaction between genes and gene products based on frequently seen verbs in MEDLINE abstracts (Sekimizu et al., 1998). It achieved precision rates of 90% and about 73% in identifying noun phrases and the right subject and object for each verb in text corpus respectively. Pustejovsky et al. (2002) developed a robust system for extracting inhibition relations from biomedical text. The system involves the construction of semantic automata from UMLS database to aid extraction of target relations and application of corpus analytics on MEDLINE sentences

pertaining to the target relations. Broadly, it consists of shallow parsing, relation identification and anaphora resolution modules. System evaluation achieved precision of 90%, recall 57% and partial recall 22%, consolidating its potential as an efficient corpusbased linguistic system. A pragmatic approach for the automatic extraction of information concerning gene interactions was reported (Proux et al., 2000). The approach entails the use of linguistics systems consisting of part-of-speech tagger and shallow parser, and knowledge processing module for generating semantic representation from pre-extracted syntactic dependencies. The text corpus consists of a set of 1200 sentences enriched with gene interaction information obtained from FlyBase, a database on *Drosophila melanogaster* (FlyBase Consortium, 2002).

A NLP-based tool using semantic dependency parse trees for extracting physical, genetic and regulatory relations between gene and proteins from MEDLINE abstract is RelEx (Fundel et al., 2007). This system employs dependency, part-of-speech taggers, simple rules and noun phrase-chunker. The dependency parse trees are built using Stanford Lexicalized Parser and they enhance the harnessing of complex phrasal relationships using few tree rules. RelEx identifies potential candidate relations by harvesting paths connecting pairs of nodes consisting of genes in the dependency parse trees. The system was used to mine about 150 000 relations from one million MEDLINE abstracts pertaining to gene and protein relations, and achieved 80% precision and 80% recall. RelEx is simple to implement and reproducible, can deal with complex sentences and also identity various types of interactions.

1.3.5.3 Pattern-matching

This approach is based on the premise that word patterns surrounding protein names embedded in text sentences can be harnessed to discover clues pertaining to the relationships amongst them. It matches part-of-speech tags obtained from segmented text sentences against pre-constructed patterns and simple matching rules. The patternmatching system avoids the complex sentence analysis of NLP by focusing on a restricted area of interest such as protein-protein interactions, which seem to appear as sources of flaws and decreased performance in NLP. A popular pattern-based system for automated extraction of protein-protein interaction from biological text has been described by (Ono et al., 2001). This system combines protein name lookup via named protein dictionary, surface clues on word pattern and rule-based part-of-speech tagging. The performance of this system was evaluated on text sentences using yeast (recall = 86.8% and precision = 94.3%) and *E.coli* (recall= 82.5% and precision = 93.5%) protein named dictionaries. The high rates of precision and recall achieved pinpoint to the fact that this approach can be adopted for any species-specific name protein dictionary.

SUISEKI is another system for automated detection of protein names as well as biological interactions (Blaschke and Valencia, 2001). The steps here describe the implementation of SUISEKI: (1) text corpus obtained from user query via MEDLINE is segmented and parsed by part-of-speech tagger to serve as data source. Rule-based algorithm and dictionaries are combined with data source to detect protein names, (2) sentences containing a minimum of two detected proteins are matched against predefined protein interaction description frames and (3) the resultant data is housed in a protein-protein interaction database equipped with an integrated user query interface which provide modules for analysis and protein information extraction on synonyms and functional descriptions. The efficiency of SUISEKI is demonstrated by the fact that majority of identified interactions have higher chances of being true interactions. A total of 4657 interactions were extracted from 5283 abstracts pertaining to cell cycle corpus. The system achieved between 80% to 50% precision range for high scoring interactions to low scoring ones, and relatively highly recall of more than 70%.

The HypertenGene system automatically extracts etiological relations among genes and diseases in text sentences by combining the advantages of machine learning models and pattern matching including part-of-speech (POS) patterns and extracted phrase chunk features (Tsai et al., 2009). Both NLP and pattern match-based systems display deficiencies in their output results. Even though NLP defy the simplicity and robust character of pattern matching systems, pattern-matching systems overlooks coordinative,


conjunctive and appositive grammatical structures of text (Huang et al., 2006). A hybrid system has been developed as response to the above deficiencies, by integrating a shallow parser to improve remarkably the performance of pattern matching to extract relations between proteins from biomedical texts (Huang et al., 2006). This system achieved an average F-score of 80% and 66% on individual verbs and all verbs respectively. The shallow parser enabled the system to achieve 7% increase in both F-score and precision when compared to the traditional pattern matching-based systems. As part of the implementation, the shallow parser analyzes the coordinative and appositive structures, followed by the application of pattern matching on segmented long sentences to enhance matching precision. Prior to matching, the coordinative structures are encapsulated and then unfolded after extracting. A dynamic programming algorithm computes unique patterns by aligning relevant sentences and key verbs that describe protein interactions and thereafter, a matching algorithm extract the interaction relations (Huang et al., 2004a).




1.3.5.4 Hypothesis generation and Literature-based discovery (LBD)


Relationship extraction deals with harvesting relationships between biomedical entities explicitly stated in a text corpus whiles hypothesis generation aims to unravel implicit relationships existing between disjoint sets of literature pertaining to biomedical concepts. The implicit relations could lead to unraveling of plausible novel knowledge/discovery, which is potentially testable and worthy of further exploration. Swanson originally popularized the concept of text-mined hypothesis in his famous derivation of fish oil/Raynaud's diseases hypothesis. He used disjointed sets of literature pertaining to both fish oil and Raynaud's disease to propose a therapeutic relationship between them. The fish oil/Raynaud's disease hypothesis relied on the premises that: (a) fish oil decreases platelet activities, vascular reactivity, and blood viscosity, and (b) these same physiological changes ameliorate Raynaud's symptoms (Swanson, 1986). This "premier" hypothesis was confirmed later in a study involving the clinical effects of fishoil fatty acid ingestion in patients with Raynaud's symptoms (DiGiacomo et al., 1989),

where fish oil was demonstrated to have beneficial effects by delaying the onset of Raynaud's disease complications. Similar hypothesis were proposed for Migraine and Magnesium, as well as Somatomedin C and Arginine (Swanson et al., 1990). The above hypothesized discourses influenced the proposition of the concept known as the complementary structures in disjoint science literatures (CSD) (Swanson, 1991). Complementary means the relationship between two separate scientific arguments, which when consolidated together could yield inferences or insights that are not obvious in the separate arguments. Disjoint literature refers to the scenario when literatures are not cocited or co-mentioned and have no articles in common. The CSD has been simplified in a concept widely referred to as Swanson's ABC discovery model (Figure 1.9), which stipulates that if a concept A associate with B, and B associate with C, then there could be implicit relationship between concepts A and C (Weeber et al., 2003). A current approach assigns statistical weights to the strength of the hidden relationship (Frijters et al., 2010). The ABC model is further reconstructed separately into hypothesis generating approach referred to as the open discovery system (Figure 1.10) and a testing approach known as the closed discovery system (Weeber et al., 2001; Figure 1.11). The open discovery system is analogous to Swanson's Fish/Raynaud's disease hypothesis, where a starting concept that connects to a linking concept, also connect to the target concept. The open discovery approach leads to hypothesis generation that originate from the quest to answer a specific scientific problem. The closed discovery system involves the use of a bridging concept to establish a link between two other concepts that do not directly cooccur. This also involves the testing and explanation of already generated hypothesis. For example, starting from a disease concept C and substance A, the researcher can intuitively find common intermediate B-terms. If reasonable number of "pathways" are found between A and C, then the propensity for it to be a potentially insightful hypothesis is high (Figure 1.11). The differences between the two discovery approaches are that, literatures pertaining to C and B are interrogated in the open discovery whiles literatures on C and A are interrogated in the closed discovery system. The open and closed discovery processes have been simplified in Figure 1.12 (Cohen et al., 2010a).





The solid arrows denoted by AB and BC represent explicit relationships. The dashed arrows denoted by AC represent an implicit relationship and may serve as a potential source of novel hypothesis (Weeber et al., 2003).





The starting, linking and target concepts are CBA respectively. Solid arrows indicate "pathways" worthy of further exploration for discovery, and the dashed ones are "pathways" that do not lead to discoveries (Weeber et al., 2001).




FIGURE 1.11. CLOSED DISCOVERY SYSTEM.

The starting concepts are C and A. Concept Bs result from C and A overlapping. Solid arrows indicate "pathways" worthy of further exploration for discovery, and the dashed ones are "pathways" that do not lead to discoveries (Weeber et al., 2001).




FIGURE 1.12. A SIMPLIFIED VERSION OF THE OPEN AND CLOSED DISCOVERY SYSTEMS. In both instances, the starting concept A for generating discoveries has thick borders, and the target or endpoint concepts are surrounded by starbursts (Cohen et al., 2010a).

A typical biological example of closed discovery system is illustrated here. Among patients suffering from multiple myeloma treated with thalidomide, some experienced improvement in chronic hepatitis C. A closed system approach will involve trying to unravel the potential mechanisms underpinning how thalidomide treats chronic hepatitis C (Weeber et al., 2005).

Although original implementation of LBD involved overwhelming human intervention, current approaches are augmented with automated systems developed using machine learning/statistical models and/or NLP techniques. LBD is defined as computer-aided generation of functionally relevant hypotheses with potential for further scientific exploration. A number of LBD systems have been implemented using co-occurrencebased approaches (Cohen and Hersh, 2005; Weeber et al., 2005). Additionally, LBDs have been utilized to simulate already published or described novel discoveries (Weeber et al., 2000; Weeber et al., 2003; Kwofie et al., 2011). The limitations of co-occurrencebased systems are that they sometimes overlook semantic nature of the inferred relations and may not offer any concrete explanation for the generated hypothesis, and users are required to scrutinize manually the myriad of texts accompanying the suggested hypothesis (Hristovski et al., 2006). The performance of co-occurrence-based approach has been improved in BITOLA (Hristovski et al., 2005) by integrating with NLP derived semantic predications extracted from SemRep (Rindflesch and Fiszman, 2003) and BioMedLee (Lussier et al., 2006). This integrated approach provides details and support explanation for inferred discoveries or relationships. The system exhibited the potential to achieve fewer numbers of false positive results. Another LBD system, EpiphaNet (Cohen et al., 2010a), has been implemented using predication-based semantic indexing (PSI) and reflective random indexing (RRI). RRI is a scalable method for detecting implicit connections (Cohen et al., 2010b). Additionally, RRI methods augment the ability of EpiphaNet to harvest associations between concepts or terms that do not directly cooccur. The predications used in EpiphaNet were also obtained from SemRep (Rindflesch and Fiszman, 2003) by mining abstracts and MEDLINE titles. In simple terms, predications are also referred to as "object relation object triplets", for example, "merlot IS-A wine". PSI enables the quick extraction of strongly associated concepts based on

their distribution across all of the predications present in SemRep (Cohen et al., 2010a). A similar LBD approach which does not depend on direct co-occurrence of concepts within abstracts of journal articles was used to generate a ranked hit list of genes related to periodontitis and atherosclerosis (Hettne et al., 2007). This approach generates concept vectors that represent the textual context surrounding a specific concept. Entities sharing most common concepts have much higher likelihood of being associated with each other and likely to be assigned higher association scores. Association based on overlapping or sharing of concepts has also been implemented in CoPub, a LBD system (Frijters et al., 2010).

The future potential of text mining systems, including LBDs far outweighs their limitations for the simple reason that information retrieval/extraction systems are still considered as potent approaches that can be used to glean knowledge from enormous amounts of published texts. Irrespective of the accuracy or statistical scores assigned to generated hypothesis, interpretive exploration of biomedical literature can still serve to augment the logic underpinning the discovery.

UNIVERSITY of the WESTERN CAPE

1.4 Protein-Protein Interactions

A typical pathway consists of a series of interconnected cellular events between biomolecular entities such as proteins, genes and metabolites (Chowbina et al., 2009). Furthermore, it is estimated that 80% of proteins do not operate alone but in complexes, and protein-protein interactions (PPIs) constitute a part of a bigger cellular network (Berggård et al., 2007). Therefore cataloging PPIs is key for the study of protein interactome to enhance current understanding of regulatory mechanisms.

1.4.1 Efforts towards harnessing predicted protein-protein interactions

Section 1.3.5 of this thesis deals comprehensively with text mining approaches and tools used in extracting PPI information from published biomedical texts. Efforts towards developing robust and efficient text mining extraction models were given a boost under BioCreative II (Krallinger et al., 2008), a community platform that dealt with tasks for evaluating algorithms employed in extracting PPI. The task assigned to the teams were (i) identifying protein interaction relevant articles; (ii) harvesting and normalizing protein interaction pairs; (iii) cataloging experimental methods used in detecting interactions; and (iv) retrieving the blocks of text reporting the protein interactions. Some of the difficulties encountered by the task teams were: conversion of full text article formats, detecting, annotating and cross referencing of PPI to external databases. Other limitations were in the field of protein name normalization, restricting PPIs elucidation to cooccurrence techniques and the complexities involved in distinguishing between novel, already known or experimentally determined PPI. Nevertheless, BioCreative II was useful because benchmark datasets for both training and testing of models were made available for comparing the performance of various algorithms and it also provided standardized approaches for comparing text-mining procedures with manual annotation of PPIs (Chatr-aryamontri et al., 2008).

Other computational methods used for modeling and predicting PPI are based on coevolution (Pazos et al., 2008; Sharon et al., 2009; Lewis et al., 2010), combination of structural information and sequence pattern in protein interfaces (Aytuna et al., 2005; Espadaler et al., 2005; Keskin et al., 2008), and domain-domain interactions (Singhal and Resat, 2007; Yellaboina et al., 2011). To support current usage of machine learning models for predicting PPIs (Chen et al., 2008; Martin et al., 2008; Guo et al., 2010), a number of resources are being developed to provide protein specific features as training datasets. KUPS (The University of Kansas Proteomics Service) provides high quality benchmark data for developing and evaluating PPI prediction algorithms (Chen et al., 2011). KUPS provides lists comprising of interacting protein pairs (IPPs) as positive data and non-interacting protein pairs (NIPs) as negative data, as well their features for each data point (instance). While protein interaction datasets are currently readily available for downloads from many databases but obtaining non-interaction datasets with computed machine learning features used to be a difficult task. Negatome (Smialowski et al., 2010) and GRIP (Browne et al., 2009) are additional web-based resources providing noninteracting protein pairs for mammalian models (experimentally supported) and Saccharomyces cerevisiae (both IPPs and NIPs) respectively. Even though both Negatome and GRIP presently do not provide computed features, they do in fact augment existing PPI resources. Another community platform that provide benchmark dataset for assessing the quality of predicted PPI through structural analysis of protein complexes is the Critical Assessment of PRedicted Interactions (CAPRI) experiment which started in 2000 (Janin, 2005). These efforts have led to the introduction of two scoring functions based on the similarity of the interfaces of the complex, namely interfacial Template Modeling score (iTM-score) and Interface Similarity score (IS-score). The iTM-score calculates the geometric distance between the protein interfaces whiles the IS-score calculates residue-residue contact similarity plus their geometric similarity (Gao and Skolnick, 2011). Plewczyński and Ginalski (2008) have comprehensively reviewed some of the approaches and challenges involved in predicting PPIs, and additionally have supported the consensus approach adopted by Sen et al. (2004). Sen et al. (2004) employed a metadata mining approach by combining support vector models, protein structural threading, phylogenetic analysis to predict conserved residues on protein interfaces, and the Conservatism of Conservatism method of Mirny and Shakhnovich (1999). It was illustrated that the combinatorial approach yielded improved predictions over the individual methods.

A trend has emerged where some databases house both experimental and computationally derived PPI obtained from multiple data sources. HAPPI, the Human Annotated Protein-Protein Interactions contains data integrated from complementary sources consisting of the HPRD, BIND, MINT, STRING, and OPHID databases (Chen et al., 2009). Experimentally derived PPIs data from both low and high-throughput techniques are obtained from BIND and HPRD; literature curated PPI from BIND; text-mined PPI from STRING; and computationally predicted PPI from both STRING and OPHID. HAPPI assigns confidence scores ranging from 1 to 5 to enable users gauge the reliability of the

interactions and also enhance the generation of high confidence interaction networks. The interaction data in HAPPI is also enriched with computed annotations, including biological pathways, gene functions, protein families, protein structures, sequence features, and literature sources.

As mentioned earlier, STRING, a Search Tool for the Retrieval of Interacting Genes also provides comprehensive and reliable PPI data composed of both experimentally determined and predicted interaction information (Szklarczyk et al., 2011). As in the case of HAPPI, STRING also provides confidence scores for judging reliability of interactions and interacting partners are mutually cross-referenced via HTML with a number of popular knowledgebases, including UniProt (UniProt Consortium, 2010), SMART (Letunic et al., 2009), GeneCards (Safran et al., 2010) and SwissModelRepository (Kiefer et al., 2009). In STRING, interactions are not restricted to direct, physical interactions between two proteins but proteins can also be linked when they exhibit a genetic interaction or are reported to catalyze subsequent steps in a regulatory or metabolic pathway. Most associations between proteins inferred using prediction algorithms cannot be defined precisely in the context of their mode of interaction, nor cellular conditions under which they occur, and may be viewed rather as functional associations (Szklarczyk et al., 2011). Other resources providing predicted PPI data are PIPs (McDowall et al., 2009), IntNetDB (Xia et al., 2006), POINT (Huang et al., 2004b), HPID (Han et al., 2004a), PreSPI (Han et al., 2004b), PIPE (Pitre et al., 2006) and OPHID (Brown and Jurisica, 2005).

1.4.2 Towards the storage and utilization of curated protein-protein interactions

Experimentally derived PPI data is primarily obtained from: (i) literature-curated interactions and (ii) directly from both low throughput and large scale screening of pairwise physical interactions (de Chassey et al., 2008). Literature-curated interaction datasets are hypothesis-driven and may allow the determination of biological functions of

the interacting proteins from the actual study while high-throughput datasets are discovery-based but are not geared towards inferring of functions of the interacting proteins (Cusick et al., 2009). High-quality binary interaction information is warehoused in public databases for protein interactome exploration. The notable detection and analysis methods (Phizicky and Fields, 1995) for protein-protein interactions are: (i) physical methods to select and detect proteins that bind another protein (e.g. affinity chromatography, affinity blotting, immunopreciptation and cross-linking); (ii) library-based methods (e.g. protein probing, phage display and two-hybrid system (high-throughput technique)); and (iii) genetic methods (e.g. extragenic suppressors, synthetic lethal effects and overproduction phenotypes). Techniques for verifying PPIs are confocal microscopy for intracellular colocalization of proteins, coimmunoprecipitation, surface plasmon and spectroscopic studies (Berggård et al., 2007). Additionally, 3-dimensional X-ray crystallography and nuclear magnetic resonance structural analysis are used to elucidate PPI. Comprehensive reviews detailing the merits and demerits of the various interaction detection methods are discussed elsewhere (Lalonde et al., 2008).

Since curated interactions and their associated metadata can be obtained from multiple database sources, a concerted effort must be made to provide standardized and comprehensive procedures for judging the quality of the data sources. Metamining databases consist of consolidated PPIs obtained from multiple source databases. Metamining database authors may choose not to integrate some data from their sources based on in-house curation quality checks. Therefore a user queried interaction may fail in the metamining database, even though it is present in the source data (Plewczynski and Klingström, 2011). Furthermore, each source database may assign its own unique identifiers to interaction metadata, necessitating the need to unify multiple database identifiers pertaining to the same query. The "Good Interaction Data Metamining Practice" standard (GIDMP) has been proposed (Plewczynski and Klingström, 2011) and when adopted could provide PPI warehousing community with: (i) a standardized approach to judging the statistics made available by each metamining database, thus enhancing user satisfaction; (ii) a stable contact point for each database, enabling the smooth transition of statistics; and (iii) a fully automated system, enhancing time- and

cost-effectiveness. It is recommended that databases complying with GIDMP standards should provide a page titled Source Databases (SourceDB) composed of a table consisting of columns that capture relevant information and statistics. The table would consist of seven columns arranged in the order: name of source database, link to resource, notes, version, latest version, and coverage. The first five columns are static data provided by the metamining database authors and the last two are obtained from the source database. It is expected that a simple script would be embedded within the www pages of both metamining and source databases to automatically update the last two columns thereby providing synchronized information including statistics.

An empirical approach has been employed to quantitatively evaluate the level of agreement across major public databases concerning curated PPI data (Turinsky et al., 2010). The analysis was carried out on a global landscape of PPI data that was consolidated from nine key databases that are known to be composed primarily of curated experimentally detected physical interactions: BIND, BioGRID, CORUM, DIP, IntAct, HPRD, MINT, MPact and MPPI. The iRefIndex (Razick et al., 2008) and iRefWeb (Turner et al., 2010) were used for both data consolidation and analysis. The analysed data comprised of 271,716 distinct physical interactions involving 7,449 proteins associated with 1324 different organism-taxonomy identifiers and were gleaned from 42,651 publications. Computationally predicted and genetic interactions representing phenotype alterations produced by the mutation/deletion of genes were excluded from the analysis. Annotated PPI data derived from the same journal article but co-cited by different databases were evaluated for agreement using similarity scores. After quantifying agreement between curated interactions from a total of 15,471 publications, the results revealed that on average, two databases fully agree on 42% of the interactions and 62% of the proteins curated from the same publication. It further revealed that a sizeable portion of the measured differences could be attributed divergent annotations of organism or splice isoforms, different organism focus and alternative representations of multi-protein complexes. This study highlights the impact of the divergent in-house curation policies of data providers (Turinsky et al., 2010) and is a motivator for the PPI research community to adopt data standardization practices. To buttress above concerns,

evaluation of existing curations of protein interaction experiments reported in journal articles revealed that curation could be error-prone and that the quality may be of lower standard than what is already assumed (Cusick et al., 2009).

A large amount of PPI data emanating from both small- and large-scale experiments are scattered across databases, web pages or in journal articles prompting the need to unify and standardize details describing such interactions. The Human Proteome Organization Proteomics Standards Initiative Molecular Interactions (HUPO PSI-MI) format XML1.0 was established as a single, unified format by which molecular interactions, particularly PPIs are presented (Hermjakob et al., 2004). Notable interaction data producers and providers, including BIND, DIP, IntAct, MINT, MIPS, Hybrigenics and STRING, jointly formulated this community standard data model for representation and exchanging of PPI data. Included in the PSI-MI schema are the controlled vocabularies (CVs), which are used to standardize the meaning of data objects. The continuous use of CVs prevents data providers from using synonyms or name variants repeatedly and also allow consistent interpretation of terms among multiple data producers and users. The CVs are hierarchically structured and consist of higher and lower level descriptors assigned to parents and child terms. This organization enables data to be annotated to an appropriate level of granularity and enhance easy retrieval of information by search tools via the child and parents terms when applicable. The CVs are maintained in the Open Biological and Biomedical Ontologies al., 2007) accessible web pages (Smith et via http://www.obofoundry.org/ and can also be retrieved using the EBI Ontology Lookup Service (Barsnes et al., 2010) accessible via http://www.ebi.ac.uk/ontology-lookup/. For illustration purposes, a binary protein interaction between two protein molecules inferred using yeast two hybrid as detection method is assigned the PSI-MI term name "two hybrid" and term ID "MI:0018". Currently, PSI-MI has been updated to PSI-MI XML2.5 and MITAB2.5 formats to facilitate data exchange among repositories and users without loss of information. The updated version expanded the scope of the described interactions to cover a broader range of molecular types, including nucleic acids, chemical entities, and molecular complexes. PSI-MI XML2.5 provides detailed description about each molecular interaction, including the biological role of each interacting molecule,

interacting domains, and the kinetic parameters governing the interactions. MITAB2.5 provides only minimal interaction information in a tab-delimited format for easy systems configuration through fast Perl parsing or loading into Microsoft Excel (Kerrien et al., 2007).

It is extremely difficult for curators to extract all the essential information describing PPI and associated metadata from published journal articles when authors of such articles provide sparse details describing the interactions. Even though enormous amount of energy may be spent in trying to guess the missing data in the poorly described interaction, this approach is still fraught with error. According to anecdotal estimates, about 70% of total curation time is spent by curators on disambiguating molecule identifiers (Orchard et al., 2005). The minimum information required for reporting a molecular interaction experiment (MIMIx), a community effort seek to provide a checklist on information to supply when describing experimental molecular interaction data in a journal article, displaying on a web page or incorporating into PPI repositories (Orchard et al., 2005). The MIMIx checklist provides details on: (i) interaction submission profile, including author contact addresses and publication identifier; (ii) experimental setup including host organism taxonomy and interactions in PSI-MI ontology vocabularies; (iii) interaction participant list; and (iv) confidence scores assigned to the interactions.

Although PPI databases constitute a smaller portion of the total number of reported biological databases, it is important that they comply with global approaches aimed at promoting consistency and interoperability among knowledgebases as well as semantic and syntactic standards. BioDBCore, a community-defined, uniform, generic description of the core attributes of biological databases seek to provide guidelines that would help achieve the above (Gaudet et al., 2011). BioDBCore would make available a catalogue of database attributes contained in a checklist to facilitate the sharing of rich information among diverse research communities. Researchers may have easy access to information outside their area of expertise by way of browsing the descriptors for various biological databases. This approach may enable developers to avoid repeating of routine mistakes

committed when implementing new resources. The proposed BioDBCore descriptors are: database name, main resource URL, contact information, date resource established, conditions of use (free, or type of license), scope (data types captured, curation policy, and standards used), Standards (data formats and terminologies), taxonomic coverage, data accessibility/output options, data release frequency, versioning policy and access to historical files, documentation availability, user support options, data submission policy, relevant publications, resource's Wikipedia URL, and tools available. BioDBCore is in line with the MIBBI project, which aims to promote coherent minimum reporting guidelines for biological and biomedical investigations (Taylor et al., 2008). Embracing the BioDBCore project could make PPI databases accessible to the greater biological community and enhance cross integration of PPI data with other high-throughput data for exploration.

1.4.3 Available resources and tools for exploring PPI data


Online repositories do not merely warehouse PPI information but also provide means for data exploration, comparison and integration into other secondary databases. Key among them is iRefIndex (Razick et al., 2008) and its update iRefWeb (Turner et al., 2010). Currently, iRefWeb is made up of data consolidated from 10 public PPI databases, comprising of BIND, BioGRID, CORUM, DIP, IntAct, HPRD, MINT, MPact, MPPI and OPHID. Notably, iRefWeb provides global view of PPI exploration and also gives users the option to examine discrepancies among same PPI information provided by multiple databases and be able to choose interactions that closely resemble the reported interaction in the journal article. Additionally, statistical summaries of interactions based on simple modalities such as the number of journal articles reporting interactions and whether the detection methods were low or high throughout techniques. The iRefIndex database originally provided a unifying index for retrieving PPI data and assigned a key for each PPI record and a key for each interacting partner. Using primary sequences of the interacting proteins, their taxonomy identifiers and the Secure Hash Algorithm, users

can generate these keys. The indexing is useful because redundant or equivalent PPIs are assigned as a single group. Additionally, the system enables data integrity to be verified and helps to identify problematic PPI entries across different repositories. Other web servers or software plug-ins that allow retrieval of consolidated interaction datasets and generation of interaction networks are APID (Prieto and De Las Rivas, 2006), APID2NET (Hernandez-Toro et al., 2007), MiMI (Tarcea et al., 2008), UniHI (Chaurasia et al., 2007), DASMI (Blankenburg et al., 2009), ConsensusPathDB (Kamburov et al., 2011), BisoGenet (Martin et al., 2010), PIANA (Aragues et al., 2006), BioNetBuilder (Avila-Campillo et al., 2007), cPath (Cerami et al., 2006) and BioGRID access tools, namely BioGRID REST Service, BiogridPlugin2 and BioGRID WebGraph (Winter et al., 2011).

Users of PPI data aim to identify multiple-drug targets within pathogenic protein-protein interaction networks (PPINs) by way of perturbing known pathways or complexes (Hormozdiari et al., 2010) and also by analyzing protein-protein interaction binding pockets (Meireles et al., 2010). It is also interesting to note that topological and clustering analysis of PPI networks have been employed to predict new interactions (Bu et al., 2003; Sen et al., 2006). Therefore software systems and web servers that enable graph theoric analysis and modeling of both experimentally and predicted interactions are of optimal importance. Some of the available tools for analysis and graph theoric explorations of PPI networks are BiNoM (Zinovyev et al., 2008), NetworkAnalyzer (Assenov et al, 2008), NeAT (Brohée et al., 2008) and frequently used software libraries, including JUNG- the Java Universal Network/Graph Framework (http://jung.sourceforge.net/), LEDA (http://algorithmic-solutions.com/leda/index.htm), NetworkX (https://networkx.lanl.gov/) and yFiles (http://www.yworks.com/en/index.html). PPI visualization tools or platforms are Cytoscape (Smoot et al., 2011), ProViz (Iragne et al., 2005), PIMWalker (Meil et al., 2005), VisANT (Hu et al., 2009), Osprey (Breitkreutz et al., 2003), and PATIKA (Demir et al., 2002) and its web version PATIKAweb (Dogrusoz et al., 2006). A comprehensive review on tools for visualizing biological networks is presented elsewhere (Suderman and Hallett, 2007).

1.5 THESIS RATIONALE

From the aforementioned (Section 1.2) with particular emphasis on HCV pathobiology and therapeutic challenges, it is imperative that diverse approaches must be adapted to outwit a "skillful and deceitful medical foe" such as HCV and its accompanying pathobiological ramifications. Provision of resources that separately integrate text mining and protein-protein interactions can go a long way to aid in the search for therapeutic drugs and possibly augment efforts to generate functional hypotheses that can be further investigated for the development of non-invasive diagnostic biomarkers and novel therapeutics. Computational text mining has been highlighted as an important component of the modern-day drug discovery pipelines (Yao et al., 2009, 2010). It has particular utility in the following stages: analysis of disease mechanisms and "disease genes". genomics, structure-based compound design, analysis of mechanisms of drug actions, toxicology, pharmcovigilance, and drug repurposing. Similarly, text mining and PPI feature prominently as part of workflows for the discovery of therapeutic targets or diagnostic biomarkers (Figure 1.13). This thesis aims to develop freely available HCVfocused integrated online resources providing enriched biomedical knowledge as baseline information for further exploration and to also aid in computational prediction of functional hypothesis of therapeutic relevance.



interaction data

FIGURE 1.13. A DRUG DISCOVERY WORKFLOW.

The workflow incorporating text mining and protein interaction data combined with other high-throughput data (e.g. microarray data mining) to aid discovery of therapeutic targets or diagnostic biomarkers (modified from Yang et al., 2009). This workflow supports the data mining approach adopted in this research, which involved harnessing of integrated data consisting of protein-protein interactions and HCV related hepatocellular carcinoma associated genes identified from proteomic and microarray experiments. Text mining approach was utilized in proposing literature-based discoveries of therapeutic relevance.

1.5.1 Aims and Objectives

- 1. Development of HCV-focused web-based text mining resource
- 2. Development of HCV online protein knowledgebase
- 3. Harnessing the myriad of data in the developed knowledgebases to facilitate generation of functional hypothesis of therapeutic relevance.

1.5.2 Thesis outline

This thesis consists of four chapters:

Chapter 1:

• Gives a brief over view on: (i) HCV biology and therapeutic challenges, (ii) general text mining principles and applications, (iii) extraction and utilization of protein-protein interactions, and (iv) thesis rationale and aims (as outlined in this section 1.5).

Chapter 2

UNIVERSITY of the

 Provides an overview on the development and implementation of an HCVcustomized web-based text mining resource known as the Dragon Exploratory System on Hepatitis C Virus (DESHCV) (Kwofie et al., 2011). It further describes how DESHCV has been used to reproduce already published literaturebased discovery and also generate novel hypothesis relevant to the current efforts geared towards HCV combination therapy search.

Chapter 3

 Describes the development and implementation of HCVpro, Hepatitis C Virus Protein Interaction Database. And demonstrate how the incorporated data in HCVpro could be used to generate baseline hypothesis relevant to unraveling potential diagnostic markers and therapeutic targets. Chapter 4

• Discusses the relevance of this work towards ongoing HCV research efforts and provides the conclusion of this thesis. Additionally, it discusses the limitations and proposes future work.

1.6 References

- Agnello, V., Abel, G., Elfahal, M., Knight, G. B., & Zhang, Q. X. (1999). Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. *Proc Natl Acad Sci U S A*, 96(22), 12766-12771.
- Alako, B. T., Veldhoven, A., van Baal, S., Jelier, R., Verhoeven, S., Rullmann, T., et al. (2005). CoPub Mapper: mining MEDLINE based on search term co-publication. *BMC Bioinformatics*, 6, 51.
- Aphinyanaphongs, Y., & Aliferis, C. F. (2003). Text categorization models for retrieval of high quality articles in internal medicine. *AMIA Annu Symp Proc*, 31-35.
- Aphinyanaphongs, Y., Tsamardinos, I., Statnikov, A., Hardin, D., & Aliferis, C. F. (2005). Text categorization models for high-quality article retrieval in internal medicine. J Am Med Inform Assoc, 12(2), 207-216.
- Aragues, R., Jaeggi, D., & Oliva, B. (2006). PIANA: protein interactions and network analysis. *Bioinformatics*, 22(8), 1015-1017.
- Assenov, Y., Ramirez, F., Schelhorn, S. E., Lengauer, T., & Albrecht, M. (2008). Computing topological parameters of biological networks. *Bioinformatics*, 24(2), 282-284.
- Avila-Campillo, I., Drew, K., Lin, J., Reiss, D. J., & Bonneau, R. (2007). BioNetBuilder: automatic integration of biological networks. *Bioinformatics*, 23(3), 392-393.
- Aytuna, A. S., Gursoy, A., & Keskin, O. (2005). Prediction of protein-protein interactions by combining structure and sequence conservation in protein interfaces. *Bioinformatics*, 21(12), 2850-2855.
- Baldo, V., Baldovin, T., Trivello, R., & Floreani, A. (2008). Epidemiology of HCV infection. *Curr Pharm Des*, 14(17), 1646-1654.
- Barsnes, H., Cote, R. G., Eidhammer, I., & Martens, L. (2010). OLS dialog: an opensource front end to the ontology lookup service. *BMC Bioinformatics*, 11, 34.
- Bartenschlager, R., Frese, M., & Pietschmann, T. (2004). Novel insights into hepatitis C virus replication and persistence. *Adv Virus Res*, *63*, 71-180.
- Barth, H., Schafer, C., Adah, M. I., Zhang, F., Linhardt, R. J., Toyoda, H., et al. (2003). Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. *J Biol Chem*, 278(42), 41003-41012.
- Bartosch, B., Vitelli, A., Granier, C., Goujon, C., Dubuisson, J., Pascale, S., et al. (2003). Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem, 278(43), 41624-41630.
- Berggard, T., Linse, S., & James, P. (2007). Methods for the detection and analysis of

protein-protein interactions. Proteomics, 7(16), 2833-2842.

- Blankenburg, H., Finn, R. D., Prlic, A., Jenkinson, A. M., Ramirez, F., Emig, D., et al. (2009). DASMI: exchanging, annotating and assessing molecular interaction data. *Bioinformatics*, 25(10), 1321-1328.
- Blaschke, C., & Valencia, A. (2001). The potential use of SUISEKI as a protein interaction discovery tool. *Genome Inform, 12*, 123-134.
- Bowers, P. M., Pellegrini, M., Thompson, M. J., Fierro, J., Yeates, T. O., & Eisenberg, D. (2004). Prolinks: a database of protein functional linkages derived from coevolution. *Genome Biol*, 5(5), R35.
- Breitkreutz, B. J., Stark, C., & Tyers, M. (2003). Osprey: a network visualization system. *Genome Biol*, 4(3), R22.
- Brohee, S., Faust, K., Lima-Mendez, G., Sand, O., Janky, R., Vanderstocken, G., et al. (2008). NeAT: a toolbox for the analysis of biological networks, clusters, classes and pathways. *Nucleic Acids Res*, 36(Web Server issue), W444-451.
- Brown, K. R., & Jurisica, I. (2005). Online predicted human interaction database. *Bioinformatics*, 21(9), 2076-2082.
- Browne, F., Wang, H., Zheng, H., & Azuaje, F. (2009). GRIP: A web-based system for constructing Gold Standard datasets for protein-protein interaction prediction. *Source Code Biol Med*, *4*, 2.
- Bu, D., Zhao, Y., Cai, L., Xue, H., Zhu, X., Lu, H., et al. (2003). Topological structure analysis of the protein-protein interaction network in budding yeast. *Nucleic Acids Res*, 31(9), 2443-2450.
- Caillot, F., Hiron, M., Goria, O., Gueudin, M., Francois, A., Scotte, M., et al. (2009). Novel serum markers of fibrosis progression for the follow-up of hepatitis C virus-infected patients. *Am J Pathol*, 175(1), 46-53.
- Cerami, E. G., Bader, G. D., Gross, B. E., & Sander, C. (2006). cPath: open source software for collecting, storing, and querying biological pathways. *BMC Bioinformatics*, 7, 497.
- Chang, J. T., Schutze, H., & Altman, R. B. (2004). GAPSCORE: finding gene and protein names one word at a time. *Bioinformatics*, 20(2), 216-225.
- Chatr-aryamontri, A., Kerrien, S., Khadake, J., Orchard, S., Ceol, A., Licata, L., et al. (2008). MINT and IntAct contribute to the Second BioCreative challenge: serving the text-mining community with high quality molecular interaction data. *Genome Biol*, 9 Suppl 2, S5.
- Chaurasia, G., Iqbal, Y., Hanig, C., Herzel, H., Wanker, E. E., & Futschik, M. E. (2007). UniHI: an entry gate to the human protein interactome. *Nucleic Acids Res*, 35(Database issue), D590-594.
- Chaussabel, D., & Sher, A. (2002). Mining microarray expression data by literature profiling. *Genome Biol*, 3(10), RESEARCH0055.
- Chen, D., Muller, H. M., & Sternberg, P. W. (2006). Automatic document classification of biological literature. *BMC Bioinformatics*, *7*, 370.
- Chen, J. Y., Mamidipalli, S., & Huan, T. (2009). HAPPI: an online database of comprehensive human annotated and predicted protein interactions. *BMC Genomics*, 10 Suppl 1, S16.
- Chen, X. W., Han, B., Fang, J., & Haasl, R. J. (2008). Large-scale Protein-Protein Interaction prediction using novel kernel methods. *Int J Data Min Bioinform*,

2(2), 145-156.

- Chen, X. W., Jeong, J. C., & Dermyer, P. (2011). KUPS: constructing datasets of interacting and non-interacting protein pairs with associated attributions. *Nucleic Acids Res*, 39(Database issue), D750-754.
- Chevaliez, S., & Pawlotsky, J. M. (2006). HCV Genome and Life Cycle.
- Choo, Q. L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W., & Houghton, M. (1989). Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. *Science*, 244(4902), 359-362.
- Chowbina, S. R., Wu, X., Zhang, F., Li, P. M., Pandey, R., Kasamsetty, H. N., et al. (2009). HPD: an online integrated human pathway database enabling systems biology studies. *BMC Bioinformatics*, 10 Suppl 11, S5.
- Chun, H. W., Tsuruoka, Y., Kim, J. D., Shiba, R., Nagata, N., Hishiki, T., et al. (2006). Extraction of gene-disease relations from Medline using domain dictionaries and machine learning. *Pac Symp Biocomput*, 4-15.
- Codran, A., Royer, C., Jaeck, D., Bastien-Valle, M., Baumert, T. F., Kieny, M. P., et al. (2006). Entry of hepatitis C virus pseudotypes into primary human hepatocytes by clathrin-dependent endocytosis. *J Gen Virol*, 87(Pt 9), 2583-2593.
- Coelho, L. P., Ahmed, A., Arnold, A., Kangas, J., Sheikh, A. S., Xing, E. P., et al. (2010). Structured Literature Image Finder: Extracting Information from Text and Images in Biomedical Literature. *Lect Notes Comput Sci*, 6004, 23-32.
- Cohen, A. M., & Hersh, W. R. (2005). A survey of current work in biomedical text mining. *Brief Bioinform*, 6(1), 57-71.
- Cohen, K. B., & Hunter, L. (2008). Getting started in text mining. *PLoS Comput Biol*, 4(1), e20.
- Cohen, T., Schvaneveldt, R., & Widdows, D. (2010b). Reflective Random Indexing and indirect inference: a scalable method for discovery of implicit connections. J Biomed Inform, 43(2), 240-256.
- Cohen, T., Whitfield, G. K., Schvaneveldt, R. W., Mukund, K., & Rindflesch, T. (2010a). EpiphaNet: An Interactive Tool to Support Biomedical Discoveries. J Biomed Discov Collab, 5, 21-49.
- FlyBase Consortium (2002). The FlyBase database of the Drosophila genome projects and community literature. *Nucleic Acids Res*, 30(1), 106-108.
- UniProt Consortium (2010). The Universal Protein Resource (UniProt) in 2010. Nucleic Acids Res, 38(Database issue), D142-148.
- Cusick, M. E., Yu, H., Smolyar, A., Venkatesan, K., Carvunis, A. R., Simonis, N., et al. (2009). Literature-curated protein interaction datasets. *Nat Methods*, *6*(1), 39-46.
- Daraselia, N., Yuryev, A., Egorov, S., Novichkova, S., Nikitin, A., & Mazo, I. (2004). Extracting human protein interactions from MEDLINE using a full-sentence parser. *Bioinformatics*, 20(5), 604-611.
- de Chassey, B., Navratil, V., Tafforeau, L., Hiet, M. S., Aublin-Gex, A., Agaugue, S., et al. (2008). Hepatitis C virus infection protein network. *Mol Syst Biol*, *4*, 230.
- Demir, E., Babur, O., Dogrusoz, U., Gursoy, A., Nisanci, G., Cetin-Atalay, R., et al. (2002). PATIKA: an integrated visual environment for collaborative construction and analysis of cellular pathways. *Bioinformatics*, 18(7), 996-1003.
- DiGiacomo, R. A., Kremer, J. M., & Shah, D. M. (1989). Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind,

controlled, prospective study. Am J Med, 86(2), 158-164.

- Ding, J., Berleant, D., Nettleton, D., & Wurtele, E. (2002). Mining MEDLINE: abstracts, sentences, or phrases? *Pac Symp Biocomput*, 326-337.
- Dogrusoz, U., Erson, E. Z., Giral, E., Demir, E., Babur, O., Cetintas, A., et al. (2006). PATIKAweb: a Web interface for analyzing biological pathways through advanced querying and visualization. *Bioinformatics*, 22(3), 374-375.
- Dubuisson, J. (2007). Hepatitis C virus proteins. World J Gastroenterol, 13(17), 2406-2415.
- Dubuisson, J., Helle, F., & Cocquerel, L. (2008). Early steps of the hepatitis C virus life cycle. *Cell Microbiol*, 10(4), 821-827.
- Durantel, D. (2009). Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection. *Curr Opin Investig Drugs*, 10(8), 860-870.
- Egger, D., Wolk, B., Gosert, R., Bianchi, L., Blum, H. E., Moradpour, D., et al. (2002). Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. *J Virol*, 76(12), 5974-5984.
- Egorov, S., Yuryev, A., & Daraselia, N. (2004). A simple and practical dictionary-based approach for identification of proteins in Medline abstracts. *J Am Med Inform Assoc*, 11(3), 174-178.
- EHRN (2007). HCV infection in Europe: Eurasian Harm Reduction Network.
- Elazar, M., Liu, P., Rice, C. M., & Glenn, J. S. (2004). An N-terminal amphipathic helix in hepatitis C virus (HCV) NS4B mediates membrane association, correct localization of replication complex proteins, and HCV RNA replication. *J Virol*, 78(20), 11393-11400.
- Elbers, K., Tautz, N., Becher, P., Stoll, D., Rumenapf, T., & Thiel, H. J. (1996). Processing in the pestivirus E2-NS2 region: identification of proteins p7 and E2p7. J Virol, 70(6), 4131-4135.
- Espadaler, J., Romero-Isart, O., Jackson, R. M., & Oliva, B. (2005). Prediction of protein-protein interactions using distant conservation of sequence patterns and structure relationships. *Bioinformatics*, 21(16), 3360-3368.
- Evans, J. A., & Foster, J. G. (2011). Metaknowledge. Science, 331(6018), 721-725.
- Flint, M., Thomas, J. M., Maidens, C. M., Shotton, C., Levy, S., Barclay, W. S., et al. (1999). Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein. J Virol, 73(8), 6782-6790.
- Fontaine, J. F., Barbosa-Silva, A., Schaefer, M., Huska, M. R., Muro, E. M., & Andrade-Navarro, M. A. (2009). MedlineRanker: flexible ranking of biomedical literature. *Nucleic Acids Res*, 37(Web Server issue), W141-146.
- Franzen, K., Eriksson, G., Olsson, F., Asker, L., Liden, P., & Coster, J. (2002). Protein names and how to find them. *Int J Med Inform*, 67(1-3), 49-61.
- Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Goncales, F. L., Jr., et al. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med, 347(13), 975-982.
- Frijters, R., van Vugt, M., Smeets, R., van Schaik, R., de Vlieg, J., & Alkema, W. (2010). Literature mining for the discovery of hidden connections between drugs, genes and diseases. *PLoS Comput Biol*, 6(9).
- Fukuda, K., Tamura, A., Tsunoda, T., & Takagi, T. (1998). Toward information extraction: identifying protein names from biological papers. *Pac Symp*

Biocomput, 707-718.

- Fundel, K., Kuffner, R., & Zimmer, R. (2007). RelEx--relation extraction using dependency parse trees. *Bioinformatics*, 23(3), 365-371.
- Gabow, A. P., Leach, S. M., Baumgartner, W. A., Hunter, L. E., & Goldberg, D. S. (2008). Improving protein function prediction methods with integrated literature data. *BMC Bioinformatics*, 9, 198.
- Gambarin-Gelwan, M., & Jacobson, I. M. (2008). Optimal dose of peginterferon and ribavirin for treatment of chronic hepatitis C. *J Viral Hepat*, *15*(9), 623-633.
- Gangadharan, B., Antrobus, R., Dwek, R. A., & Zitzmann, N. (2007). Novel serum biomarker candidates for liver fibrosis in hepatitis C patients. *Clin Chem*, 53(10), 1792-1799.
- Gao, M., & Skolnick, J. (2011). New benchmark metrics for protein-protein docking methods. *Proteins*, 79(5), 1623-1634.
- Gardelli, C., Attenni, B., Donghi, M., Meppen, M., Pacini, B., Harper, S., et al. (2009). Phosphoramidate prodrugs of 2'-C-methylcytidine for therapy of hepatitis C virus infection. J Med Chem, 52(17), 5394-5407.
- Gardner, J. P., Durso, R. J., Arrigale, R. R., Donovan, G. P., Maddon, P. J., Dragic, T., et al. (2003). L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. *Proc Natl Acad Sci U S A*, 100(8), 4498-4503.
- Gaudet, P., Bairoch, A., Field, D., Sansone, S. A., Taylor, C., Attwood, T. K., et al. (2011). Towards BioDBcore: a community-defined information specification for biological databases. *Nucleic Acids Res*, 39(Database issue), D7-10.
- Gouttenoire, J., Penin, F., & Moradpour, D. (2010). Hepatitis C virus nonstructural protein 4B: a journey into unexplored territory. *Rev Med Virol*, 20(2), 117-129.
- Guo, Y., Li, M., Pu, X., Li, G., Guang, X., Xiong, W., et al. (2010). PRED_PPI: a server for predicting protein-protein interactions based on sequence data with probability assignment. *BMC Res Notes*, 3, 145.
- Han, D. S., Kim, H. S., Jang, W. H., Lee, S. D., & Suh, J. K. (2004b). PreSPI: design and implementation of protein-protein interaction prediction service system. *Genome Inform*, 15(2), 171-180.
- Han, K., Park, B., Kim, H., Hong, J., & Park, J. (2004a). HPID: the Human Protein Interaction Database. *Bioinformatics*, 20(15), 2466-2470.
- Hanisch, D., Fluck, J., Mevissen, H. T., & Zimmer, R. (2003). Playing biology's name game: identifying protein names in scientific text. *Pac Symp Biocomput*, 403-414.
- Hanisch, D., Fundel, K., Mevissen, H. T., Zimmer, R., & Fluck, J. (2005). ProMiner: rule-based protein and gene entity recognition. *BMC Bioinformatics*, 6 Suppl 1, S14.
- Helle, F., Wychowski, C., Vu-Dac, N., Gustafson, K. R., Voisset, C., & Dubuisson, J. (2006). Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. *J Biol Chem*, 281(35), 25177-25183.
- Hermjakob, H., Montecchi-Palazzi, L., Bader, G., Wojcik, J., Salwinski, L., Ceol, A., et al. (2004). The HUPO PSI's molecular interaction format--a community standard for the representation of protein interaction data. *Nat Biotechnol*, 22(2), 177-183.
- Hernandez-Toro, J., Prieto, C., & De las Rivas, J. (2007). APID2NET: unified interactome graphic analyzer. *Bioinformatics*, 23(18), 2495-2497.
- Hettne, K. M., Weeber, M., Laine, M. L., ten Cate, H., Boyer, S., Kors, J. A., et al.

(2007). Automatic mining of the literature to generate new hypotheses for the possible link between periodontitis and atherosclerosis: lipopolysaccharide as a case study. *J Clin Periodontol*, *34*(12), 1016-1024.

- Hirschman, L., Morgan, A. A., & Yeh, A. S. (2002). Rutabaga by any other name: extracting biological names. *J Biomed Inform*, 35(4), 247-259.
- Hormozdiari, F., Salari, R., Bafna, V., & Sahinalp, S. C. (2010). Protein-protein interaction network evaluation for identifying potential drug targets. *J Comput Biol*, 17(5), 669-684.
- Hou, W., Tian, Q., Zheng, J., & Bonkovsky, H. L. (2010). Zinc mesoporphyrin induces rapid proteasomal degradation of hepatitis C nonstructural 5A protein in human hepatoma cells. *Gastroenterology*, 138(5), 1909-1919.
- Hristovski, D., Friedman, C., Rindflesch, T. C., & Peterlin, B. (2006). Exploiting semantic relations for literature-based discovery. AMIA Annu Symp Proc, 349-353.
- Hristovski, D., Peterlin, B., Mitchell, J. A., & Humphrey, S. M. (2005). Using literaturebased discovery to identify disease candidate genes. *Int J Med Inform*, 74(2-4), 289-298.
- Hu, Z., Hung, J. H., Wang, Y., Chang, Y. C., Huang, C. L., Huyck, M., et al. (2009). VisANT 3.5: multi-scale network visualization, analysis and inference based on the gene ontology. *Nucleic Acids Res*, 37(Web Server issue), W115-121.
- Huang, M., Zhu, X., Hao, Y., Payan, D. G., Qu, K., & Li, M. (2004a). Discovering patterns to extract protein-protein interactions from full texts. *Bioinformatics*, 20(18), 3604-3612.
- Huang, M., Zhu, X., & Li, M. (2006). A hybrid method for relation extraction from biomedical literature. *Int J Med Inform*, 75(6), 443-455.
- Huang, T. W., Tien, A. C., Huang, W. S., Lee, Y. C., Peng, C. L., Tseng, H. H., et al. (2004b). POINT: a database for the prediction of protein-protein interactions based on the orthologous interactome. *Bioinformatics*, 20(17), 3273-3276.
- Hunter, L., & Cohen, K. B. (2006). Biomedical language processing: what's beyond PubMed? *Mol Cell*, 21(5), 589-594.
- Iragne, F., Nikolski, M., Mathieu, B., Auber, D., & Sherman, D. (2005). ProViz: protein interaction visualization and exploration. *Bioinformatics*, 21(2), 272-274.
- Janin, J. (2005). Assessing predictions of protein-protein interaction: the CAPRI experiment. *Protein Sci*, 14(2), 278-283.
- Jelier, R., Jenster, G., Dorssers, L. C., van der Eijk, C. C., van Mulligen, E. M., Mons, B., et al. (2005). Co-occurrence based meta-analysis of scientific texts: retrieving biological relationships between genes. *Bioinformatics*, 21(9), 2049-2058.
- Jensen, L. J., Saric, J., & Bork, P. (2006). Literature mining for the biologist: from information retrieval to biological discovery. *Nat Rev Genet*, 7(2), 119-129.
- Jenssen, T. K., Laegreid, A., Komorowski, J., & Hovig, E. (2001). A literature network of human genes for high-throughput analysis of gene expression. *Nat Genet*, 28(1), 21-28.
- Kahn, C. E., Jr., & Thao, C. (2007). GoldMiner: a radiology image search engine. *AJR Am J Roentgenol*, *188*(6), 1475-1478.
- Kamburov, A., Pentchev, K., Galicka, H., Wierling, C., Lehrach, H., & Herwig, R. (2011). ConsensusPathDB: toward a more complete picture of cell biology.

Nucleic Acids Res, 39(Database issue), D712-717.

- Kerrien, S., Orchard, S., Montecchi-Palazzi, L., Aranda, B., Quinn, A. F., Vinod, N., et al. (2007). Broadening the horizon--level 2.5 of the HUPO-PSI format for molecular interactions. *BMC Biol*, 5, 44.
- Keskin, O., Nussinov, R., & Gursoy, A. (2008). PRISM: protein-protein interaction prediction by structural matching. *Methods Mol Biol*, 484, 505-521.
- Kiefer, F., Arnold, K., Kunzli, M., Bordoli, L., & Schwede, T. (2009). The SWISS-MODEL Repository and associated resources. *Nucleic Acids Res*, 37(Database issue), D387-392.
- Kim, W. R., Brown, R. S., Jr., Terrault, N. A., & El-Serag, H. (2002). Burden of liver disease in the United States: summary of a workshop. *Hepatology*, 36(1), 227-242.
- Koike, A., Niwa, Y., & Takagi, T. (2005). Automatic extraction of gene/protein biological functions from biomedical text. *Bioinformatics*, 21(7), 1227-1236.
- Kou, Z., Cohen, W. W., & Murphy, R. F. (2005). High-recall protein entity recognition using a dictionary. *Bioinformatics, 21 Suppl 1*, i266-273.
- Krallinger, M., Leitner, F., Rodriguez-Penagos, C., & Valencia, A. (2008). Overview of the protein-protein interaction annotation extraction task of BioCreative II. *Genome Biol*, 9 Suppl 2, S4.
- Krekulova, L., Rehak, V., & Riley, L. W. (2006). Structure and functions of hepatitis C virus proteins: 15 years after. *Folia Microbiol (Praha)*, 51(6), 665-680.
- Kremsdorf, D., & Brezillon, N. (2007). New animal models for hepatitis C viral infection and pathogenesis studies. *World J Gastroenterol*, *13*(17), 2427-2435.
- Kuiken, C., & Simmonds, P. (2009). Nomenclature and numbering of the hepatitis C virus. *Methods Mol Biol*, 510, 33-53.
- Kwofie, S. K., Radovanovic, A., Sundararajan, V. S., Maqungo, M., Christoffels, A., & Bajic, V. B. (2011). Dragon exploratory system on hepatitis C virus (DESHCV). *Infect Genet Evol*, 11(4), 734-739.
- Lalonde, S., Ehrhardt, D. W., Loque, D., Chen, J., Rhee, S. Y., & Frommer, W. B. (2008). Molecular and cellular approaches for the detection of protein-protein interactions: latest techniques and current limitations. *Plant J*, 53(4), 610-635.
- Lanford, R. E., Bigger, C., Bassett, S., & Klimpel, G. (2001). The chimpanzee model of hepatitis C virus infections. *ILAR J*, 42(2), 117-126.
- Lawitz, E., Godofsky, E., Rouzier, R., Marbury, T., Nguyen, T., Ke, J., et al. (2011). Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy. *Antiviral Res*, 89(3), 238-245.
- Leaman, R., & Gonzalez, G. (2008). BANNER: an executable survey of advances in biomedical named entity recognition. *Pac Symp Biocomput*, 652-663.
- Lee, K. J., Hwang, Y. S., Kim, S., & Rim, H. C. (2004). Biomedical named entity recognition using two-phase model based on SVMs. *J Biomed Inform*, 37(6), 436-447.
- Lemm, J. A., O'Boyle, D., 2nd, Liu, M., Nower, P. T., Colonno, R., Deshpande, M. S., et al. (2010). Identification of hepatitis C virus NS5A inhibitors. J Virol, 84(1), 482-491.
- Leroy, G., & Chen, H. (2002). Filling preposition-based templates to capture information

from medical abstracts. Pac Symp Biocomput, 350-361.

- Leroy, G., Chen, H., & Martinez, J. D. (2003). A shallow parser based on closed-class words to capture relations in biomedical text. *J Biomed Inform*, *36*(3), 145-158.
- Letunic, I., Doerks, T., & Bork, P. (2009). SMART 6: recent updates and new developments. *Nucleic Acids Res*, *37*(Database issue), D229-232.
- Lewis, A. C., Saeed, R., & Deane, C. M. (2010). Predicting protein-protein interactions in the context of protein evolution. *Mol Biosyst*, 6(1), 55-64.
- Li, Y., Hu, X., Lin, H., & Yang, Z. (2011). A framework for semisupervised feature generation and its applications in biomedical literature mining. *IEEE/ACM Trans Comput Biol Bioinform*, 8(2), 294-307.
- Liu, F., Ackerman, M., & Fontelo, P. (2006). BabelMeSH: development of a crosslanguage tool for MEDLINE/PubMed. *AMIA Annu Symp Proc*, 1012.
- Liu, S., Yang, W., Shen, L., Turner, J. R., Coyne, C. B., & Wang, T. (2009). Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J Virol, 83(4), 2011-2014.
- Lohmann, V., Korner, F., Koch, J., Herian, U., Theilmann, L., & Bartenschlager, R. (1999). Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. *Science*, 285(5424), 110-113.
- Long, G., Hiet, M. S., Windisch, M. P., Lee, J. Y., Lohmann, V., & Bartenschlager, R. (2011). Mouse Hepatic Cells Support Assembly of Infectious Hepatitis C Virus Particles. *Gastroenterology*.
- Lozach, P. Y., Amara, A., Bartosch, B., Virelizier, J. L., Arenzana-Seisdedos, F., Cosset, F. L., et al. (2004). C-type lectins L-SIGN and DC-SIGN capture and transmit infectious hepatitis C virus pseudotype particles. J Biol Chem, 279(31), 32035-32045.
- Lu, Z. (2011). PubMed and beyond: a survey of web tools for searching biomedical literature. *Database (Oxford), 2011*, baq036.
- Lussier, Y., Borlawsky, T., Rappaport, D., Liu, Y., & Friedman, C. (2006). PhenoGO: assigning phenotypic context to gene ontology annotations with natural language processing. *Pac Symp Biocomput*, 64-75.
- Ma, S., Boerner, J. E., TiongYip, C., Weidmann, B., Ryder, N. S., Cooreman, M. P., et al. (2006). NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon. *Antimicrob Agents Chemother*, 50(9), 2976-2982.
- Martell, M., Esteban, J. I., Quer, J., Genesca, J., Weiner, A., Esteban, R., et al. (1992). Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. *J Virol*, 66(5), 3225-3229.
- Martin, A., Ochagavia, M. E., Rabasa, L. C., Miranda, J., Fernandez-de-Cossio, J., & Bringas, R. (2010). BisoGenet: a new tool for gene network building, visualization and analysis. *BMC Bioinformatics*, 11, 91.
- Martin, S., Brown, W. M., & Faulon, J. L. (2008). Using product kernels to predict protein interactions. *Adv Biochem Eng Biotechnol*, 110, 215-245.
- Mas, V. R., Maluf, D. G., Archer, K. J., Yanek, K., Bornstein, K., & Fisher, R. A. (2009). Proteomic analysis of HCV cirrhosis and HCV-induced HCC: identifying

biomarkers for monitoring HCV-cirrhotic patients awaiting liver transplantation. *Transplantation*, 87(1), 143-152.

- McDowall, M. D., Scott, M. S., & Barton, G. J. (2009). PIPs: human protein-protein interaction prediction database. *Nucleic Acids Res*, 37(Database issue), D651-656.
- Meil, A., Durand, P., & Wojcik, J. (2005). PIMWalker: visualising protein interaction networks using the HUPO PSI molecular interaction format. *Appl Bioinformatics*, 4(2), 137-139.
- Meireles, L. M., Domling, A. S., & Camacho, C. J. (2010). ANCHOR: a web server and database for analysis of protein-protein interaction binding pockets for drug discovery. *Nucleic Acids Res*, 38(Web Server issue), W407-411.
- Mercadal, C. M., Martin, S., & Rouse, B. T. (1991). Apparent requirement for CD4+ T cells in primary anti-herpes simplex virus cytotoxic T-lymphocyte induction can be overcome by optimal antigen presentation. *Viral Immunol*, *4*(3), 177-186.
- Mika, S., & Rost, B. (2004). NLProt: extracting protein names and sequences from papers. *Nucleic Acids Res*, 32(Web Server issue), W634-637.
- Mirny, L. A., & Shakhnovich, E. I. (1999). Universally conserved positions in protein folds: reading evolutionary signals about stability, folding kinetics and function. J Mol Biol, 291(1), 177-196.
- Monazahian, M., Bohme, I., Bonk, S., Koch, A., Scholz, C., Grethe, S., et al. (1999). Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol, 57(3), 223-229.
- Muller, H., Michoux, N., Bandon, D., & Geissbuhler, A. (2004a). A review of contentbased image retrieval systems in medical applications-clinical benefits and future directions. *Int J Med Inform*, 73(1), 1-23.
- Muller, H. M., Kenny, E. E., & Sternberg, P. W. (2004b). Textpresso: an ontology-based information retrieval and extraction system for biological literature. *PLoS Biol*, 2(11), e309.
- Narayanaswamy, M., Ravikumar, K. E., & Vijay-Shanker, K. (2003). A biological named entity recognizer. *Pac Symp Biocomput*, 427-438.
- Neveol, A., Zeng, K., & Bodenreider, O. (2006). Besides precision & recall: exploring alternative approaches to evaluating an automatic indexing tool for MEDLINE. *AMIA Annu Symp Proc*, 589-593.
- Ono, T., Hishigaki, H., Tanigami, A., & Takagi, T. (2001). Automated extraction of information on protein-protein interactions from the biological literature. *Bioinformatics*, 17(2), 155-161.
- Orchard, S., Salwinski, L., Kerrien, S., Montecchi-Palazzi, L., Oesterheld, M., Stumpflen, V., et al. (2007). The minimum information required for reporting a molecular interaction experiment (MIMIx). *Nat Biotechnol*, 25(8), 894-898.
- Outwater, E. K. (2010). Imaging of the liver for hepatocellular cancer. *Cancer Control*, *17*(2), 72-82.
- Ouzounov, S., Mehta, A., Dwek, R. A., Block, T. M., & Jordan, R. (2002). The combination of interferon alpha-2b and n-butyl deoxynojirimycin has a greater than additive antiviral effect upon production of infectious bovine viral diarrhea virus (BVDV) in vitro: implications for hepatitis C virus (HCV) therapy. *Antiviral Res*, 55(3), 425-435.
- Park, J. C., Kim, H. S., & Kim, J. J. (2001). Bidirectional incremental parsing for

automatic pathway identification with combinatory categorial grammar. *Pac Symp Biocomput*, 396-407.

- Payer, B. A., Reiberger, T., Rutter, K., Beinhardt, S., Staettermayer, A. F., Peck-Radosavljevic, M., et al. (2010). Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient. *J Clin Virol*, 49(2), 131-133.
- Pazos, F., Juan, D., Izarzugaza, J. M., Leon, E., & Valencia, A. (2008). Prediction of protein interaction based on similarity of phylogenetic trees. *Methods Mol Biol*, 484, 523-535.
- Penin, F., Dubuisson, J., Rey, F. A., Moradpour, D., & Pawlotsky, J. M. (2004). Structural biology of hepatitis C virus. *Hepatology*, 39(1), 5-19.
- Petracca, R., Falugi, F., Galli, G., Norais, N., Rosa, D., Campagnoli, S., et al. (2000). Structure-function analysis of hepatitis C virus envelope-CD81 binding. J Virol, 74(10), 4824-4830.
- Phizicky, E. M., & Fields, S. (1995). Protein-protein interactions: methods for detection and analysis. *Microbiol Rev*, 59(1), 94-123.
- Pileri, P., Uematsu, Y., Campagnoli, S., Galli, G., Falugi, F., Petracca, R., et al. (1998). Binding of hepatitis C virus to CD81. *Science*, 282(5390), 938-941.
- Pitre, S., Dehne, F., Chan, A., Cheetham, J., Duong, A., Emili, A., et al. (2006). PIPE: a protein-protein interaction prediction engine based on the re-occurring short polypeptide sequences between known interacting protein pairs. BMC Bioinformatics, 7, 365.
- Plewczynski, D., & Ginalski, K. (2009). The interactome: predicting the protein-protein interactions in cells. *Cell Mol Biol Lett*, 14(1), 1-22.
- Plewczynski, D., & Klingstrom, T. (2011). GIDMP: Good protein-protein interaction data metamining practice. *Cell Mol Biol Lett*, 16(2), 258-263.
- Plikus, M. V., Zhang, Z., & Chuong, C. M. (2006). PubFocus: semantic MEDLINE/PubMed citations analytics through integration of controlled biomedical dictionaries and ranking algorithm. *BMC Bioinformatics*, 7, 424.
- Ploss, A., Evans, M. J., Gaysinskaya, V. A., Panis, M., You, H., de Jong, Y. P., et al. (2009). Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. *Nature*, 457(7231), 882-886.
- Prieto, C., & De Las Rivas, J. (2006). APID: Agile Protein Interaction DataAnalyzer. *Nucleic Acids Res, 34*(Web Server issue), W298-302.
- Proux, D., Rechenmann, F., & Julliard, L. (2000). A pragmatic information extraction strategy for gathering data on genetic interactions. *Proc Int Conf Intell Syst Mol Biol*, 8, 279-285.
- Proux, D., Rechenmann, F., Julliard, L., Pillet, V. V., & Jacq, B. (1998). Detecting Gene Symbols and Names in Biological Texts: A First Step toward Pertinent Information Extraction. *Genome Inform Ser Workshop Genome Inform*, 9, 72-80.
- Pustejovsky, J., Castano, J., Zhang, J., Kotecki, M., & Cochran, B. (2002). Robust relational parsing over biomedical literature: extracting inhibit relations. *Pac Symp Biocomput*, 362-373.
- Qian, Y., & Murphy, R. F. (2008). Improved recognition of figures containing fluorescence microscope images in online journal articles using graphical models. *Bioinformatics*, 24(4), 569-576.

- Razick, S., Magklaras, G., & Donaldson, I. M. (2008). iRefIndex: a consolidated protein interaction database with provenance. *BMC Bioinformatics*, *9*, 405.
- Rindflesch, T. C., & Fiszman, M. (2003). The interaction of domain knowledge and linguistic structure in natural language processing: interpreting hypernymic propositions in biomedical text. J Biomed Inform, 36(6), 462-477.
- Robertson, B., Myers, G., Howard, C., Brettin, T., Bukh, J., Gaschen, B., et al. (1998). Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. *Arch Virol*, 143(12), 2493-2503.
- Rossignol, J. F., Elfert, A., & Keeffe, E. B. (2010). Treatment of chronic hepatitis C using a 4-week lead-in with nitazoxanide before peginterferon plus nitazoxanide. *J Clin Gastroenterol*, 44(7), 504-509.
- Rychlowska, M., & Bienkowska-Szewczyk, K. (2007). Hepatitis C--new developments in the studies of the viral life cycle. *Acta Biochim Pol*, *54*(4), 703-715.
- Safran, M., Dalah, I., Alexander, J., Rosen, N., Iny Stein, T., Shmoish, M., et al. (2010). GeneCards Version 3: the human gene integrator. *Database (Oxford), 2010*, baq020.
- Sasaki, Y., Tsuruoka, Y., McNaught, J., & Ananiadou, S. (2008). How to make the most of NE dictionaries in statistical NER. *BMC Bioinformatics*, 9 Suppl 11, S5.
- Saunier, B., Triyatni, M., Ulianich, L., Maruvada, P., Yen, P., & Kohn, L. D. (2003). Role of the asialoglycoprotein receptor in binding and entry of hepatitis C virus structural proteins in cultured human hepatocytes. *J Virol*, 77(1), 546-559.
- Sayers, E. W., Barrett, T., Benson, D. A., Bolton, E., Bryant, S. H., Canese, K., et al. (2011). Database resources of the National Center for Biotechnology Information. *Nucleic Acids Res*, 39(Database issue), D38-51.
- Scarselli, E., Ansuini, H., Cerino, R., Roccasecca, R. M., Acali, S., Filocamo, G., et al. (2002). The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. *EMBO J*, 21(19), 5017-5025.
- Sekimizu, T., Park, H. S., & Tsujii, J. (1998). Identifying the Interaction between Genes and Gene Products Based on Frequently Seen Verbs in Medline Abstracts. *Genome Inform Ser Workshop Genome Inform*, 9, 62-71.
- Sen, T. Z., Kloczkowski, A., & Jernigan, R. L. (2006). Functional clustering of yeast proteins from the protein-protein interaction network. *BMC Bioinformatics*, 7, 355.
- Sen, T. Z., Kloczkowski, A., Jernigan, R. L., Yan, C., Honavar, V., Ho, K. M., et al. (2004). Predicting binding sites of hydrolase-inhibitor complexes by combining several methods. *BMC Bioinformatics*, 5, 205.
- Sharma, S. D. (2010). Hepatitis C virus: molecular biology & current therapeutic options. *Indian J Med Res*, 131, 17-34.
- Sharon, I., Davis, J. V., & Yona, G. (2009). Prediction of protein-protein interactions: a study of the co-evolution model. *Methods Mol Biol, 541*, 61-88.
- Shatkay, H., Chen, N., & Blostein, D. (2006). Integrating image data into biomedical text categorization. *Bioinformatics*, 22(14), e446-453.
- Sievert, W., Altraif, I., Razavi, H. A., Abdo, A., Ahmed, E. A., Alomair, A., et al. (2011). A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. *Liver Int*, *31 Suppl 2*, 61-80.

- Simmonds, P., Alberti, A., Alter, H. J., Bonino, F., Bradley, D. W., Brechot, C., et al. (1994). A proposed system for the nomenclature of hepatitis C viral genotypes. *Hepatology*, 19(5), 1321-1324.
- Simmonds, P., Bukh, J., Combet, C., Deleage, G., Enomoto, N., Feinstone, S., et al. (2005). Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. *Hepatology*, 42(4), 962-973.
- Simmonds, P., Holmes, E. C., Cha, T. A., Chan, S. W., McOmish, F., Irvine, B., et al. (1993). Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol, 74 (Pt 11), 2391-2399.
- Singhal, M., & Resat, H. (2007). A domain-based approach to predict protein-protein interactions. *BMC Bioinformatics*, *8*, 199.
- Smialowski, P., Pagel, P., Wong, P., Brauner, B., Dunger, I., Fobo, G., et al. (2010). The Negatome database: a reference set of non-interacting protein pairs. *Nucleic Acids Res*, 38(Database issue), D540-544.
- Smith, B., Ashburner, M., Rosse, C., Bard, J., Bug, W., Ceusters, W., et al. (2007). The OBO Foundry: coordinated evolution of ontologies to support biomedical data integration. *Nat Biotechnol*, 25(11), 1251-1255.
- Smith, L., Tanabe, L. K., Ando, R. J., Kuo, C. J., Chung, I. F., Hsu, C. N., et al. (2008). Overview of BioCreative II gene mention recognition. *Genome Biol*, 9 Suppl 2, S2.
- Smoot, M. E., Ono, K., Ruscheinski, J., Wang, P. L., & Ideker, T. (2011). Cytoscape 2.8: new features for data integration and network visualization. *Bioinformatics*, 27(3), 431-432.
- Song, Y., Kim, E., Lee, G. G., & Yi, B. K. (2005). POSBIOTM-NER: a trainable biomedical named-entity recognition system. *Bioinformatics*, 21(11), 2794-2796.
- Spasic, I., Ananiadou, S., McNaught, J., & Kumar, A. (2005). Text mining and ontologies in biomedicine: making sense of raw text. *Brief Bioinform*, 6(3), 239-251.
- Stapley, B. J., & Benoit, G. (2000). Biobibliometrics: information retrieval and visualization from co-occurrences of gene names in Medline abstracts. *Pac Symp Biocomput*, 529-540.
- Strader, D. B., Wright, T., Thomas, D. L., & Seeff, L. B. (2004). Diagnosis, management, and treatment of hepatitis C. *Hepatology*, 39(4), 1147-1171.
- Suderman, M., & Hallett, M. (2007). Tools for visually exploring biological networks. *Bioinformatics*, 23(20), 2651-2659.
- Suzuki, R., Suzuki, T., Ishii, K., Matsuura, Y., & Miyamura, T. (1999). Processing and functions of Hepatitis C virus proteins. *Intervirology*, 42(2-3), 145-152.
- Suzuki, T., Aizaki, H., Murakami, K., Shoji, I., & Wakita, T. (2007). Molecular biology of hepatitis C virus. *J Gastroenterol*, 42(6), 411-423.
- Swanson, D. R. (1991). *Complementary structures in disjoint science literatures*. Paper presented at the Proceedings of the 14th Annual International ACM SIGIR Conference on Research and Development in Information Retrieval.
- Swanson, D. R. (1990). Medical literature as a potential source of new knowledge. *Bull Med Libr Assoc*, 78(1), 29-37.
- Swanson, D. R. (1986). Fish oil, Raynaud's syndrome, and undiscovered public

knowledge. Perspect Biol Med, 30(1), 7-18.

- Sy, T., & Jamal, M. M. (2006). Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci, 3(2), 41-46.
- Szklarczyk, D., Franceschini, A., Kuhn, M., Simonovic, M., Roth, A., Minguez, P., et al. (2011). The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. *Nucleic Acids Res, 39*(Database issue), D561-568.
- Tamames, J. (2005). Text detective: a rule-based system for gene annotation in biomedical texts. *BMC Bioinformatics, 6 Suppl 1*, S10.
- Taylor, C. F., Field, D., Sansone, S. A., Aerts, J., Apweiler, R., Ashburner, M., et al. (2008). Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project. *Nat Biotechnol*, 26(8), 889-896.
- Taylor, D. P. (2007). An integrated biomedical knowledge extraction and analysis platform: using federated search and document clustering technology. *Methods Mol Biol*, *356*, 293-300.
- Tencate, V., Sainz, B., Cotler, S. J., & Uprichard, S. L. (2010). Potential treatment options and future research to increase hepatitis C virus treatment response rate. *Hepat Med*, 2010(2), 125-145.
- Torii, M., Hu, Z., Wu, C. H., & Liu, H. (2009). BioTagger-GM: a gene/protein name recognition system. J Am Med Inform Assoc, 16(2), 247-255.
- Tsai, R. T., Lai, P. T., Dai, H. J., Huang, C. H., Bow, Y. Y., Chang, Y. C., et al. (2009). HypertenGene: extracting key hypertension genes from biomedical literature with position and automatically-generated template features. *BMC Bioinformatics*, 10 *Suppl 15*, S9.
- Tsuruoka, Y., McNaught, J., Tsujii, J., & Ananiadou, S. (2007). Learning string similarity measures for gene/protein name dictionary look-up using logistic regression. *Bioinformatics*, 23(20), 2768-2774.
- Tsuruoka, Y., & Tsujii, J. (2004). Improving the performance of dictionary-based approaches in protein name recognition. *J Biomed Inform*, 37(6), 461-470.
- Turinsky, A. L., Razick, S., Turner, B., Donaldson, I. M., & Wodak, S. J. (2010). Literature curation of protein interactions: measuring agreement across major public databases. *Database (Oxford)*, 2010, baq026.
- Turner, B., Razick, S., Turinsky, A. L., Vlasblom, J., Crowdy, E. K., Cho, E., et al. (2010). iRefWeb: interactive analysis of consolidated protein interaction data and their supporting evidence. *Database (Oxford)*, 2010, baq023.
- Uwimana, E., & Ruiz, M. E. (2008). Integrating an automatic classification method into the medical image retrieval process. *AMIA Annu Symp Proc*, 747-751.
- Vassilaki, N., & Mavromara, P. (2009). The HCV ARFP/F/core+1 protein: production and functional analysis of an unconventional viral product. *IUBMB Life*, 61(7), 739-752.
- von Mering, C., Jensen, L. J., Snel, B., Hooper, S. D., Krupp, M., Foglierini, M., et al. (2005). STRING: known and predicted protein-protein associations, integrated and transferred across organisms. *Nucleic Acids Res, 33*(Database issue), D433-437.
- Wakita, T., Pietschmann, T., Kato, T., Date, T., Miyamoto, M., Zhao, Z., et al. (2005). Production of infectious hepatitis C virus in tissue culture from a cloned viral

genome. Nat Med, 11(7), 791-796.

- Wang, J., Cetindil, I., Ji, S., Li, C., Xie, X., Li, G., et al. (2010). Interactive and fuzzy search: a dynamic way to explore MEDLINE. *Bioinformatics*, 26(18), 2321-2327.
- Weeber, M., Klein, H., De Jong-van den Berg, L. T. W. and Vos, R. (2001). Using concepts in literature-based discovery: Simulating Swanson's Raynaud–fish oil and migraine–magnesium discoveries. J. Amer. Soc. Inf. Sci. Tech, 52(7), 254– 262.
- Weeber, M., Klein, H., Aronson, A. R., Mork, J. G., de Jong-van den Berg, L. T., & Vos, R. (2000). Text-based discovery in biomedicine: the architecture of the DADsystem. *Proc AMIA Symp*, 903-907.
- Weeber, M., Kors, J. A., & Mons, B. (2005). Online tools to support literature-based discovery in the life sciences. *Brief Bioinform*, 6(3), 277-286.
- Weeber, M., Vos, R., Klein, H., De Jong-Van Den Berg, L. T., Aronson, A. R., & Molema, G. (2003). Generating hypotheses by discovering implicit associations in the literature: a case report of a search for new potential therapeutic uses for thalidomide. J Am Med Inform Assoc, 10(3), 252-259.
- WHO (2009). Hepatitis C Virus. Viral Cancers- World Health Organization (WHO) Initiative for Vaccine Research (IVR) Retrieved 11/23/2009, 2009, from http://www.who.int/vaccine_research/diseases/viral_cancers/en/
- Winter, A. G., Wildenhain, J., & Tyers, M. (2011). BioGRID REST Service, BiogridPlugin2 and BioGRID WebGraph: new tools for access to interaction data at BioGRID. *Bioinformatics*, 27(7), 1043-1044.
- Wren, J. D., & Garner, H. R. (2004). Shared relationship analysis: ranking set cohesion and commonalities within a literature-derived relationship network. *Bioinformatics*, 20(2), 191-198.
- Xia, K., Dong, D., & Han, J. D. (2006). IntNetDB v1.0: an integrated protein-protein interaction network database generated by a probabilistic model. *BMC Bioinformatics*, 7, 508.
- Xu, S., McCusker, J., & Krauthammer, M. (2008). Yale Image Finder (YIF): a new search engine for retrieving biomedical images. *Bioinformatics*, 24(17), 1968-1970.
- Xu, Z., Choi, J., Yen, T. S., Lu, W., Strohecker, A., Govindarajan, S., et al. (2001). Synthesis of a novel hepatitis C virus protein by ribosomal frameshift. *EMBO J*, 20(14), 3840-3848.
- Yahia, M. (2011). Global health: a uniquely Egyptian epidemic. *Nature*, 474(7350), S12-13.
- Yang, W., Qiu, C., Biswas, N., Jin, J., Watkins, S. C., Montelaro, R. C., et al. (2008). Correlation of the tight junction-like distribution of Claudin-1 to the cellular tropism of hepatitis C virus. *J Biol Chem*, 283(13), 8643-8653.
- Yang, Y., Adelstein, S. J., & Kassis, A. I. (2009). Target discovery from data mining approaches. *Drug Discov Today*, 14(3-4), 147-154.
- Yao, L., Evans, J. A., & Rzhetsky, A. (2010). Novel opportunities for computational biology and sociology in drug discovery. *Trends Biotechnol*, 28(4), 161-170.
- Yao, L., Evans, J. A., & Rzhetsky, A. (2009). Novel opportunities for computational biology and sociology in drug discovery. *Trends Biotechnol*, 27(9), 531-540.
- Yeh, A., Morgan, A., Colosimo, M., & Hirschman, L. (2005). BioCreAtIvE task 1A:

gene mention finding evaluation. BMC Bioinformatics, 6 Suppl 1, S2.

- Yeh, A. S., Hirschman, L., & Morgan, A. A. (2003). Evaluation of text data mining for database curation: lessons learned from the KDD Challenge Cup. *Bioinformatics*, 19 Suppl 1, i331-339.
- Yellaboina, S., Tasneem, A., Zaykin, D. V., Raghavachari, B., & Jothi, R. (2011). DOMINE: a comprehensive collection of known and predicted domain-domain interactions. *Nucleic Acids Res*, 39(Database issue), D730-735.
- Yu, H., Kim, T., Oh, J., Ko, I., Kim, S., & Han, W. S. (2010). Enabling multi-level relevance feedback on PubMed by integrating rank learning into DBMS. *BMC Bioinformatics*, 11 Suppl 2, S6.
- Yu, N. C., Chaudhari, V., Raman, S. S., Lassman, C., Tong, M. J., Busuttil, R. W., et al. (2011). CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. *Clin Gastroenterol Hepatol*, 9(2), 161-167.
- Zender, L., & Kubicka, S. (2008). Molecular pathogenesis and targeted therapy of hepatocellular carcinoma. *Onkologie*, *31*(10), 550-555.
- Zhou, G., Zhang, J., Su, J., Shen, D., & Tan, C. (2004). Recognizing names in biomedical texts: a machine learning approach. *Bioinformatics*, 20(7), 1178-1190.
- Zinovyev, A., Viara, E., Calzone, L., & Barillot, E. (2008). BiNoM: a Cytoscape plugin for manipulating and analyzing biological networks. *Bioinformatics*, 24(6), 876-877.
- Zweigenbaum, P., Demner-Fushman, D., Yu, H., & Cohen, K. B. (2007). Frontiers of biomedical text mining: current progress. *Brief Bioinform*, 8(5), 358-375.

UNIVERSITY of the WESTERN CAPE



2.1 Abstract

Even though Hepatitis C Virus (HCV) cDNA was characterized about 20 years ago, there is insufficient understanding of the molecular etiology underlying HCV infections. Current global rates of infection and its increasingly chronic character are causes of concern for health policy experts. Vast amount of data accumulated from biochemical, genomic, proteomic, and other biological analyses allows for novel insights into the HCV viral structure, life cycle and functions of its proteins. Biomedical text-mining is a useful approach for analyzing the increasing corpus of published scientific literature on HCV. This is the first reported comprehensive HCV customized biomedical text-mining based online web resource, dragon exploratory system on Hepatitis C Virus (DESHCV), a biomedical text-mining and relationship exploring knowledgebase was developed by exploring literature on HCV. The pre-compiled dictionaries existing in the dragon exploratory system (DES) were enriched with biomedical concepts pertaining to HCV proteins, their name variants and symbols to make it suitable for targeted information exploration and knowledge extraction as focused on HCV. A list of 32,895 abstracts retrieved via the PubMed database using specific keywords searches related to HCV were processed based on concept recognition of terms from several dictionaries. The web query interface enables retrieval of information using specified concepts, keywords and phrases, generating text-derived association networks and hypotheses, which could be tested to identify potentially novel relationships between different concepts. Such an approach could also augment efforts in the search for diagnostic or even therapeutic targets. DESHCV thus represents an online literature-based discovery resource freely accessible for academic and non-profit users via http://apps.sanbi.ac.za/DESHCV/ and its mirror site http://cbrc.kaust.edu.sa/deshcv/.

2.2 Introduction

The skyrocketing chronicity and global infection rate of Hepatitis C Virus (HCV) necessitate the need to unlock the molecular etiology underlying the pathophysiology of HCV related diseases such as liver cancer. The plethora of essential molecular data in the corpus of published biomedical literature could be leveraged to augment efforts towards

discovery of novel anti-viral drugs, cellular receptors and appropriate predictive biomarkers. Most of the data derived from high throughput and "omics" experiments exist in variety of formats, thereby making cross data integration difficult. The development of HCV specific databases as repositories of information utilizable in cross discipline biology research is therefore vital. The Los Alamos Hepatitis C Virus sequence database (http://hcv.lanl.gov) offers annotated sequences and analysis tools (Kuiken et al.. 2005). The Los Alamos hepatitis С immunology database (http://hcv.lanl.gov/content/immuno/immuno-main.html) is a repository of biocurated immunological epitopes integrated with retrieval and analysis tools (Yusim et al., 2005). The Japanese HCV database integrated in the HVDB (http://s2as02.genes.nig.ac.jp) comprises data on phylogenetic and provides java embedded viewers for visualizing phylogenetic trees and the HCV genome. The European Hepatitis C Virus database (euHCVdb, http://euhcvdb.ibcp.fr) provides annotated sequences and tools for analysis, and information on protein structure and function (Combet et al., 2007). Hepatitis C Virus sequence and immunology database and analytical applications (HCVdb, http://www.hcvdb.org/index.asp?bhcp=1) offers data on analyzed protein sequence and features, epitopes, and curated knowledge on protein interactions and function. Binding site finder (BSFINDER, http://wilab.inha.ac.kr/bsfinder) enables prediction of HCV binding site residues and potential interacting protein partners using support vector machine (Chen and Han, 2009). A comprehensive review of selected HCV related database has highlighted the useful capabilities, utilities and applications of these resources (Kuiken et al., 2006). Hepatitis C Virus-specific databases store useful information on molecular biology, sequences, immunology, protein structure and function, viral evolution and genetics. Nevertheless, there is no resource that allows for the exploration of potential links (associations) between different biomedical concepts of relevance to HCV. One such resource is the dragon exploratory system on Hepatitis C Virus (DESHCV. http://apps.sanbi.ac.za/DESHCV/ mirror and its site http://cbrc.kaust.edu.sa/deshcv/), based on text-mining approach to complement the existing HCV resources and to enable different insights into the molecular context of HCV functioning.

As reported by Cohen and Hersh (2005), the biomedical knowledgebase is growing at an increasing rate. PubMed database is currently a repository of about 20 million citations for biomedical articles from MEDLINE and life science related journals. MeSH indexers index about 500,000 journal articles annually for PubMed/MEDLINE (Mitchell et al., 2003). A search by publication dates in PubMed shows over 20,000 HCV related records published over the last decade. At the time when this study was conducted a total of 32,895 HCV related documents were available that makes it virtually impossible for a single researcher or a research group to process in any reasonable time. However, a biomedical text-mining approach could be utilized to analyze this large volume of scientific data and reports published on HCV. Biomedical text-mining employs different techniques to extract and summarize information from text (Cohen and Hunter, 2008). Its algorithms may derive putative relationships between disjunct sets of concepts to unravel potentially new associations and hypotheses for possible novel discovery. The cooccurrence of the concepts of interests, either in a portion of text (say abstract) or in a sentence, is identified computationally, and provides useful clues on the potential associations between these concepts, some of which may be completely new. For example, using text-mining techniques fish oil was proposed to have a potential therapeutic effect on Raynaud's disease (Swanson, 1986). The relationship between fish oil and Raynaud's disease was hypothesized via physiological concepts such as high blood pressure and platelet aggregation and subsequently this relationship was confirmed. As another example, literature based discovery was previously used to predict thalidomide as a possible therapeutic drug for HCV infection after detecting implicit associations in biomedical text (Weeber et al., 2003). A text-mining approach was also employed in identifying some of the hepatocellular proteins used in generating the human HCV interactome (de Chassey et al., 2008).

The essential features and characteristics of some of the available text-mining tools have been discussed elsewhere (Bajic et al., 2005; Weeber et al., 2005). Shi and Campagne (2005) have described in detail the various concepts, principles, challenges and algorithms behind development of biomedical text-mining tools during the building of protein catalogue and implementation of the Textractor Framework

(http://icb.med.cornell.edu/crt/textractor/index.xml). 2.0 Anni (http://biosemantics.org/anni/), a web-based biomedical text-mining tool offers an ontology-based interface to MEDLINE and enables retrieval of documents and possible association amongst biomedical concepts (Jelier et al., 2008). PolySearch (http://wishart.biology.ualberta.ca/polysearch), a web-based text-mining system allows the retrieval of relationships between human diseases, genes, mutations, drugs and metabolites (Cheng et al., 2008). Nowadays, customized knowledgebases or topicspecific text-mining resources are increasingly becoming popular. Typical examples are the dragon exploratory system (DES) based resources: dragon TF association miner (DTFAM, http://research.i2r.a-star.edu.sg/DRAGON/TFAM), useful for exploring functional association amongst transcription factors (Pan et al., 2004); dragon database for exploration of sodium channels in human (DDESC, http://apps.sanbi.ac.za/ddesc), which provides comprehensive text-mining information related to sodium channels (Sagar et al., 2008). DES and its previous versions were successfully used in compilation of several other resources such as in database on ovarian cancer (Kaur et al., 2009) and esophageal cancer (Essack et al., 2009), as well as in studies on prioritizing disease genes (Tiffin et al., 2005; Lombard et al., 2007).

WESTERN CAPE

At the time of initiating this thesis project, there was no single database solely focused on HCV research that allowed for the comprehensive exploration of the association between the biomedical concepts related to HCV. This thesis describes dragon exploratory system on Hepatitis C Virus (DESHCV), the previous version of it being reported earlier (Kwofie et al., 2009). DESHCV is developed using DES. The HCV proteins and their name variants have been integrated into the pre-compiled dictionaries of biological concepts present in DES. These concepts are cross-referenced to database such as gene ontologies (GO), UNIPROT, KEGG Pathway, REACTOME and Entrez Gene. A list of abstracts was retrieved via PubMed database using keywords related to HCV. These abstracts were analyzed using concepts in the following dictionaries: "human genes and proteins", "metabolites and enzymes", "pathways", "chemicals with pharmacological effects", "Hepatitis C Virus concepts", and "disease concepts".

The user-friendly online interface allows concepts, keywords and phrases searches. A concept query could generate networks and hypothesis. The computationally suggested associations between genes and other concepts such as diseases may assist experimental biologist to explore which genes amongst a pool of genes need to be characterized for further molecular analysis. Such an approach could in principle also lead to possible discovery of new vaccines; and enhance the development of appropriate diagnostic method. The user has the possibility to inspect the post-processed PubMed abstracts with colour-coded tagged concepts from the used dictionaries as found in the text. The downloadable concept lists sheet could be a primary source of data for biocuration. The paired concept list spreadsheet can serve as the essential preliminary data for exploring associations between concepts and can be converted easily into simple interaction file format (SIF) compatible with some of the interaction visualization and analysis tools such as Cytoscape (Killcoyne et al., 2009). Researchers with minimal or no knowledge on text-mining can explore DESHCV with ease via system's simplified user query interface. The integrated downloadable tutorial manual and frequently asked questions (FAQ) information further aids easy use of the system (appendix I and II). DESHCV is an online text-mining developed knowledgebase freely available for non-commercial use via http://apps.sanbi.ac.za/DESHCV and http://cbrc.kaust.edu.sa/deshcv.

2.3 Construction and content

2.3.1 Implementation

A list of 32,895 MEDLINE abstracts was collected via PubMed interface using the following keywords query: HCV OR "Hepatitis C Virus". The PubMed textual data downloaded in the extensible markup language (XML) format allow for easy data integration into DES for semantic processing and analysis. The DESHCV data files were generated by DES, a proprietary biomedical text-mining tool of OrionCell (http://www.orioncell.org). The HCV proteins symbols and name variants were added to the "human protein and genes" dictionaries, and were mapped onto external annotation database. The HCV name variants have been disambiguated and integrated in the database. For example, a concept query with the word "core" retrieves "core protein" and

not the words "score" or "core". The word core apart from being part of the morphological features of HCV core protein has different meanings in various English dictionaries.

Post processed PubMed abstracts containing found concepts from used dictionaries constitute part of the database files. The DESHCV precompiled dictionary data files systems are composed of categories of terms such as names of "genes", "proteins", "metabolites", enzymes", "pathways", "pharmacological chemicals", and "diseases". The categories of terms consist of biological entities that are referred to as concepts. Therefore for the purpose of this work, each dictionary consists of a catalogue of related concepts. The DESHCV system is organized into 6 distinct dictionaries: "human genes and proteins", "metabolites and enzymes", "pathways", "chemicals with pharmacological effects", "Hepatitis C Virus concepts", and "disease concepts". Hierarchically, each dictionary is considered as a parent with no subcategories. For example, both human gene "interferon alpha 2" and human protein "alanine aminotransferase" are concepts belonging to the same parent "human genes and proteins" dictionary and not separate subcategories. In some instances certain concepts are assigned to one dictionary, even though they could belong to another. For example the concept name ribavirin, a therapeutic drug for hepatitis C infection has been assigned to the "metabolites and enzymes" dictionary, even though it could also belong to "chemicals with pharmacological effects" dictionary. The decision is influenced by the belief that most literature reports ribavirin as a metabolite.

For the purpose of hypothesis generation, the DES association module generates association maps in the form of graphs. The nodes of these graphs represent various concepts and the edges linking the nodes are weighted with frequencies of occurrence in the PubMed abstracts. Hypotheses are generated if for example, concepts X and Y are correlated, as well as concepts Y and Z, but no correlation is found between X and Z. Then the hypotheses generator module will suggest a potential link between concepts X and Z.

2.3.2 Database architecture

The database comprises of an Apache HTTP web server integrated with a back-end MySQL server whilst HTML/CSS and JavaScript scripts constitute the front-end (Figure 2.1). The data files consist of precompiled concept dictionaries, post processed PubMed abstracts, and cross-referenced annotations. The logic systems consist of Perl and PHP modules.



UNIVERSITY of the WESTERN CAPE





FIGURE 2.1. SCHEMATIC DIAGRAM OF THE INTEGRATED DATABASE OF DESHCV. A layout of the DESHCV database architecture showing the relationship between the incorporated data files, logic systems and user query interface.

2.3.3 The database interfaces

DESHCV is based on a client-server model and can be accessed by any user with a standard web browser. The user interfaces in DESHCV allow easy navigation, query, inspection, and retrieval of data. It comprises of concept and abstract search menus (Figure 2.2). The concept search menu allows users to search the database using specified concepts. The hypothesis generator is an integral functional component of the concept search menu.



WESTERN CAPE





A structured workflow outlining the various steps and decision-making processes involved in retrieving enriched biological data from DESHCV.

2.4 Results and discussions

2.4.1 Concepts queries

DESHCV is the first text-mining based web accessible resource developed using published abstracts of scientific reports on HCV as referenced in PubMed. DESHCV provides comprehensive information on HCV and enables users to gain easy insights through exploration of potential associations between the concepts of interest. Users can query the database using concepts such as genes, proteins, metabolites, enzymes, pathway, disease concepts, and pharmacological chemicals to retrieve useful associations that may suggest new insights into the problem. DESHCV provides users the chance to query the compiled abstracts within the framework of concept-based retrieval and extraction system.

For example, a concept query "thalidomide" retrieves all associated concepts from their respective dictionaries found in the analyzed text. These could be displayed either in a graphical or tabular format. These identified concepts co-occur with thalidomide in the PubMed abstracts. The frequency of occurrence of the concepts is shown and the link can be clicked to view the abstracts. The user has the option of either viewing the abstract with or without tagged concepts. All disease concepts associated with thalidomide are retrieved including chronic hepatitis C, which co-occurs with thalidomide within three abstracts. This result can be displayed in the form of an association map by using the "draw network" generator. The association map is a graph consisting of interacting network of nodes representing thalidomide and its associated concepts. The edges linking the nodes shows the relationship between the concepts and are weighted with the frequency of co-occurrence. To ensure effective interpretation and evaluation of results, users have the option of limiting the number of interactions for display by ignoring links with fewer frequencies. The association map can be resized from A0 to A5 and the detail slider can be used to alter viewing capabilities. For the purpose of this discussion, concepts with less than three links were ignored to obtain high degree of details without obscuring vital information. The association established between thalidomide and chronic hepatitis C is a loose relationship and no inference may be deduced until the literature is manually verified to either accept or reject the relationship (Figure 2.3). The linking abstracts were manually inspected to ascertain the proposed relationship. Accordingly, thalidomide is a promising novel compound for chronic hepatitis C therapy since thalidomide decreased liver enzymes in six out of eight patients suffering from chronic hepatitis C (Milazzo et al., 2006).



UNIVERSITY of the WESTERN CAPE




FIGURE 2.3. A DIAGRAM DISPLAYING THALIDOMIDE CONCEPT QUERY OUTPUT.

This shows the association map comprising of a network of interaction nodes consisting of concepts assigned to various biomedical dictionaries.

2.4.2 Abstract queries

The abstract search menu allows users to do keywords searches, use quotes for "phrase search", and Boolean logical operators such as "OR", "AND" or "NOT". An abstract search with the keyword "hypervariability" therefore returns a list of abstracts containing the queried keyword "hypervariability". The retrieved abstracts also contain tagged colour-coded concepts assigned to their respective dictionaries. The abstract search results can serve as rich source of data useful for curation since it contains automatically identified biomedical concepts. Even though manual curation using human expertise could yield high quality results (Muller et al., 2004), it is sometimes fraught with errors since the human eyes may unintentionally overlook useful data. In addition, the rapidly increasing volume of published literature sometimes could render it herculean for researchers to manually inspect and efficiently locate or identify biomedical concepts of interest embedded in literature. This feature of DESHCV is aimed at complimenting the already existing information search, retrieval and extraction resources.

2.4.3 Evaluation of DES by reproducing a known hypothesis

The performance of DES has been evaluated recently by Sagar et al. (2008) in the context of sodium channels in human. Since it was not possible to evaluate all the concepts embedded in the 5243 documents used in Sagar's analysis, SCN1A was chosen as a reference gene for the analysis. DES accurately identified most of the concepts present in the 131 abstracts associated with SCN1A. The analysis showed both precision and recall for identified concepts from different dictionaries that ranged between 81% and 100% whilst the *F*-measure was between 87% and 100%.

In this report, a different approach was used to evaluate the performance of DES by simulating an already confirmed scientific discovery. Such approach has been used during the implementation of the DAD-system, Swanson's Raynaud's disease-fish oil discovery was simulated to test the performance of the system (Weeber et al., 2000). Swanson's discovery of a hidden connection between disjunct literatures on magnesium and migraine was successfully re-implemented in the LitLinker systems (Meredith et al.,

2005). Anni biomedical text-mining tool was used to reproduce a previously published thalidomide-chronic hepatitis C discovery (Jelier et al., 2008). Here, DESHCV is used successfully to simulate the thalidomide-chronic hepatitis C association (Weeber et al., 2003). By clicking on the hypothesis generator, the user can retrieve hypothesis to reveal potential relationships existing between concepts. The hypothesis generator query menu allows users to automatically or manually select categories with which to generate hypothesis. The open discovery approach previously described by Swanson and adapted by Meredith has been employed here. Thalidomide (from "metabolites and enzymes" dictionaries) was used as the starting term to retrieve all linking concepts within the human proteins and genes category. The tumor necrosis factor (TNF) was manually selected as the linking term whilst concepts within the diseases catalogues were defined as the target (Figure 2.4). The system successfully generated hypothesis to infer potential relationships between thalidomide and the following disease concepts: chronic liver disease, chronic viral hepatitis, chronic persistent hepatitis and chronic renal failure. The system used disjuncted literature between the different concepts to predict implicit relationship amongst them. Chronic liver disease, chronic viral hepatitis and chronic persistent hepatitis are possible name variants and these conditions are implicated in liver failure. By clicking on the test button linking the chronic viral hepatitis and thalidomide retrieved an abstract on a case report concerning thalidomide-associated hepatitis where the patient had medical history including chronic hepatitis C (Fowler and Imrie, 2001). The hypothesis generated by DESHCV was reasonable since the verification of the literature supported the "discovery".




FIGURE 2.4. A DIAGRAM DISPLAYING THALIDOMIDE-CHRONIC HEPATITIS C HYPOTHESIS. This shows an implicit relationship between thalidomide and chronic hepatitis C inferring potentially new hypotheses. The biomedical concepts "thalidomide", "tumor necrosis factor" and "chronic hepatitis C" belongs to the "metabolites and enzymes", "human genes and proteins", and 'disease concepts" dictionaries respectively.

2.4.4 Generation of thalidomide-amantadine association

DESHCV has also been used to generate potentially new hypotheses, which propose relationships between thalidomide and amantadine as possible combination therapy for chronic viral hepatitis C. All disease concepts associated with thalidomide were retrieved and chronic hepatitis C was selected as linking term with concepts in metabolites and enzymes dictionaries considered as target terms. This hypothesis was tested automatically by checking the auto test radio button. This inferred an implicit relationship between thalidomide and amantadine but no PubMed abstract was retrieved implying a potentially new discovery (Figure 2.5). This means that these two concepts do not co-occur in any of the PubMed abstracts. This potential discovery is based on textual analysis of abstracts and not full text papers. The standard treatment for chronic hepatitis C is a combination therapy of pegylated IFN-alpha to elicit immune response and antiviral effect of ribavirin. Patients infected with certain genotypes of HCV do not respond to this treatment, necessitating the need for enhanced combination therapy. Reports on available data concerning triple therapy comprising of pegylated IFN-alpha, ribavirin and protease inhibitors targeting NS3-4SA protease looks promising, and this could become standard treatment feature in the near future (Zeuzem, 2008; Flisiak and Parfieniuk, 2010). The usage of thalidomide in the treatment of chronic hepatitis C unresponsive to alphainterferon and ribavirin has been investigated (Caseiro, 2006; Milazzo et al., 2006), whilst amantadine has been combined with interferon-alpha plus ribavirin (Chrissafidou and Musch, 2009; von Wagner et al., 2008).

The possibility of a triple therapy for effective management of chronic hepatitis C should prompt researchers on the need to investigate combining any one of the available treatment drugs (IFN-alpha and ribavirin) or possibly protease inhibitors to thalidomide and amantadine as implied by the generated hypotheses. Although the beneficial effect of amantadine and other antiviral drug for the treatment of chronic hepatitis C is controversial and sometimes contentious, potent analogues with less toxicity, augmented pharmacophore and enhanced pharmacokinetics could be explored further. The possibility of augmenting the above therapy with hepatoprotective drug such as silibinin could be explored. Any discovery proposed using biomedical text-mining approach should undergo the rigour of laboratory evaluations and ethical consideration and possibly must conform to existing legislation before usage.



UNIVERSITY of the WESTERN CAPE




FIGURE 2.5. A DIAGRAM DISPLAYING THALIDOMIDE-AMANTADINE HYPOTHESIS.

This shows an implicit relationship between thalidomide and amantadine inferring potentially new hypotheses. The biomedical concepts "thalidomide" and "amantadine" belong to the "metabolites and enzymes" dictionaries whilst "chronic hepatitis C" concept belongs to the "disease" dictionary.

2.4.5 Systems reports

Comprehensive summary reports generated from DESHCV are made available on the left menu of the user interface. The "concept list report" groups concepts by dictionaries and frequency of appearance inside documents. The frequency of document report lists abstract with their total number of embedded tagged concepts. The frequencies of pairs report group pairs of concepts that co-occur in documents. Another useful feature is the document clustering report which displays clusters of concepts sorted by frequency of appearance and is compiled using artificial neural networking algorithm. Its usefulness lies in the fact that similar documents tend to cluster together, thereby allowing biologist to harness potential information amongst clustered abstracts. Recommended readings displays the link to top 10 documents with most concepts, though not manually generated they could give an overview of HCV research to a new researcher in virology. For example, the most recommended reading is an abstract on a review describing in detail the current antiviral drugs in clinical usage (De Clercq, 2004).

2.5 Limitations

UNIVERSITY of the

Associations generated between paired concepts are inferred from co-occurrences and may not necessarily relate to any molecular functionality. Textual data is obtained from abstracts, which are easy to index. Some details of research are present in full body text and as such vital information may not be reported in abstract. Full text documents were not analyzed in this study.

2.6 Future directions

Integrating blast and identifier queries to enhance querying capabilities of DESHCV is currently being investigated. The possibility of integrating full text document is currently being explored and could be added to the database as a separate feature. The database would be updated every six months to meet the demands of ever increasing PubMed records related to HCV.

2.7 Conclusions

This chapter described the implementation of Hepatitis C Virus customized web-based text-mining resource that allows researchers to intuitively use the system to get insight into possible novel associations between concepts. This system has been used successfully to reproduce already published thalidomide-chronic hepatitis C biomedical text-mining discovery (Weeber et al., 2003). DESHCV database is free to use for academic and non-profit purposes.

2.8 References

- Bajic, V. B., Veronika, M., Veladandi, P. S., Meka, A., Heng, M. W., Rajaraman, K., et al. (2005). Dragon Plant Biology Explorer. A text-mining tool for integrating associations between genetic and biochemical entities with genome annotation and biochemical terms lists. *Plant Physiol*, 138(4), 1914-1925.
- Caseiro, M. M. (2006). Treatment of chronic hepatitis C in non-responsive patients with pegylated interferon associated with ribavirin and thalidomide: report of six cases of total remission. *Rev Inst Med Trop Sao Paulo*, 48(2), 109-112.
- Chen, Y., & Han, K. (2009). BSFINDER: finding binding sites of HCV proteins using a support vector machine. *Protein Pept Lett*, 16(4), 373-382.
- Cheng, D., Knox, C., Young, N., Stothard, P., Damaraju, S., & Wishart, D. S. (2008). PolySearch: a web-based text mining system for extracting relationships between human diseases, genes, mutations, drugs and metabolites. *Nucleic Acids Res*, 36(Web Server issue), W399-405.
- Chrissafidou, A., & Musch, E. (2009). [Peripheral polyneuropathy and bilateral optic neuropathy during treatment of chronic hepatitis C]. Dtsch Med Wochenschr, 134(18), 927-930.
- Cohen, A. M., & Hersh, W. R. (2005). A survey of current work in biomedical text mining. *Brief Bioinform*, 6(1), 57-71.
- Cohen, K. B., & Hunter, L. (2008). Getting started in text mining. *PLoS Comput Biol*, 4(1), e20.
- Combet, C., Garnier, N., Charavay, C., Grando, D., Crisan, D., Lopez, J., et al. (2007). euHCVdb: the European hepatitis C virus database. *Nucleic Acids Res*, 35(Database issue), D363-366.
- de Chassey, B., Navratil, V., Tafforeau, L., Hiet, M. S., Aublin-Gex, A., Agaugue, S., et al. (2008). Hepatitis C virus infection protein network. *Mol Syst Biol*, *4*, 230.
- De Clercq, E. (2004). Antiviral drugs in current clinical use. J Clin Virol, 30(2), 115-133.
- Essack, M., Radovanovic, A., Schaefer, U., Schmeier, S., Seshadri, S. V., Christoffels, A., et al. (2009). DDEC: Dragon database of genes implicated in esophageal cancer. *BMC Cancer*, 9, 219.
- Flisiak, R., & Parfieniuk, A. (2010). Investigational drugs for hepatitis C. *Expert Opin Investig Drugs*, 19(1), 63-75.

- Fowler, R., & Imrie, K. (2001). Thalidomide-associated hepatitis: a case report. Am J *Hematol*, 66(4), 300-302.
- Jelier, R., Schuemie, M. J., Veldhoven, A., Dorssers, L. C., Jenster, G., & Kors, J. A. (2008). Anni 2.0: a multipurpose text-mining tool for the life sciences. *Genome Biol*, 9(6), R96.
- Kaur, M., Radovanovic, A., Essack, M., Schaefer, U., Maqungo, M., Kibler, T., et al. (2009). Database for exploration of functional context of genes implicated in ovarian cancer. *Nucleic Acids Res*, 37(Database issue), D820-823.
- Killcoyne, S., Carter, G. W., Smith, J., & Boyle, J. (2009). Cytoscape: a communitybased framework for network modeling. *Methods Mol Biol*, 563, 219-239.
- Kuiken, C., Mizokami, M., Deleage, G., Yusim, K., Penin, F., Shin, I. T., et al. (2006). Hepatitis C databases, principles and utility to researchers. *Hepatology*, 43(5), 1157-1165.
- Kuiken, C., Yusim, K., Boykin, L., & Richardson, R. (2005). The Los Alamos hepatitis C sequence database. *Bioinformatics*, 21(3), 379-384.
- Kwofie, S. K., Radovanovic, A., Maqungo, M., Bajic, V.B., Christoffels, A. (2009, December 01–03, 2009). *Hepatitis C Virus discovery database (HCVdd): a biomedical text mining and relationship exploring knowledgebase*. Abstract presented at the ISCB Africa ASBCB Joint Conference on Bioinformatics of Infectious Diseases. Bamako, Mali.
- Lombard, Z., Tiffin, N., Hofmann, O., Bajic, V. B., Hide, W., & Ramsay, M. (2007). Computational selection and prioritization of candidate genes for fetal alcohol syndrome. *BMC Genomics*, 8, 389.
- Meredith, M., Skeels, H., Kiera, Y.Y., Meliha, Wanda, P. (2005, April 02–07, 2005). Interaction design for literature-based discovery. Paper presented at the CHI '05 Extended Abstracts on Human factors in Computing Systems Portland, USA
- Milazzo, L., Biasin, M., Gatti, N., Piacentini, L., Niero, F., Zanone Poma, B., et al. (2006). Thalidomide in the treatment of chronic hepatitis C unresponsive to alfainterferon and ribavirin. Am J Gastroenterol, 101(2), 399-402.
- Mitchell, J. A., Aronson, A. R., Mork, J. G., Folk, L. C., Humphrey, S. M., & Ward, J. M. (2003). Gene indexing: characterization and analysis of NLM's GeneRIFs. *AMIA Annu Symp Proc*, 460-464.
- Muller, H. M., Kenny, E. E., & Sternberg, P. W. (2004). Textpresso: an ontology-based information retrieval and extraction system for biological literature. *PLoS Biol*, 2(11), e309.
- Pan, H., Zuo, L., Choudhary, V., Zhang, Z., Leow, S. H., Chong, F. T., et al. (2004). Dragon TF Association Miner: a system for exploring transcription factor associations through text-mining. *Nucleic Acids Res, 32*(Web Server issue), W230-234.
- Sagar, S., Kaur, M., Dawe, A., Seshadri, S. V., Christoffels, A., Schaefer, U., et al. (2008). DDESC: Dragon database for exploration of sodium channels in human. *BMC Genomics*, 9, 622.
- Shi, L., & Campagne, F. (2005). Building a protein name dictionary from full text: a machine learning term extraction approach. *BMC Bioinformatics*, *6*, 88.
- Tiffin, N., Kelso, J. F., Powell, A. R., Pan, H., Bajic, V. B., & Hide, W. A. (2005). Integration of text- and data-mining using ontologies successfully selects disease

gene candidates. Nucleic Acids Res, 33(5), 1544-1552.

- von Wagner, M., Hofmann, W. P., Teuber, G., Berg, T., Goeser, T., Spengler, U., et al. (2008). Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection. *Hepatology*, 48(5), 1404-1411.
- Weeber, M., Klein, H., Aronson, A. R., Mork, J. G., de Jong-van den Berg, L. T., & Vos, R. (2000). Text-based discovery in biomedicine: the architecture of the DADsystem. *Proc AMIA Symp*, 903-907.
- Weeber, M., Kors, J. A., & Mons, B. (2005). Online tools to support literature-based discovery in the life sciences. *Brief Bioinform*, 6(3), 277-286.
- Weeber, M., Vos, R., Klein, H., De Jong-Van Den Berg, L. T., Aronson, A. R., & Molema, G. (2003). Generating hypotheses by discovering implicit associations in the literature: a case report of a search for new potential therapeutic uses for thalidomide. J Am Med Inform Assoc, 10(3), 252-259.
- Yusim, K., Richardson, R., Tao, N., Dalwani, A., Agrawal, A., Szinger, J., et al. (2005). Los alamos hepatitis C immunology database. *Appl Bioinformatics*, 4(4), 217-225.
- Zeuzem, S. (2008). Interferon-based therapy for chronic hepatitis C: current and future perspectives. *Nat Clin Pract Gastroenterol Hepatol*, 5(11), 610-622.
- Zeuzem, S. (2008). Interferon-based therapy for chronic hepatitis C: current and future perspectives. *Nat Clin Pract Gastroenterol Hepatol*, 5(11), 610-622.



UNIVERSITY of the WESTERN CAPE



Chapter 3: Hepatitis C Virus Protein Interaction Database (HCVpro)

UNIVERSITY of the WESTERN CAPE

3.1 ABSTRACT

It is essential to catalog characterized Hepatitis C Virus (HCV) protein-protein interaction (PPI) data and the associated plethora of vital functional information to augment the search for therapies, vaccines and diagnostic biomarkers. Hepatitis C Virus Protein Interaction Database (HCVpro) has been developed in furtherance of these goals. HCVpro contains manually verified hepatitis C virus-virus and virus-human protein interactions curated from literature and databases. HCVpro is a comprehensive and integrated HCV-specific knowledgebase housing consolidated information on PPIs, functional genomics and molecular data obtained a from variety of virus databases (VirHostNet, VirusMint, HCVdb and euHCVdb), and from BIND and other relevant biology repositories. HCVpro is further populated with information on hepatocellular carcinoma (HCC) related genes that are mapped onto their encoded cellular proteins. Incorporated proteins have been mapped onto Gene Ontologies, canonical pathways, Online Mendelian Inheritance in Man (OMIM) and extensively cross-referenced to other essential annotations. The database is enriched with exhaustive reviews on structure and functions of HCV proteins, current state of drug and vaccine development, and links to recommended journal articles. Users can query the database using specific protein identifiers (IDs), chromosomal locations of a gene, interaction detection methods, indexed PubMed sources as well as HCVpro, BIND and VirusMint IDs. The use of HCVpro is free and the resource can be accessed via http://apps.sanbi.ac.za/hcvpro/ or http://cbrc.kaust.edu.sa/hcvpro/.

3.2 Introduction

Protein-protein interactions (PPIs) are vital in orchestrating molecular cellular events and constitute the basis for multitudes of signal transduction pathways and transcriptional regulatory networks (Raman, 2010). Efforts towards elucidating HCV protein interactions through the use of proteome-wide mapping techniques and the computational construction of the entire HCV-human protein interactome map have been reported (Flajolet et al., 2000; de Chassey et al., 2008). Additionally, several other HCV research

groups have published large amounts of information on HCV PPIs and related enriched functionally analysed data vital for the understanding of HCV infection mechanisms. This progress has been facilitated by the advent of highly innovative low and high throughput techniques essential for the elucidation and characterization of protein interactions. Various experimental methods have been widely used to either screen or confirm HCV protein-protein interactions, including yeast two-hybrid (Dimitrova et al., 2003; Ahn et al., 2004; Huang et al., 2005), confocal microscopy (Tong et al., 2002; Lan et al., 2003), coimmunoprecipitation (Dimitrova et al., 2003; Wang et al., 2005), surface plasmon resonance studies (Sabile et al., 1999; Jennings et al., 2008), spectroscopy (Kang et al., 2005; Masumi et al., 2005), immunoblotting (Tan et al., 1999), cross-linking (Wang et al., 2002), affinity chromatography (Masumi et al., 2005) and 3-dimensional protein structures (Op De Beeck et al., 2000). The use of several types of methods in elucidating PPIs has led to the availability of interaction data in heterogeneous formats thus requiring standardization. In response, numerous efforts have focused on formatting the ever-increasing protein-protein interactions and associated meta-data as well as integrating them into public online repositories. The proteomics standards initiativemolecular interaction (PSI-MI) format (Hermjakob et al., 2004), a community standard data model for the representation and exchange of protein interaction data, and MIMIx, the minimum information required for reporting a molecular interaction experiment guidelines (Orchard et al., 2007) are platforms for harnessing information from structured PPI data.

Towards consolidating viral PPI data, VirusMint (Chatr-aryamontri et al., 2009) and VirHostNet (Navratil et al., 2009) databases have been developed to house viral PPI data. VirHostNet represents more than 180 distinct viral species with unique taxonomy identifications as well as a broad diversity spanning about 36 distinct viral families. VirusMint represents more than 110 different viral strains and provides PPI information on viruses involved in human infections and cancer, including adenovirus, Simian virus 40 (SV40), human papilloma viruses, Epstein–Barr virus (EBV), hepatitis B virus (HBV), hepatitis C virus (HCV), herpes viruses, influenza A virus, vaccinia virus and human immunodeficiency virus (HIV). Primarily, both VirusMint and VirHostNet are

geared towards online network visualization and analysis of integrated human viral interactome maps. A trend is emerging where databases solely dedicated to single organisms are constructed instead of multi-organism PPI databases, and a typical example is HIV-1 Human Protein Interactions Database (Fu et al., 2009). It is believed that a knowledgebase solely focused or customized to answer pertinent biological questions related to HCV has the potential to provide detailed and exhaustive information suitable to generate functional hypotheses in-silico. In this regard, this thesis describes the development of a new online hepatitis C virus protein interaction database (HCVpro), an integrated and comprehensive warehouse for storing and managing manually verified HCV virus-virus and virus-human protein interactions curated from literature and databases. HCVpro stores interaction information on human and viral interacting partners as well as meta-data, including interaction detection methods and journal articles reporting the interactions. Additionally, HCVpro contains useful contextual data and is distinct from other curated viral PPI databases because it provides: (1) consolidated PPI data from BIND (Alfarano et al., 2005) and key viral databases comprising of VirusMint and VirHostNet, (2) an integrated query platform enabling users to retrieve interaction data using HCVpro and other PPI database identifiers (BIND and MINT IDs), experiment types and journal article sources, and other genomic qualifiers, (3) useful genomic and functional information from notable HCV knowledgebases, including VBRC HCVdb (Greene et al., 2007), and euHCVdb (Combet et al., 2007), (4) compiled current knowledge on the molecular functions and biochemical features of HCV proteins, including post-translational modifications, subunit structure, domains, subcellular localization, diseases and links to essential PubMed articles, (5) a detailed review on viral drug development and challenges particularly concerning current therapy options and state of antiviral discovery, (6) genes transcriptionally regulated by NetPath curated signaling pathways (Kandasamy et al., 2010) as well as information concerning canonical pathways comprising of NCI-Nature curated pathways (Schaefer et al., 2009), KEGG (Kanehisa et al., 2010), Reactome (Matthews et al., 2009) and HPD (Chowbina et al., 2009), (7) links to external databases such as HPRD (Keshava Prasad et al., 2009), OMIM (Amberger et al., 2009), PharmGKB (Hodge et al., 2007), PDB (Berman et al., 2002), Gene Ontologies (Gene Ontology Consortium, 2010) and other essential

biological knowledgebases, and (8) comprehensive integration of high-confidence HCVrelated hepatocellular carcinoma (HCC) genes deciphered from gene expression and proteomics studies, HCC gene expression pattern from EHCO (Hsu et al., 2007) and links to other major HCC databases consisting of HCCNet (He et al., 2010) and OncoDB.HCC (Su et al., 2007).

The diverse integrated information in HCVpro can accelerate the understanding of HCV mediated molecular mechanisms and also enable postulation of appropriate hypothesis to guide discovery of new knowledge of potential use in drug discovery. Additionally, HCVpro can augment efforts towards uncovering novel HCV-related tumorigenic biomarkers with therapeutic potential by harnessing integrated data composed of PPIs, canonical pathways, and HCC-related gene expression information on the genes encoding

the host cellular proteins.



3.3 Construction and content

3.3.1 Protein interaction data curation and integration

Hepatitis C Virus-virus and virus-human protein interactions were manually curated from published peer-reviewed journal articles and database sources including BIND, VirusMint and VirHostNet. Protein interactions were annotated with associated meta-data such as experiment types used in inferring interactions and PubMed identification numbers (PMIDs) of journal articles reporting the interactions. The Entrez gene symbols of the human genes encoding the interacting cellular proteins were used as protein identifiers as well as their assigned non-redundant gene ID. The interacting viral proteins consist of 11 distinct proteins encoded by the HCV genome comprising core, E1, E2, p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B and F proteins. It must be noted that existing curation protocols were followed with particularly emphasis on that of VirHostNet (Navratil et al., 2009). Interactions curated from literature must meet the following baseline criteria to be considered: (i) physical binary interactions between HCV-HCV proteins or HCV-human proteins only; (ii) the interactions must not be predicted (iii) interactions merely mentioned in the review section of a journal article are rejected; and

(iv) there should be sufficient information in the manuscript to support the reported interaction, for example the names of the interacting protein partners and the detection methods used to infer the interactions. Interactions obtained from database sources must meet the following extra criteria: (i) the source database must be published in a peer-reviewed journal and details of the curation procedures must be accessible; (ii) each provided interaction must be assigned a unique interaction ID; (iii) interaction must be annotated with the minimum information comprising the journal article reporting the interactions, experimental methods used for detecting the interaction and protein names as well as their IDs. Interactions that do not meet the above criteria are not considered for incorporation into HCVpro.

For the purpose of HCVpro construction, each annotated protein-protein interaction curated from a specific journal article was assigned a unique HCVpro ID (appendix III). Therefore, a single type of interaction being reported by many journal sources was assigned multiple HCVpro IDs. For example, the binary interactions between HCV core and LTBR proteins were assigned two separate HCVpro IDs hcv0001 and hcv0004 since they have been reported by two different journal articles (Matsumoto et al., 1997) and (Chen et al., 1997), respectively. The hcv0001 has been annotated with interaction metadata consisting of PubMed ID 8995654, BIND ID 133606, and experiment types comprising of yeast two-hybrid, far-western blot and affinity chromatography. Similar to aforementioned convention, hcv0004 has been annotated with interaction meta-data consisting of PubMed ID 9371602, BIND IDs 181950 and 182177, and experiment types comprising of yeast two-hybrid, affinity chromatography and coimmunoprecipitation. As evident, BIND database appears to use a similar convention for annotation as core-LTBR interactions reported from separate journal articles were assigned different BIND IDs. In addition, different types of interactions being reported in a single journal article are assigned different HCVpro IDs. For example, a total of 307 unique viral-human protein interactions were obtained from proteome-wide analysis studies (de Chassey et al., 2008), although these interactions were curated from a single journal source (PubMed ID 18985028), each was assigned a unique HCVpro ID. The unique HCVpro IDs assigned to multiple protein interactions, number of experiment types confirming the interactions and multiple journal articles reporting the interactions could serve as parameters to evaluate the confidence of HCV molecular interaction data. These parameters could, for example, serve as weights for scoring binary interactions between two proteins and may be used to filter out interactions with a lower confidence threshold. Comprehensive reviews of PPI detection methods and challenges involved in curation have been presented elsewhere (Phizicky and Fields, 1995; Alfarano et al., 2005; Mathivanan et al., 2006; Berggard et al., 2007; Cusick et al., 2009; Turinsky et al., 2010).

The curated experimental methods describing PPIs were converted into PSI-MI 2.5 controlled vocabularies and assigned PSI-MI 2.5 Term IDs (Hermjakob et al., 2004) using the EMBL-EBI Ontology Lookup Service (http://www.ebi.ac.uk/ontology-lookup/) (Barsnes et al., 2010). Similar to the approach adopted by VirHostNet, HCVpro provide information concerning the two interacting protein partners, experiment type PSI-MI Term IDs and PubMed IDs of articles reporting the interactions. The PPI data can be downloaded as a tab-delimited file enabling users to convert to any machine-readable format of their choice with ease. The downloadable data could be harnessed for functional enrichment analysis and the interacting proteins could be leveraged as seed nodes for modeling protein network and pathways using third-party software such as Cytoscape and its associated plug-ins (Smoot et al., 2010). Furthermore, the data could augment efforts towards an integrated bioinformatics approach where the manually verified interactions could be employed as datasets for training machine learning models to predict protein-protein interactions as well as used in combination with a plethora of genomic data to prioritize and identify potential candidate hepatocellular carcinoma related genes, therapeutic targets and diagnostic markers associated with HCV infections. Due to HCV genetic heterogeneity, this repository provides another downloadable dataset supplemented with information on HCV genotypes/strains from which the HCV proteins were characterized and obtained from published literature, BIND and VirHostNet (appendix IV). This data can be utilized in modeling of genotype- or strain-specific interaction networks and could potentially aid in simulating the effect of genetic variability on pathobiology of HCV associated diseases.

3.3.2 HCV and human protein contextual data sources

There is an emerging consensus where HCV strain 1a (Isolate H77) has been adopted as the reference HCV (Kuiken and Simmonds, 2009), and therefore the HCV protein knowledgebase, sequences and annotations housed in VBRC HCVdb are overwhelmingly based on this strain. This approach was adopted in the development of HCVpro where HCV protein data integrated from Uniprot (UniProt Consortium, 2010), euHCVdb (Combet et al., 2007), VBRC HCVdb (Greene et al., 2007), GenBank (Benson, et al., 2009) and Entrez gene (Maglott et al., 2007) are based on this strain. Other biologically relevant HCV data were obtained from OMIM (Amberger et al., 2009), PDB (Berman et al., 2002), Gene Ontology (Gene Ontology Consortium, 2010) and published literature reviews (Penin et al., 2004; Krekulova et al., 2006; Dubuisson, 2007; Sharma, 2010). Additionally, enriched human protein functional data was obtained from Entrez gene (Maglott et al., 2007), HPRD (Keshava Prasad et al., 2009), Ensembl (Flicek et al., 2008), GenBank (Benson et al., 2009), Uniprot (Uniprot Consortium, 2010), Gene Ontology (Gene Ontology Consortium, 2010), GeneCards (Safran et al., 2010), Gene ID converter (Alibes et al., 2007), Netpath (Kandasamy et al., 2010) and Nature curated pathways (Schaefer et al., 2009). Hepatocellular carcinoma associated genes were consolidated from the following databases (appendix V): HCCNet (He et al., 2010), OncoDB.HCC (Su et al., 2007) and EHCO (Hsu et al., 2007),

In total, HCVpro consist of 621 unique HCVpro IDs comprising of 549 HCV viralhuman protein and 72 viral-viral protein interactions. The detection method and number of method distributions are shown in Figures 3.1 and 3.2 respectively. Comprehensive information on HCVpro data statistics is also provided on the HCVpro website under the menu item 'Statistics' (appendix VI).




FIGURE 3.1. DISTRIBUTION OF EXPERIMENTAL METHODS TO VERIFY PPIS.

A pie chart showing the detailed breakdown in percentage of the experiment types used in verifying the protein-protein interactions. The majority of interactions were detected using two-hybrid test (41%). Coimmunoprecipitation, pull down and other experimental techniques constituted 14%, 7% and 38% respectively.




FIGURE 3.2. PROTEIN-PROTEIN INTERACTION VERIFICATION METHOD DISTRIBUTION. A pie chart showing the detailed breakdown in percentage of the number of methods used jointly for verifying the protein-protein interactions. 64% of detected interactions were inferred by single experimental method, 16% were inferred by two methods whiles 20% were inferred by 3 or more methods.

3.3.3 Database architecture

HCVpro is a web-based resource running on platform independent Apache HTTP server with MySQL Server as the back-end and open source application programs such as PHP, HTML, CSS and JavaScript as the front-end. The database contents are stored in MySQL relational database tables and the data fields constituting the tables are linked by unique or non-redundant keys to enable cross table integration, multithreading, multipurpose and multiuser querying environments.

3.4 Utility and discussion

3.4.1 Database usage

This chapter describes the implementation of a biological repository known as HCV protein interaction database (HCVpro) that integrates a multitude of enriched data from a variety of protein and genomic platforms relevant to HCV research. This knowledgebase is intended to serve as a "one stop shop" for retrieval of comprehensive data on HCV-HCV and HCV-human protein interactions, and associated vital information relevant for functional characterization experiments. The search menu on the index page of HCVpro enables users to navigate through the enhanced or simplified user query interfaces. The user query interfaces enable users to perform searches via the HCVpro by browsing three sub query menu tabs: (i) protein select, (ii) evidence select, and (iii) identifier search. Additionally, HCVpro enables retrieval of data via string searches using gene IDs, names and symbols (Figure 3.3).




FIGURE 3.3. A DIAGRAM DISPLAYING THE HCVPRO USER QUERY INTERFACE.

This depicts a screenshot of the integrated query platform enabling users to retrieve interaction data using database identifiers, genomic qualifiers and information on experiment types as well as PubMed IDs of journal articles reporting the interactions.

3.4.1.1 Protein Select

A search via the "protein select" sub-menu by browsing any of the HCV proteins returns a list of entries comprising of HCV-HCV and HCV-human protein interaction data as well as relevant contextual data associated with both HCV and human proteins participating in the binary interactions. Users can also perform searches by using gene names of proteins to retrieve a list of viral-human protein interaction data. For example, a query with the protein GRB2 returned an entry result composed of an interaction between the oncogenic HCV protein NS5A and cellular protein GRB2 with cross-referenced links to external protein interaction databases consisting of BIND and VirusMint. The binary interaction between the two proteins was confirmed using affinity chromatography, yeast-two hybrid, coimmunoprecipitation, and immunoblotting experiments (Tan et al., 1999). An additional search option via "chromosome search" allows users to retrieve a list of genes located on a particular chromosome, which interact with HCV proteins.



3.4.1.2 Evidence Search

The "evidence search" allows users to perform searches via HCVpro using the experiment types used in inferring the interactions and the PubMed sources. By performing search using experimental evidence. a the for example coimmunoprecipitation, HCVpro returns a list of interactions that were confirmed by using coimmunoprecipitation as the experimental technique. This search menu is particularly useful during characterization of protein interactions. At a glance experimental biologists would narrow down the lists of techniques that may be used to elucidate interaction with any of the HCV proteins. For example, knowing the experimental evidence for a gene may aid in choosing an appropriate experiment type for orthologous genes or genes sharing a variety of genomic features with the retrieved genes. Users can also query HCVpro by clicking on a PubMed ID to retrieve all proteinprotein interactions reported in the corresponding journal article present in HCVpro.

3.4.1.3 Identifier Search

The "identifier search" option enables users to search HCVpro using HCVpro, VirusMint and BIND IDs. This search option therefore returns the list of interactions annotated with HCVpro ID and also integrated from both MINT and BIND databases. Allowing users to query HCVpro with other protein interaction database identifiers represents an integrated platform for data retrieval. For example, querying HCVpro using VirusMint ID MINT-16518 returned a binary interaction between NS5A and NS4A proteins confirmed using coimmunoprecipitation. This entry is designated as hcv0437 with linked BIND ID 130456. Users may click the links to freely access other relevant interaction meta-data provided by the external databases even though resources such as BIND require user registration.



3.4.2 Value of the database to prediction of diagnostic biomarkers

The usefulness of the integrated canonical pathways, Gene Ontologies and microarray expression data for exploration of HCV infection associated biomarkers having therapeutic potential has been demonstrated using the protein vimentin (for more details refer to Section C of the online manual and Figure 3.4). Vimentin was chosen as an example query since its potential as a tumor biomarker for HCV-associated hepatocellular carcinoma is widely studied. Vimentin-overexpressing and vimentinknocked-down experiments showed that cellular vimentin expression enhanced the proteasomal degradation of HCV core protein and eventually restricted HCV particle production (Nitahara-Kasahara et al., 2009). Performing a string search with the term "vimentin" via HCVpro retrieves interaction of vimentin with key oncogenic proteins HCV NS3 and core proteins. The interaction with NS3 protein was established using high throughput yeast two-hybrid screening, whilst immunoblotting and immunofluorescence microscopy were employed with other techniques to confirm interactions with HCV core protein. EHCO microarray expression data incorporated in HCVpro indicated vimentin to be significantly upregulated in HCV associated hepatocellular carcinoma (HCV-HCC) samples in 3 independent datasets (PubMed, mRNA, Protein). Clicking the HCCNet and

OncoDB.HCC links in the user interface of HCVpro retrieved information corroborating the expression levels of vimentin in HCC samples. Additionally, pathway examination pinpointed vimentin as one of the genes transcriptionally upregulated by the NetPath curated immune related IL-2 pathway (Kovanen et al., 2003). The IL-2 pathway is associated with HCV-host immunologic mechanisms (Morshed et al., 1993; Serti et al., 2010). Furthermore, IL-2 is involved in the activation of the Ras/MAPK, JAK/Stat and PI 3-kinase/Akt signaling modules. Interestingly, the JAK/Stat signaling module is a well characterized HCV infection pathway (Basu et al., 2001; Luquin et al., 2007). Vimentin is also involved in HCV infection associated TLR4 signaling (Agaugue et al., 2007) and innate immunity signaling pathways with Reactome IDs 166016 and 168249 respectively. Vimentin has been mapped onto Gene Ontology terms comprising of structural constituents of cytoskeleton, cellular component movement and protein binding. Particularly noteworthy are the cytoskeleton constituents comprising of microtubules and filaments which are implicated in the provision of tracks for the movement of HCV replication complexes (Lai et al., 2008). The significant gene expression levels in HCC patient samples coupled with binary protein interaction with notable oncogenic HCV proteins and transcriptional regulation by IL-2 signaling pathway, provide additional hints that can entice researchers to explore further the potential of vimentin as a plausible diagnostic biomarker or therapeutic target for chronic hepatitis C related HCC.

To further investigate the relevance of HCVpro to candidate disease biomarker discovery, the diagnostic utilities of the other HCVpro integrated cellular proteins were accessed. Even though changes in gene expression levels sometimes may not necessarily correlate well with protein levels in hepatic tissues or serum (Caillot et al., 2009), it could serve as a potentially useful diagnostic indicator. HCC related genes reported in all the three major HCC databases (OncoDB.HCC, HCCNet and EHCO) were selected. In all, 23 genes passed this stringent filter and literature was explored to determine if the genes have been reported previously as potential biomarkers. Six genes comprising of *APOE* (Yokoyama et al., 2006), *CD5L* (Gangadharan et al., 2007), *CTGF* (Kovalenko et al., 2009), *FAS* (El Bassiouny et al., 2008), *TP53* (Jeng et al., 2000; Peng et al., 2004; El

Bassiouny et al., 2008) and *CD81* (Schoniger-Hekele et al., 2005) were suggested or exhibited potential as biomarkers earlier, whilst nine consisting of *APOA1* (Yokoyama et al., 2006), *CDKN1A* (Kasprzak et al., 2009), *CTSB* (Lee et al., 2009), *FN1* (Yoon et al., 2006), *HSPD1* (Looi et al., 2008), *KRT19* (Chang et al., 2009), *MCL1* (Sieghart et al., 2006), *SERPINF2* (Caillot et al., 2009), and *TF* (Mas et al., 2009) have been explored in biomarker research. It appears no article has reported the diagnostic exploration or potential of the remaining eight genes comprising of *ACLY*, *AZGP1*, *DDX3X*, *FGG*, *H19*, *SIAH1*, *SERPING1* and *THBS1*, and these can serve as a rich source of data for further validation. Additionally, some of the 23 genes are associated with cancer related pathways and Gene Ontology terms. Although the approach adopted here is purely qualitative, the above discourses have amply demonstrated how an integrated repository such as HCVpro could be used to harness already existing data to elucidate predictive biomarkers with plausible therapeutic potential.



HCCNet Link	http://www.megabionet.org/hcc/detail.php?symbol=VIM	
EHCO Dataset	PubMed, mRNA, Protein	
EHCO UP regulated	3	
EHCO Down regulated	0	
Oncodb.hcc link	http://oncodb.hcc.ibms.sinica.edu.tw /hcc/display_by_gene.cgi?stable_id=ENSG00000026025& cut_off=1&option=simple	
KEGG		
Reactome Pathway ID	166016, 166054, 166058, 168138, 168142, 168176, 168179, 168181, 168188, 168249, 168256, 168898, 181438	
Nature Pathway		
Nature Pathway ID	'penenenenen'	
NCI Nature curated pathways links		
HPD link		
Netpath ID	NetPath_14	
Gene transcriptionally regulated by Netpath Pathway	IL-2 Signaling Pathway	
Netpath Description	Interleukin-2 belongs to a family of cytokines, which includes IL-4, IL-7, IL-9, IL-15 and IL-21. IL-2 signals through a receptor complex consisting of IL-2 specific IL-2 receptor alpha (CD25), IL-2 receptor beta (CD122) and a common gamma chain (?c), which is shared by all members of this family of cytokines. Binding of IL-2 activates the Ras/MAPK, JAK/Stat and PI 3-kinase/Akt signaling modules.	
Netpath Links	http://www.netpath.org/pathways?path_id=NetPath_14	
Gene Ontology	GO:0005198, GO:0005200, GO:0005515, GO:0005737, GO:0005856, GO:0005882, GO:0006928, GO:0045103	

FIGURE 3.4. A SCREENSHOT OUTPUT AFTER DATABASE SEARCH WITH VIMENTIN. A diagram displaying a portion of information on vimentin as well as links to integrated canonical pathways, Gene Ontologies and hepatocellular carcinoma databases.

3.4.3 Additional system features

For ease of usage and understanding of the various data fields incorporated in HCVpro, a user manual and frequently asked questions (FAQ) have been provided via the corresponding menu items on the HCVpro website (appendix VII and VIII). Users may send feedback by writing to the authors via the information given under 'Contact' and also submit novel interactions either before or after publications in MIMIx format (Orchard et al., 2007). In addition, links to biologically relevant HCV related and other protein interactions resources are provided to facilitate retrieval and harnessing of enriched biological data. The links are comprised of VirusMint (Chatr-aryamontri et al., 2009), VirHostNet (Navratil et al., 2009), BSFINDER (Y. Chen and Han, 2009), euHCVdb (Combet et al., 2007), LANL HCV-db (Kuiken et al., 2005), HVDB (Shin et al., 2008), VBRC HCVdb (Greene et al., 2007), BIND (Alfarano et al., 2005), DIP (Salwinski et al., 2004), HPRD (Keshava Prasad et al., 2009), INTACT (Kerrien et al., 2007), MINT (Ceol et al., 2010) and DESHCV (Kwofie et al., 2011).



UNIVERSITY of the WESTERN CAPE

3.5 Future prospects

A content curator and database administrator will constantly be improving the database based on user comments and updates will be released twice every year to accommodate the ever-growing published protein interactions. Future update will explore the possibility of incorporating features that compute the druggability of the integrated interactions, and also allow the online screening of potential drugs and cellular drug targets of interest in HCV research into HCVpro. Furthermore, data on interaction details such as domains, motifs and residues involved in the interaction will be incorporated. HCVpro will be integrated with Java web applets that support the visualization and analyze interactions such as the Java Universal Network/Graph Framework (http://jung.sourceforge.net/).

3.6 Conclusions

Herein, this report described the development of HCV protein interaction knowledgebase (HCVpro), a relational database dedicated to HCV protein interactions. It contains manually verified hepatitis C virus-virus and virus-human host cellular protein interactions obtained from other databases and curated literature. HCVpro provides multitudes of contextualized and functional genomic data pertaining to human and HCV proteins and cross-referenced links to enriched biological databases. From the aforementioned, the reported resource is therefore not an alternative to the existing panoply of protein interaction databases but could augment currents efforts aimed at elucidating the complex molecular interplay between viral and host cellular proteins after HCV infection.



3.7 References

- Agaugue, S., Perrin-Cocon, L., Andre, P., & Lotteau, V. (2007). Hepatitis C lipo-Viroparticle from chronically infected patients interferes with TLR4 signaling in dendritic cell. *PLoS One*, 2(3), e330.
- Ahn, J., Chung, K. S., Kim, D. U., Won, M., Kim, L., Kim, K. S., et al. (2004). Systematic identification of hepatocellular proteins interacting with NS5A of the hepatitis C virus. *J Biochem Mol Biol*, 37(6), 741-748.
- Alfarano, C., Andrade, C. E., Anthony, K., Bahroos, N., Bajec, M., Bantoft, K., et al. (2005). The Biomolecular Interaction Network Database and related tools 2005 update. *Nucleic Acids Res*, 33(Database issue), D418-424.
- Alibes, A., Yankilevich, P., Canada, A., & Diaz-Uriarte, R. (2007). IDconverter and IDClight: conversion and annotation of gene and protein IDs. BMC Bioinformatics, 8, 9.
- Amberger, J., Bocchini, C. A., Scott, A. F., & Hamosh, A. (2009). McKusick's Online Mendelian Inheritance in Man (OMIM). *Nucleic Acids Res*, 37(Database issue), D793-796.
- Barsnes, H., Cote, R. G., Eidhammer, I., & Martens, L. (2010). OLS dialog: an opensource front end to the ontology lookup service. *BMC Bioinformatics*, 11, 34.
- Basu, A., Meyer, K., Ray, R. B., & Ray, R. (2001). Hepatitis C virus core protein modulates the interferon-induced transacting factors of Jak/Stat signaling pathway but does not affect the activation of downstream IRF-1 or 561 gene. *Virology*, 288(2), 379-390.
- Benson, D. A., Karsch-Mizrachi, I., Lipman, D. J., Ostell, J., & Sayers, E. W. (2009). GenBank. *Nucleic Acids Res*, 37(Database issue), D26-31.
- Berggard, T., Linse, S., & James, P. (2007). Methods for the detection and analysis of

protein-protein interactions. *Proteomics*, 7(16), 2833-2842.

- Berman, H. M., Battistuz, T., Bhat, T. N., Bluhm, W. F., Bourne, P. E., Burkhardt, K., et al. (2002). The Protein Data Bank. Acta Crystallogr D Biol Crystallogr, 58(Pt 6 No 1), 899-907.
- Caillot, F., Hiron, M., Goria, O., Gueudin, M., Francois, A., Scotte, M., et al. (2009). Novel serum markers of fibrosis progression for the follow-up of hepatitis C virus-infected patients. *Am J Pathol*, 175(1), 46-53.
- Ceol, A., Chatr Aryamontri, A., Licata, L., Peluso, D., Briganti, L., Perfetto, L., et al. (2010). MINT, the molecular interaction database: 2009 update. *Nucleic Acids Res*, 38(Database issue), D532-539.
- Chang, Q., Chen, J., Beezhold, K. J., Castranova, V., Shi, X., & Chen, F. (2009). JNK1 activation predicts the prognostic outcome of the human hepatocellular carcinoma. *Mol Cancer*, *8*, 64.
- Chatr-aryamontri, A., Ceol, A., Peluso, D., Nardozza, A., Panni, S., Sacco, F., et al. (2009). VirusMINT: a viral protein interaction database. *Nucleic Acids Res*, 37(Database issue), D669-673.
- Chen, C. M., You, L. R., Hwang, L. H., & Lee, Y. H. (1997). Direct interaction of hepatitis C virus core protein with the cellular lymphotoxin-beta receptor modulates the signal pathway of the lymphotoxin-beta receptor. *J Virol*, 71(12), 9417-9426.
- Chen, Y., & Han, K. (2009). BSFINDER: finding binding sites of HCV proteins using a support vector machine. *Protein Pept Lett*, 16(4), 373-382.
- Chowbina, S. R., Wu, X., Zhang, F., Li, P. M., Pandey, R., Kasamsetty, H. N., et al. (2009). HPD: an online integrated human pathway database enabling systems biology studies. *BMC Bioinformatics*, 10 Suppl 11, S5.
- Combet, C., Garnier, N., Charavay, C., Grando, D., Crisan, D., Lopez, J., et al. (2007). euHCVdb: the European hepatitis C virus database. *Nucleic Acids Res*, 35(Database issue), D363-366.
- Cusick, M. E., Yu, H., Smolyar, A., Venkatesan, K., Carvunis, A. R., Simonis, N., et al. (2009). Literature-curated protein interaction datasets. *Nat Methods*, 6(1), 39-46.
- de Chassey, B., Navratil, V., Tafforeau, L., Hiet, M. S., Aublin-Gex, A., Agaugue, S., et al. (2008). Hepatitis C virus infection protein network. *Mol Syst Biol*, *4*, 230.
- Dimitrova, M., Imbert, I., Kieny, M. P., & Schuster, C. (2003). Protein-protein interactions between hepatitis C virus nonstructural proteins. *J Virol*, 77(9), 5401-5414.
- Dubuisson, J. (2007). Hepatitis C virus proteins. World J Gastroenterol, 13(17), 2406-2415.
- El Bassiouny, A. E., El-Bassiouni, N. E., Nosseir, M. M., Zoheiry, M. M., El-Ahwany, E. G., Salah, F., et al. (2008). Circulating and hepatic Fas expression in HCV-induced chronic liver disease and hepatocellular carcinoma. *Medscape J Med*, 10(6), 130.
- Flajolet, M., Rotondo, G., Daviet, L., Bergametti, F., Inchauspe, G., Tiollais, P., et al. (2000). A genomic approach of the hepatitis C virus generates a protein interaction map. *Gene*, 242(1-2), 369-379.
- Flicek, P., Aken, B. L., Beal, K., Ballester, B., Caccamo, M., Chen, Y., et al. (2008). Ensembl 2008. *Nucleic Acids Res, 36*(Database issue), D707-714.

- Fu, W., Sanders-Beer, B. E., Katz, K. S., Maglott, D. R., Pruitt, K. D., & Ptak, R. G. (2009). Human immunodeficiency virus type 1, human protein interaction database at NCBI. *Nucleic Acids Res*, 37(Database issue), D417-422.
- Gangadharan, B., Antrobus, R., Dwek, R. A., & Zitzmann, N. (2007). Novel serum biomarker candidates for liver fibrosis in hepatitis C patients. *Clin Chem*, 53(10), 1792-1799.
- Gene Ontology Consortium (2010). The Gene Ontology in 2010: extensions and refinements. *Nucleic Acids Res, 38*(Database issue), D331-335.
- Greene, J. M., Collins, F., Lefkowitz, E. J., Roos, D., Scheuermann, R. H., Sobral, B., et al. (2007). National Institute of Allergy and Infectious Diseases bioinformatics resource centers: new assets for pathogen informatics. *Infect Immun*, 75(7), 3212-3219.
- He, B., Qiu, X., Li, P., Wang, L., Lv, Q., & Shi, T. (2010). HCCNet: an integrated network database of hepatocellular carcinoma. *Cell Res*, 20(6), 732-734.
- Hermjakob, H., Montecchi-Palazzi, L., Bader, G., Wojcik, J., Salwinski, L., Ceol, A., et al. (2004). The HUPO PSI's molecular interaction format--a community standard for the representation of protein interaction data. *Nat Biotechnol*, 22(2), 177-183.
- Hodge, A. E., Altman, R. B., & Klein, T. E. (2007). The PharmGKB: integration, aggregation, and annotation of pharmacogenomic data and knowledge. *Clin Pharmacol Ther*, *81*(1), 21-24.
- Hsu, C. N., Lai, J. M., Liu, C. H., Tseng, H. H., Lin, C. Y., Lin, K. T., et al. (2007).
 Detection of the inferred interaction network in hepatocellular carcinoma from EHCO (Encyclopedia of Hepatocellular Carcinoma genes Online). BMC Bioinformatics, 8, 66.
- Huang, Y. P., Zhang, S. L., Cheng, J., Wang, L., Guo, J., Liu, Y., et al. (2005). Screening of genes of proteins interacting with p7 protein of hepatitis C virus from human liver cDNA library by yeast two-hybrid system. World J Gastroenterol, 11(30), 4709-4714.
- Jeng, K. S., Sheen, I. S., Chen, B. F., & Wu, J. Y. (2000). Is the p53 gene mutation of prognostic value in hepatocellular carcinoma after resection? *Arch Surg*, 135(11), 1329-1333.
- Jennings, T. A., Chen, Y., Sikora, D., Harrison, M. K., Sikora, B., Huang, L., et al. (2008). RNA unwinding activity of the hepatitis C virus NS3 helicase is modulated by the NS5B polymerase. *Biochemistry*, 47(4), 1126-1135.
- Kandasamy, K., Mohan, S. S., Raju, R., Keerthikumar, S., Kumar, G. S., Venugopal, A. K., et al. (2010). NetPath: a public resource of curated signal transduction pathways. *Genome Biol*, 11(1), R3.
- Kanehisa, M., Goto, S., Furumichi, M., Tanabe, M., & Hirakawa, M. (2010). KEGG for representation and analysis of molecular networks involving diseases and drugs. *Nucleic Acids Res*, 38(Database issue), D355-360.
- Kang, S. M., Shin, M. J., Kim, J. H., & Oh, J. W. (2005). Proteomic profiling of cellular proteins interacting with the hepatitis C virus core protein. *Proteomics*, 5(8), 2227-2237.
- Kasprzak, A., Adamek, A., Przybyszewska, W., Olejniczak, K., Biczysko, W., Mozer-Lisewska, I., et al. (2009). p21/Wafl/Cipl cellular expression in chronic longlasting hepatitis C: correlation with HCV proteins (C, NS3, NS5A), other cell-

cycle related proteins and selected clinical data. *Folia Histochem Cytobiol*, 47(3), 385-394.

- Kerrien, S., Alam-Faruque, Y., Aranda, B., Bancarz, I., Bridge, A., Derow, C., et al. (2007). IntAct--open source resource for molecular interaction data. *Nucleic Acids Res*, 35(Database issue), D561-565.
- Keshava Prasad, T. S., Goel, R., Kandasamy, K., Keerthikumar, S., Kumar, S., Mathivanan, S., et al. (2009). Human Protein Reference Database--2009 update. *Nucleic Acids Res*, 37(Database issue), D767-772.
- Kovalenko, E., Tacke, F., Gressner, O. A., Zimmermann, H. W., Lahme, B., Janetzko, A., et al. (2009). Validation of connective tissue growth factor (CTGF/CCN2) and its gene polymorphisms as noninvasive biomarkers for the assessment of liver fibrosis. J Viral Hepat, 16(9), 612-620.
- Kovanen, P. E., Rosenwald, A., Fu, J., Hurt, E. M., Lam, L. T., Giltnane, J. M., et al. (2003). Analysis of gamma c-family cytokine target genes. Identification of dualspecificity phosphatase 5 (DUSP5) as a regulator of mitogen-activated protein kinase activity in interleukin-2 signaling. *J Biol Chem*, 278(7), 5205-5213.
- Krekulova, L., Rehak, V., & Riley, L. W. (2006). Structure and functions of hepatitis C virus proteins: 15 years after. *Folia Microbiol (Praha)*, *51*(6), 665-680.
- Kuiken, C., & Simmonds, P. (2009). Nomenclature and numbering of the hepatitis C virus. *Methods Mol Biol*, 510, 33-53.
- Kuiken, C., Yusim, K., Boykin, L., & Richardson, R. (2005). The Los Alamos hepatitis C sequence database. *Bioinformatics*, 21(3), 379-384.
- Kwofie, S. K., Radovanovic, A., Sundararajan, V. S., Maqungo, M., Christoffels, A., & Bajic, V. B. (2011). Dragon exploratory system on hepatitis C virus (DESHCV). *Infect Genet Evol*, 11(4), 734-739.
- Lai, C. K., Jeng, K. S., Machida, K., & Lai, M. M. (2008). Association of hepatitis C virus replication complexes with microtubules and actin filaments is dependent on the interaction of NS3 and NS5A. J Virol, 82(17), 8838-8848.
- Lan, S., Wang, H., Jiang, H., Mao, H., Liu, X., Zhang, X., et al. (2003). Direct interaction between alpha-actinin and hepatitis C virus NS5B. *FEBS Lett*, *554*(3), 289-294.
- Lee, N. P., Chen, L., Lin, M. C., Tsang, F. H., Yeung, C., Poon, R. T., et al. (2009). Proteomic expression signature distinguishes cancerous and nonmalignant tissues in hepatocellular carcinoma. *J Proteome Res*, 8(3), 1293-1303.
- Looi, K. S., Nakayasu, E. S., Diaz, R. A., Tan, E. M., Almeida, I. C., & Zhang, J. Y. (2008). Using proteomic approach to identify tumor-associated antigens as markers in hepatocellular carcinoma. *J Proteome Res*, 7(9), 4004-4012.
- Luquin, E., Larrea, E., Civeira, M. P., Prieto, J., & Aldabe, R. (2007). HCV structural proteins interfere with interferon-alpha Jak/STAT signalling pathway. *Antiviral Res*, 76(2), 194-197.
- Maglott, D., Ostell, J., Pruitt, K. D., & Tatusova, T. (2007). Entrez Gene: gene-centered information at NCBI. *Nucleic Acids Res, 35*(Database issue), D26-31.
- Mas, V. R., Maluf, D. G., Archer, K. J., Yanek, K., Bornstein, K., & Fisher, R. A. (2009). Proteomic analysis of HCV cirrhosis and HCV-induced HCC: identifying biomarkers for monitoring HCV-cirrhotic patients awaiting liver transplantation. *Transplantation*, 87(1), 143-152.
- Masumi, A., Aizaki, H., Suzuki, T., DuHadaway, J. B., Prendergast, G. C., Komuro, K.,

et al. (2005). Reduction of hepatitis C virus NS5A phosphorylation through its interaction with amphiphysin II. *Biochem Biophys Res Commun, 336*(2), 572-578.

- Mathivanan, S., Periaswamy, B., Gandhi, T. K., Kandasamy, K., Suresh, S., Mohmood, R., et al. (2006). An evaluation of human protein-protein interaction data in the public domain. *BMC Bioinformatics*, 7 Suppl 5, S19.
- Matsumoto, M., Hsieh, T. Y., Zhu, N., VanArsdale, T., Hwang, S. B., Jeng, K. S., et al. (1997). Hepatitis C virus core protein interacts with the cytoplasmic tail of lymphotoxin-beta receptor. *J Virol*, 71(2), 1301-1309.
- Matthews, L., Gopinath, G., Gillespie, M., Caudy, M., Croft, D., de Bono, B., et al. (2009). Reactome knowledgebase of human biological pathways and processes. *Nucleic Acids Res*, *37*(Database issue), D619-622.
- Morshed, S. A., Fukuma, H., Kimura, Y., Watanabe, S., & Nishioka, M. (1993). Interferon-gamma, interleukin (IL)-2 and IL-2 receptor expressions in hepatitis C virus-infected liver. *Gastroenterol Jpn, 28 Suppl 5*, 59-66.
- Navratil, V., de Chassey, B., Meyniel, L., Delmotte, S., Gautier, C., Andre, P., et al. (2009). VirHostNet: a knowledge base for the management and the analysis of proteome-wide virus-host interaction networks. *Nucleic Acids Res, 37*(Database issue), D661-668.
- Nitahara-Kasahara, Y., Fukasawa, M., Shinkai-Ouchi, F., Sato, S., Suzuki, T., Murakami, K., et al. (2009). Cellular vimentin content regulates the protein level of hepatitis C virus core protein and the hepatitis C virus production in cultured cells. *Virology*, 383(2), 319-327.
- Op De Beeck, A., Montserret, R., Duvet, S., Cocquerel, L., Cacan, R., Barberot, B., et al. (2000). The transmembrane domains of hepatitis C virus envelope glycoproteins E1 and E2 play a major role in heterodimerization. *J Biol Chem*, 275(40), 31428-31437.
- Orchard, S., Salwinski, L., Kerrien, S., Montecchi-Palazzi, L., Oesterheld, M., Stumpflen, V., et al. (2007). The minimum information required for reporting a molecular interaction experiment (MIMIx). *Nat Biotechnol*, 25(8), 894-898.
- Peng, S. Y., Chen, W. J., Lai, P. L., Jeng, Y. M., Sheu, J. C., & Hsu, H. C. (2004). High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. *Int J Cancer*, 112(1), 44-50.
- Penin, F., Dubuisson, J., Rey, F. A., Moradpour, D., & Pawlotsky, J. M. (2004). Structural biology of hepatitis C virus. *Hepatology*, 39(1), 5-19.
- Phizicky, E. M., & Fields, S. (1995). Protein-protein interactions: methods for detection and analysis. *Microbiol Rev*, 59(1), 94-123.
- Raman, K. (2010). Construction and analysis of protein-protein interaction networks. *Autom Exp*, 2(1), 2.
- Sabile, A., Perlemuter, G., Bono, F., Kohara, K., Demaugre, F., Kohara, M., et al. (1999). Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates. *Hepatology*, 30(4), 1064-1076.
- Safran, M., Dalah, I., Alexander, J., Rosen, N., Iny Stein, T., Shmoish, M., et al. (2010). GeneCards Version 3: the human gene integrator. *Database (Oxford), 2010*, baq020.
- Salwinski, L., Miller, C. S., Smith, A. J., Pettit, F. K., Bowie, J. U., & Eisenberg, D.

(2004). The Database of Interacting Proteins: 2004 update. *Nucleic Acids Res,* 32(Database issue), D449-451.

- Schaefer, C. F., Anthony, K., Krupa, S., Buchoff, J., Day, M., Hannay, T., et al. (2009). PID: the Pathway Interaction Database. *Nucleic Acids Res*, 37(Database issue), D674-679.
- Schoniger-Hekele, M., Hanel, S., Wrba, F., & Muller, C. (2005). Hepatocellular carcinoma--survival and clinical characteristics in relation to various histologic molecular markers in Western patients. *Liver Int*, 25(1), 62-69.
- Serti, E., Doumba, P. P., Thyphronitis, G., Tsitoura, P., Katsarou, K., Foka, P., et al. (2010). Modulation of IL-2 expression after uptake of hepatitis C virus nonenveloped capsid-like particles: the role of p38 kinase. *Cell Mol Life Sci*, 68(3), 505-522.
- Sharma, S. D. (2010). Hepatitis C virus: molecular biology & current therapeutic options. *Indian J Med Res*, 131, 17-34.
- Shin, I. T., Tanaka, Y., Tateno, Y., & Mizokami, M. (2008). Development and public release of a comprehensive hepatitis virus database. *Hepatol Res*, *38*(3), 234-243.
- Sieghart, W., Losert, D., Strommer, S., Cejka, D., Schmid, K., Rasoul-Rockenschaub, S., et al. (2006). Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. *J Hepatol*, 44(1), 151-157.
- Smoot, M. E., Ono, K., Ruscheinski, J., Wang, P. L., & Ideker, T. (2010). Cytoscape 2.8: new features for data integration and network visualization. *Bioinformatics*, 27(3), 431-432.
- Su, W. H., Chao, C. C., Yeh, S. H., Chen, D. S., Chen, P. J., & Jou, Y. S. (2007). OncoDB.HCC: an integrated oncogenomic database of hepatocellular carcinoma revealed aberrant cancer target genes and loci. *Nucleic Acids Res*, 35(Database issue), D727-731.
- Tan, S. L., Nakao, H., He, Y., Vijaysri, S., Neddermann, P., Jacobs, B. L., et al. (1999). NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptorbound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. *Proc Natl Acad Sci U S A*, 96(10), 5533-5538.
- Tong, W. Y., Nagano-Fujii, M., Hidajat, R., Deng, L., Takigawa, Y., & Hotta, H. (2002). Physical interaction between hepatitis C virus NS4B protein and CREB-RP/ATF6beta. *Biochem Biophys Res Commun*, 299(3), 366-372.
- Turinsky, A. L., Razick, S., Turner, B., Donaldson, I. M., & Wodak, S. J. (2010). Literature curation of protein interactions: measuring agreement across major public databases. *Database (Oxford)*, 2010, baq026.
- UniProt Consortium (2010). The Universal Protein Resource (UniProt) in 2010. Nucleic Acids Res, 38(Database issue), D142-148.
- Wang, C., Gale, M., Jr., Keller, B. C., Huang, H., Brown, M. S., Goldstein, J. L., et al. (2005). Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. *Mol Cell*, 18(4), 425-434.
- Wang, Q. M., Hockman, M. A., Staschke, K., Johnson, R. B., Case, K. A., Lu, J., et al. (2002). Oligomerization and cooperative RNA synthesis activity of hepatitis C virus RNA-dependent RNA polymerase. *J Virol*, 76(8), 3865-3872.
- Yokoyama, Y., Kuramitsu, Y., Takashima, M., Iizuka, N., Terai, S., Oka, M., et al.

(2006). Protein level of apolipoprotein E increased in human hepatocellular carcinoma. *Int J Oncol*, 28(3), 625-631.

Yoon, S. Y., Kim, J. M., Oh, J. H., Jeon, Y. J., Lee, D. S., Kim, J. H., et al. (2006). Gene expression profiling of human HBV- and/or HCV-associated hepatocellular carcinoma cells using expressed sequence tags. *Int J Oncol*, 29(2), 315-327.



UNIVERSITY of the WESTERN CAPE



4.1 Research aims revisited

This section presents solutions to the research aims posed in this thesis.

4.1.1 Aim 1

Development of Hepatitis C Virus (HCV)-focused web-based text mining resource.

Solution

Chapter 2 of this thesis describes the development of Hepatitis C Virus (HCV) customized online text mining resource, the Dragon Exploratory System on Hepatitis C Virus (DESHCV) (Kwofie et al., 2011). DESHCV is a dictionary lookup system that employs named concept recognition to locate concepts present in a list of HCV-related PubMed abstracts. Two concepts are suggested to be associated when both concepts co-occur in a particular PubMed abstract. As part of the DESHCV implementation, the existing data files in the dragon exploratory system were enriched with HCV-related biomedical concepts, including their name variants and symbols. The concepts consist of the names of biomedical entities that were assigned to variety of dictionaries, including "human genes and proteins", "metabolites and enzymes", "pathways", "chemicals with pharmacological effects", "Hepatitis C Virus concepts", and "disease concepts". DESHCV is therefore a literature-based discovery resource and enables users to query the system using specified keywords, phrases and concept names to retrieve text-derived association networks, hypothesis and a list of PubMed abstracts containing colour-coded tagged concepts.

4.1.2 Research aim 2

Development of HCV online protein knowledgebase.

Solution

Chapter 2 of this thesis described the development of an online knowledgebase, known as the Hepatitis C Virus Protein Interaction Database (HCVpro). HCVpro is a relational database that houses manually verified HCV-HCV and HCV-human protein interactions obtained from external databases and curated from published biomedical literature as well as their associated metadata. A user query via HCVpro retrieves comprehensive information on protein-protein interactions (PPIs), as well as rich data on functional annotations, hepatocellular carcinoma (HCC) related genes, drug development, canonical pathways, and cross-referenced links to other essential biological databases.



4.1.3 Research aim 3

Harnessing the myriad of data in the developed knowledgebases to facilitate generation of functional hypothesis of therapeutic relevance.

Solution

DESHCV is a text mining system that computes possible association between concepts and additionally generate hypothesis that can lead to potentially novel discovery. DESHCV has been used to reproduce the already confirmed thalidomide-chronic hepatitis C hypothesis (Weeber et al., 2003). This system has also been employed to suggest a novel hypothesis composed of thalidomide-amantadine association. The generated hypotheses were influenced by Swanson's ABC model and the open discovery approach (Swanson, 1991; Weeber et al., 2001).

HCVpro is an integrated database composed of myriads of data that can be harnessed to generate potentially testable baseline hypothesis or obtain clues that may pinpoint to a

novel research paradigm to aid in circumventing HCV therapeutic challenges. For instance, by combining information on canonical pathways, interactions with key oncogenic HCV proteins and gene expression levels in HCC samples, a clue was obtained which corroborate the need to further support the ongoing exploration of vimentin as a potential therapeutic target or diagnostic biomarker. Additionally, the diagnostic potential of a list of 23 HCC associated genes obtained from database sources were investigated using literature exploration. Some of the 23 investigated genes were related to cancer associated Gene Ontology terms and pathways. Apparently, no literature was found to have provided results on the diagnostic potential of the following eight genes: *ACLY*, *AZGP1*, *DDX3X*, *FGG*, *H19*, *SIAH1*, *SERPING1* and *THBS1*. Using this simple interpretive approach, it is therefore tempting to suggest that the above-mentioned eight genes can be investigated to unearth any diagnostic or therapeutic role.



4.2 Research contribution

Understanding the mechanisms underlying viral pathogenesis requires robust approaches, including the provision of resources that integrate multiple biologically relevant data to augment HCV research. The text mining system and HCV protein knowledgebase developed in pursuance of the research aims reported here provide potential platforms that can aid researchers with harvested data with which to generate biologically relevant hypotheses or formulate plausible research questions worthy of investigation. A significant amount of biological data originating from both small- and large-scale experiments are reported in published biomedical text. Therefore, harvesting these data in a structured format for usage by researchers is critical. The primary data source of DESHCV is published biomedical text. HCVpro harvests data from both literature and external databases. The availability of both DESHCV and HCVpro is very timely because these resources provide enriched consolidated HCV-specific information.

Currently, patients infected with certain HCV genotypes do not derive maximum therapeutic benefits from the standard regimen composed of interferon alpha and ribavirin. A number of pharmacological targets are being investigated for HCV therapy, including cellular receptors mediating HCV entry, factors facilitating HCV replication and assembly, and intracellular pathways (Sato et al., 2008). The essential benefits of computational techniques to support investigation of HCV proteins as targets for drug development have been highlighted (Lahm et al., 2002). DESHCV utilizes biomedical entities such as HCV proteins, cellular receptors and pathways as query concepts to generate functional hypothesis. By adding user intuition, the search for therapeutic targets with potential to improve sustained virologic response rates, and reduce undesirable side effects can be enhanced.

Patients suffering from chronic hepatitis C infection may eventually develop HCVinduced HCC. HCVpro is populated with protein interaction data consolidated with information on HCC genes and this can be harnessed to leverage the current search for plausible non-invasive diagnostic markers as well as therapeutic targets. Computed topological features obtained from protein networks generated using the interaction datasets provided by HCVpro can be combined with the integrated genomic data to prioritize candidate HCC related genes.

WESTERN CAPE

4.3 Limitations and future work

4.3.1 Limitations and future work on DESHCV

The heuristic filtering modules of DESHCV will be augmented with simple handcrafted rules to enhance the ability of the system to recognize named concepts with poorly defined morphological features. Associations suggested by DESHCV must be confirmed by manual verification of accompanying literature and also via laboratory experimentation when necessary. The updated version of DESHCV will utilize pattern-matching based approaches to predict the types of association that exist between entities within suggested hypothesis or relationships. Full text articles were not used as source of data but rather abstracts. Unfortunately, abstracts provide only a bird's eye view of the summarized results. Currently, the possibility of combining both abstracts and full text journal articles as sources of text corpora in DESHCV is being explored. Additionally,

robust systems will be designed to circumvent challenges that arise as a result of tokenization and indexing of full text documents.

4.3.2 Limitations and future work on HCVpro

HCVpro does not provide interaction reliability scores nor support online exploitation of the incorporated data. With possible increase in interaction metadata in the near future, protein interactions will be assigned with reliability scores. Subsequent versions of HCVpro will accommodate the online visualization and manipulation of protein interactions via the use of embedded Java web applets. HCVpro will be integrated with separate modules that allow online screening of drugs and drug targets, as well as computing of the druggability of incorporated interactions.



4.4 References

- Kwofie, S. K., Radovanovic, A., Sundararajan, V. S., Maqungo, M., Christoffels, A., & Bajic, V. B. (2011). Dragon exploratory system on hepatitis C virus (DESHCV). *Infect Genet Evol*, 11(4), 734-739.
- Lahm, A., Yagnik, A., Tramontano, A., & Koch, U. (2002). Hepatitis C virus proteins as targets for drug development: the role of bioinformatics and modelling. *Curr Drug Targets*, 3(4), 281-296.
- Sato, K., Takagi, H., Ichikawa, T., Kakizaki, S., & Mori, M. (2008). Emerging therapeutic strategies for hepatitis C virus infection. *Curr Mol Pharmacol*, 1(2), 130-150.
- Swanson, D. R. (1991). *Complementary structures in disjoint science literatures*. Paper presented at the Proceedings of the 14th Annual International ACM SIGIR Conference on Research and Development in Information Retrieval.
- Weeber, M., Klein, H., De Jong-van den Berg, L. T. W. and Vos, R. (2001). Using concepts in literature-based discovery: Simulating Swanson's Raynaud–fish oil and migraine–magnesium discoveries. J. Amer. Soc. Inf. Sci. Tech, 52(7), 254– 262.
- Weeber, M., Vos, R., Klein, H., De Jong-Van Den Berg, L. T., Aronson, A. R., & Molema, G. (2003). Generating hypotheses by discovering implicit associations in the literature: a case report of a search for new potential therapeutic uses for thalidomide. J Am Med Inform Assoc, 10(3), 252-259.



UNIVERSITY of the WESTERN CAPE

Appendix I (Chapter 2)

User Manual for Dragon Exploratory System on Hepatitis C Virus (DESHCV)

Section A

A typical user query interface showing the various utility components. DESHCV is free for academic and non-profit users via http://apps.sanbi.ac.za/DESHCV/ and its mirror site http://cbrc.kaust.edu.sa/deshcv/

- Const	2 Dragon Exploratory System on Hepatitis C Virus (DESHCV)
Home Q	uery Contributors	
Home Page		HepatitisC 🔻
Abstracts		
Summary of results	Easy graphical visualisation of selected results.	
Concept list		
Frequency of documents		
Frequency of pairs	A CONTRACTOR OF CONTRACTOR	
Document Clustering	UNIVERSITY of the	
Recommended Reading	FESTERN CAPE	
Sentences Summary		
Download	and the second sec	
Concept list spreadsheet		
Pair list spreadsheet Search Concepts Abstracts Association Search	The Dragon Exploratory System on Hepatitis C Virus (DESHCV), a biomedical text-mining and relationship exploring knowledgebase is the first reported comprehensive Hepatitis C Virus (HCV) customized biomedical text-mining based online web resource. Users can retrieve information using specified concepts, keywords and phrases. Each concept search generates text-derived association networks and hypotheses which could be tested to identify potentially novel relationship between different concepts.	
Type keywords to search, use quotes for "phrase search".	The user also has the option of either viewing the retrieved abstracts with or without embedded tagged concepts. Biomedical concepts related to HCV are retrieved from the following dictionaries: "Human genes and proteins", "Metabolites and Enzymes", "Pathways", "Chemicals with pharmacological effects", and "Disease concepts". This approach may lead to the identification of possible new discovery and could augment efforts in the search for diagnostic or even therapeutic targets. DESHCV is free for academic and non-profit users.	

Figure 1. DESHCV user Interface

1. For Abstract and Concept queries

[For further details consult sections B, C and D of this manual]

2. Help

Click on help menu for detailed explanations of concepts and help manual on DESHCV usage.

Section B: Abstract query

,	Allows access to simplified user query interface	Help Contact
×1 0	Dra. Contributors	gon Exploratory System on Hepatitis C Virus (DESHCV)
Query Page		HepatitisC 🗸
Abstracts		
Summary of results	T	
Concept list		Abstract
Frequency of documents		searches
Frequency of pairs		
Document Clustering		Concepts O Abstracts 💿
Recommended Reading	UNIVE	R hypervariability
Sentences Summary	WESTR	
Download	WLSII	KN UAIL
Concept list spreadsheet	Concent O	uery: Enter a concept name(s); for example : NS5A or "P7 Protein"
Pair list spreadsheet	Conceptia	Jery, Enter a concept name(s), for example . NSSA of 17 Protein
Search	Abst	ract Query: Enter a keyword(s); for example : hypervariability
Concepts Abstracts Search		
Type keywords to search, use quotes for "phrase search".		

Figure 2. Displays the simplified abstract query interface

A typical Analysis Flow

Type any keyword for example: hypervariability -> check abstract radio button -> click on search -> a display of PubMed abstracts with tagged colour-coded concepts

Section C: Concept query





Figure 3. Displays the simplified concept query interface

A typical Analysis Flow

Type any concept name for example: "F protein" -> check concept radio button -> click on search -> a graphical display of colour-coded concept

Concept Search Output and Analysis Flow



1. Concept query term "F protein"

2. Type: F protein -> click on either display as dictionary or table -> click on concepts search button ->concept lists output

Note: do not re-type F protein if it has been queried already (this is an illustration)

3. Lists of the various color-coded concepts assigned to their respective dictionaries. Users can retrieve cross-referenced annotations by clicking on any of the concepts.

Green: Human proteins and genes

Light pink: Metabolites and enzymes

Blue: Pathways

Yellow: Chemicals with Pharmacological effects

Purple: Diseases concepts

4. Visualization

Network generator: click on draw network -> generates a network of interconnected concepts

Hypothesis Generator: click on show hypothesis -> generates correlated concepts in a graphical format as hypothesis

Download: click on table download -> retrieves a list of concepts in a CSV format

Interactive Association Map




Figure 5. Graphical display of interacting concepts

5. Association Map Analysis flow

Click on any of the specified dictionaries (For example: metabolites and enzymes) -> click on draw graph -> redraws the graph with the newly defined concepts.

Buttons

Ignore links less than: enable the user to display the network according to the number of links.

Paper size: enables the user to resize the map by choosing from a range of A0 to A5.

Details [%]: enable the user to enhance the visualization clarity by varying the detail slider.

6. Indicates the number of occurrences of the selected concept in PubMed abstracts. Clicking on the link retrieves the related PubMed abstracts.

Note: The network consist of proposed correlations and the user is required to manually verify the abstract to either reject or accept the suggested association

Hypothesis Generator

UNIVERSITY of the

Generate implicit relationships between disjunct literatures associated with concepts. This proposed hypothesis must be manually verified by consulting the linked PubMed abstracts




Figure 6. Graphical display of generated hypothesis

7. Buttons:

Frequency Sort: enable users to sort the generated hypothesis according to the frequency of occurrence of the concepts.

Name Sort: enable users to retrieve the generated hypothesis in an alphabetical order.

Graph: enables users to visualize the generated hypothesis in an interactive map

Text: displays the hypothesis in a textual format

Manual Test: by checking on this button, users are required to manually verify the abstract to ascertain the veracity of the proposed hypothesis.

Auto test: automatically verifies the abstracts to ascertain whether the proposed correlation suggested via the hypothesis has been reported in PubMed abstracts.

8. This drop down menu enables users to select dictionaries and associated concepts with which to generate the hypothesis. This concept is known as the linking term since it links the starting and the targets terms respectively.

According to Figure 6:

Starting term: F protein belongs to the human proteins and genes dictionary **Linking term:** Hepatocellular Carcinoma belongs to the disease dictionary **Target term:** Any Concept in the pharmacological chemicals dictionary

9. Click on Get hypothesis -> generates hypothesis according to specified dictionary concepts

10. Allow browsing of hypothesis by page

11. Displays the number of PubMed abstracts reporting the association

12. Indicate whether the displayed correlation has been reportedNot confirmed: Hypothesis has not been reported which could mean a novel discoveryFound: 68, means 68 abstracts have reported the hypothesis

Section D: Simulated concept query examples

1. Concept query: "Thalidomide"




Figure 7. A screenshot montage of thalidomide concept query. This displays both the tabular and graphical output of query. Each concept is assigned a color according to its dictionary. Concepts belonging to the same dictionary are grouped together in the tabular format. The association map displays a network of interaction nodes consisting of concepts.

2. Thalidomide-Chronic Hepatitis C Association

Generate concept query for "thalidomide" -> Click on Get hypothesis -> generates hypothesis -> Specify the dictionaries as indicated in figure 8 and re-generate hypothesis. -> Click on the linked abstract to verify the hypothesis. -> Explore results for potential novel insights.




Figure 8. A screenshot montage showing thalidomide-chronic hepatitis C hypothesis. This displays the implicit relationship existing between the two concepts. The red arrow linking the hypothesis and PubMed abstract displays the verification of the hypothesis. The yellow dash lines and the white question mark sign displays the implicit relationship existing between the two concepts.

3. Thalidomide-Amantadine Association

Generate concept query for "thalidomide" -> Click on Get hypothesis -> generates hypothesis -> Specify the dictionaries as indicated in figure 9 and re-generate hypothesis. -> Explore results for potential novel insights.




Figure 9. A screenshot montage displaying thalidomide-amantadine hypothesis. The yellow dash lines and the white question mark sign displays the implicit relationship existing between the two concepts.

Appendix II (Chapter 2)

Frequently asked questions (FAQ)

1. What is DESHCV?

Dragon Exploratory System on Hepatitis C Virus (DESHCV) is the first reported comprehensive Hepatitis C Virus (HCV) customized biomedical text-mining based online web resource. A list of abstracts retrieved via PubMed database using specific keywords searches related to HCV were processed based on concept recognition of concepts from several dictionaries. It is a tool with the potential to assist in discovering associations between biomedical concepts and could lead to new research focus and possible novel discoveries.

2. What are the benefits of using DESHCV?

The web query interface enables retrieval of information using specified concepts, keywords and phrases, generating text-derived association networks and hypotheses which could be tested to identify potentially novel relationship between different concepts.

3. Which dictionaries can be retrieved from DESHCV?

Biomedical concepts related to HCV are retrieved from the following dictionaries: "Human genes and proteins", "Metabolites and Enzymes", "Pathways", "Chemicals with pharmacological effects", and "Disease concepts".

4. What makes DESHCV unique?

DESHCV contains pre-compiled dictionaries enriched with biomedical concepts pertaining to HCV proteins, their name variants and symbols to make it suitable for targeted information exploration and knowledge extraction as focused on HCV.

5. Can I download the query results retrieved from the DESHCV?

Yes, you can download the concept list and pair list spreadsheet. And also the user has the option of downloading the retrieved table of concepts for further analysis. The user may right-click on the images or figures generated to download.

6. Are there any limitations in the usage of DESHCV?

Yes, associations generated between paired concepts are inferred from co-occurrences and may not necessarily relate to any molecular functionality. Users are required to manually confirm the text accompanying the hypothesis to either accept or reject the suggested hypothesis.

7. Are there any future updates or modification in the pipeline?

Yes, we would like to integrate Blast and identifier queries to enhance querying capabilities of DESHCV. The possibility of integrating full text document is currently being explored and could be added to the database as a separate feature. The database would be updated every six months to meet the demands of ever increasing PubMed records related to HCV

WESTERN CAPE

8. Is there a help manual on DESHCV?

Yes, a help manual has been developed to ease the exploration of this database and can be accessed by clicking the help menu on index page (http://apps.sanbi.ac.za/DESHCV/) or via http://apps.sanbi.ac.za/DESHCV/help.pdf/.

9. To whom can I report a bug or discrepancy?

Please refer all queries via:

http://apps.sanbi.ac.za/DESHCV/Contact.php

Appendix III (Chapter 3)

Annotated protein-protein interactions assigned with HCVpro IDs and experimental evidence mapped onto PSI-MI term IDs.

		Molecule B Gene	Molecule		
HCVpro ID	Molecule A	Symbols	B Gene ID	PMID	Experimental Evidence (PSI-MI Term ID)
hcv0001	CORE	LTBR	4055	8995654	Two Hybrid Test (MI:0018); Far-Western blot (MI:0047); Affinity Chromatography (MI:0004)
hcv0002	CORE	APOA2	336	9037030	Confocal microscopy (MI:0663)
hcv0003	CORE	TP53	7157	9110985	Mutational analysis (MI:0074)
hcv0004	CORE	LTBR	4055	9371602	Two Hybrid Test (MI:0018); Coimmunoprecipitation (MI:0019); Affinity Chromatography (MI:0004) Two Hybrid Test (MI:0018); GST pull-down
hcv0005	CORE	HNRNPK	3190	9651361	(MI:0059); Far-Western blot (MI:0047); Coimmunoprecipitation (MI:0019); Affinity Chromatography (MI:0004)
hcv0006	CORE	CORE	951475	9851697	Two Hybrid Test (MI:0018); Mass spectrometry (MI:0943); Gel filtration (MI:0071)
hcv0007	CORE	DDX3X	1654	10074132	Two Hybrid Test (MI:0018); Coimmunoprecipitation (MI:0019); GST pull- down (MI:0059) Two Hybrid Test (MI:0018); GST pull-down
hcv0008	CORE	DDX3X	1654	10329544	(MI:0059); Affinity Chromatography (MI:0004) Two Hybrid Test (MI:0018); Affinity
hcv0009	CORE	DDX3X	1654	10336476	Chromatography (MI:0004); Immunostaining (MI:0022)
hcv0010	CORE	APOA2	336	10498661	Two Hybrid Test (MI:0018); Confocal microscopy (MI:0663); surface plasmon resonance (MI:0107); Colocalization (MI:0403)
hcv0011	CORE	TP53	7157	10544138	Coimmunoprecipitation (MI:0019); GST pull- down (MI:0059); Far-Western blot (MI:0047); Mutational analysis (MI:0074); Affinity Chromatography (MI:0004); Colocalization (MI:0403)
hcv0012	CORE	YWHAB	7529	10644344	Two Hybrid Test (MI:0018); Colocalization (MI:0403); Coimmunoprecipitation (MI:0019); Affinity Chromatography (MI:0004)
hcv0013	CORE	YWHAZ	7534	10644344	Two Hybrid Test (MI:0018); GST pull-down (MI:0059); Coimmunoprecipitation (MI:0019); Western blot (MI:0113); Affinity Chromatography (MI:0004)
hcv0014	CORE	CREB3	10488	10675342	Two Hybrid Test (MI:0018); Coimmunoprecipitation (MI:0019); GST pull- down (MI:0059)
hcv0015	CORE	CORE	951475	10721731	Two Hybrid Test (MI:0018)
hcv0016	CORE	CDKN1A	1026	10873631	GST pull-down (MI:0059); Mutational analysis (MI:0074); Affinity Chromatography (MI:0004)
hcv0017	CORE	TAF11	6882	10924497	GST pull-down (MI:0059)
hcv0018	CORE	TP53	7157	10924497	Western blot (MI:0113); GST pull-down (MI:0059)
hcv0019	CORE	C1QBP	708	11086025	Two Hybrid Test (MI:0018); GST pull-down (MI:0059)
hcv0020	CORE	TNFRSF1A	7132	11226577	GST pull-down (MI:0059); Kinase assay (MI:0424) (MI:0424); Affinity Chromatography (MI:0004)
hcv0021	CORE	FADD	8772	11336543	Coimmunoprecipitation (MI:0019); GST pull- down (MI:0059)

					Western blot (MI:0113); GST pull-down
hcv0022	CORE	TNF	7124	11374864	(MI:0059); Coimmunoprecipitation (MI:0019) Western blot (MI:0113); GST pull-down
hcv0023	CORE	TRADD	8717	11374864	(MI:0059); Coimmunoprecipitation (MI:0019)
hcv0024	CORE	TRAF2	7186	11374864	Western blot (MI:0113); GST pull-down (MI:0059); Coimmunoprecipitation (MI:0019)
hcv0025	CORE	RXRA	6256	11915042	GST pull-down (MI:0059); Coimmunoprecipitation (MI:0019)
110 00023	COKE	KAKA	0230	11913042	Coimmunoprecipitation (MI:0019) Coimmunoprecipitation (MI:0019); Western blot
hcv0026	CORE	STAT3	6774	12208879	(MI:0113); GST pull-down (MI:0059) Two Hybrid Test (MI:0018);
hcv0027	CORE	TSN	7247	12532453	Coimmunoprecipitation (MI:0019)
hcv0028	CORE	FUNDC2	65991	12665903	Two Hybrid Test (MI:0018)
hcv0029	CORE	TP73	7161	12730672	Coimmunoprecipitation (MI:0019); Mutational analysis (MI:0074); Immunostaining (MI:0022)
hcv0030	CORE	TP53	7157	12730672	Coimmunoprecipitation (MI:0019)
hcv0031	CORE	JAK1	3716	12764155	Coimmunoprecipitation (MI:0019); Western blot (MI:0113)
					Coimmunoprecipitation (MI:0019); Western blot
hcv0032	CORE	JAK2	3717	12764155	(MI:0113) Immunoblotting (MI:0113);
hcv0033	CORE	FAS	355	12919737	Coimmunoprecipitation (MI:0019)
					Immunofluorescence (MI:0022); Confocal microscopy (MI:0663); GST pull-down (MI:0059); Immunoblotting (MI:0113); Coimmunoprecipitation (MI:0019); Western blot
hcv0034	CORE	CCNH	902	14711830	(MI:0113); Immunostaining (MI:0022)
hcv0035	CORE	TBP	6908	14730212	Affinity Chromatography (MI:0004) Two Hybrid Test (MI:0018); Affinity
hcv0036	CORE	TP53BP2	7159	14985081	Chromatography (MI:0004); Communoprecipitation (MI:0019); Immunostaining (MI:0022) Communoprecipitation (MI:0019); GST pull-
hcv0037	CORE	SMAD3	4088	15334054	down (MI:0059); Affinity Chromatography (MI:0004)
hcv0038	CORE	EP300	2033	15380363	Coimmunoprecipitation (MI:0019); GST pull- down (MI:0059); Western blot (MI:0113); Affinity Chromatography (MI:0004)
hcv0039	CORE	CREBBP	1387	15380363	GST pull-down (MI:0059); Western blot (MI:0113); Affinity Chromatography (MI:0004)
hcv0040	CORE	TLR2 HLA-A	7097	15521019 15681828	Enzyme-linked immunosorbent assay (MI:0411); Electrophoretic mobility shift assay (MI:0413); Western blot (MI:0113); Kinase assay (MI:0424) (MI:0424); Confocal microscopy (MI:0663); Flow cytometry (MI:0054); Colocalization (MI:0403) Fluorescence-activated cell sorting (MI:0054); Immunostaining (MI:0022)
hcv0042	CORE	HLA-E	3133	15681828	Fluorescence-activated cell sorting (MI:0054); Immunostaining (MI:0022)
					Coimmunoprecipitation (MI:0019); Western blot
hcv0043	CORE	STAT1	6772	15825084	(MI:0113) 2-DE (MI:0982); Mass spectrometry (MI:0943);
hcv0044	CORE	ACP1	52	15846844	Immunoblotting (MI:0113); Immunofluorescence (MI:0022)
hcv0045	CORE	CFL1	1072	15846844	2-DE (MI:0982); Mass spectrometry (MI:0943); Immunoblotting (MI:0113); Immunofluorescence (MI:0022) 2-DE (MI:0982); Mass spectrometry (MI:0943);
hcv0046	CORE	FKBP7	51661	15846844	Immunoblotting (MI:0113); Immunofluorescence (MI:0022)
hcv0047	CORE	HSPD1	3329	15846844	2-DE (MI:0982); Mass spectrometry (MI:0943); Immunoblotting (MI:0113); Immunofluorescence (MI:0022)
hcv0048	CORE	KRT18	3875	15846844	2-DE (MI:0982); Mass spectrometry (MI:0943); Immunoblotting (MI:0113); Immunofluorescence (MI:0022)

					2-DE (MI:0982); Mass spectrometry (MI:0943);
					Immunoblotting (MI:0113); Immunofluorescence
hcv0049	CORE	KRT19	3880	15846844	(MI:0022) 2-DE (MI:0982); Mass spectrometry (MI:0943);
					Immunoblotting (MI:0113); Immunofluorescence
hcv0050	CORE	KRT8	3856	15846844	(MI:0022) 2-DE (MI:0982); Mass spectrometry (MI:0943);
					Immunoblotting (MI:0113); Immunofluorescence
hcv0051	CORE	SLC22A7	10864	15846844	(MI:0022)
					2-DE (MI:0982); Mass spectrometry (MI:0943); Immunoblotting (MI:0113); Immunofluorescence
hcv0052	CORE	TATDN1	83940	15846844	(MI:0022)
					2-DE (MI:0982); Mass spectrometry (MI:0943); Immunoblotting (MI:0113); Immunofluorescence
hcv0053	CORE	GLRX3	10539	15846844	(MI:0022)
					2-DE (MI:0982); Mass spectrometry (MI:0943); Immunoblotting (MI:0113); Immunofluorescence
hcv0054	CORE	VIM	7431	15846844	(MI:0022)
hcv0055	CORE	NPM1	4869	16170350	Coimmunoprecipitation (MI:0019); GST pull- down (MI:0059)
hcv0056	CORE	YY1	7528	16170350	Coimmunoprecipitation (MI:0019); GST pull- down (MI:0059)
10057	CODE	DM	5271	1(222222	Western blot (MI:0113); Coimmunoprecipitation
hcv0057	CORE	PML	5371	16322229	(MI:0019); Colocalization (MI:0403) Confocal microscopy (MI:0663);
					Immunofluorescence (MI:0022);
hcv0058	CORE	DICER1	23405	16530526	Coimmunoprecipitation (MI:0019); Western blot (MI:0113)
hcv0059	CORE	PSME3	10197	16611896	Western blot (MI:0113)
ne voos y	CORE	1 SIVILS	10177	10011070	Western blot (MI:0113); Coimmunoprecipitation
					(MI:0019); Immunofluorescence (MI:0022); Immunostaining (MI:0022); Mutational analysis
hcv0060	CORE	DICER1	23405	18325616	(MI:0074)
hcv0061	CORE	AGRN	375790	18985028	Two Hybrid Test (MI:0018)
hcv0062	CORE	BCAR1	9564	18985028	Two Hybrid Test (MI:0018)
hcv0063	CORE	CD68	968	18985028	Two Hybrid Test (MI:0018)
hcv0064	CORE	COL4A2	1284	18985028	Two Hybrid Test (MI:0018)
hcv0065	CORE	DDX3Y	8653	18985028	Two Hybrid Test (MI:0018)
hcv0066	CORE	EGFL7	51162	18985028	Two Hybrid Test (MI:0018)
hcv0067	CORE	FBLN2	2199	18985028	Two Hybrid Test (MI:0018)
hcv0068	CORE	FBLN5	10516	18985028	Two Hybrid Test (MI:0018)
hcv0069	CORE	GAPDH	2597	18985028	Two Hybrid Test (MI:0018)
hcv0070	CORE	GRN	2896	18985028	Two Hybrid Test (MI:0018)
hcv0071	CORE	HIVEP2	3097	18985028	Two Hybrid Test (MI:0018)
hcv0072	CORE	HOXD8	3234	18985028	Two Hybrid Test (MI:0018)
hcv0073	CORE	LPXN	9404	18985028	Two Hybrid Test (MI:0018)
hcv0074	CORE	LRRTM1	347730	18985028	Two Hybrid Test (MI:0018)
hcv0075	CORE	LTBP4	8425	18985028	Two Hybrid Test (MI:0018)
hcv0076	CORE	MAGED1	9500	18985028	Two Hybrid Test (MI:0018)
hcv0077	CORE	MEGF6	1953	18985028	Two Hybrid Test (MI:0018)
hcv0078	CORE	MMRN2	79812	18985028	Two Hybrid Test (MI:0018)
hcv0079	CORE	NR4A1	3164	18985028	Two Hybrid Test (MI:0018)
hcv0080	CORE	PABPN1	8106	18985028	Two Hybrid Test (MI:0018)
hcv0081	CORE	PAK4	10298	18985028	Two Hybrid Test (MI:0018)

hcv0082	CORE	PLSCR1	5359	18985028	Two Hybrid Test (MI:0018)
hcv0083	CORE	RNF31	55072	18985028	Two Hybrid Test (MI:0018)
hcv0084	CORE	SETD2	29072	18985028	Two Hybrid Test (MI:0018)
hcv0085	CORE	SLC31A2	1318	18985028	Two Hybrid Test (MI:0018)
hcv0086	CORE	VWF	7450	18985028	Two Hybrid Test (MI:0018)
hcv0087	CORE	ZNF271	10778	18985028	Two Hybrid Test (MI:0018) Affinity Chromatography (MI:0004);
hcv0088	CORE	YWHAE	7531	10644344	Coimmunoprecipitation (MI:0019); Two Hybrid Test (MI:0018)
hcv0089	CORE	NS5A	951475	11883187	Two Hybrid Test (MI:0018); Coimmunoprecipitation (MI:0019); Colocalization (MI:0403); Affinity Chromatography (MI:0004)
hcv0090	CORE	NS5B	951475	11929715	Immunofluorescence (MI:0022); Coimmunoprecipitation (MI:0019)
hcv0091	CORE	RSF1	51773	12401801	GST pull-down (MI:0059)
hcv0092	CORE	E1	951475	12466485	GST pull-down (MI:0059); Affinity Chromatography (MI:0004); Coimmunoprecipitation (MI:0019) Two Hybrid Test (MI:0018);
hcv0093	CORE	SP110	3431	14559998	Coimmunoprecipitation (MI:0019); GST pull- down (MI:0059)
hcv0094	CORE	KPNA1	3836	15613354	GST pull-down (MI:0059)
hcv0095	CORE	DDX5	1655	15846844	2-DE (MI:0982); Mass spectrometry (MI:0943)
hcv0096	CORE	NS5A	951475	16166788	Two Hybrid Test (MI:0018)
hcv0097	CORE	EIF2AK2	5610	17267064	Two Hybrid Test (MI:0018); Colocalization (MI:0403); Coimmunoprecipitation (MI:0019)
hcv0098	CORE	PPARA	5465	17764115	Immunoblotting (MI:0113); Affinity Chromatography (MI:0004)
hcv0099	CORE	ACY3	91703	18158989	Two Hybrid Test (MI:0018)
hcv0100	CORE	MCL1	4170	19605477	Coimmunoprecipitation (MI:0019); Western blot (MI:0113)
hcv0101	CORE	CORE	951475	8615040	Two Hybrid Test (MI:0018); Far-Western blot (MI:0047); Mutational analysis (MI:0074); GST pull-down (MI:0059); Affinity Chromatography (MI:0004); Far-Western blot (MI:0047); Cross Linking (MI:0030) Affinity Chromatography (MI:0004); Two Hybrid
hcv0102	CORE	CORE	951475	9191926	Test (MI:0018) Coimmunoprecipitation (MI:0019); Colocalization
hcv0103	E1	E2	951475	8083956	(MI:0403); sedimentation (MI:0029)
hcv0104	E1	CORE	951475	8764026	Mutational analysis (MI:0074); Coimmunoprecipitation (MI:0019)
hcv0105	E1	LTF	4057	9223490	Far-Western blot (MI:0047); Coimmunoprecipitation (MI:0019); Pull-down (MI:0096)
hcv0106	E1	CALR	811	9557669	Metabolic labeling (MI:2131); Coimmunoprecipitation (MI:0019); Western blot (MI:0113)
hcv0107	E1	CANX	821	9557669	Metabolic labeling (MI:2131); Coimmunoprecipitation (MI:0019); Western blot (MI:0113)
hcv0108	E1	HSPA5	3309	9557669	Metabolic labeling (MI:2131); Coimmunoprecipitation (MI:0019); Western blot (MI:0113)
hcv0109	E1	E2	951475	10807921	Coimmunoprecipitation (MI:0019); Mutational analysis (MI:0074); circular dichroism spectroscopy (MI:0016); Three dimensional structure (MI:0105)
hcv0110	E1	E2	951475	12502883	Coimmunoprecipitation (MI:0019)
hcv0111	E1	CD209	30835	12634366	Enzyme-linked immunosorbent assay (MI:0411)

hcv0112	E1	CLEC4M	10332	12634366	Enzyme-linked immunosorbent assay (MI:0411)
hcv0113	E1	E2	951475	15136562	Mutational analysis (MI:0074); Coimmunoprecipitation (MI:0019)
hcv0114	E1	CD209	30835	15254204	Mutational analysis (MI:0074); Enzyme-linked immunosorbent assay (MI:0411)
hcv0115	E1	JUN	3725	18985028	Two Hybrid Test (MI:0018)
hcv0116	E1	NR4A1	3164	18985028	Two Hybrid Test (MI:0018)
hcv0117	E1	PFN1	5216	18985028	Two Hybrid Test (MI:0018)
hcv0118	E1	SETD2	29072	18985028	Two Hybrid Test (MI:0018)
hcv0119	E1	TMSB4X	7114	18985028	Two Hybrid Test (MI:0018)
hcv0120	E1	NS5A	951475	10721731	Two Hybrid Test (MI:0018)
hcv0121	E1	E2	951475	8212557	Coimmunoprecipitation (MI:0019)
hcv0122	E2	LTF	4057	9223490	Far-Western blot (MI:0047); Coimmunoprecipitation (MI:0019); Pull-down (MI:0096)
hcv0123	E2	CALR	811	9557669	Metabolic labeling (MI:2131); Coimmunoprecipitation (MI:0019); Western blot (MI:0113)
hcv0124	E2	CANX	821	9557669	Metabolic labeling (MI:2131); Coimmunoprecipitation (MI:0019); Western blot (MI:0113)
					Metabolic labeling (MI:2131); Coimmunoprecipitation (MI:0019); Western blot
hcv0125	E2	HSPA5	3309	9557669	(MI:0113)
hcv0126	E2	EIF2AK2	5610	10390359	Kinase assay (MI:0424) (MI:0424); His pull-down (MI:0061)
hcv0127	E2	NS3	951475	10721731	Two Hybrid Test (MI:0018)
hcv0128	E2	CD81	975	10846074	Competition Binding Experiment (MI:0405); Enzyme-linked immunosorbent assay (MI:0411)
nevorzo		CD01	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		Enzyme-linked immunosorbent assay (MI:0411);
hcv0129	E2	CD81	975	11080483	Immunofluorescence (MI:0022); Competition Binding Experiment (MI:0405)
hcv0130	E2	SCARB1	949	12356718	Coimmunoprecipitation (MI:0019); Western blot (MI:0113)
hcv0131	E2	CD81	975	12522210	Far-Western blot (MI:0047)
hcv0132	E2	LTF	4057	12522210	Far-Western blot (MI:0047)
hcv0133	E2	TF	7018	12522210	Far-Western blot (MI:0047)
hcv0134	E2	CD81	975	12604806	Affinity Chromatography (MI:0004)
hcv0135	E2	EIF2AK3	9451	12610133	Coimmunoprecipitation (MI:0019); Western blot (MI:0113); Kinase assay (MI:0424) (MI:0424)
					Fluorescence-activated cell sorting (MI:0054); Enzyme-linked immunosorbent assay (MI:0411); Flow cytometry (MI:0054); Western blot
hcv0136	E2	CD209	30835	12634366	(MI:0113); Immunostaining (MI:0022)
					Fluorescence-activated cell sorting (MI:0054); Enzyme-linked immunosorbent assay (MI:0411);
hcv0137	E2	CLEC4M	10332	12634366	Immunostaining (MI:0022) Enzyme-linked immunosorbent assay (MI:0411);
hcv0138	E2	SDC2	6383	12867431	Flow cytometry (MI:0054)
hcv0139	E2	CD209	30835	15254204	Mutational analysis (MI:0074); Enzyme-linked immunosorbent assay (MI:0411)
hcv0140	E2	HOXD8	3234	18985028	Two Hybrid Test (MI:0018)
hcv0141	E2	ITGB1	3688	18985028	Two Hybrid Test (MI:0018)
hcv0142	E2	FAM135A	57579	18985028	Two Hybrid Test (MI:0018)
hcv0143	E2	NR4A1	3164	18985028	Two Hybrid Test (MI:0018)
hcv0144	E2	PSMA6	5687	18985028	Two Hybrid Test (MI:0018)

hcv0145	E2	SETD2	29072	18985028	Two Hybrid Test (MI:0018)
hcv0146	E2	SMEK2	57223	18985028	Two Hybrid Test (MI:0018)
hcv0147	F	C14orf135	64430	16237761	Two Hybrid Test (MI:0018)
hcv0148	F	ZNF83	55769	16237761	Two Hybrid Test (MI:0018) Two Hybrid Test (MI:0018); Confocal microscopy
hcv0149	F	PFDN2	5202	16876117	(MI:0663); Immunofluorescence (MI:0022); Coimmunoprecipitation (MI:0019)
hcv0150	F	PFDN5	5204	18398700	Two Hybrid Test (MI:0018); GST pull-down (MI:0059); Coimmunoprecipitation (MI:0019); Confocal microscopy (MI:0663)
hcv0151	F	AGT	183	16237761	Two Hybrid Test (MI:0018)
hcv0152	F	AZGP1	563	16237761	Two Hybrid Test (MI:0018)
hcv0153	F	CTSB	1508	16237761	Two Hybrid Test (MI:0018)
hcv0154	F	MPDU1	9526	16237761	Two Hybrid Test (MI:0018)
hcv0155	F	RAB14	51552	16237761	Two Hybrid Test (MI:0018)
hcv0156	F	SERPINC1	462	16237761	Two Hybrid Test (MI:0018)
hcv0157	F	ST3GAL1	6482	16237761	Two Hybrid Test (MI:0018)
hcv0158	F	vitronectin	7448	16237761	Two Hybrid Test (MI:0018)
hcv0159	F	ZG16	653808	16237761	Two Hybrid Test (MI:0018)
hcv0160	NS2	NS4A	951475	10721731	Two Hybrid Test (MI:0018); Affinity Chromatography (MI:0004)
					Size-exclusion chromatography (MI:0071);
hcv0161	NS2	NS3	951475	11559826	Mutational analysis (MI:0074) Two Hybrid Test (MI:0018); Colocalization
101/20	NCO	CIDED	27141	12505522	(MI:0403); Coimmunoprecipitation (MI:0019);
hcv0162	NS2	CIDEB	27141	12595532	Affinity Chromatography (MI:0004) GST pull-down (MI:0059);
hcv0163	NS2	NS4B	951475	12692242	Coimmunoprecipitation (MI:0019); Two Hybrid Test (MI:0018); Confocal microscopy (MI:0663)
10,0103	102	TIGHD	WEST	ERN CA	GST pull-down (MI:0059);
hcv0164	NS2	NS4A	951475	12692242	Coimmunoprecipitation (MI:0019); Two Hybrid Test (MI:0018); Confocal microscopy (MI:0663)
-					GST pull-down (MI:0059);
hcv0165	NS2	NS5B	951475	12692242	Coimmunoprecipitation (MI:0019); Two Hybrid Test (MI:0018); Confocal microscopy (MI:0663)
					GST pull-down (MI:0059); Coimmunoprecipitation (MI:0019); Two Hybrid Test (MI:0018); Confocal microscopy (MI:0663);
hcv0166	NS2	NS2	951475	12692242	Affinity Chromatography (MI:0004) GST pull-down (MI:0059);
					Coimmunoprecipitation (MI:0019); Two Hybrid Test (MI:0018); Confocal microscopy (MI:0663); Affinity Chromatography (MI:0004);
hcv0167	NS2	NS3	951475	12692242	Immunostaining (MI:0022)
hcv0168	NS2	C7	730	18985028	Two Hybrid Test (MI:0018)
hcv0169	NS2	FBLN5	10516	18985028	Two Hybrid Test (MI:0018)
hcv0170	NS2	HOXD8	3234	18985028	Two Hybrid Test (MI:0018)
hcv0171	NS2	NR4A1	3164	18985028	Two Hybrid Test (MI:0018)
hcv0172	NS2	POU3F2	5454	18985028	Two Hybrid Test (MI:0018)
hcv0173	NS2	SETD2	29072	18985028	Two Hybrid Test (MI:0018)
hcv0174	NS2	TRIM27	5987	18985028	Two Hybrid Test (MI:0018)
hcv0175	NS2	NS5A	951475	12692242	Coimmunoprecipitation (MI:0019)
hcv0176	NS3	NS4A	951475	7494258	Coimmunoprecipitation (MI:0019); Mutational analysis (MI:0074)

hcv0177	NS3	MBP	4155	8647104	Affinity Chromatography (MI:0004)
hcv0178	NS3	PRM1	5619	8647104	Affinity Chromatography (MI:0004)
hcv0179	NS3	HIST4H4	121504	8647104	Affinity Chromatography (MI:0004)
hcv0180	NS3	HIST3H2B B	128312	8647104	Affinity Chromatography (MI:0004)
					GST pull-down (MI:0059); autoradiography
hcv0181	NS3	PRKACA	5566	8647104	(MI:0833); Affinity Chromatography (MI:0004) Competition Binding Experiment (MI:0405); Far-
hcv0182	NS3	PRKACA	5566	9060639	Western blot (MI:0047)
hcv0183	NS3	NS3	951475	9187654	Three dimensional structure (MI:0105)
hcv0184	NS3	TP53	7157	9827557	Coimmunoprecipitation (MI:0019)
hcv0185	NS3	NS4A	951475	9827557	Coimmunoprecipitation (MI:0019) Gel filtration (MI:0071); Affinity Chromatography
hcv0186	NS3	NS4A	951475	10220351	(MI:0004)
hcv0187	NS3	HIST3H2B B	128312	10405893	Proteolytic fragmentation (MI:0079); microsequencing (MI:0093); specific histone binding assay (MI:0079); Gel filtration (MI:0071) Proteolytic fragmentation (MI:0079);
hcv0188	NS3	HIST4H4	121504	10405893	 proteorytic fragmentation (WI:0079); microsequencing (MI:0093); specific histone binding assay (MI:0079); Gel filtration (MI:0071) Immunoblotting (MI:0113); Western blot
hcv0189	NS3	SERPINF2	5345	10570951	(MI:0113)
hcv0190	NS3	SERPING1	710	10570951	Immunoblotting (MI:0113); Western blot (MI:0113)
hcv0191	NS3	NS4A	951475	10721731	Two Hybrid Test (MI:0018)
hcv0192	NS3	PRMT5	10419	11152681	Two Hybrid Test (MI:0018); Western blot (MI:0113)
hcv0193	NS3	PRMT1	3276	11483748	Coimmunoprecipitation (MI:0019); Immunoblotting (MI:0113); Affinity Chromatography (MI:0004); Immunoblotting (MI:0113); GST pull-down (MI:0059)
hcv0194	NS3	NS3	951475	12465917	Three dimensional structure (MI:0105)
hcv0195	NS3	NS4B	951475	12692242	Coimmunoprecipitation (MI:0019); Two Hybrid Test (MI:0018); Confocal microscopy (MI:0663); GST pull-down (MI:0059)
hcv0196	NS3	NS4A	951475	12692242	Coimmunoprecipitation (MI:0019); Two Hybrid Test (MI:0018); Confocal microscopy (MI:0663); Immunostaining (MI:0022); GST pull-down (MI:0059)
hcv0197	NS3	NS3	951475	12692242	Coimmunoprecipitation (MI:0019); Two Hybrid Test (MI:0018); Confocal microscopy (MI:0663); GST pull-down (MI:0059)
hcv0198	NS3	IRF3	3661	12702807	Mutational analysis (MI:0074); Immunoblotting (MI:0113)
hcv0199	NS3	SNRPD1	6632	14524621	Two Hybrid Test (MI:0018); Mutational analysis (MI:0074); Affinity Chromatography (MI:0004); Coimmunoprecipitation (MI:0019)
hcv0200	NS3	NS4A	951475	14627400	Three dimensional structure (MI:0105)
hcv0201	NS3	NS4A	951475	14984200	Three dimensional structure (MI:0105)
					Two Hybrid Test (MI:0018); Coimmunoprecipitation (MI:0019); Affinity
hcv0202	NS3	PSMB8	5696	15303969	Chromatography (MI:0004)
hcv0203	NS3	SMAD3	4088	15334054	Coimmunoprecipitation (MI:0019); Affinity Chromatography (MI:0004)
hcv0204	NS3	NS4A	951475	15501035	Three dimensional structure (MI:0105)
hcv0205	NS3	TLR2	7097	15521019	Electrophoretic mobility shift assay (MI:0413); Western blot (MI:0113); Confocal microscopy (MI:0663); Flow cytometry (MI:0054)
hcv0206	NS3	TICAM1	148022	15767257	Immunoblotting (MI:0113); Affinity Chromatography (MI:0004); Immunofluorescence (MI:0022); circular dichroism spectroscopy

					(MI:0016); Three dimensional structure (MI:0105)
hcv0207	NS3	PTBP2	58155	15823607	Immunofluorescence (MI:0022); GST pull-down (MI:0059); Colocalization (MI:0403); Coimmunoprecipitation (MI:0019)
hcv0208	NS3	IKBKE	9641	15841462	Western blot (MI:0113); Coimmunoprecipitation (MI:0019)
hcv0209	NS3	TBK1	29110	15841462	Western blot (MI:0113); Coimmunoprecipitation (MI:0019)
hcv0210	NS3	ERC1	23085	16033967	Coimmunoprecipitation (MI:0019); GST pull- down (MI:0059); Confocal microscopy (MI:0663); immunoelectron microscopy (MI:0040); Two Hybrid Test (MI:0018)
hcv0211	NS3	NS4A	951475	16078825	Three dimensional structure (MI:0105)
hcv0212	NS3	NS4A	951475	16112862	Three dimensional structure (MI:0105)
hcv0213	NS3	NS4A	951475	16413182	Three dimensional structure (MI:0105)
hcv0214	NS3	NS4A	951475	16876765	Confocal microscopy (MI:0663); Colocalization (MI:0403)
hcv0215	NS3	VISA	57506	17289677	Immunoblotting (MI:0113); Coimmunoprecipitation (MI:0019); Confocal microscopy (MI:0663)
hcv0216	NS3	NS5B	951475	18179252	Pull-down (MI:0096); surface plasmon resonance (MI:0107); fluorescence polarization binding assay (MI:0053)
hcv0217	NS3	ACTN1	87	18985028	Two Hybrid Test (MI:0018)
hcv0218	NS3	ACTN2	88	18985028	Two Hybrid Test (MI:0018)
hcv0219	NS3	AEBP1	165	18985028	Two Hybrid Test (MI:0018)
hcv0220	NS3	ANKRD12	23253	18985028	Two Hybrid Test (MI:0018)
hcv0221	NS3	ANKRD28	23243	18985028	Two Hybrid Test (MI:0018)
hcv0222	NS3	ARFIP2	23647	18985028	Two Hybrid Test (MI:0018)
hcv0223	NS3	ARHGEF6	9459	18985028	Two Hybrid Test (MI:0018)
hcv0224	NS3	ARNT	405	18985028	Two Hybrid Test (MI:0018)
hcv0225	NS3	ARS2	51593	18985028	Two Hybrid Test (MI:0018)
hcv0226	NS3	ASXL1	171023	18985028	Two Hybrid Test (MI:0018)
hcv0227	NS3	B2M	567	18985028	Two Hybrid Test (MI:0018)
hcv0228	NS3	BCAN	63827	18985028	Two Hybrid Test (MI:0018)
hcv0229	NS3	BCKDK	10295	18985028	Two Hybrid Test (MI:0018); Co-affinity purification (MI:0025)
hcv0230	NS3	BCL2A1	597	18985028	Two Hybrid Test (MI:0018)
hcv0231	NS3	BCL6	604	18985028	Two Hybrid Test (MI:0018)
hcv0232	NS3	BZRAP1	9256	18985028	Two Hybrid Test (MI:0018)
hcv0233	NS3	C10orf18	54906	18985028	Two Hybrid Test (MI:0018)
hcv0234	NS3	C10orf6	55719	18985028	Two Hybrid Test (MI:0018)
hcv0235	NS3	C12orf41	54934	18985028	Two Hybrid Test (MI:0018)
hcv0236	NS3	INF2	64423	18985028	Two Hybrid Test (MI:0018)
hcv0237	NS3	C16orf7	9605	18985028	Two Hybrid Test (MI:0018)
hcv0238	NS3	BEND5	79656	18985028	Two Hybrid Test (MI:0018)
hcv0239	NS3	C1orf94	84970	18985028	Two Hybrid Test (MI:0018)
hcv0240	NS3	C9orf30	91283	18985028	Two Hybrid Test (MI:0018)
hcv0241	NS3	CALCOCO 2	10241	18985028	Two Hybrid Test (MI:0018); Co-affinity purification (MI:0025)

hcv0242	NS3	CBY1	25776	18985028	Two Hybrid Test (MI:0018)
hcv0243	NS3	CCDC21	64793	18985028	Two Hybrid Test (MI:0018); Co-affinity purification (MI:0025)
hcv0244	NS3	CCDC37	348807	18985028	Two Hybrid Test (MI:0018)
hcv0245	NS3	CCDC52	152185	18985028	Two Hybrid Test (MI:0018)
hcv0246	NS3	CCDC66	285331	18985028	Two Hybrid Test (MI:0018)
hcv0247	NS3	INO80E	283899	18985028	Two Hybrid Test (MI:0018)
hcv0248	NS3	CCHCR1	54535	18985028	Two Hybrid Test (MI:0018)
hcv0249	NS3	CD5L	922	18985028	Two Hybrid Test (MI:0018)
hcv0250	NS3	CDC23	8697	18985028	Two Hybrid Test (MI:0018)
hcv0251	NS3	CELSR2	1952	18985028	Two Hybrid Test (MI:0018)
hcv0252	NS3	CEP152	22995	18985028	Two Hybrid Test (MI:0018)
hcv0253	NS3	CEP192	55125	18985028	Two Hybrid Test (MI:0018)
hcv0254	NS3	CFP	5199	18985028	Two Hybrid Test (MI:0018)
hcv0255	NS3	CHPF	79586	18985028	Two Hybrid Test (MI:0018)
hcv0256	NS3	CORO1B	57175	18985028	Two Hybrid Test (MI:0018)
hcv0257	NS3	CSNK2B	1460	18985028	Two Hybrid Test (MI:0018)
hcv0258	NS3	CTGF	1490	18985028	Two Hybrid Test (MI:0018)
hcv0259	NS3	ALG13	79868	18985028	Two Hybrid Test (MI:0018)
hcv0260	NS3	DEAF1	10522	18985028	Two Hybrid Test (MI:0018)
hcv0261	NS3	DES	1674	18985028	Two Hybrid Test (MI:0018)
hcv0262	NS3	DLAT	1737	18985028	Two Hybrid Test (MI:0018)
hcv0263	NS3	DOCK7	85440	18985028	Two Hybrid Test (MI:0018)
hcv0264	NS3	DPF1	8193	18985028	Two Hybrid Test (MI:0018)
hcv0265	NS3	DPP7	29952	18985028	Two Hybrid Test (MI:0018)
hcv0266	NS3	EEF1A1	1915	18985028	Two Hybrid Test (MI:0018)
hcv0267	NS3	EFEMP1	2202	18985028	Two Hybrid Test (MI:0018)
hcv0268	NS3	EFEMP2	30008	18985028	Two Hybrid Test (MI:0018)
hcv0269	NS3	EIF1	10209	18985028	Two Hybrid Test (MI:0018)
hcv0270	NS3	EIF4ENIF1	56478	18985028	Two Hybrid Test (MI:0018); Co-affinity purification (MI:0025)
hcv0271	NS3	FAM120B	84498	18985028	Two Hybrid Test (MI:0018)
hcv0272	NS3	FAM65A	79567	18985028	Two Hybrid Test (MI:0018)
hcv0273	NS3	FBF1	85302	18985028	Two Hybrid Test (MI:0018)
hcv0274	NS3	FBLN1	2192	18985028	Two Hybrid Test (MI:0018)
hcv0275	NS3	FBLN2	2199	18985028	Two Hybrid Test (MI:0018)
hcv0276	NS3	FBLN5	10516	18985028	Two Hybrid Test (MI:0018)
hcv0277	NS3	FBN1	2200	18985028	Two Hybrid Test (MI:0018)
hcv0278	NS3	FBN3	84467	18985028	Two Hybrid Test (MI:0018)
hcv0279	NS3	FES	2242	18985028	Two Hybrid Test (MI:0018)
hcv0280	NS3	FIGNL1	63979	18985028	Two Hybrid Test (MI:0018)
hcv0281	NS3	FLAD1	80308	18985028	Two Hybrid Test (MI:0018)
hcv0282	NS3	C19orf66	55337	18985028	Two Hybrid Test (MI:0018)

hcv0283	NS3	FN1	2335	18985028	Two Hybrid Test (MI:0018)
hcv0284	NS3	FRMPD4	9758	18985028	Two Hybrid Test (MI:0018)
hcv0285	NS3	FRS3	10817	18985028	Two Hybrid Test (MI:0018); Co-affinity purification (MI:0025)
hcv0286	NS3	FTH1	2495	18985028	Two Hybrid Test (MI:0018)
hcv0287	NS3	FUCA2	2519	18985028	Two Hybrid Test (MI:0018)
hcv0288	NS3	GAA	2548	18985028	Two Hybrid Test (MI:0018)
hcv0289	NS3	GBP2	2634	18985028	Two Hybrid Test (MI:0018); Co-affinity purification (MI:0025)
hcv0290	NS3	GFAP	2670	18985028	Two Hybrid Test (MI:0018)
hcv0291	NS3	GNB2	2783	18985028	Two Hybrid Test (MI:0018)
hcv0292	NS3	GON4L	54856	18985028	Two Hybrid Test (MI:0018)
hcv0293	NS3	HIVEP2	3097	18985028	Two Hybrid Test (MI:0018)
hcv0294	NS3	HNRNPK	3190	18985028	Two Hybrid Test (MI:0018)
hcv0295	NS3	HOMER3	9454	18985028	Two Hybrid Test (MI:0018)
hcv0296	NS3	IQWD1	55827	18985028	Two Hybrid Test (MI:0018)
hcv0297	NS3	ITGB4	3691	18985028	Two Hybrid Test (MI:0018)
hcv0298	NS3	JAG2	3714	18985028	Two Hybrid Test (MI:0018)
hcv0299	NS3	JUN	3725	18985028	Two Hybrid Test (MI:0018)
hcv0300	NS3	KHDRBS1	10657	18985028	Two Hybrid Test (MI:0018)
hcv0301	NS3	KIAA1549	57670	18985028	Two Hybrid Test (MI:0018)
hcv0302	NS3	KIF17	57576	18985028	Two Hybrid Test (MI:0018)
hcv0303	NS3	KIF7	374654	18985028	Two Hybrid Test (MI:0018)
hcv0304	NS3	KPNA1	3836	18985028	Two Hybrid Test (MI:0018); Co-affinity purification (MI:0025)
hcv0305	NS3	L3MBTL3	84456	18985028	Two Hybrid Test (MI:0018)
hcv0306	NS3	LAMA5	3911	18985028	Two Hybrid Test (MI:0018)
hcv0307	NS3	LAMB2	3913	18985028	Two Hybrid Test (MI:0018)
hcv0308	NS3	LAMC3	10319	18985028	Two Hybrid Test (MI:0018)
hcv0309	NS3	LDB1	8861	18985028	Two Hybrid Test (MI:0018)
hcv0310	NS3	LRRC7	57554	18985028	Two Hybrid Test (MI:0018)
hcv0311	NS3	LRRCC1	85444	18985028	Two Hybrid Test (MI:0018)
hcv0312	NS3	LTBP4	8425	18985028	Two Hybrid Test (MI:0018)
hcv0313	NS3	LZTS2	84445	18985028	Two Hybrid Test (MI:0018)
hcv0314	NS3	MAGED1	9500	18985028	Two Hybrid Test (MI:0018)
hcv0315	NS3	MAPK7	5598	18985028	Two Hybrid Test (MI:0018)
hcv0316	NS3	MEGF8	1954	18985028	Two Hybrid Test (MI:0018)
hcv0317	NS3	MLLT4	4301	18985028	Two Hybrid Test (MI:0018)
hcv0318	NS3	MLXIP	22877	18985028	Two Hybrid Test (MI:0018)
hcv0319	NS3	MORC4	79710	18985028	Two Hybrid Test (MI:0018)
hcv0320	NS3	MORF4L1	10933	18985028	Two Hybrid Test (MI:0018)
hcv0321	NS3	MVP	9961	18985028	Two Hybrid Test (MI:0018)
hcv0322	NS3	NAP1L1	4673	18985028	Two Hybrid Test (MI:0018)
hcv0323	NS3	NAP1L2	4674	18985028	Two Hybrid Test (MI:0018)

hcv0324	NS3	NCAN	1463	18985028	Two Hybrid Test (MI:0018)
hcv0325	NS3	NDC80	10403	18985028	Two Hybrid Test (MI:0018)
hcv0326	NS3	NEFL	4747	18985028	Two Hybrid Test (MI:0018)
hcv0327	NS3	NEFM	4741	18985028	Two Hybrid Test (MI:0018)
hcv0328	NS3	NELL1	4745	18985028	Two Hybrid Test (MI:0018)
hcv0329	NS3	NELL2	4753	18985028	Two Hybrid Test (MI:0018)
hcv0330	NS3	NID1	4811	18985028	Two Hybrid Test (MI:0018)
hcv0331	NS3	NID2	22795	18985028	Two Hybrid Test (MI:0018)
hcv0332	NS3	NOTCH1	4851	18985028	Two Hybrid Test (MI:0018)
hcv0333	NS3	N-PAC	84656	18985028	Two Hybrid Test (MI:0018)
hcv0334	NS3	NUP62	23636	18985028	Two Hybrid Test (MI:0018)
hcv0335	NS3	OBSCN	84033	18985028	Two Hybrid Test (MI:0018)
hcv0336	NS3	PARP4	143	18985028	Two Hybrid Test (MI:0018)
hcv0337	NS3	PCYT2	5833	18985028	Two Hybrid Test (MI:0018)
hcv0338	NS3	PDE4DIP	9659	18985028	Two Hybrid Test (MI:0018)
hcv0339	NS3	PDLIM5	10611	18985028	Two Hybrid Test (MI:0018)
hcv0340	NS3	PICK1	9463	18985028	Two Hybrid Test (MI:0018)
hcv0341	NS3	PKNOX1	5316	18985028	Two Hybrid Test (MI:0018)
hcv0342	NS3	PLEKHG4	25894	18985028	Two Hybrid Test (MI:0018)
hcv0343	NS3	PNPLA8	50640	18985028	Two Hybrid Test (MI:0018)
hcv0344	NS3	PRRC1	133619	18985028	Two Hybrid Test (MI:0018)
hcv0345	NS3	PSMB9	5698	18985028	Two Hybrid Test (MI:0018); Co-affinity purification (MI:0025)
hcv0346	NS3	PSME3	10197	18985028	Two Hybrid Test (MI:0018)
hcv0347	NS3	PTPRN2	5799	18985028	Two Hybrid Test (MI:0018)
hcv0348	NS3	RABEP1	9135	18985028	Two Hybrid Test (MI:0018)
hcv0349	NS3	RAI14	26064	18985028	Two Hybrid Test (MI:0018)
					Two Hybrid Test (MI:0018); Co-affinity
hcv0350	NS3	RASAL2	9462	18985028	purification (MI:0025)
hcv0351	NS3	RBM4	5936	18985028	Two Hybrid Test (MI:0018)
hcv0352	NS3	RCN3	57333	18985028	Two Hybrid Test (MI:0018)
hcv0353	NS3	RGNEF	64283	18985028	Two Hybrid Test (MI:0018)
hcv0354	NS3	RICS	9743	18985028	Two Hybrid Test (MI:0018)
hcv0355	NS3	RINT1	60561	18985028	Two Hybrid Test (MI:0018)
hcv0356	NS3	RNF31	55072	18985028	Two Hybrid Test (MI:0018)
hcv0357	NS3	ROGDI	79641	18985028	Two Hybrid Test (MI:0018)
hcv0358	NS3	KIAA2022	340533	18985028	Two Hybrid Test (MI:0018)
hcv0359	NS3	RUSC2	9853	18985028	Two Hybrid Test (MI:0018)
hcv0360	NS3	SBF1	6305	18985028	Two Hybrid Test (MI:0018)
hcv0361	NS3	SDCCAG8	10806	18985028	Two Hybrid Test (MI:0018)
hcv0362	NS3	SECISBP2	79048	18985028	Two Hybrid Test (MI:0018)
hcv0363	NS3	10-Sep	151011	18985028	Two Hybrid Test (MI:0018)
hcv0364	NS3	SERTAD1	29950	18985028	Two Hybrid Test (MI:0018)

hcv0365	NS3	SESTD1	91404	18985028	Two Hybrid Test (MI:0018)
				18985028	
hcv0366	NS3 NS3	SF3B2	10992 6477		Two Hybrid Test (MI:0018)
hcv0367 hcv0368		SIAH1		18985028 18985028	Two Hybrid Test (MI:0018)
	NS3	SLIT1	6585		Two Hybrid Test (MI:0018)
hcv0369	NS3	SLIT2	9353	18985028	Two Hybrid Test (MI:0018)
hcv0370	NS3	SLIT3	6586	18985028	Two Hybrid Test (MI:0018) Two Hybrid Test (MI:0018); Co-affinity
hcv0371	NS3	SMURF2	64750	18985028	purification (MI:0025)
hcv0372	NS3	SNX4	8723	18985028	Two Hybrid Test (MI:0018)
hcv0373	NS3	SPOCK3	50859	18985028	Two Hybrid Test (MI:0018)
hcv0374	NS3	SPON1	10418	18985028	Two Hybrid Test (MI:0018)
hcv0375	NS3	SRPX2	27286	18985028	Two Hybrid Test (MI:0018)
hcv0376	NS3	SSX2IP	117178	18985028	Two Hybrid Test (MI:0018)
hcv0377	NS3	STAB1	23166	18985028	Two Hybrid Test (MI:0018)
hcv0378	NS3	STAT3	6774	18985028	Two Hybrid Test (MI:0018)
hcv0379	NS3	SVEP1	79987	18985028	Two Hybrid Test (MI:0018)
hcv0380	NS3	SYNE1	23345	18985028	Two Hybrid Test (MI:0018)
hcv0381	NS3	SYNPO2	171024	18985028	Two Hybrid Test (MI:0018)
hcv0382	NS3	TAF1	6872	18985028	Two Hybrid Test (MI:0018)
hcv0383	NS3	TBC1D2B	23102	18985028	Two Hybrid Test (MI:0018)
hcv0384	NS3	TBXAS1	6916	18985028	Two Hybrid Test (MI:0018)
hcv0385	NS3	TGFB1I1	7041	18985028	Two Hybrid Test (MI:0018)
hcv0386	NS3	THAP1	55145	18985028	Two Hybrid Test (MI:0018)
hcv0387	NS3	TMEM63B	55362	18985028	Two Hybrid Test (MI:0018)
hcv0388	NS3	TRIM23	373	18985028	Two Hybrid Test (MI:0018)
hcv0389	NS3	TRIM27	5987	18985028	Two Hybrid Test (MI:0018)
hcv0390	NS3	TRIO	7204	18985028	Two Hybrid Test (MI:0018)
hcv0391	NS3	TRIP11	9321	18985028	Two Hybrid Test (MI:0018)
hcv0392	NS3	TXNDC11	51061	18985028	Two Hybrid Test (MI:0018)
hcv0393	NS3	UBA3	9039	18985028	Two Hybrid Test (MI:0018)
hcv0394	NS3	USHBP1	83878	18985028	Two Hybrid Test (MI:0018)
hcv0395	NS3	UXT	8409	18985028	Two Hybrid Test (MI:0018)
hcv0396	NS3	VCAN	1462	18985028	Two Hybrid Test (MI:0018)
hcv0397	NS3	VIM	7431	18985028	Two Hybrid Test (MI:0018)
hcv0398	NS3	VWF	7450	18985028	Two Hybrid Test (MI:0018)
hcv0399	NS3	XAB2	56949	18985028	Two Hybrid Test (MI:0018)
hcv0400	NS3	XRN2	22803	18985028	Two Hybrid Test (MI:0018)
hcv0401	NS3	YY1AP1	55249	18985028	Two Hybrid Test (MI:0018)
hcv0402	NS3	ZBTB1	22890	18985028	Two Hybrid Test (MI:0018)
hcv0403	NS3	ZCCHC7	84186	18985028	Two Hybrid Test (MI:0018)
hcv0404	NS3	ZHX3	23051	18985028	Two Hybrid Test (MI:0018)
hcv0405	NS3	ZMYM2	7750	18985028	Two Hybrid Test (MI:0018)

hcv0406	NS3	ZNF281	23528	18985028	Two Hybrid Test (MI:0018)
hcv0407	NS3	ZNF410	57862	18985028	Two Hybrid Test (MI:0018)
hcv0408	NS3	ZZZ3	26009	18985028	Two Hybrid Test (MI:0018)
hcv0409	NS3	NS5B	951475	10721731	Two Hybrid Test (MI:0018) Coimmunoprecipitation (MI:0019); Two Hybrid
hcv0410	NS3	NS3	951475	11119590	Test (MI:0018)
hcv0411	NS3	NS5B	951475	12235135	Far-Western blot (MI:0047)
hcv0412	NS3	NS4B	951475	12235135	Far-Western blot (MI:0047)
hcv0413	NS3	NS5B	951475	12692242	Coimmunoprecipitation (MI:0019); Two Hybrid Test (MI:0018)
hcv0414	NS3	CASP8	841	15476874	Coimmunoprecipitation (MI:0019)
hcv0415	NS3	NS3	951475	16166788	Two Hybrid Test (MI:0018)
hcv0416	NS3	NS4A	951475	16324764	Immunofluorescence (MI:0022); Coimmunoprecipitation (MI:0019)
hcv0417	NS3	RSPH3	83861	18985028	Two Hybrid Test (MI:0018)
hcv0418	NS4A	NS3	951475	8861917	Three dimensional structure (MI:0105)
hcv0419	NS4A	NS3	951475	9568891	Three dimensional structure (MI:0105)
hcv0420	NS4A	NS3	951475	10702283	Three dimensional structure (MI:0105)
hcv0421	NS4A	NS3	951475	12465917	Three dimensional structure (MI:0105)
					Affinity Chromatography (MI:0004); Coimmunoprecipitation (MI:0019); Two Hybrid
hcv0422	NS4A	NS4A	951475	12692242	Test (MI:0018); Confocal microscopy (MI:0663); GST pull-down (MI:0059)
					Affinity Chromatography (MI:0004); Coimmunoprecipitation (MI:0019); Two Hybrid Test (MI:0018); Confocal microscopy (MI:0663); Immunostaining (MI:0022); Affinity
hcv0423	NS4A	NS4B	951475	12692242	Chromatography (MI:0004)
hcv0424	NS4A	NS5B	WEST 951475	12692242	Affinity Chromatography (MI:0004); Coimmunoprecipitation (MI:0019); Two Hybrid Test (MI:0018); Confocal microscopy (MI:0663); Immunostaining (MI:0022)
hcv0425	NS4A	CREB3	10488	18985028	Two Hybrid Test (MI:0018)
hcv0426	NS4A	ELAC2	60528	18985028	Two Hybrid Test (MI:0018)
hcv0427	NS4A	HOXD8	3234	18985028	Two Hybrid Test (MI:0018)
hcv0428	NS4A	NR4A1	3164	18985028	Two Hybrid Test (MI:0018)
hcv0429	NS4A	TRAF3IP3	80342	18985028	Two Hybrid Test (MI:0018)
hcv0430	NS4A	UBOLN1	29979	18985028	Two Hybrid Test (MI:0018)
hcv0431	NS4A	NS5A	951475	12692242	Coimmunoprecipitation (MI:0019); Two Hybrid Test (MI:0018); Affinity Chromatography (MI:0004); Immunostaining (MI:0022)
hcv0432	NS4A	MT2A	4502	16248944	Two Hybrid Test (MI:0018)
hcv0433	NS4A	TUT1	64852	16248944	Two Hybrid Test (MI:0018)
hcv0434	NS4A	MT-CO2	4513	16248944	Two Hybrid Test (MI:0018)
hcv0435	NS4A	EEF1A1	1915	16927014	GST pull-down (MI:0059)
hcv0436	NS4A	CAMLG	819	17429534	Two Hybrid Test (MI:0018)
hcv0437	NS4A	NS5A	951475	9261364	Coimmunoprecipitation (MI:0019)
hcv0438	NS4B	NS4A	951475	9261364	Coimmunoprecipitation (MI:0019)
hcv0439	NS4B	ATF6B	1388	12445808	Two Hybrid Test (MI:0018); Coimmunoprecipitation (MI:0019); Confocal microscopy (MI:0663)

					Two Hybrid Test (MI:0018);
					Coimmunoprecipitation (MI:0019); Confocal
hcv0440	NS4B	ATF6A	22926	12445808	microscopy (MI:0663) GST pull-down (MI:0059);
					Coimmunoprecipitation (MI:0019); Two Hybrid
					Test (MI:0018); Confocal microscopy (MI:0663);
hcv0441	NS4B	NS5B	951475	12692242	Immunostaining (MI:0022); Affinity Chromatography (MI:0004)
110/0441	INS4B	INSE	931473	12092242	GST pull-down (MI:0059);
					Coimmunoprecipitation (MI:0019); Two Hybrid
hcv0442	NS4B	NS4B	951475	12692242	Test (MI:0018); Confocal microscopy (MI:0663); Affinity Chromatography (MI:0004)
hcv0443	NS4B	NS5B	951475	12235135	Far-Western blot (MI:0047) Two Hybrid Test (MI:0018);
					Coimmunoprecipitation (MI:0019); Confocal
hcv0444	NS4B	TNXB	7148	12445808	microscopy (MI:0663)
hcv0445	NS4B	NS5A	951475	12692242	Coimmunoprecipitation (MI:0019)
hcv0446	NS4B	NESA	051475	15016971	Coimmunoprecipitation (MI:0019); Affinity Chromatography (MI:0004)
		NS5A	951475	15016871	
hcv0447	NS4B	RTN3	10313	16261208	Two Hybrid Test (MI:0018)
hcv0448	NS4B	RBP4	5950	16261208	Two Hybrid Test (MI:0018)
hcv0449	NS4B	NDUFV3	4731	16261208	Two Hybrid Test (MI:0018)
hcv0450	NS4B	FGG	2266	16261208	Two Hybrid Test (MI:0018)
hcv0451	NS4B	MT-CO3	4514	16261208	Two Hybrid Test (MI:0018)
hcv0452	NS4B	RAB5A	5868	17301141	Coimmunoprecipitation (MI:0019)
hcv0453	NS5A	EIF2AK2	5610	9143277	Two Hybrid Test (MI:0018)
					GST pull-down (MI:0059); Affinity
					Chromatography (MI:0004); Kinase assay (MI:0424) (MI:0424); Mutational analysis
hcv0454	NS5A	CSNK2A1	1457	10208859	(MI:0074)
			UNIVE	RSITY	Immunoblotting (MI:0113); Affinity Chromatography (MI:0004); Two Hybrid Test
hcv0455	NS5A	GRB2	2885	10318918	(MI:0018); Coimmunoprecipitation (MI:0019)
					Coimmunoprecipitation (MI:0019);
hcv0456	NS5A	VAPA	9218	10544080	Immunofluorescence (MI:0022); Immunostaining (MI:0022); Affinity Chromatography (MI:0004)
11010450	NSJA	VAIA	7210	10544080	Two Hybrid Test (MI:0018);
					Coimmunoprecipitation (MI:0019); Affinity
hcv0457	NS5A	SRCAP	10847	10702287	Chromatography (MI:0004); Immunostaining (MI:0022); Pull-down (MI:0096)
nevo is /	110011	bitterii	10017	10/02207	Two Hybrid Test (MI:0018);
1 0450	2054	1005	2042	10700500	Coimmunoprecipitation (MI:0019); Affinity
hcv0458	NS5A	IPO5	3843	10799599	Chromatography (MI:0004) Pull-down (MI:0096); Coimmunoprecipitation
					(MI:0019); Two Hybrid Test (MI:0018); Confocal
					microscopy (MI:0663); Colocalization (MI:0403);
hcv0459	NS5A	TP53	7157	11152513	Affinity Chromatography (MI:0004); Immunostaining (MI:0022)
ine to to y	1,0011		, 10,	11102010	Western blot (MI:0113); Coimmunoprecipitation
hcv0460	NS5A	CDC2	983	11278402	(MI:0019)
hcv0461	NS5A	CDK2	1017	11278402	Western blot (MI:0113); Coimmunoprecipitation (MI:0019)
					Immunofluorescence (MI:0022); Confocal
					microscopy (MI:0663); Coimmunoprecipitation (MI:0019); Affinity Chromatography (MI:0004);
		A DO A 1	335	11878923	Immunostaining (MI:0022)
hcv0462	NS5A	APOA1			Coimmunoprecipitation (MI:0019); Confocal
hcv0462	NS5A	APOAI			
			7157	12101418	microscopy (MI:0663); Affinity Chromatography
hcv0462 hcv0463	NS5A NS5A	TP53	7157	12101418	microscopy (MI:0663); Affinity Chromatography (MI:0004) Coimmunoprecipitation (MI:0019);
			7157 6880	12101418 12101418	microscopy (MI:0663); Affinity Chromatography (MI:0004)

hcv0466	NS5A	TP53	7157	12379483	Coimmunoprecipitation (MI:0019); Pull-down (MI:0096); Affinity Chromatography (MI:0004)
hcv0467	NS5A	TBP	6908	12379483	Coimmunoprecipitation (MI:0019); Pull-down (MI:0096); Affinity Chromatography (MI:0004)
					Mass spectrometry (MI:0943); Mutational analysis (MI:0074); Coimmunoprecipitation (MI:0019); Colocalization (MI:0403); Affinity
hcv0468	NS5A	BIN1	274	12604805	Chromatography (MI:0004); Immunostaining (MI:0022)
110 100				12004005	Two Hybrid Test (MI:0018);
hcv0469	NS5A	PITX1	5307	12620797	Coimmunoprecipitation (MI:0019) GST pull-down (MI:0059);
hcv0470	NS5A	NS5B	951475	12692242	Coimmunoprecipitation (MI:0019); Two Hybrid Test (MI:0018); Confocal microscopy (MI:0663); Immunostaining (MI:0022); Affinity Chromatography (MI:0004)
hcv0471	NS5A	NS5A	951475	12692242	GST pull-down (MI:0059); Coimmunoprecipitation (MI:0019); Two Hybrid Test (MI:0018); Confocal microscopy (MI:0663); Affinity Chromatography (MI:0004)
hcv0472	NS5A	BAX	581	12925958	Immunofluorescence (MI:0022); Coimmunoprecipitation (MI:0019)
hcv0473	NS5A	SSB	6741	12963047	Coimmunoprecipitation (MI:0019); Affinity Chromatography (MI:0004)
hcv0474	NS5A	НСК	3055	14993658	Coimmunoprecipitation (MI:0019); Affinity Chromatography (MI:0004)
hcv0475	NS5A	LCK	3932	14993658	Coimmunoprecipitation (MI:0019); Affinity Chromatography (MI:0004)
hcv0476	NS5A	LYN	4067	14993658	Coimmunoprecipitation (MI:0019); Affinity Chromatography (MI:0004)
hcv0477	NS5A	FYN	2534	14993658	Coimmunoprecipitation (MI:0019); Affinity Chromatography (MI:0004)
					Coimmunoprecipitation (MI:0019); GST pull- down (MI:0059); autoradiography (MI:0833);
hcv0478	NS5A	VAPA	9218	15016871	Affinity Chromatography (MI:0004) GST pull-down (MI:0059); Immunoblotting
			UNIVI	RSITY	(MI:0113); Coimmunoprecipitation (MI:0019);
hcv0479	NS5A	OAS1	4938	15039538	Immunofluorescence (MI:0022)
hcv0480	NS5A	JAK1	3716	15063116	Coimmunoprecipitation (MI:0019)
hcv0481	NS5A	APOE	348	15326295	Two Hybrid Test (MI:0018) Western blot (MI:0113); Two Hybrid Test
hcv0482	NS5A	VAPA	9218	15326295	(MI:0018)
hcv0483	NS5A	NS5A	951475	15326295	Two Hybrid Test (MI:0018)
hcv0484	NS5A	AHNAK	79026	15607035	Two Hybrid Test (MI:0018); GST pull-down (MI:0059)
hcv0485	NS5A	SFRP4	6424	15607035	Two Hybrid Test (MI:0018)
hcv0486	NS5A	CRABP1	1381	15607035	Two Hybrid Test (MI:0018); GST pull-down (MI:0059)
hcv0487	NS5A	FTH1	2495	15607035	Two Hybrid Test (MI:0018)
hcv0488	NS5A	CCDC86	79080	15607035	Two Hybrid Test (MI:0018); GST pull-down (MI:0059)
hcv0489	NS5A	TACSTD2	4070	15607035	Two Hybrid Test (MI:0018)
hcv0490	NS5A	PI4KA	5297	15607035	Two Hybrid Test (MI:0018); GST pull-down (MI:0059)
hcv0491	NS5A	PTMA	5757	15607035	Two Hybrid Test (MI:0018)
hcv0492	NS5A	ARAP1	116985	15607035	Two Hybrid Test (MI:0018); GST pull-down (MI:0059)
hcv0493	NS5A	NDRG1	10397	15607035	Two Hybrid Test (MI:0018)
hcv0494	NS5A	MGP	4256	15607035	Two Hybrid Test (MI:0018)
hcv0495	NS5A	CEP57	9702	15607035	Two Hybrid Test (MI:0018)
hcv0496	NS5A	C9orf6	54942	15607035	Two Hybrid Test (MI:0018)

hcv0497	NS5A	FBXL2	25827	15893726	[(3)H]mevalonate labeling (MI:2131); Coimmunoprecipitation (MI:0019)
	NS5A	NS5A			Three dimensional structure (MI:0105)
hcv0498 hcv0499	NS5A NS5A	CSK	951475 1445	15902263 16139795	Affinity Chromatography (MI:0004); Mass spectrometry (MI:0943); GST pull-down (MI:0059)
hcv0500	NS5A	SRC	6714	16139795	Affinity Chromatography (MI:0004); Mass spectrometry (MI:0943); GST pull-down (MI:0059)
hcv0501	NS5A	APOB	338	16203724	Coimmunoprecipitation (MI:0019)
hcv0502	NS5A	VAPB	9217	16227268	Coimmunoprecipitation (MI:0019); Mutational analysis (MI:0074)
hcv0503	NS5A	RAF1	5894	16405965	Affinity Chromatography (MI:0004); Coimmunoprecipitation (MI:0019); Immunofluorescence (MI:0022); Western blot (MI:0113) GST pull-down (MI:0059);
hcv0504	NS5A	TGFBR1	7046	16407286	Coimmunoprecipitation (MI:0019)
hcv0505	NS5A	PPP2R4	5524	16460864	GST pull-down (MI:0059); His pull-down (MI:0061); Immunofluorescence (MI:0022); Coimmunoprecipitation (MI:0019); Immunoblotting (MI:0113) Two Hybrid Test (MI:0018);
hcv0506	NS5A	BIN1	274	16530520	Coimmunoprecipitation (MI:0019); Confocal microscopy (MI:0663); Mutational analysis (MI:0074)
hcv0507	NS5A	TRAF2	7186	16581780	Coimmunoprecipitation (MI:0019)
hcv0508	NS5A	FKBP8	23770	16844119	Two Hybrid Test (MI:0018)
hcv0509	NS5A	FKBP8	23770	17024179	Coimmunoprecipitation (MI:0019)
hcv0510	NS5A	HSP90AA1	3320	17024179	Coimmunoprecipitation (MI:0019)
hcv0511	NS5A	PTPLAD1	51495	18160438	Two Hybrid Test (MI:0018)
hcv0512	NS5A	ACLY	47NIVE	18985028	Two Hybrid Test (MI:0018)
hcv0513	NS5A	ARFIP1	27236	18985028	Two Hybrid Test (MI:0018)
hcv0514	NS5A	AXIN1	8312	18985028	Two Hybrid Test (MI:0018)
hcv0515	NS5A	BEND7	222389	18985028	Two Hybrid Test (MI:0018)
hcv0516	NS5A	CADPS	8618	18985028	Two Hybrid Test (MI:0018)
hcv0517	NS5A	CADPS2	93664	18985028	Two Hybrid Test (MI:0018)
hcv0518	NS5A	CEP120	153241	18985028	Two Hybrid Test (MI:0018)
hcv0519	NS5A	CENPC1	1060	18985028	Two Hybrid Test (MI:0018)
hcv0520	NS5A	CEP250	11190	18985028	Two Hybrid Test (MI:0018)
hcv0521	NS5A	CEP63	80254	18985028	Two Hybrid Test (MI:0018)
hcv0522	NS5A	DNAJA3	9093	18985028	Two Hybrid Test (MI:0018)
hcv0523	NS5A	EFEMP1	2202	18985028	Two Hybrid Test (MI:0018); Co-affinity purification (MI:0025)
hcv0524	NS5A	FHL2	2274	18985028	Two Hybrid Test (MI:0018)
hcv0525	NS5A	GOLGA2	2801	18985028	Two Hybrid Test (MI:0018); Co-affinity purification (MI:0025)
hcv0526	NS5A	GPS2	2874	18985028	Two Hybrid Test (MI:0018); Co-affinity purification (MI:0025)
hcv0527	NS5A	IGLL1	3543	18985028	Two Hybrid Test (MI:0018)
hcv0528	NS5A	ITGAL	3683	18985028	Two Hybrid Test (MI:0018); Co-affinity purification (MI:0025)
hcv0529	NS5A	LIMS2	55679	18985028	Two Hybrid Test (MI:0018)
hcv0530	NS5A	MOBK1B	55233	18985028	Two Hybrid Test (MI:0018); Co-affinity purification (MI:0025)

hcv0531	NS5A	NAP1L1	4673	18985028	Two Hybrid Test (MI:0018)
					Two Hybrid Test (MI:0018); Co-affinity
hcv0532	NS5A	NAP1L2	4674	18985028	purification (MI:0025)
hcv0533	NS5A	NFE2	4778	18985028	Two Hybrid Test (MI:0018)
hcv0534	NS5A	NUCB1	4924	18985028	Two Hybrid Test (MI:0018)
hcv0535	NS5A	PARVG	64098	18985028	Two Hybrid Test (MI:0018)
hcv0536	NS5A	PMVK	10654	18985028	Two Hybrid Test (MI:0018) Two Hybrid Test (MI:0018); Co-affinity
hcv0537	NS5A	PPP1R13L	10848	18985028	purification (MI:0025)
hcv0538	NS5A	PSMB9	5698	18985028	Two Hybrid Test (MI:0018); Co-affinity purification (MI:0025)
hcv0539	NS5A	RPL18A	6142	18985028	Two Hybrid Test (MI:0018)
hcv0540	NS5A	RRBP1	6238	18985028	Two Hybrid Test (MI:0018)
hcv0541	NS5A	SHARPIN	81858	18985028	Two Hybrid Test (MI:0018)
hcv0542	NS5A	SMYD3	64754	18985028	Two Hybrid Test (MI:0018)
hcv0543	NS5A	SORBS2	8470	18985028	Two Hybrid Test (MI:0018); Co-affinity purification (MI:0025)
hcv0544	NS5A	SORBS3	10174	18985028	Two Hybrid Test (MI:0018)
hcv0545	NS5A	THBS1	7057	18985028	Two Hybrid Test (MI:0018)
hcv0546	NS5A	TMF1	7110	18985028	Two Hybrid Test (MI:0018)
hcv0547	NS5A	TP53BP2	7159	18985028	Two Hybrid Test (MI:0018)
hcv0548	NS5A	TRIOBP	11078	18985028	Two Hybrid Test (MI:0018)
hcv0549	NS5A	TXNDC11	51061	18985028	Two Hybrid Test (MI:0018); Co-affinity purification (MI:0025)
hcv0550	NS5A	UBASH3A	53347	18985028	Two Hybrid Test (MI:0018)
hcv0551	NS5A	USP19	10869	18985028	Two Hybrid Test (MI:0018)
hcv0552	NS5A	VPS52	6293	18985028	Two Hybrid Test (MI:0018); Co-affinity purification (MI:0025)
hcv0553	NS5A	GIN1	54826	18985028	Two Hybrid Test (MI:0018)
hcv0554	NS5A	ZNF646	9726	18985028	Two Hybrid Test (MI:0018)
					GST pull-down (MI:0059); Affinity
hcv0555	NS5A NS5A	NS5B TRAF2	951475 7186	11801599 11821416	Chromatography (MI:0004) Coimmunoprecipitation (MI:0019); Colocalization (MI:0403); Immunostaining (MI:0022); Affinity Chromatography (MI:0004)
hav0557	NC5A	TRADD	0717	11006260	Pull-down (MI:0096); Coimmunoprecipitation
hcv0557	NS5A		8717	11886269	(MI:0019); Colocalization (MI:0403)
hcv0558	NS5A	GAB1	2549	12186904	Coimmunoprecipitation (MI:0019)
hcv0559 hcv0560	NS5A NS5A	NS3 PIK3CB	951475 5291	12692242	GST pull-down (MI:0059) Coimmunoprecipitation (MI:0019); GST pull- down (MI:0059)
hcv0561	NS5A NS5A	FBXL20	84961	15893726	Coimmunoprecipitation (MI:0019)
10/0301					Coimmunoprecipitation (MI:0019); Confocal
hcv0562	NS5A	STAT1	6772	17275127	microscopy (MI:0663)
hcv0563	NS5A	MYD88	4615	17567694	Coimmunoprecipitation (MI:0019) GST pull-down (MI:0059); Kinase assay
hcv0564	NS5A	PDPK1	5170	17616579	(MI:0424) (MI:0424) GST pull-down (MI:0059); Kinase assay
hcv0565	NS5A	AKT1	207	17616579	(MI:0424) (MI:0424)
hcv0566	NS5A	VPS35	55737	17616579	Two Hybrid Test (MI:0018)
hcv0567	NS5A	MAPK12	6300	17616579	Kinase assay (MI:0424) (MI:0424); GST pull- down (MI:0059)
hcv0568	NS5A	IPO4	79711	17616579	Two Hybrid Test (MI:0018)

hcv0569	NS5A	GSK3B	2932	17616579	GST pull-down (MI:0059); Kinase assay (MI:0424) (MI:0424)		
hcv0570	NS5A	AHSA1	10598	17616579	Two Hybrid Test (MI:0018)		
110/05/10	NSJA	AIISAI	10398	17010579	GST pull-down (MI:0059); Kinase assay		
hcv0571	NS5A	GSK3A	2931	17616579	(MI:0424) (MI:0424) Kinase assay (MI:0424) (MI:0424); GST pull-		
hcv0572	NS5A	CDK6	1021	17616579	down (MI:0059)		
hcv0573	NS5A	TBC1D20	128637	17686842	Two Hybrid Test (MI:0018)		
hcv0574	NS5B	VAPA	9218	10544080	Two Hybrid Test (MI:0018); Coimmunoprecipitation (MI:0019); Immunofluorescence (MI:0022); Affinity Chromatography (MI:0004); Immunostaining (MI:0022) Two Hybrid Test (MI:0018);		
hcv0575	NS5B	EIF4A2	1974	11922617	Coimmunoprecipitation (MI:0019); Affinity Chromatography (MI:0004)		
hcv0576	NS5B	NCL	4691	12427757	GST pull-down (MI:0059); Affinity Chromatography (MI:0004); Immunostaining (MI:0022)		
hcv0577	NS5B	NS5B	951475	12692242	Two Hybrid Test (MI:0018)		
hcv0578	NS5B	HAO1	54363	14623081	Coimmunoprecipitation (MI:0019); Immunofluorescence (MI:0022); Confocal microscopy (MI:0663); Two Hybrid Test (MI:0018)		
					Coimmunoprecipitation (MI:0019); Immunofluorescence (MI:0022); Confocal		
1 0570	NGED	TTCA	72.00	14600001	microscopy (MI:0663); Two Hybrid Test		
hcv0579	NS5B	TTC4	7268	14623081	(MI:0018) Two Hybrid Test (MI:0018);		
hcv0580	NS5B	ACTN1	87	14623081	Coimmunoprecipitation (MI:0019); Immunofluorescence (MI:0022); Confocal microscopy (MI:0663); Immunostaining (MI:0022)		
			1		Coimmunoprecipitation (MI:0019); GST pull-		
hcv0581	NS5B	VAPA	9218	15016871	down (MI:0059) Coimmunoprecipitation (MI:0019);		
hcv0582	NS5B	DDX5	1655	15113910	Immunostaining (MI:0022); Two Hybrid Test		
hcv0583	NS5B	PKN2	5586	15364941	Coimmunoprecipitation (MI:0019); Colocalization (MI:0403); Kinase assay (MI:0424) (MI:0424); Metabolic labeling (MI:2131)		
hcv0584	NS5B	PTBP2	58155	15823607	Immunofluorescence (MI:0022); GST pull-down (MI:0059); Colocalization (MI:0403); Coimmunoprecipitation (MI:0019)		
hcv0585	NS5B	FBXL2	25827	15893726	[(3)H]mevalonate labeling (MI:2131); Coimmunoprecipitation (MI:0019)		
hcv0586	NS5B	PPIB	5479	15989969	GST pull-down (MI:0059); Coimmunoprecipitation (MI:0019); Colocalization (MI:0403); Cross Linking (MI:0030)		
hcv0587	NS5B	VAPB	9217	16227268	Coimmunoprecipitation (MI:0019); Mutational analysis (MI:0074); Affinity Chromatography (MI:0004)		
hcv0588	NS5B	CHUK	1147	16581780	Coimmunoprecipitation (MI:0019)		
hcv0589	NS5B	CEP250	11190	18985028	Two Hybrid Test (MI:0018)		
hcv0590	NS5B	CEP68	23177	18985028	Two Hybrid Test (MI:0018)		
hcv0591	NS5B	HOXD8	3234	18985028	Two Hybrid Test (MI:0018)		
hcv0592	NS5B	MGC2752	65996	18985028	Two Hybrid Test (MI:0018)		
hcv0593	NS5B	MOBK1B	55233	18985028	Two Hybrid Test (MI:0018); Co-affinity purification (MI:0025)		
hcv0594	NS5B	NR4A1	3164	18985028	Two Hybrid Test (MI:0018)		
hcv0595	NS5B	OS9	10956	18985028	Two Hybrid Test (MI:0018); Co-affinity purification (MI:0025)		
hcv0596	NS5B	PKM2	5315	18985028	Two Hybrid Test (MI:0018)		

hcv0597	NS5B	PSMB9	5698	18985028	Two Hybrid Test (MI:0018); Co-affinity purification (MI:0025)
hcv0598	NS5B	SETD2	29072	18985028	Two Hybrid Test (MI:0018)
hcv0599	NS5B	SHARPIN	81858	18985028	Two Hybrid Test (MI:0018)
hcv0600	NS5B	TUBB2C	10383	18985028	Two Hybrid Test (MI:0018)
hcv0601	NS5B	NS5B	951475	11907226	Gel filtration (MI:0071); Cross Linking (MI:0030); Two Hybrid Test (MI:0018); Three dimensional structure (MI:0105); Temperature sensitivity (MI:0271)
hcv0602	NS5B	UBQLN1	29979	12634373	Two Hybrid Test (MI:0018); Coimmunoprecipitation (MI:0019)
hcv0603	NS5B	CINP	51550	14623081	Two Hybrid Test (MI:0018)
hcv0604	NS5B	PSMB4	5692	14623081	Two Hybrid Test (MI:0018)
hcv0605	NS5B	6-Sep	23157	17229681	Coimmunoprecipitation (MI:0019); Two Hybrid Test (MI:0018)
hcv0606	NS5B	HNRNPA1	3178	17229681	Coimmunoprecipitation (MI:0019); Two Hybrid Test (MI:0018)
hcv0607	р7	P7	951475	12560074	Cross Linking (MI:0030); Immunoblotting (MI:0113)
hcv0608	p7	FMNL1	752	16094715	Two Hybrid Test (MI:0018)
hcv0609	p7	H19	283120	16094715	Two Hybrid Test (MI:0018)
hcv0610	p7	ISLR	3671	16094715	Two Hybrid Test (MI:0018)
hcv0611	p7	MS4A6A	64231	16094715	Two Hybrid Test (MI:0018)
hcv0612	p7	NUP214	8021	16094715	Two Hybrid Test (MI:0018)
hcv0613	p7	SSR4	6748	16094715	Two Hybrid Test (MI:0018)
hcv0614	p7	STRBP	55342	16094715	Two Hybrid Test (MI:0018)
hcv0615	р7	CREB3	10488	18985028	Two Hybrid Test (MI:0018)
hcv0616	p7	FBLN2	2199	18985028	Two Hybrid Test (MI:0018)
hcv0617	p7	FXYD6	53826	18985028	Two Hybrid Test (MI:0018)
hcv0618	p7	LMNB1	4001	18985028	Two Hybrid Test (MI:0018)
hcv0619	p7	SLIT2	9353	18985028	Two Hybrid Test (MI:0018)
hcv0620	p7	UBQLN1	29979	18985028	Two Hybrid Test (MI:0018)
hcv0621	p7	UBQLN4	56893	18985028	Two Hybrid Test (MI:0018)

Appendix IV (Chapter 3)

HCVpro ID	Molecule A	HCV Genotype	HCV isolate/strain	HCV Molecule A Protein Accession	Molecule B Gene Symbols	HCV Molecule B Protein Accession	Genotype Source
hcv0001	CORE	HCV genotype 1a	H77	NP_751919	LTBR		VirHostNet
hcv0002	CORE	HCV genotype 1b			APOA2		HCVpro
hcv0003	CORE	HCV genotype 1b			TP53		HCVpro
hcv0004	CORE	HCV genotype 1a	H77	NP_751919	LTBR		VirHostNet
hcv0005	CORE	HCV genotype 1a	H77	NP_751919	HNRNPK		BIND
hcv0006	CORE	HCV genotype 1a	H77	NP_751919	CORE	NP_751919	BIND
hcv0007	CORE	HCV genotype 1a	H77	NP_751919	DDX3X		VirHostNet
hcv0008	CORE	HCV genotype 1a	H77	NP_751919	DDX3X		BIND
hcv0009	CORE	HCV genotype 1a		AAA45676	DDX3X		BIND
hcv0010	CORE	HCV genotype 1a	H77	NP_751919	APOA2		VirHostNet
hcv0011	CORE	HCV genotype 1a	H77	NP_751919	TP53		BIND
hcv0012	CORE	HCV genotype 1b		u u u	YWHAB		HCVpro
hcv0013	CORE	HCV genotype 1b	UNIV	ERSITY	YWHAZ		HCVpro
hcv0014	CORE	HCV genotype 1a	H77	NP_751919	CREB3		VirHostNet
hcv0015	CORE	HCV genotype 1a	strain H	AAA45534	CORE	AAA45534	HCVpro
hcv0016	CORE	HCV genotype 1b	Isolate S98	BAC54273	CDKN1A		BIND
hcv0017	CORE	HCV genotype 1b			TAF11		HCVpro
hcv0018	CORE	HCV genotype 1b			TP53		HCVpro
hcv0019	CORE	HCV genotype 1a	H77	NP_751919	C1QBP		VirHostNet
hcv0020	CORE	HCV genotype 1b	Isolate S98	BAC54273	TNFRSF1A		BIND
hcv0021	CORE	HCV genotype 1a	H77	NP_751919	FADD		VirHostNet
hcv0022	CORE	Genotype 1b	Korean isolate	BAA01943.1	TNF		HCVpro
hcv0023	CORE	Genotype 1b	Korean isolate	BAA01943.1	TRADD		HCVpro
hcv0024	CORE	Genotype 1b	Korean isolate	BAA01943.1	TRAF2		HCVpro
hcv0025	CORE	HCV genotype 1a	H77	NP_751919	RXRA		VirHostNet
hcv0026	CORE	HCV genotype 1a	H77	NP_751919	STAT3		VirHostNet
hcv0027	CORE	HCV genotype 1a	H77	NP_671491	TSN		BIND
hcv0028	CORE	HCV genotype 1a	H77	NP_751919	FUNDC2		VirHostNet

HCV proteins assigned with information relating to their genotype/strain sources.

		HCV				
hcv0029	CORE	genotype 1a			TP73	HCVpro
hcv0030	CORE	HCV genotype 1a			TP53	HCVpro
hcv0031	CORE	HCV genotype 1b			JAK1	HCVpro
hcv0032	CORE	HCV genotype 1b			JAK2	HCVpro
hcv0033	CORE	HCV genotype 1a			FAS	HCVpro
hcv0034	CORE	HCV genotype 1a	H77	NP_751919	CCNH	VirHostNet
hcv0035	CORE	HCV genotype 1a	H77	NP_751919	ТВР	VirHostNet
		HCV	П//			
hcv0036	CORE	genotype 1b HCV		AAR06173.1	TP53BP2	BIND
hcv0037	CORE	genotype 1a HCV	H77	NP_751919	SMAD3	VirHostNet
hcv0038	CORE	genotype 1b HCV	L02	AB077729.1	EP300	HCVpro
hcv0039	CORE	genotype 1b	L02	AB077729.1	CREBBP	HCVpro
hcv0040	CORE				TLR2	Not assigned
hcv0041	CORE	HCV genotype 1a	H77	NP_751919	HLA-A	VirHostNet
hcv0042	CORE	HCV genotype 1a	H77	NP_751919	HLA-E	VirHostNet
hcv0043	CORE	HCV genotype 1a	H77	NP_751919	STAT1	VirHostNet
hcv0044	CORE	HCV genotype 1b	pCV-J4L8	AAC15730	ACP1	HCVpro
hcv0045	CORE	HCV genotype 1b	pCV-J4L8	AAC15730	CFL1	HCVpro
hcv0046	CORE	HCV genotype 1b	pCV-J4L8	AAC15730	FKBP7	HCVpro
hcv0047	CORE	HCV genotype 1b	pCV-J4L8	AAC15730	HSPD1	HCVpro
hcv0048	CORE	HCV genotype 1b	pCV-J4L8	AAC15730	KRT18	HCVpro
hcv0049	CORE	HCV genotype 1b	pCV-J4L8	AAC15730	KRT19	HCVpro
hcv0050	CORE	HCV genotype 1b	pCV-J4L8	AAC15730	KRT8	HCVpro
hcv0051	CORE	HCV genotype 1b	pCV-J4L8	AAC15730	SLC22A7	HCVpro
hcv0051	CORE	HCV genotype 1b	pCV-J4L8	AAC15730	TATDN1	HCVpro
		HCV	1			
hcv0053	CORE	genotype 1b HCV	pCV-J4L8	AAC15730	GLRX3	HCVpro
hcv0054	CORE	genotype 1b HCV	pCV-J4L8	AAC15730	VIM	HCVpro
hcv0055	CORE	genotype 1a HCV	H77	NP_751919	NPM1	VirHostNet
hcv0056	CORE	genotype 1a	H77	NP_751919	YY1	VirHostNet
hcv0057	CORE	HCV genotype 1a	H77	NP_751919	PML	VirHostNet
hcv0058	CORE	HCV genotype 1a	strain H77	NP_751919	DICER1	VirHostNet
hcv0059	CORE	HCV genotype 1a			PSME3	HCVpro
hcv0060	CORE	HCV genotype 1a			DICER1	 HCVpro
hcv0061	CORE	HCV genotype 1b	isolate con1	AJ238799	AGRN	HCVpro
hcv0062	CORE	HCV genotype 1b	isolate con1	AJ238799	BCAR1	 HCVpro

	1	HCV					
hcv0063	CORE	genotype 1b	isolate con1	AJ238799	CD68		HCVpro
hcv0064	CORE	HCV genotype 1b	isolate con1	AJ238799	COL4A2		HCVpro
hcv0065	CORE	HCV genotype 1b	isolate con1	AJ238799	DDX3Y		HCVpro
hcv0066	CORE	HCV genotype 1b	isolate con1	AJ238799	EGFL7		HCVpro
hcv0067	CORE	HCV genotype 1b	isolate con1	AJ238799	FBLN2		HCVpro
hcv0068	CORE	HCV genotype 1b	isolate con1	AJ238799	FBLN5		HCVpro
		HCV					
hcv0069	CORE	genotype 1b HCV	isolate con1	AJ238799	GAPDH		HCVpro
hcv0070	CORE	genotype 1b HCV	isolate con1	AJ238799	GRN		HCVpro
hcv0071	CORE	genotype 1b HCV	isolate con1	AJ238799	HIVEP2		HCVpro
hcv0072	CORE	genotype 1b HCV	isolate con1	AJ238799	HOXD8		HCVpro
hcv0073	CORE	genotype 1b	isolate con1	AJ238799	LPXN		HCVpro
hcv0074	CORE	HCV genotype 1b	isolate con1	AJ238799	LRRTM1		HCVpro
hcv0075	CORE	HCV genotype 1b	isolate con1	AJ238799	LTBP4		HCVpro
hcv0076	CORE	HCV genotype 1b	isolate con1	AJ238799	MAGED1		HCVpro
hcv0077	CORE	HCV genotype 1b	isolate con1	AJ238799	MEGF6		HCVpro
hcv0078	CORE	HCV genotype 1b	isolate con1	AJ238799	MMRN2		HCVpro
		HCV		AJ238799			
hcv0079	CORE	genotype 1b HCV	isolate con1		NR4A1		HCVpro
hcv0080	CORE	genotype 1b HCV	isolate con1	AJ238799	PABPN1		HCVpro
hcv0081	CORE	genotype 1b HCV	isolate con1	AJ238799	PAK4		HCVpro
hcv0082	CORE	genotype 1b HCV	isolate con1	AJ238799	PLSCR1		HCVpro
hcv0083	CORE	genotype 1b HCV	isolate con1	AJ238799	RNF31		HCVpro
hcv0084	CORE	genotype 1b	isolate con1	AJ238799	SETD2		HCVpro
hcv0085	CORE	HCV genotype 1b	isolate con1	AJ238799	SLC31A2		HCVpro
hcv0086	CORE	HCV genotype 1b	isolate con1	AJ238799	VWF		HCVpro
hcv0087	CORE	HCV genotype 1b	isolate con1	AJ238799	ZNF271		HCVpro
hcv0088	CORE	HCV genotype 1b			YWHAE		HCVpro
hcv0089	CORE	HCV	H77	NP_751919	NS5A	NP 751927	BIND
		genotype 1a HCV		_			
hcv0090	CORE	genotype 1a HCV	H77	NP_751919	NS5B	NP_751928	VirHostNet
hcv0091	CORE	genotype 1a HCV	H77	NP_751919	RSF1		VirHostNet
hcv0092	CORE	genotype 1a HCV	H77	NP_751919	E1	NP_751920	BIND
hcv0093	CORE	genotype 1a HCV	H77	NP_751919	SP110		VirHostNet
hcv0094	CORE	genotype 1a	H77	NP_751919	KPNA1		VirHostNet
hcv0095	CORE	HCV genotype 1b	pCV-J4L8	AAC15730	DDX5		HCVpro
		HCV	Singapore				

hcv0097	CORE	HCV	studio 1177	ND 751010	EIE2AK2		VirHeatNat
		genotype 1a HCV	strain H77	NP_751919	EIF2AK2		VirHostNet
hcv0098	CORE	genotype 1a HCV	strain H77	NP_751919	PPARA		VirHostNet
hcv0099	CORE	genotype 1a HCV	strain H77	NP_751919	ACY3		VirHostNet
hcv0100	CORE	genotype 1a HCV	H77	NP_751919	MCL1		VirHostNet
hcv0101	CORE	genotype 1a	H77	NP_751919	CORE	NP_751919	VirHostNet
hcv0102	CORE	HCV genotype 1a	H77	NP_751919	CORE		VirHostNet
hcv0103	E1	HCV genotype 1a	H77	NP_751920	E2	NP_751921	VirHostNet
hcv0104	E1	HCV genotype 1a	H77	NP_751920	CORE	NP_751919	VirHostNet
hcv0105	E1	HCV genotype 1a	H77	NP_751920	LTF		VirHostNet
hcv0106	E1	HCV genotype 1a	H77	NP_751920	CALR		VirHostNet
hcv0107	E1	HCV genotype 1a	H77	NP_751920	CANX		VirHostNet
hcv0108	E1	HCV genotype 1a	H77	NP_751920	HSPA5		VirHostNet
hcv0109	E1	HCV genotype 1a	Isolate H	P27958	E2	P27958	BIND
hcv0110	E1	HCV genotype 1a	H77	NP 751920	E2	NP 751921	BIND
hcv0111	E1	HCV genotype 1a	H77	AF009606	CD209		HCVpro
	El	HCV	m – m	- n - n - n -	111		1
hcv0112		genotype 1a HCV	H77	AF009606	CLEC4M		HCVpro
hcv0113	E1	genotype 1a HCV	H77	NP_671491	E2		BIND
hcv0114	E1	genotype 1b HCV	UNIV	ERSITY	CD209		HCVpro
hcv0115	E1	genotype 1b HCV	isolate con1	AJ238799	JUN		HCVpro
hcv0116	E1	genotype 1b HCV	isolate con1	AJ238799	NR4A1		HCVpro
hcv0117	E1	genotype 1b HCV	isolate con1	AJ238799	PFN1		HCVpro
hcv0118	E1	genotype 1b	isolate con1	AJ238799	SETD2		HCVpro
hcv0119	E1	HCV genotype 1b	isolate con1	AJ238799	TMSB4X		HCVpro
hcv0120	E1	HCV genotype 1a	strain H	AAA45534	NS5A	AAA45534	HCVpro
hcv0121	E1	HCV genotype 1a	H77	NP_751920	E2	NP_751921	VirHostNet
hcv0122	E2	HCV genotype 1a	H77	NP_751921	LTF		VirHostNet
hcv0123	E2	HCV genotype 1a	H77	NP_751921	CALR		VirHostNet
hcv0124	E2	HCV genotype 1a	H77	NP_751921	CANX		VirHostNet
hcv0125	E2	HCV genotype 1a	H77	NP_751921	HSPA5		VirHostNet
hcv0126	E2	HCV genotype 1a	H77	NP_751921	EIF2AK2		VirHostNet
hcv0120	E2	HCV genotype 1a	strain H	AAA45534	NS3	AAA45534	HCVpro
		HCV				56643334	
hcv0128	E2	genotype 1a HCV	H77	NP_671491	CD81		BIND
hcv0129	E2	genotype 1a HCV	isolate H	P27958	CD81		BIND
hcv0130	E2	genotype 1a	H77	NP_751921	SCARB1		VirHostNet

h0121	EQ	HCV			CD91		UCVere
hcv0131	E2	genotype 1b HCV			CD81		HCVpro
hcv0132	E2	genotype 1b HCV			LTF		HCVpro
hcv0133	E2	genotype 1b HCV			TF		HCVpro
hcv0134	E2	genotype 1a HCV	H77	NP_751921	CD81		BIND
hcv0135	E2	genotype 1a	H77	NP_751921	EIF2AK3		VirHostNet
hcv0136	E2	HCV genotype 1a	H77	AF009606	CD209		HCVpro
hcv0137	E2	HCV genotype 1a	H77	AF009606	CLEC4M		HCVpro
hcv0138	E2	HCV genotype 1a	H77	NP_751921	SDC2		VirHostNet
hcv0139	E2	HCV genotype 1b			CD209		HCVpro
hcv0140	E2	HCV genotype 1b	isolate con1	AJ238799	HOXD8		HCVpro
		HCV					
hcv0141	E2	genotype 1b HCV	isolate con1	AJ238799	ITGB1		HCVpro
hcv0142	E2	genotype 1b HCV	isolate con1	AJ238799	FAM135A		HCVpro
hcv0143	E2	genotype 1b HCV	isolate con1	AJ238799	NR4A1		HCVpro
hcv0144	E2	genotype 1b HCV	isolate con1	AJ238799	PSMA6		HCVpro
hcv0145	E2	genotype 1b	isolate con1	AJ238799	SETD2		HCVpro
hcv0146	E2	HCV genotype 1b	isolate con1	AJ238799	SMEK2		HCVpro
hcv0147	F	HCV genotype 1b			C14orf135		HCVpro
hcv0148	F	HCV genotype 1b	TINITY	DOUDN	ZNF83		HCVpro
hcv0149	F	HCV genotype 1a	strain H77	NP_803170	PFDN2		VirHostNet
hcv0150	F	HCV genotype 1a	strain H77	NP_803170	PFDN5		VirHostNet
hcv0151	F	HCV genotype 1b			AGT		HCVpro
hcv0152	F	HCV			AZGP1		HCVpro
		genotype 1b HCV					
hcv0153	F	genotype 1b HCV			CTSB		HCVpro
hcv0154	F	genotype 1b HCV			MPDU1		HCVpro
hcv0155	F	genotype 1b HCV			RAB14		HCVpro
hcv0156	F	genotype 1b HCV			SERPINC1		HCVpro
hcv0157	F	genotype 1b			ST3GAL1		HCVpro
hcv0158	F	HCV genotype 1b			vitronectin		HCVpro
hcv0159	F	HCV genotype 1b			ZG16		HCVpro
hcv0160	NS2	HCV genotype 1a	strain H	AAA45534	NS4A	AAA45534	HCVpro
hcv0161	NS2	HCV genotype 1b	Strain J		NS3		HCVpro
hcv0162	NS2	HCV genotype 1a	Strain H		CIDEB		BIND
hcv0163	NS2	HCV genotype 1a	H77	AF009606	NS4B	AF009606	HCVpro
		HCV					1
hcv0164	NS2	genotype 1a	H77	AF009606	NS4A	AF009606	HCVpro

		HCV					
hcv0165	NS2	genotype 1a	H77	AF009606	NS5B	AF009606	HCVpro
hcv0166	NS2	HCV genotype 1a	H77	AF009606	NS2	AF009606	HCVpro
hcv0167	NS2	HCV genotype 1a	H77	AF009606	NS3	AF009606	HCVpro
hcv0168	NS2	HCV genotype 1b	isolate con1	AJ238799	C7		HCVpro
hcv0169	NS2	HCV genotype 1b	isolate con1	AJ238799	FBLN5		HCVpro
hcv0170	NS2	HCV genotype 1b	isolate con1	AJ238799	HOXD8		HCVpro
		HCV					<u> </u>
hcv0171	NS2	genotype 1b HCV	isolate con1	AJ238799	NR4A1		HCVpro
hcv0172	NS2	genotype 1b HCV	isolate con1	AJ238799	POU3F2		HCVpro
hcv0173	NS2	genotype 1b HCV	isolate con1	AJ238799	SETD2		HCVpro
hcv0174	NS2	genotype 1b HCV	isolate con1	AJ238799	TRIM27		HCVpro
hcv0175	NS2	genotype 1a	H77	AF009606	NS5A	AF009606	HCVpro Not
hcv0176	NS3				NS4A		assigned
hcv0177	NS3	HCV genotype 1b		AAA72945	MBP		VirHostNet
hcv0178	NS3	HCV genotype 1b		AAA72945	PRM1		VirHostNet
hcv0179	NS3	HCV genotype 1b	, hu cunt	AAA72945	HIST4H4		VirHostNet
hcv0180	NS3	HCV genotype 1b		AAA72945	HIST3H2BB		VirHostNet
hcv0181	NS3	HCV genotype 1b		AAA72945	PRKACA		VirHostNet
hcv0182	NS3	HCV genotype 1b	HCV isolate BK	P26663	PRKACA		BIND
		HCV	UNIV.	ERSITY	of the	ND (71401	
hcv0183	NS3	genotype 1a HCV	H77	NP_671491	NS3	NP_671491	BIND
hcv0184	NS3	genotype 1a HCV	H77	AAB66324	TP53		VirHostNet
hcv0185	NS3	genotype 1a HCV	H77 HCV isolate	AAB66324	NS4A	AAB66324	VirHostNet
hcv0186	NS3	genotype 1b HCV	BK	P26663	NS4A	P26663	BIND
hcv0187	NS3	genotype 1a HCV	H77	AAB66324	HIST3H2BB		VirHostNet
hcv0188	NS3	genotype 1a HCV	H77	AAB66324	HIST4H4		VirHostNet
hcv0189	NS3	genotype 1b	Isolate G01		SERPINF2		HCVpro
hcv0190	NS3	HCV genotype 1b	Isolate G01		SERPING1		HCVpro
hcv0191	NS3	HCV genotype 1a	strain H	AAA45534	NS4A	AAA45534	HCVpro
hcv0192	NS3	HCV genotype 1a	H77	NP_803144	PRMT5		BIND
hcv0193	NS3	HCV genotype 1b	Con1	CAB46677	PRMT1		BIND
hcv0194	NS3	HCV genotype 1a	H77	AAB66324	NS3		VirHostNet
hcv0195	NS3	HCV genotype 1a	H77	AF009606	NS4B	AF009606	HCVpro
hcv0196	NS3	HCV	H77	AF009606	NS4A	AF009606	HCVpro
		genotype 1a HCV					
hcv0197	NS3	genotype 1a HCV	H77	AF009606	NS3	AF009606	HCVpro
hcv0198	NS3	genotype 1a			IRF3		HCVpro

hcv0199	NS3	HCV genotype 1a		AAA45676.1	SNRPD1	BIND
hcv0200	NS3				NS4A	Not assigned
hcv0201	NS3				NS4A	Not assigned
hcv0202	NS3	HCV genotype 1b	Isolate HCV- S1	AAL00900	PSMB8	BIND
hcv0203	NS3	HCV genotype 1a	H77	NP_803144	SMAD3	VirHostNet
hcv0204	NS3	0 01			NS4A	Not assigned
hcv0204	NS3				TLR2	Not assigned
hcv0206	NS3	HCV genotype 1a	H77	NP_803144	TICAM1	VirHostNet
hcv0207	NS3	HCV	H77	NP_803144	PTBP2	VirHostNet
		genotype 1a HCV				
hcv0208	NS3	genotype 1a HCV	H77	NP_803144	IKBKE	VirHostNet
hcv0209	NS3	genotype 1a HCV	H77	NP_803144	TBK1	VirHostNet
hcv0210	NS3	genotype 1a	H77	NP_803144	ERC1	VirHostNet Not
hcv0211	NS3				NS4A	assigned
hcv0212	NS3				NS4A	Not assigned
hcv0213	NS3		'preme		NS4A	Not assigned
hcv0214	NS3				NS4A	Not assigned
hcv0215	NS3	HCV genotype 1a			VISA	HCVpro
hcv0216	NS3	HCV genotype 1b		DOVERN	NS5B	HCVpro
hcv0217	NS3	HCV genotype 1b	isolate con1	AJ238799	ACTN1	HCVpro
hcv0218	NS3	HCV genotype 1b	isolate con1	AJ238799	ACTN2	HCVpro
hcv0219	NS3	HCV genotype 1b	isolate con1	AJ238799	AEBP1	HCVpro
	NS3	HCV	isolate con1			
hcv0220		genotype 1b HCV		AJ238799	ANKRD12	HCVpro
hcv0221	NS3	genotype 1b HCV	isolate con1	AJ238799	ANKRD28	HCVpro
hcv0222	NS3	genotype 1b HCV	isolate con1	AJ238799	ARFIP2	HCVpro
hcv0223	NS3	genotype 1b HCV	isolate con1	AJ238799	ARHGEF6	HCVpro
hcv0224	NS3	genotype 1b	isolate con1	AJ238799	ARNT	HCVpro
hcv0225	NS3	HCV genotype 1b	isolate con1	AJ238799	ARS2	HCVpro
hcv0226	NS3	HCV genotype 1b	isolate con1	AJ238799	ASXL1	HCVpro
hcv0227	NS3	HCV genotype 1b	isolate con1	AJ238799	B2M	HCVpro
hcv0228	NS3	HCV genotype 1b	isolate con1	AJ238799	BCAN	HCVpro
hcv0229	NS3	HCV genotype 1b	isolate con1	AJ238799	BCKDK	HCVpro
hcv0230	NS3	HCV genotype 1b	isolate con1	AJ238799	BCL2A1	HCVpro
hcv0231	NS3	HCV genotype 1b	isolate con1	AJ238799	BCL6	HCVpro
hcv0232	NS3	HCV genotype 1b	isolate con1	AJ238799	BZRAP1	HCVpro

		HCV				
hcv0233	NS3	genotype 1b HCV	isolate con1	AJ238799	C10orf18	HCVpro
hcv0234	NS3	genotype 1b	isolate con1	AJ238799	C10orf6	HCVpro
hcv0235	NS3	HCV genotype 1b	isolate con1	AJ238799	C12orf41	HCVpro
hcv0236	NS3	HCV genotype 1b	isolate con1	AJ238799	INF2	HCVpro
hcv0237	NS3	HCV genotype 1b	isolate con1	AJ238799	C16orf7	HCVpro
hcv0238	NS3	HCV genotype 1b	isolate con1	AJ238799	BEND5	HCVpro
hcv0239	NS3	HCV genotype 1b	isolate con1	AJ238799	C1orf94	HCVpro
hcv0240	NS3	HCV genotype 1b	isolate con1	AJ238799	C9orf30	HCVpro
hcv0240	NS3	HCV	isolate con1	AJ238799	CALCOCO2	HCVpro
		genotype 1b HCV				
hcv0242	NS3	genotype 1b HCV	isolate con1	AJ238799	CBY1	HCVpro
hcv0243	NS3	genotype 1b HCV	isolate con1	AJ238799	CCDC21	HCVpro
hcv0244	NS3	genotype 1b HCV	isolate con1	AJ238799	CCDC37	HCVpro
hcv0245	NS3	genotype 1b HCV	isolate con1	AJ238799	CCDC52	HCVpro
hcv0246	NS3	genotype 1b HCV	isolate con1	AJ238799	CCDC66	HCVpro
hcv0247	NS3	genotype 1b	isolate con1	AJ238799	INO80E	HCVpro
hcv0248	NS3	HCV genotype 1b	isolate con1	AJ238799	CCHCR1	HCVpro
hcv0249	NS3	HCV genotype 1b	isolate con1	AJ238799	CD5L	HCVpro
hcv0250	NS3	HCV genotype 1b	isolate con1	AJ238799	CDC23	HCVpro
hcv0251	NS3	HCV genotype 1b	isolate con1	AJ238799	CELSR2	HCVpro
hcv0252	NS3	HCV genotype 1b	isolate con1	AJ238799	CEP152	HCVpro
hcv0253	NS3	HCV genotype 1b	isolate con1	AJ238799	CEP192	HCVpro
hcv0254	NS3	HCV genotype 1b	isolate con1	AJ238799	CFP	HCVpro
hcv0255	NS3	HCV genotype 1b	isolate con1	AJ238799	CHPF	
		HCV				HCVpro
hcv0256	NS3	genotype 1b HCV	isolate con1	AJ238799	CORO1B	HCVpro
hcv0257	NS3	genotype 1b HCV	isolate con1	AJ238799	CSNK2B	HCVpro
hcv0258	NS3	genotype 1b HCV	isolate con1	AJ238799	CTGF	HCVpro
hcv0259	NS3	genotype 1b HCV	isolate con1	AJ238799	ALG13	HCVpro
hcv0260	NS3	genotype 1b HCV	isolate con1	AJ238799	DEAF1	HCVpro
hcv0261	NS3	genotype 1b HCV	isolate con1	AJ238799	DES	HCVpro
hcv0262	NS3	genotype 1b	isolate con1	AJ238799	DLAT	HCVpro
hcv0263	NS3	HCV genotype 1b	isolate con1	AJ238799	DOCK7	HCVpro
hcv0264	NS3	HCV genotype 1b	isolate con1	AJ238799	DPF1	HCVpro
hcv0265	NS3	HCV genotype 1b	isolate con1	AJ238799	DPP7	HCVpro
hcv0266	NS3	HCV genotype 1b	isolate con1	AJ238799	EEF1A1	HCVpro

		HCV				
hcv0267	NS3	genotype 1b HCV	isolate con1	AJ238799	EFEMP1	HCVpro
hcv0268	NS3	genotype 1b HCV	isolate con1	AJ238799	EFEMP2	HCVpro
hcv0269	NS3	genotype 1b	isolate con1	AJ238799	EIF1	HCVpro
hcv0270	NS3	HCV genotype 1b	isolate con1	AJ238799	EIF4ENIF1	HCVpro
hcv0271	NS3	HCV genotype 1b	isolate con1	AJ238799	FAM120B	HCVpro
hcv0272	NS3	HCV genotype 1b	isolate con1	AJ238799	FAM65A	HCVpro
hcv0273	NS3	HCV genotype 1b	isolate con1	AJ238799	FBF1	HCVpro
hcv0274	NS3	HCV genotype 1b	isolate con1	AJ238799	FBLN1	HCVpro
	NS3	HCV	isolate con1		FBLN2	^
hcv0275		genotype 1b HCV		AJ238799		HCVpro
hcv0276	NS3	genotype 1b HCV	isolate con1	AJ238799	FBLN5	HCVpro
hcv0277	NS3	genotype 1b HCV	isolate con1	AJ238799	FBN1	HCVpro
hcv0278	NS3	genotype 1b HCV	isolate con1	AJ238799	FBN3	HCVpro
hcv0279	NS3	genotype 1b	isolate con1	AJ238799	FES	HCVpro
hcv0280	NS3	HCV genotype 1b	isolate con1	AJ238799	FIGNL1	HCVpro
hcv0281	NS3	HCV genotype 1b	isolate con1	AJ238799	FLAD1	HCVpro
hcv0282	NS3	HCV genotype 1b	isolate con1	AJ238799	C19orf66	HCVpro
hcv0283	NS3	HCV genotype 1b	isolate con1	AJ238799	FN1	HCVpro
hcv0284	NS3	HCV genotype 1b	isolate con1	AJ238799	FRMPD4	HCVpro
hcv0285	NS3	HCV genotype 1b	isolate con1	AJ238799	FRS3	HCVpro
hcv0286	NS3	HCV genotype 1b	isolate con1	AJ238799	FTH1	HCVpro
		HCV				
hcv0287	NS3	genotype 1b HCV	isolate con1	AJ238799	FUCA2	HCVpro
hcv0288	NS3	genotype 1b HCV	isolate con1	AJ238799	GAA	HCVpro
hcv0289	NS3	genotype 1b HCV	isolate con1	AJ238799	GBP2	HCVpro
hcv0290	NS3	genotype 1b HCV	isolate con1	AJ238799	GFAP	HCVpro
hcv0291	NS3	genotype 1b	isolate con1	AJ238799	GNB2	HCVpro
hcv0292	NS3	HCV genotype 1b	isolate con1	AJ238799	GON4L	HCVpro
hcv0293	NS3	HCV genotype 1b	isolate con1	AJ238799	HIVEP2	HCVpro
hcv0294	NS3	HCV genotype 1b	isolate con1	AJ238799	HNRNPK	HCVpro
hcv0295	NS3	HCV genotype 1b	isolate con1	AJ238799	HOMER3	HCVpro
hcv0296	NS3	HCV genotype 1b	isolate con1	AJ238799	IQWD1	HCVpro
hcv0297	NS3	HCV genotype 1b	isolate con1	AJ238799	ITGB4	HCVpro
		HCV				^
hcv0298	NS3	genotype 1b HCV	isolate con1	AJ238799	JAG2	HCVpro
hcv0299	NS3	genotype 1b HCV	isolate con1	AJ238799	JUN	HCVpro
hcv0300	NS3	genotype 1b	isolate con1	AJ238799	KHDRBS1	HCVpro

hcv0301	NS3	HCV genotype 1b	isolate con1	AJ238799	KIAA1549	HCVpro
hcv0302	NS3	HCV genotype 1b	isolate con1	AJ238799	KIF17	HCVpro
		HCV				· · · · ·
hcv0303	NS3	genotype 1b HCV	isolate con1	AJ238799	KIF7	HCVpro
hcv0304	NS3	genotype 1b HCV	isolate con1	AJ238799	KPNA1	HCVpro
hcv0305	NS3	genotype 1b	isolate con1	AJ238799	L3MBTL3	HCVpro
hcv0306	NS3	HCV genotype 1b	isolate con1	AJ238799	LAMA5	HCVpro
hcv0307	NS3	HCV genotype 1b	isolate con1	AJ238799	LAMB2	HCVpro
hcv0308	NS3	HCV genotype 1b	isolate con1	AJ238799	LAMC3	HCVpro
hcv0309	NS3	HCV genotype 1b	isolate con1	AJ238799	LDB1	HCVpro
hcv0310	NS3	HCV genotype 1b	isolate con1	AJ238799	LRRC7	HCVpro
hcv0311	NS3	HCV genotype 1b	isolate con1	AJ238799	LRRCC1	HCVpro
hcv0312	NS3	HCV genotype 1b	isolate con1	AJ238799	LTBP4	HCVpro
hcv0313	NS3	HCV genotype 1b	isolate con1	AJ238799	LZTS2	HCVpro
hcv0314	NS3	HCV genotype 1b	isolate con1	AJ238799	MAGED1	HCVpro
		HCV	THE REAL			
hcv0315	NS3	genotype 1b HCV	isolate con1	AJ238799	MAPK7	HCVpro
hcv0316	NS3	genotype 1b HCV	isolate con1	AJ238799	MEGF8	HCVpro
hcv0317	NS3	genotype 1b HCV	isolate con1	AJ238799	MLLT4	HCVpro
hcv0318	NS3	genotype 1b HCV	isolate con1	AJ238799	MLXIP	HCVpro
hcv0319	NS3	genotype 1b HCV	isolate con1	AJ238799	MORC4	HCVpro
hcv0320	NS3	genotype 1b	isolate con1	AJ238799	MORF4L1	HCVpro
hcv0321	NS3	HCV genotype 1b	isolate con1	AJ238799	MVP	HCVpro
hcv0322	NS3	HCV genotype 1b	isolate con1	AJ238799	NAP1L1	HCVpro
hcv0323	NS3	HCV genotype 1b	isolate con1	AJ238799	NAP1L2	HCVpro
hcv0324	NS3	HCV genotype 1b	isolate con1	AJ238799	NCAN	HCVpro
hcv0325	NS3	HCV genotype 1b	isolate con1	AJ238799	NDC80	HCVpro
hcv0326	NS3	HCV genotype 1b	isolate con1	AJ238799	NEFL	HCVpro
hcv0327	NS3	HCV genotype 1b	isolate con1	AJ238799	NEFM	HCVpro
hcv0328	NS3	HCV genotype 1b	isolate con1	AJ238799	NELL1	HCVpro
hcv0329	NS3	HCV	isolate con1	AJ238799	NELL2	
		genotype 1b HCV				HCVpro
hcv0330	NS3	genotype 1b HCV	isolate con1	AJ238799	NID1	HCVpro
hcv0331	NS3	genotype 1b HCV	isolate con1	AJ238799	NID2	HCVpro
hcv0332	NS3	genotype 1b HCV	isolate con1	AJ238799	NOTCH1	HCVpro
hcv0333	NS3	genotype 1b HCV	isolate con1	AJ238799	N-PAC	HCVpro
hcv0334	NS3	genotype 1b	isolate con1	AJ238799	NUP62	HCVpro

hcv0335	NS3	HCV genotype 1b	isolate con1	AJ238799	OBSCN	HCVpro
hcv0336	NS3	HCV genotype 1b	isolate con1	AJ238799	PARP4	HCVpro
hcv0337	NS3	HCV genotype 1b	isolate con1	AJ238799	PCYT2	HCVpro
		HCV				
hcv0338	NS3	genotype 1b HCV	isolate con1	AJ238799	PDE4DIP	HCVpro
hcv0339	NS3	genotype 1b HCV	isolate con1	AJ238799	PDLIM5	HCVpro
hcv0340	NS3	genotype 1b	isolate con1	AJ238799	PICK1	HCVpro
hcv0341	NS3	HCV genotype 1b	isolate con1	AJ238799	PKNOX1	HCVpro
hcv0342	NS3	HCV genotype 1b	isolate con1	AJ238799	PLEKHG4	HCVpro
hcv0343	NS3	HCV genotype 1b	isolate con1	AJ238799	PNPLA8	HCVpro
hcv0344	NS3	HCV genotype 1b	isolate con1	AJ238799	PRRC1	HCVpro
hcv0345	NS3	HCV genotype 1b	isolate con1	AJ238799	PSMB9	HCVpro
		HCV				
hcv0346	NS3	genotype 1b HCV	isolate con1	AJ238799	PSME3	HCVpro
hcv0347	NS3	genotype 1b HCV	isolate con1	AJ238799	PTPRN2	HCVpro
hcv0348	NS3	genotype 1b HCV	isolate con1	AJ238799	RABEP1	HCVpro
hcv0349	NS3	genotype 1b	isolate con1	AJ238799	RAI14	HCVpro
hcv0350	NS3	HCV genotype 1b	isolate con1	AJ238799	RASAL2	HCVpro
hcv0351	NS3	HCV genotype 1b	isolate con1	AJ238799	RBM4	HCVpro
hcv0352	NS3	HCV genotype 1b	isolate con1	AJ238799	RCN3	HCVpro
hcv0353	NS3	HCV genotype 1b	isolate con1	AJ238799	RGNEF	HCVpro
hcv0354	NS3	HCV genotype 1b	isolate con1	AJ238799	RICS	HCVpro
hcv0355	NS3	HCV genotype 1b	isolate con1	AJ238799	RINT1	HCVpro
hcv0356	NS3	HCV genotype 1b	isolate con1	AJ238799	RNF31	HCVpro
		HCV				
hcv0357	NS3	genotype 1b HCV	isolate con1	AJ238799	ROGDI	HCVpro
hcv0358	NS3	genotype 1b HCV	isolate con1	AJ238799	KIAA2022	HCVpro
hcv0359	NS3	genotype 1b HCV	isolate con1	AJ238799	RUSC2	HCVpro
hcv0360	NS3	genotype 1b HCV	isolate con1	AJ238799	SBF1	HCVpro
hcv0361	NS3	genotype 1b	isolate con1	AJ238799	SDCCAG8	HCVpro
hcv0362	NS3	HCV genotype 1b	isolate con1	AJ238799	SECISBP2	HCVpro
hcv0363	NS3	HCV genotype 1b	isolate con1	AJ238799	10-Sep	HCVpro
hcv0364	NS3	HCV genotype 1b	isolate con1	AJ238799	SERTAD1	HCVpro
hcv0365	NS3	HCV genotype 1b	isolate con1	AJ238799	SESTD1	HCVpro
hcv0366	NS3	HCV genotype 1b	isolate con1	AJ238799	SF3B2	HCVpro
hcv0367	NS3	HCV genotype 1b	isolate con1	AJ238799	SIAH1	HCVpro
1010307	NS3	HCV genotype 1b	isolate con1	AJ238799	SLIT1	HCVpro

h0260	NG2	HCV		41228700	SL IT2	UCVara
hcv0369	NS3	genotype 1b HCV	isolate con1	AJ238799	SLIT2	HCVpro
hcv0370	NS3	genotype 1b HCV	isolate con1	AJ238799	SLIT3	HCVpro
hcv0371	NS3	genotype 1b HCV	isolate con1	AJ238799	SMURF2	HCVpro
hcv0372	NS3	genotype 1b HCV	isolate con1	AJ238799	SNX4	HCVpro
hcv0373	NS3	genotype 1b	isolate con1	AJ238799	SPOCK3	HCVpro
hcv0374	NS3	HCV genotype 1b	isolate con1	AJ238799	SPON1	HCVpro
hcv0375	NS3	HCV genotype 1b	isolate con1	AJ238799	SRPX2	HCVpro
hcv0376	NS3	HCV genotype 1b	isolate con1	AJ238799	SSX2IP	HCVpro
hcv0377	NS3	HCV genotype 1b	isolate con1	AJ238799	STAB1	HCVpro
hcv0378	NS3	HCV genotype 1b	isolate con1	AJ238799	STAT3	HCVpro
hcv0379	NS3	HCV genotype 1b	isolate con1	AJ238799	SVEP1	HCVpro
hcv0380	NS3	HCV genotype 1b	isolate con1	AJ238799	SYNE1	HCVpro
hcv0381	NS3	HCV genotype 1b	isolate con1	AJ238799	SYNPO2	HCVpro
hcv0382	NS3	HCV genotype 1b	isolate con1	AJ238799	TAF1	HCVpro
		HCV	THE RULE			
hcv0383	NS3	genotype 1b HCV	isolate con1	AJ238799	TBC1D2B	HCVpro
hcv0384	NS3	genotype 1b HCV	isolate con1	AJ238799	TBXAS1	HCVpro
hcv0385	NS3	genotype 1b HCV	isolate con1	AJ238799	TGFB1I1	HCVpro
hcv0386	NS3	genotype 1b HCV	isolate con1	AJ238799	THAP1	HCVpro
hcv0387	NS3	genotype 1b HCV	isolate con1	AJ238799	TMEM63B	HCVpro
hcv0388	NS3	genotype 1b	isolate con1	AJ238799	TRIM23	HCVpro
hcv0389	NS3	HCV genotype 1b	isolate con1	AJ238799	TRIM27	HCVpro
hcv0390	NS3	HCV genotype 1b	isolate con1	AJ238799	TRIO	HCVpro
hcv0391	NS3	HCV genotype 1b	isolate con1	AJ238799	TRIP11	HCVpro
hcv0392	NS3	HCV genotype 1b	isolate con1	AJ238799	TXNDC11	HCVpro
hcv0393	NS3	HCV genotype 1b	isolate con1	AJ238799	UBA3	HCVpro
hcv0394	NS3	HCV genotype 1b	isolate con1	AJ238799	USHBP1	HCVpro
hcv0395	NS3	HCV genotype 1b	isolate con1	AJ238799	UXT	HCVpro
hcv0396	NS3	HCV genotype 1b	isolate con1	AJ238799	VCAN	HCVpro
		HCV				^
hcv0397	NS3	genotype 1b HCV	isolate con1	AJ238799	VIM	HCVpro
hcv0398	NS3	genotype 1b HCV	isolate con1	AJ238799	VWF	HCVpro
hcv0399	NS3	genotype 1b HCV	isolate con1	AJ238799	XAB2	HCVpro
hcv0400	NS3	genotype 1b HCV	isolate con1	AJ238799	XRN2	HCVpro
hcv0401	NS3	genotype 1b HCV	isolate con1	AJ238799	YY1AP1	HCVpro
hcv0402	NS3	genotype 1b	isolate con1	AJ238799	ZBTB1	HCVpro

		HCV			1		
hcv0403	NS3	genotype 1b	isolate con1	AJ238799	ZCCHC7		HCVpro
hcv0404	NS3	HCV genotype 1b	isolate con1	AJ238799	ZHX3		HCVpro
hcv0405	NS3	HCV genotype 1b	isolate con1	AJ238799	ZMYM2		HCVpro
hcv0406	NS3	HCV genotype 1b	isolate con1	AJ238799	ZNF281		HCVpro
hcv0407	NS3	HCV genotype 1b	isolate con1	AJ238799	ZNF410		HCVpro
hcv0408	NS3	HCV genotype 1b	isolate con1	AJ238799	ZZZ3		HCVpro
hcv0409	NS3	HCV genotype 1a	strain H	AAA45534	NS5B	AAA45534	HCVpro
		HCV					
hcv0410	NS3	genotype 1a HCV	H77	NP_803144	NS3	NP_803144	VirHostNet
hcv0411	NS3	genotype 1b HCV			NS5B		HCVpro
hcv0412	NS3	genotype 1b HCV			NS4B		HCVpro
hcv0413	NS3	genotype 1a HCV	H77	AF009606	NS5B	AF009606	HCVpro
hcv0414	NS3	genotype 1a	H77	NP_803144	CASP8		VirHostNet
hcv0415	NS3	HCV genotype 1b	Singapore strain		NS3		HCVpro
hcv0416	NS3	HCV genotype 1a	H77	NP_803144	NS4A	NP_751925	VirHostNet
hcv0417	NS3	HCV genotype 1b	isolate con1	AJ238799	RSPH3		HCVpro
hcv0418	NS4A	HCV genotype 1a	H77	NP_751925	NS3	NP_803144	VirHostNet
		HCV					
hcv0419	NS4A	genotype 1b HCV isolate	Isolate Bk Isolate	1JXP_D	NS3	BAA09073	BIND
hcv0420	NS4A	1 HCV	Taiwanese	1DY9_D	NS3	BAA28515	BIND
hcv0421	NS4A	genotype 1a HCV	H77	AAB66324	NS3		VirHostNet
hcv0422	NS4A	genotype 1a	H77	AF009606	NS4A	AF009606	HCVpro
hcv0423	NS4A	genotype 1a	H77	AF009606	NS4B	AF009606	HCVpro
hcv0424	NS4A	HCV genotype 1a	H77	AF009606	NS5B	AF009606	HCVpro
hcv0425	NS4A	HCV genotype 1b	isolate con1	AJ238799	CREB3		HCVpro
hcv0426	NS4A	HCV genotype 1b	isolate con1	AJ238799	ELAC2		HCVpro
hcv0427	NS4A	HCV genotype 1b	isolate con1	AJ238799	HOXD8		HCVpro
hcv0428	NS4A	HCV genotype 1b	isolate con1	AJ238799	NR4A1		HCVpro
		HCV					^
hcv0429	NS4A	genotype 1b HCV	isolate con1	AJ238799	TRAF3IP3		HCVpro
hcv0430	NS4A	genotype 1b HCV	isolate con1	AJ238799	UBQLN1		HCVpro
hcv0431	NS4A	genotype 1a HCV	H77	AF009606	NS5A	AF009606	HCVpro
hcv0432	NS4A	genotype 1a HCV	H77	NP_751925	MT2A		VirHostNet
hcv0433	NS4A	genotype 1a	H77	NP_751925	TUT1		VirHostNet
hcv0434	NS4A	HCV genotype 1a	H77	NP_751925	MT-CO2		VirHostNet
hcv0435	NS4A	HCV genotype 1a	strain H77	NP_751925	EEF1A1		VirHostNet
		HCV	strain H77	NP_751925			VirHostNet

		UCV		1	1		
hcv0437	NS4A	HCV genotype 1a	H77	AAB66324	NS5A	AAB66324	VirHostNet
hcv0438	NS4B	HCV genotype 1a	H77	AAB66324	NS4A	AAB66324	VirHostNet
hcv0439	NS4B	HCV genotype 1b			ATF6B		HCVpro
hcv0440	NS4B	HCV genotype 1b			ATF6A		HCVpro
		HCV	1177	A E000/0/		45000000	
hcv0441	NS4B	genotype 1a HCV	H77	AF009606	NS5B	AF009606	HCVpro
hcv0442	NS4B	genotype 1a HCV	H77	AF009606	NS4B	AF009606	HCVpro
hcv0443	NS4B	genotype 1b HCV			NS5B		HCVpro
hcv0444	NS4B	genotype 1b HCV			TNXB		HCVpro
hcv0445	NS4B	genotype 1a	H77	AF009606	NS5A	AF009606	HCVpro
hcv0446	NS4B	HCV genotype 1b			NS5A		HCVpro
hcv0447	NS4B	HCV genotype 1a	H77	NP_751926	RTN3		VirHostNet
hcv0448	NS4B	HCV genotype 1a	H77	NP_751926	RBP4		VirHostNet
hcv0449	NS4B	HCV genotype 1a	H77	NP_751926	NDUFV3		VirHostNet
hcv0450	NS4B	HCV genotype 1a	H77	NP_751926	FGG		VirHostNet
hcv0451	NS4B	HCV genotype 1a	H77	NP_751926	MT-CO3		VirHostNet
		HCV	10 - O		- m		
hcv0452	NS4B	genotype 1a HCV	strain H77	NP_751926	RAB5A		VirHostNet
hcv0453	NS5A	genotype 1a HCV	H77	NP_751927	EIF2AK2		BIND
hcv0454	NS5A	genotype 1b HCV	UNIV	ERSITY	CSNK2A1		HCVpro
hcv0455	NS5A	genotype 1b HCV	Con1	CAB46677	GRB2		BIND
hcv0456	NS5A	genotype 1a	H77	NP_751927	VAPA		VirHostNet
hcv0457	NS5A	HCV genotype 1a	H77	NP_751927	SRCAP		BIND
hcv0458	NS5A	HCV genotype 1a	H77	NP_751927	IPO5		BIND
hcv0459	NS5A	HCV genotype 1a	H77	NP_751927	TP53		BIND
hcv0460	NS5A	HCV genotype 1a	strain H	AAA45534	CDC2		HCVpro
hcv0461	NS5A	HCV genotype 1a	strain H	AAA45534	CDK2		HCVpro
hcv0462	NS5A	HCV genotype 1a	H77	NP_751927	APOA1		BIND
hcv0463	NS5A	HCV genotype 1b			TP53		HCVpro
		HCV					1
hcv0464	NS5A	genotype 1b HCV			TAF9		HCVpro
hcv0465	NS5A	genotype 1b HCV			PIK3R1		HCVpro
hcv0466	NS5A	genotype 1b HCV			TP53		HCVpro
hcv0467	NS5A	genotype 1b HCV			ТВР		HCVpro
hcv0468	NS5A	genotype 1b	isolate con1	CAB46677	BIN1		BIND
hcv0469	NS5A	HCV genotype 1a	H77	NP_751927	PITX1		VirHostNet
hcv0470	NS5A	HCV genotype 1a	H77	AF009606	NS5B	AF009606	HCVpro

		HCV					
hcv0471	NS5A	genotype 1a HCV	H77	AF009606	NS5A	AF009606	HCVpro
hcv0472	NS5A	genotype 1a HCV	H77	NP_751927	BAX		VirHostNet
hcv0473	NS5A	genotype 1a	H77	NP_671491.1	SSB		BIND
hcv0474	NS5A	HCV genotype 1a	H77	AF009606	НСК		HCVpro
hcv0475	NS5A	HCV genotype 1a	H77	AF009606	LCK		HCVpro
hcv0476	NS5A	HCV genotype 1a	H77	AF009606	LYN		HCVpro
hcv0477	NS5A	HCV genotype 1a	H77	AF009606	FYN		HCVpro
hcv0478	NS5A	HCV genotype 1b			VAPA		HCVpro
hcv0479	NS5A	HCV genotype 1a	H77	NP_751927	OAS1		VirHostNet
hcv0480	NS5A	HCV genotype 1a	H77	NP_751927	JAK1		BIND
hcv0481	NS5A	HCV genotype 1b	Con1	CAB46677	APOE		HCVpro
hcv0482	NS5A	HCV genotype 1b	Con1	CAB46677	VAPA		HCVpro
hcv0483	NS5A	HCV genotype 1b	Con1	CAB46677	NS5A		HCVpro
hcv0484	NS5A	HCV genotype 1b	Con1	CAB46677	AHNAK		VirHostNet
hcv0485	NS5A	HCV genotype 1b	Con1	CAB46677	SFRP4		VirHostNet
hcv0486	NS5A	HCV genotype 1b	Con1	CAB46677	CRABP1		VirHostNet
hcv0487	NS5A	HCV genotype 1b	Con1	CAB46677	FTH1		VirHostNet
hcv0488	NS5A	HCV genotype 1b	Con1	CAB46677	CCDC86		VirHostNet
hcv0489	NS5A	HCV genotype 1b	Con1	CAB46677	TACSTD2		VirHostNet
hcv0490	NS5A	HCV genotype 1b	Con1	CAB46677	PI4KA		VirHostNet
hcv0491	NS5A	HCV genotype 1b	Con1	CAB46677	РТМА		VirHostNet
hcv0492	NS5A	HCV genotype 1b	Con1	CAB46677	ARAP1		VirHostNet
hcv0493	NS5A	HCV genotype 1b	Con1	CAB46677	NDRG1		VirHostNet
hcv0494	NS5A	HCV genotype 1b	Con1	CAB46677	MGP		VirHostNet
hcv0495	NS5A	HCV genotype 1b	Con1	CAB46677	CEP57		VirHostNet
hcv0496	NS5A	HCV genotype 1b	Con1	CAB46677	C9orf6		VirHostNet
hcv0497	NS5A	HCV genotype 1b			FBXL2		HCVpro
hcv0498	NS5A	HCV genotype 1b	strain MD13	AAF65944.1	NS5A		BIND
hcv0499	NS5A	HCV genotype 1a	H77	NP_751927	CSK		VirHostNet
hcv0500	NS5A	HCV genotype 1a	H77	NP_751927	SRC		VirHostNet
hcv0501	NS5A	HCV genotype 1a	H77	NP_751927	APOB		VirHostNet
hcv0502	NS5A	HCV genotype 1b	Strain J1	D89815	VAPB		HCVpro
hcv0503	NS5A	HCV genotype 1a	H77	NP_751927	RAF1		VirHostNet
hcv0504	NS5A	HCV genotype 1b	Korean isolate		TGFBR1		HCVpro

hcv0505	NS5A	HCV genotype 1a	strain H77	NP_751927	PPP2R4	VirHostNet
hcv0506	NS5A	HCV genotype 1a	strain H77	NP_751927	BIN1	VirHostNet
hcv0507	NS5A	HCV genotype 1b			TRAF2	HCVpro
hcv0508	NS5A	HCV genotype 1a	strain H77	NP_751927	FKBP8	VirHostNet
hcv0509	NS5A	HCV genotype 1a	strain H77C	_	FKBP8	HCVpro
hcv0510	NS5A	HCV	strain H77C		HSP90AA1	HCVpro
		genotype 1a HCV				
hcv0511	NS5A	genotype 1a HCV	strain H77	NP_751927	PTPLAD1	VirHostNet
hcv0512	NS5A	genotype 1b HCV	isolate con1	AJ238799	ACLY	HCVpro
hcv0513	NS5A	genotype 1b HCV	isolate con1	AJ238799	ARFIP1	HCVpro
hcv0514	NS5A	genotype 1b	isolate con1	AJ238799	AXIN1	HCVpro
hcv0515	NS5A	HCV genotype 1b	isolate con1	AJ238799	BEND7	HCVpro
hcv0516	NS5A	HCV genotype 1b	isolate con1	AJ238799	CADPS	HCVpro
hcv0517	NS5A	HCV genotype 1b	isolate con1	AJ238799	CADPS2	HCVpro
hcv0518	NS5A	HCV genotype 1b	isolate con1	AJ238799	CEP120	HCVpro
hcv0519	NS5A	HCV genotype 1b	isolate con1	AJ238799	CENPC1	HCVpro
hcv0520	NS5A	HCV genotype 1b	isolate con1	AJ238799	CEP250	HCVpro
		HCV				
hcv0521	NS5A	genotype 1b HCV	isolate con1	AJ238799	CEP63	HCVpro
hcv0522	NS5A	genotype 1b HCV	isolate con1	AJ238799	DNAJA3	HCVpro
hcv0523	NS5A	genotype 1b HCV	isolate con1	AJ238799	EFEMP1	HCVpro
hcv0524	NS5A	genotype 1b HCV	isolate con1	AJ238799	FHL2	HCVpro
hcv0525	NS5A	genotype 1b	isolate con1	AJ238799	GOLGA2	HCVpro
hcv0526	NS5A	HCV genotype 1b	isolate con1	AJ238799	GPS2	HCVpro
hcv0527	NS5A	HCV genotype 1b	isolate con1	AJ238799	IGLL1	HCVpro
hcv0528	NS5A	HCV genotype 1b	isolate con1	AJ238799	ITGAL	HCVpro
hcv0529	NS5A	HCV genotype 1b	isolate con1	AJ238799	LIMS2	HCVpro
hcv0530	NS5A	HCV genotype 1b	isolate con1	AJ238799	MOBK1B	HCVpro
		HCV				
hcv0531	NS5A	genotype 1b HCV	isolate con1	AJ238799	NAP1L1	HCVpro
hcv0532	NS5A	genotype 1b HCV	isolate con1	AJ238799	NAP1L2	HCVpro
hcv0533	NS5A	genotype 1b HCV	isolate con1	AJ238799	NFE2	HCVpro
hcv0534	NS5A	genotype 1b HCV	isolate con1	AJ238799	NUCB1	HCVpro
hcv0535	NS5A	genotype 1b	isolate con1	AJ238799	PARVG	HCVpro
hcv0536	NS5A	HCV genotype 1b	isolate con1	AJ238799	PMVK	HCVpro
hcv0537	NS5A	HCV genotype 1b	isolate con1	AJ238799	PPP1R13L	HCVpro
hcv0538	NS5A	HCV genotype 1b	isolate con1	AJ238799	PSMB9	HCVpro

		HCV					
hcv0539	NS5A	genotype 1b	isolate con1	AJ238799	RPL18A		HCVpro
hcv0540	NS5A	HCV genotype 1b	isolate con1	AJ238799	RRBP1		HCVpro
hcv0541	NS5A	HCV genotype 1b	isolate con1	AJ238799	SHARPIN		HCVpro
hcv0542	NS5A	HCV genotype 1b	isolate con1	AJ238799	SMYD3		HCVpro
hcv0543	NS5A	HCV genotype 1b	isolate con1	AJ238799	SORBS2		HCVpro
hcv0544	NS5A	HCV genotype 1b	isolate con1	AJ238799	SORBS3		HCVpro
hcv0545	NS5A	HCV genotype 1b	isolate con1	AJ238799	THBS1		HCVpro
hcv0546	NS5A	HCV genotype 1b	isolate con1	AJ238799	TMF1		HCVpro
hcv0547	NS5A	HCV genotype 1b	isolate con1	AJ238799	TP53BP2		HCVpro
hcv0548	NS5A	HCV genotype 1b	isolate con1	AJ238799	TRIOBP		HCVpro
hcv0549	NS5A	HCV genotype 1b	isolate con1	AJ238799	TXNDC11		HCVpro
	NS5A	HCV	isolate con1	AJ238799	UBASH3A		HCVpro
hcv0550		genotype 1b HCV					1
hcv0551	NS5A	genotype 1b HCV	isolate con1	AJ238799	USP19		HCVpro
hcv0552	NS5A	genotype 1b HCV	isolate con1	AJ238799	VPS52		HCVpro
hcv0553	NS5A	genotype 1b HCV	isolate con1	AJ238799	GIN1		HCVpro
hcv0554	NS5A	genotype 1b HCV	isolate con1	AJ238799	ZNF646		HCVpro
hcv0555	NS5A	genotype 1a HCV	H77	NP_751927	NS5B	NP_751928	BIND
hcv0556	NS5A	genotype 1a HCV	H77	NP_751927	TRAF2		BIND
hcv0557	NS5A	genotype 1a HCV	H77	NP_751927	TRADD		VirHostNet
hcv0558	NS5A	genotype 1b			GAB1		HCVpro
hcv0559	NS5A	HCV genotype 1a	H77	AF009606	NS3	AF009606	HCVpro
hcv0560	NS5A	HCV genotype 1a	H77	NP_751927	PIK3CB		VirHostNet
hcv0561	NS5A	HCV genotype 1b			FBXL20		HCVpro
hcv0562	NS5A	HCV genotype 1a	strain H77	NP_751927	STAT1		VirHostNet
hcv0563	NS5A	HCV genotype 1a	strain H77	NP_751927	MYD88		VirHostNet
hcv0564	NS5A	HCV genotype 2a			PDPK1		HCVpro
hcv0565	NS5A	HCV genotype 2a			AKT1		HCVpro
hcv0566	NS5A	HCV genotype 2a			VPS35		HCVpro
hcv0567	NS5A	HCV genotype 2a			MAPK12		HCVpro
hcv0568	NS5A	HCV genotype 2a			IPO4		HCVpro
hcv0569	NS5A	HCV genotype 2a			GSK3B		HCVpro
hcv0570	NS5A	HCV genotype 2a			AHSA1		HCVpro
hcv0570	NS5A	HCV genotype 2a			GSK3A		HCVpro
		HCV			CDK6		HCVpro
hcv0572	NS5A	genotype 2a			CDK0		псvpro

		HCV					
hcv0573	NS5A	genotype 1a HCV	strain H77	NP_751927	TBC1D20		VirHostNet
hcv0574	NS5B	genotype 1a HCV	H77	NP_751928	VAPA		VirHostNet
hcv0575	NS5B	genotype 1a	H77	NP_751928	EIF4A2		BIND
hcv0576	NS5B	HCV genotype 1a	H77	NP_751928	NCL		BIND
hcv0577	NS5B	HCV genotype 1a	H77	AF009606	NS5B	AF009606	HCVpro
		HCV	11//	111 009 000		11 009000	
hcv0578	NS5B	genotype 1b HCV			HAO1		HCVpro
hcv0579	NS5B	genotype 1b HCV			TTC4		HCVpro
hcv0580	NS5B	genotype 1b HCV			ACTN1		HCVpro
hcv0581	NS5B	genotype 1b			VAPA		HCVpro
hcv0582	NS5B	HCV genotype 1b	HCV-S1	AAL00900	DDX5		BIND
hcv0583	NS5B	HCV genotype 1a	H77	NP_751928	PKN2		VirHostNet
hcv0584	NS5B	HCV genotype 1a	H77	NP_751928	PTBP2		VirHostNet
		HCV			FBXL2		
hcv0585	NS5B	genotype 1b HCV					HCVpro
hcv0586	NS5B	genotype 1a HCV	H77	NP_751928	PPIB		BIND
hcv0587	NS5B	genotype 1b HCV	Strain J1 Korean	D89815	VAPB		HCVpro
hcv0588	NS5B	genotype 1b HCV	isolate		CHUK		HCVpro
hcv0589	NS5B	genotype 1b	isolate con1	AJ238799	CEP250		HCVpro
hcv0590	NS5B	HCV genotype 1b	isolate con1	AJ238799	CEP68		HCVpro
hcv0591	NS5B	HCV genotype 1b	isolate con1	AJ238799	HOXD8		HCVpro
	NS5B	HCV	isolate con1	AJ238799	MGC2752		HCVpro
hcv0592		genotype 1b HCV					
hcv0593	NS5B	genotype 1b HCV	isolate con1	AJ238799	MOBK1B		HCVpro
hcv0594	NS5B	genotype 1b HCV	isolate con1	AJ238799	NR4A1		HCVpro
hcv0595	NS5B	genotype 1b HCV	isolate con1	AJ238799	OS9		HCVpro
hcv0596	NS5B	genotype 1b	isolate con1	AJ238799	PKM2		HCVpro
hcv0597	NS5B	HCV genotype 1b	isolate con1	AJ238799	PSMB9		HCVpro
hcv0598	NS5B	HCV genotype 1b	isolate con1	AJ238799	SETD2		HCVpro
hcv0599	NS5B	HCV genotype 1b	isolate con1	AJ238799	SHARPIN		HCVpro
		HCV					L
hcv0600	NS5B	genotype 1b HCV	isolate con1	AJ238799	TUBB2C		HCVpro
hcv0601	NS5B	genotype 1b HCV	Isolate Con1	CAB46677	NS5B	CAB46677	BIND
hcv0602	NS5B	genotype 1a HCV	H77	NP_751928	UBQLN1		VirHostNet
hcv0603	NS5B	genotype 1b			CINP		HCVpro
hcv0604	NS5B	HCV genotype 1b			PSMB4		HCVpro
hcv0605	NS5B	HCV genotype 1a	strain H77	NP_751928	6-Sep		VirHostNet
		HCV		_			
hcv0606	NS5B	genotype 1a	strain H77	NP_751928	HNRNPA1		VirHostNet

		HCV	strain (HC-			
hcv0607	p7	genotype 1b	J4)		P7	HCVpro
		HCV				
hcv0608	p7	genotype 1b			FMNL1	HCVpro
		HCV				
hcv0609	p7	genotype 1b			H19	HCVpro
	_	HCV				
hcv0610	p7	genotype 1b			ISLR	HCVpro
	_	HCV				
hcv0611	p7	genotype 1b			MS4A6A	HCVpro
1 0 1 0	_	HCV				
hcv0612	p7	genotype 1b			NUP214	HCVpro
1 0 1 0	_	HCV				
hcv0613	p7	genotype 1b			SSR4	HCVpro
1 0(14	7	HCV			CTDDD	HOM
hcv0614	p7	genotype 1b			STRBP	HCVpro
hcv0615		HCV	isolate con1	AJ238799	CREB3	HCVpro
11000015	p7	genotype 1b HCV	Isolate coll1	AJ258/99	CKEDS	нстрю
hcv0616	p7	genotype 1b	isolate con1	AJ238799	FBLN2	HCVpro
110/0010	P/	HCV	Isolate coll1	AJ230199	TDLN2	петрю
hcv0617	p7	genotype 1b	isolate con1	AJ238799	FXYD6	HCVpro
nevoor	Ρ'	HCV	isolute com	10200777		110 ()10
hcv0618	p7	genotype 1b	isolate con1	AJ238799	LMNB1	HCVpro
	1	HCV				1
hcv0619	p7	genotype 1b	isolate con1	AJ238799	SLIT2	HCVpro
		HCV				
hcv0620	p7	genotype 1b	isolate con1	AJ238799	UBQLN1	HCVpro
		HCV	THE PTH	THE REPORT		
hcv0621	p7	genotype 1b	isolate con1	AJ238799	UBQLN4	HCVpro

UNIVERSITY of the WESTERN CAPE

Appendix V (Chapter 3)

Appendix Va

Hepatocellular carcinoma genes obtained from HCCNet and OncoDB.HCC databases

Gene Name	Entrez Gene	Source	Source
ACLY	47	HCCNet	Oncodb.hcc
AEBP1	165	HCCNet	
AGT	183	HCCNet	
AHNAK	79026	HCCNet	
AKT1	207	HCCNet	
APOA1	335	HCCNet	Oncodb.hcc
APOB	338	HCCNet	
APOE	348	HCCNet	Oncodb.hcc
ARNT	405	HCCNet	
AXIN1	8312	HCCNet	Oncodb.hcc
AZGP1	563	HCCNet	Oncodb.hcc
BCL2A1	597	HCCNet	
C7	730	HCCNet	
CANX	821	HCCNet	
CASP8	841	HCCNet	SITY of the
CD209	30835	HCCNet	RN CAPE
CD5L	922	HCCNet	Oncodb.hcc
CD68	968	HCCNet	
CD81	975	HCCNet	Oncodb.hcc
CDC2	983	HCCNet	
CDK2	1017	HCCNet	
CDK6	1021	HCCNet	
CDKN1A	1026	HCCNet	Oncodb.hcc
CEP152	22995	HCCNet	
CEP68	23177	HCCNet	
CFP	5199	HCCNet	
CHUK	1147	HCCNet	
CIDEB	27141	HCCNet	
CLEC4M	10332	HCCNet	
COL4A2	1284	HCCNet	
CTGF	1490	HCCNet	Oncodb.hcc
CTSB	1508	HCCNet	Oncodb.hcc
DDX3X	1654	HCCNet	

DDX3Y EEF1A1 EFEMP1 FAS	8653 1915	HCCNet	
EFEMP1	1715		
	2202	HCCNet	
	355	HCCNet	0
FBN1	2200	HCCNet	Oncodb.hcc
		HCCNet	0 11 1
FGG FHL2	2266 2274	HCCNet	Oncodb.hcc
		HCCNet	
FIGNL1	63979	HCCNet	
FN1	2335	HCCNet	
FYN	2534	HCCNet	
GAB1	2549	HCCNet	
GAPDH	2597	HCCNet	
GBP2	2634	HCCNet	
GRB2	2885	HCCNet	
H19	283120	HCCNet	Oncodb.hcc
HAO1	54363	HCCNet	
HLA-A	3105	HCCNet	
HSPD1	3329	HCCNet	
IKBKE	9641	HCCNet	
IRF3	3661	HCCNet	
JAK2	3717	HCCNet	OTEN AN
JUN	3725	HCCNet	SII Y of the
KRT19	3880	HCCNet	Oncodb.hcc
KRT8	3856	HCCNet	
LAMB2	3913	HCCNet	
APOA2	336	HCCNet	
MAGED1	9500	HCCNet	
MBP	4155	HCCNet	
MCL1	4170	HCCNet	Oncodb.hcc
MS4A6A	64231	HCCNet	
MT2A	4502	HCCNet	
MVP	9961	HCCNet	
NAP1L1	4673	HCCNet	
NDC80	10403	HCCNet	
NDRG1	10397	HCCNet	
NOTCH1	4851	HCCNet	
NUP62	23636	HCCNet	
OAS1	4938	HCCNet	
PDE4DIP	9659	HCCNet	

PDLIM5	10611	HCCNet	
PKM2	5315	HCCNet	
PPARA	5465	HCCNet	
PRKACA	5566	HCCNet	
PSMB4	5692	HCCNet	
PSMB4 PTMA	5757	HCCNet	
RAB14	51552		
RASAL2	9462	HCCNet	
RGNEF	64283	HCCNet	
RXRA	6256	HCCNet	
		HCCNet	
SCARB1	949	HCCNet	
SEPT6 SERPINC1	23157 462	HCCNet	
SERPINC1	5345	HCCNet	0 11 1
		HCCNet	Oncodb.hcc
SERPING1	710	HCCNet	Oncodb.hcc
SESTD1	91404	HCCNet	
SIAH1	6477	HCCNet	Oncodb.hcc
SLC22A7	10864	HCCNet	
SLIT2	9353	HCCNet	
SMAD3	4088	HCCNet	<u> </u>
SMURF2	64750	HCCNet	SITY of the
SMYD3	64754	HCCNet	PNCAPE
SRC	6714	HCCNet	Oncodb.hcc
STAB1	23166	HCCNet	
STAT1	6772	HCCNet	
STAT3	6774	HCCNet	
SYNE1	23345	HCCNet	
SYNPO2	171024	HCCNet	
TACSTD2	4070	HCCNet	
TBP	6908	HCCNet	
TF	7018	HCCNet	Oncodb.hcc
THBS1	7057	HCCNet	Oncodb.hcc
TMF1	7110	HCCNet	
TP53	7157	HCCNet	Oncodb.hcc
TP53BP2	7159	HCCNet	
UBQLN4	56893	HCCNet	
VCAN	1462	HCCNet	
VIM	7431	HCCNet	Oncodb.hcc

YWHAE	7531	HCCNet
YWHAZ	7534	HCCNet
YY1	7528	HCCNet
ZCCHC7	84186	HCCNet
ZG16	653808	HCCNet
ACY3	91703	HCCNet
GRN	2896	Oncodb.hcc
HSPA5	3309	Oncodb.hcc
TP73	7161	Oncodb.hcc
HSP90AA1	3320	Oncodb.hcc
BAX	581	Oncodb.hcc
GSK3A	2931	Oncodb.hcc
Vitronectin	7448	Oncodb.hcc
ATF6A	22926	Oncodb.hcc
KHDRBS1	10657	Oncodb.hcc
NR4A1	3164	Oncodb.hcc
IGLL1	3543	Oncodb.hcc
RAF1	5894	Oncodb.hcc
RBP4	5950	Oncodb.hcc
ITGB1	3688	Oncodb.hcc
YY1AP1	55249	Oncodb.hcc
HNRNPK	3190	Oncodb.hcc
FADD	8772	Oncodb.hcc
NPM1	4869	Oncodb.hcc

Appendix Vb

Gene_Symbol	Dataset	UP regulated	Down regulated
ACLY	GIS, SMD, UCSF, TOKYO	4	0
AEBP1	SMD	0	1
AGRN	SMD, UCSF	2	0
AGT	SAGE, PubMed, mRNA	1	1
AKT1	PubMed	1	0
ANKRD12	KIM	1	0
APOA1	SMD, SAGE, CGED	0	3
APOA2	SAGE, PubMed, FUDAN	1	1
APOB	SAGE	0	1
APOE	SAGE	0	1
ARNT	PubMed, UCSF	1	0
ARS2	FUDAN	0	1
AXIN1	PubMed	0	0
AZGP1	SMD, LEE, CGED	0	3
B2M	PubMed, mRNA, CGED	1	1
BAX	PubMed, mRNA	1	0
BCL2A1	FUDAN	0	1
BIN1	PubMed, mRNA, FUDAN, OncoFetal	2	1
C1QBP	ТОКҮО	0	1
C7	GIS, SMD, mRNA	0	3
CALR	UCSF, CGED	f the 2	0
CAMLG	SMD	nn 1	0
CANX	SMD, SAGE, UCSF	2	1
CASP8	PubMed	0	0
CCDC21	SMD, UCSF	2	0
CCDC66	SAGE	1	0
CD5L	GIS, KIM, TOKYO	0	3
CD68	PubMed, LEE	1	0
CD81	SMD, PubMed, mRNA	1	1
CDC2	SMD, PubMed, UCSF, FUDAN	3	0
CDC23	GIS, TOKYO	2	0
CDK2	PubMed, FUDAN	1	0
CDKN1A	PubMed, mRNA, CGED, PASTEUR	0	3
CFP	PubMed, TOKYO	0	1
CHUK	PubMed, FUDAN	0	1
CLEC4M	mRNA	0	1
COL4A2	SMD, UCSF	2	0
CRABP1	PubMed	0	0
CSNK2B	SMD, UCSF, FUDAN	3	0
CTGF	PubMed, mRNA	0	1
CTSB	PubMed, Protein	0	1
DDX3X	PubMed, mRNA	2	0
DDX3Y	SMD, FUDAN	0	2

Hepatocellular carcinoma genes obtained from EHCO database with expression levels

DES	PubMed, TOKYO	0	1
DNAJA3	OncoFetal	1	0
DPP7	SMD	0	1
EEF1A1	Protein	0	1
EFEMP1	SAGE	1	0
EFEMIFI EIF1	CGED	0	0
EIF2AK2	PubMed	0	0
FADD	PubMed, CGED	1	1
FAS	SMD, PubMed	0	1
FBLN5	mRNA	0	1
FBN1	PubMed, LEE	1	0
FES	FUDAN	1	0
FGG	SMD, SAGE, mRNA, Protein, CGED	1	5
FLAD1	SMD, UCSF	2	0
FN1	mRNA, PASTEUR	2	1
FTH1	mRNA	1	0
FUCA2	CGED	1	0
FYN	SMD, PubMed	0	1
GAA	mRNA	1	0
GAB1	SMD	1	0
GAPDH	PubMed, mRNA, Protein, OncoFetal	4	0
GFAP	PubMed	0	0
GLRX3	Protein, FUDAN	1	1
GON4L	UCSF	1	0
GRB2	Protein, PASTEUR	0	2
GRN	GIS, SMD, UCSF	3	0
H19	SAGE, PubMed	1	0
HAO1	Protein, CGED	0	2
HCK	LEE	1	0
HLA-A	SAGE, PubMed, mRNA	1	1
HNRNPA1	LEE, mRNA	2	0
HSP90AA1	mRNA, Protein, CGED	3	0
HSPA5	GIS, SAGE, Protein, CGED	3	1
HSPD1	SAGE, PubMed, mRNA, Protein	3	1
IGLL1	SMD	0	1
IQWD1	CGED	1	0
ITGB1	GIS, PubMed, mRNA	1	1
ITGB4	PASTEUR	1	0
JAK1	PubMed	0	0
JAK2	PubMed	0	0
JUN	SMD, FUDAN	1	1
KRT19	SAGE, PubMed, LEE, mRNA, Protein	5	0
KRT8	SMD, CGED, PASTEUR	1	2
LAMB2	OncoFetal	1	0
LMNB1	Protein	1	0
LTBP4	ТОКУО	0	1
LTBR	PubMed	0	0
LTDK LZTS2	SAGE	1	0
LL102	SAOL	1	0

MAPK12	PubMed	0	0
MAPK7	SMD	0	1
MBP	PubMed	0	0
MCL1	SMD, CGED	0	2
MT2A	SAGE, mRNA, CGED, TOKYO	0	4
MYD88	FUDAN	0	1
NAP1L1	SMD, UCSF	2	0
NCL	GIS, PubMed, mRNA	1	1
NDRG1	SMD, PubMed, LEE, UCSF, CGED	4	0
NEFL	PubMed	0	0
NOTCH1	LEE	1	0
	SMD, PubMed, LEE, mRNA, Protein,		-
NPM1	UCSF	6	0
NR4A1	SMD, mRNA	1	1
NUCB1	SAGE, CGED, OncoFetal	1	2
NUP62	KIM	1	0
OS9	mRNA	0	1
PABPN1	PubMed	0	0
PDPK1	KIM	1	0
PFDN2	Protein	1	0
PIK3CB	PubMed	1	0
PIK3R1	PubMed	1	0
PKM2	LEE, mRNA	2	0
PLSCR1	SMD	0	1
PML	PubMed	0	0
PPARA	PubMed	0	0
PPIB	GIS, SAGE, PubMed, mRNA	3	1
PSMB4	GIS, CGED, FUDAN	3	0
PSMB8	PubMed, FUDAN	0	1
PSMB9	PubMed	0	0
PTPLAD1	SMD, UCSF	2	0
PTPRN2	SMD	0	1
RAB14	mRNA	0	1
RAF1	PubMed	1	0
RBP4	SMD, SAGE, PubMed, Protein, CGED	1	3
RRBP1	Protein, CGED	0	2
RSF1	PubMed, CGED	1	0
RTN3	SMD, UCSF	2	0
RXRA	LEE	0	1
SCARB1	PubMed, CGED	1	0
SDC2	SAGE, mRNA, CGED	1	2
SERPINC1	SAGE, KIM, mRNA, FUDAN	0	4
SERPINF2	SAGE, mRNA, FUDAN	0	3
SERPING1	SMD, SAGE, mRNA, CGED, TOKYO	1	4
SHARPIN	UCSF	1	0
SIAH1	SMD, PubMed	0	1
SLC22A7	SAGE, CGED	0	2
SLC31A2	SMD, KIM	0	2
SMYD3	PubMed	0	0

SORBS2	mRNA	0	1
SORBS3	SMD	0	1
SRC	PubMed	0	0
SSB	PubMed	0	0
SSZ2IP	FUDAN	0	1
STAT1	PubMed	0	0
STAT3	PubMed, Protein, CGED, PASTEUR	0	3
SVEP1	SMD	0	1
TACSTD2	SAGE	1	0
TAF1	PubMed, mRNA	1	0
TAF9	GIS, CGED	2	0
TF	SMD, SAGE, PubMed, KIM, mRNA, Protein, CGED	1	6
THBS1	SMD, LEE, FUDAN	1	2
TLR2	KIM	0	1
TMSB4X	SAGE, CGED	1	1
TMSD4A TNF	PubMed	1	0
TP53	PubMed, mRNA, FUDAN, TOKYO	0	3
TP53BP2	GIS, SMD, UCSF	3	0
TP73	PubMed	0	0
TRADD	D IV I	0	0
TRAF2	PubMed PubMed, LEE, mRNA	1	1
TRIM23	FUDAN	0	1
TRIM25	PubMed	0	0
TRIO	UCSF	1	0
TRIOBP	SMD	0	1
TRIP11	UCSF	1	0
TSN	PubMed, mRNA, UCSF	2	0
UBA3	FUDAN	1	0
UBQLN1	FUDAN	0	1
UXT	PubMed	0	0
VCAN	PubMed	0	0
VIM	PubMed, mRNA, Protein	3	0
VPS35	Protein	1	0
VPS52	GIS	1	0
VWF	SMD, PubMed, UCSF	2	0
YWHAB	GIS	1	0
YWHAZ	SMD, UCSF	2	0
YY1AP1	UCSF	1	0

Appendix VI (Chapter 3)

Appendix Va

Summary of data statistics of host proteins incorporated in HCVpro

Features	Number of human proteins
Gene Name	455
Entrez Gene	455
HPRD ID	453
HCCNet	116
EHCO	178
Oncodb.hcc	41
Category	455
Description	455
Aliases	446
Previous Symbols	117
Previous Names	126
Chromosome	455
Entrez Gene Cytoband	453
Strand	455
Gene start	453
Gene end	453
Gene size	454
RefSeq RNA	453
RefSeq peptide	452
Ensembl Gene	455
UniGene	453
GenBank Accession	439
EMBL	444
OMIM	383
FUNCTION	384
SwissProt (name)	447
SwissProt (acc)	447
PDB id	186
IPI	450
Ensembl Protein ID	454
PharmGKB	398
InterPro	408
Pfam	355
KEGG	163

Reactome Pathway	
IdD	86
Nature Pathway	42
HPD	85
NetPath Pathway	187
GO	435

Appendix Vb

Summary of data statistics of viral proteins incorporated in HCVpro

Features	Number of viral proteins
Short Name	11
Recommended Name	11
Other Names	11
Enzyme Commission	3
euHCVdb	11
OMIM	11
euhcvdb protein	11
GenBank	11
VBRC HCVdb Accession	11
Uniprot Post-translational	
	ERSITY of the 10
	FERN CAPE 11
Uniprot Subunit Structure	10
Uniprot Domain	4
Uniprot Subcellular Localization	11
Functions	11
Drug Development	11
Description	11
Molecular Mass by SDS-Page	11
Current State of Antiviral	11
Antiviral Progress	7
Uniprot IDs	11
Protein Type	11
Genome	11
Family	11
Genus	11
Strain Name	11
Molecule Type	11
Amino Acid Length	11
pI	11

Gene Size	11
Molecular Weight	11
Proteolytic Enzymes	10
NCBI CDD Pfam	9
Entrez Gene ID	11
GI	11
NCBI RefSeq	11
Pfam	9
Interpro	9
PDB	7
Recommended PubMed Readings	11
GO	11

Appendix Vc

Summary of data distribution in HCVpro

Te s farmers	Numer
Features	Number
Redundant virus-virus protein interactions	— 72
Non-redundant virus-virus protein interactions	29
Redundant virus-human protein interactions	549
Non-redundant virus-human protein	,
interactions UNIVERSIT	Y of t524
Journal articles reporting interactions	CAP174
BIND IDs mapped in HCVpro	162
VirusMint IDs mapped in HCVpro	53
HCVpro IDs	621

Appendix VII (Chapter 3)


User manual for Hepatitis C Virus protein interaction database

(HCVpro)


Section A

1. Home Page

The index page accessible via <u>http://apps.sanbi.ac.za/hcvpro/</u> displays brief information about HCVpro and the menus (Search, manual, statistics, FAQ, links, download and contact)



2. Querying database



3. Sub menu queries

The enhanced user query interfaces enable users to perform searches via HCVpro by browsing the following sub query menus:

Protein Select

- HCV proteins: e.g. E2
- Human proteins: e.g. CD81
- Human Chromosome number: e.g. 10

Evidence

- Experiment type: e.g. coimmunoprecipitation
- PubMed ID: e.g. 10846074

UNIVERSITY of the WESTERN CAPE

Identifier Search

- HCVpro ID: e.g. hcv0128
- BIND ID: e.g. 183964
- MINT ID: e.g. MINT-14803


String Search

- Gene Name: e.g. Vimentin
- Gene ID: e.g. 7431
- Gene symbol: e.g. VIM

Section B

Protein Search

Here, we demonstrate querying of the HCVpro via the Hepatitis C Virus (HCV) proteins sub menu by browsing the list of HCV proteins. To retrieve interaction details on "NS5A" protein:




1. Click on "NS5A" protein

(NB: you may perform multiple queries by holding on the CTRL key and selecting the proteins simultaneously.)

2. Click on select to return a list of protein interactions as shown below:

# HCVpro ID Molecule A Molecule B Gene Symbols PubMed ID Details 1. hcv0453 NS5A EIF2Ak2 9143277 P 2. hcv0454 NS5A CSNk2A1 10208859 P 3. hcv0455 NS5A GRB2 10318918 P 4. hcv0456 NS5A VAPA 10544080 P 5. hcv0457 NS5A SRCAP 10702287 P 6. hcv0459 NS5A IPO5 10799599 P 7. hcv0460 NS5A CDC2 11278402 P 9. hcv0461 NS5A CDC2 11278402 P 10. hcv0461 NS5A CDK2 11278402 P 11. hcv0463 NS5A TP53 12101418 P 12. hcv0464 NS5A TAF9 12101418 P 13. hcv0465 NS5A TP53 12379483 P				Interact	ing proteins		
1. hcv0463 NS5A EIF2Ak2 9143277 P 2. hcv0454 NS5A CSNk2A1 10208869 P 3. hcv0455 NS5A GRB2 10318918 P 4. hcv0456 NS5A GRB2 10318918 P 4. hcv0456 NS5A GRB2 10702287 P 5. hcv0457 NS5A SRCAP 10702287 P 6. hcv0459 NS5A IPO5 10799599 P 7. hcv0460 NS5A CDC2 11278402 P 9. hcv0461 NS5A CDC2 11278402 P 10. hcv0462 NS5A TP53 12101418 P 11. hcv0464 NS5A TP53 12101418 P 12. hcv0464 NS5A TP53 12379483 P 13. hcv0465 NS5A TP53 12379483 P 14. hcv	21 inter	action	s found:				
2. hcv0454 NS5A CSNk2A1 10208859 P 3. hcv0455 NS5A GRB2 10318918 P 4. hcv0456 NS5A VAPA 10544080 P 5. hcv0457 NS5A SRCAP 10702287 P 6. hcv0459 NS5A IPO5 10799599 P 7. hcv0459 NS5A TP53 11152513 P 8. hcv0460 NS5A CDC2 11278402 P 9. hcv0461 NS5A CDC2 11278402 P 10. hcv0462 NS5A TP53 12101418 P 11. hcv0464 NS5A TP53 12101418 P 12. hcv0464 NS5A TP53 12379483 P 13. hcv0465 NS5A TP53 12379483 P 14. hcv0466 NS5A TBP 12379483 P 15. hcv04		#	HC∨pro ID	Molecule A	Molecule B Gene Symbols	PubMed ID	Details
3. hcv0455 NS5A GRB2 10318918 P 4. hcv0456 NS5A VAPA 10544080 P 5. hcv0457 NS5A SRCAP 10702287 P 6. hcv0458 NS5A IPO5 10799599 P 7. hcv0459 NS5A TP53 11152513 P 8. hcv0460 NS5A CDC2 11278402 P 9. hcv0461 NS5A CDC2 11278402 P 10. hcv0463 NS5A CDC2 11278402 P 10. hcv0461 NS5A CDK2 11278402 P 11. hcv0463 NS5A TP53 12101418 P 12. hcv0464 NS5A TAF9 12101418 P 13. hcv0465 NS5A TP53 12379483 P 14. hcv0466 NS5A TBP 12379483 P 15. hcv0467 NS5A BIN1 12604805 P 16. hcv0469		1.	hcv0453	NS5A	EIF2AK2	9143277	2
4. hcx0456 NS5A VAPA 10544080 P 5. hcx0457 NS5A SRCAP 10702287 P 6. hcx0458 NS5A IPO5 10799599 P 7. hcx0459 NS5A TP53 11152513 P 8. hcx0460 NS5A CDC2 11278402 P 9. hcx0461 NS5A CDC2 11278402 P 10. hcx0463 NS5A TP53 12101418 P 11. hcx0463 NS5A TAP53 12101418 P 12. hcx0464 NS5A TAP53 12101418 P 13. hcx0465 NS5A TP53 12379483 P 14. hcx0466 NS5A TBP 12379483 P 15. hcx0467 NS5A BIN1 12604805 P 16. hcv0468 NS5A BIN1 12604805 P 17. hcv0469 NS5A PITX1 126020797 P 18. hcv0470 <td></td> <td>2.</td> <td>hcv0454</td> <td>NS5A</td> <td>CSNK2A1</td> <td>10208859</td> <td>2</td>		2.	hcv0454	NS5A	CSNK2A1	10208859	2
5. hcv0457 NS5A SRCAP 10702287 6. hcv0458 NS5A IPO5 10799599 P 7. hcv0459 NS5A TP53 11152513 P 8. hcv0460 NS5A CDC2 11278402 P 9. hcv0461 NS5A CDC2 11278402 P 10. hcv0462 NS5A APOA1 11878923 P 10. hcv0463 NS5A TP53 12101418 P 11. hcv0463 NS5A TP53 12101418 P 12. hcv0464 NS5A TAF9 12101418 P 13. hcv0465 NS5A TP53 12379483 P 14. hcv0466 NS5A TBP 12379483 P 15. hcv0467 NS5A BIN1 12604805 P 16. hcv0468 NS5A PITX1 12620797 P 18. hcv0470 <		3.	hcv0455	NS5A	GRB2	10318918	2
6. hcv0458 NS5A IPO5 10799599 P 7. hcv0459 NS5A TP53 11152513 P 8. hcv0460 NS5A CDC2 11278402 P 9. hcv0461 NS5A CDK2 11278402 P 10. hcv0461 NS5A CDK2 11278402 P 10. hcv0463 NS5A TP53 12101418 P 11. hcv0463 NS5A TP53 12101418 P 12. hcv0464 NS5A TAF9 12101418 P 13. hcv0465 NS5A TP53 12379483 P 14. hcv0466 NS5A TBP 12379483 P 15. hcv0468 NS5A BIN1 12604805 P 16. hcv0469 NS5A PITX1 12620797 P 18. hcv0470 NS5A NS5A 12692242 P 19. hcv0		4.	hcv0456	NS5A	VAPA	10544080	2
7. hcv0459 NS5A TP53 11152513 P 8. hcv0460 NS5A CDC2 11278402 P 9. hcv0461 NS5A CDC2 11278402 P 10. hcv0462 NS5A CDK2 11278402 P 10. hcv0462 NS5A APOA1 11876923 P 11. hcv0463 NS5A TP53 12101418 P 12. hcv0464 NS5A TAF9 12101418 P 13. hcv0465 NS5A TP53 12379483 P 14. hcv0466 NS5A TBP 12379483 P 15. hcv0467 NS5A BIN1 12604805 P 16. hcv0469 NS5A PITX1 12620797 P 18. hcv0470 NS5A NS5A 12692242 P 19. hcv0471 NS5A NS5A 12692242 P 20. hc		5.	hcv0457	NS5A	SRCAP	10702287	P 🖊
8. hcv0460 NS5A CDC2 11278402 P 9. hcv0461 NS5A CDk2 11278402 P 10. hcv0462 NS5A APOA1 11878923 P 11. hcv0463 NS5A TP53 12101418 P 12. hcv0464 NS5A TAF9 12101418 P 13. hcv0465 NS5A TP53 12379483 P 14. hcv0466 NS5A TP53 12379483 P 15. hcv0468 NS5A BIN1 12604805 P 16. hcv0468 NS5A PITX1 12620797 P 18. hcv0470 NS5A NS5B 12692242 P 19. hcv0471 NS5A NS5A 12692242 P 20. hcv0472 NS5A BAX 12925958 P		6.	hcv0458	NS5A	IP05	10799599	
8. hcv0460 NS5A CDC2 11278402 P 9. hcv0461 NS5A CDk2 11278402 P 10. hcv0462 NS5A APOA1 11878923 P 11. hcv0463 NS5A TP53 12101418 P 12. hcv0464 NS5A TAF9 12101418 P 13. hcv0465 NS5A TP53 12379483 P 14. hcv0466 NS5A TP53 12379483 P 15. hcv0468 NS5A BIN1 12604805 P 16. hcv0468 NS5A PITX1 12620797 P 18. hcv0470 NS5A NS5B 12692242 P 19. hcv0471 NS5A NS5A 12692242 P 20. hcv0472 NS5A BAX 12925958 P		7.	hcv0459	NS5A	TP53	11152513	2
10. hcv0462 NS5A APOA1 11878923 P 11. hcv0463 NS5A TP53 12101418 P 12. hcv0464 NS5A TAF9 12101418 P 13. hcv0465 NS5A TP53 12101418 P 14. hcv0466 NS5A TP53 12379483 P 15. hcv0467 NS5A TBP 12379483 P 16. hcv0468 NS5A BIN1 12604805 P 17. hcv0469 NS5A PITX1 12620797 P 18. hcv0470 NS5A NS5B 12692242 P 19. hcv0471 NS5A BAX 12692242 P		8.	hcv0460	NS5A	CDC2	11278402	
11. hcv0463 NS5A TP53 12101418 P 12. hcv0464 NS5A TAF9 12101418 P 13. hcv0465 NS5A PIK3R1 12186904 P 14. hcv0466 NS5A TP53 12379483 P 15. hcv0467 NS5A TBP 12379483 P 16. hcv0468 NS5A BIN1 12604805 P 17. hcv0469 NS5A PITX1 12620797 P 18. hcv0470 NS5A NS5B 12692242 P 19. hcv0471 NS5A NS5A 12692242 P 20. hcv0472 NS5A BAX 12925958 P		9.	hcv0461	NS5A	CDK2	11278402	2
12. hcv0464 NS5A TAF9 12101418 P 13. hcv0465 NS5A Pik3R1 12186904 P 14. hcv0466 NS5A TP53 12379483 P 15. hcv0467 NS5A TBP 12379483 P 16. hcv0468 NS5A BIN1 12604805 P 17. hcv0469 NS5A PITX1 12602797 P 18. hcv0470 NS5A NS5B 12692242 P 19. hcv0471 NS5A NS5A 12692242 P 20. hcv0472 NS5A BAX 12925958 P		10.	hcv0462	NS5A	APOA1	11878923	2
13. hcv0465 NS5A Pik3R1 12186904 P 14. hcv0466 NS5A TP53 12379483 P 15. hcv0467 NS5A TBP 12379483 P 16. hcv0468 NS5A BIN1 12604805 P 17. hcv0469 NS5A PITX1 12602797 P 18. hcv0470 NS5A NS5B 12692242 P 19. hcv0471 NS5A NS5A 12692242 P 20. hcv0472 NS5A BAX 12925958 P		11.	hcv0463	NS5A	TP53	12101418	2
14. hcv0466 NS5A TP53 12379483 P 15. hcv0467 NS5A TBP 12379483 P 16. hcv0468 NS5A BIN1 12604805 P 17. hcv0469 NS5A PITX1 126020797 P 18. hcv0470 NS5A NS5B 12692242 P 19. hcv0471 NS5A NS5A 12692242 P 20. hcv0472 NS5A BAX 12925958 P		12.	hcv0464	NS5A	TAF9	12101418	2
15. hcv0467 NS5A TBP 12379483 P 16. hcv0468 NS5A BIN1 12604805 P 17. hcv0469 NS5A PITX1 12620797 P 18. hcv0470 NS5A NS5B 12692242 P 19. hcv0471 NS5A NS5A 12692242 P 20. hcv0472 NS5A BAX 12925958 P		13.	hcv0465	NS5A	PIK3R1	12186904	2
16. hcv0468 NS5A BIN1 12604805 P 17. hcv0469 NS5A PITX1 12620797 P 18. hcv0470 NS5A NS5B 12692242 P 19. hcv0471 NS5A NS5A 12692242 P 20. hcv0472 NS5A BAX 12925958 P		14.	hcv0466	NS5A	TP53	12379483	2
17. hcv0469 NS5A PITX1 12620797 P 18. hcv0470 NS5A NS5B 12692242 P 19. hcv0471 NS5A NS5A 12692242 P 20. hcv0472 NS5A BAX 12925958 P		15.	hcv0467	NS5A	TBP	12379483	2
18. hcv0470 NS5A NS5B CAPE 12692242 P 19. hcv0471 NS5A NS5A 12692242 P 20. hcv0472 NS5A BAX 12925958 P		16.	hcv0468	NS5A	BIND SITV of the	12604805	2
19. hcv0471 NS5A NS5A 12692242 P 20. hcv0472 NS5A BAX 12925958 P		17.	hcv0469	NS5A	PITX1	12620797	2
20. hcv0472 NS5A BAX 12925958 🔎		18.	hcv0470	NS5A	NS5B CAPE	12692242	2
		19.	hcv0471	NS5A	NS5A	12692242	2
21. hcv0473 NS5A SSB 12963047 🔎		20.	hcv0472	NS5A	BAX	12925958	2
		21.	hcv0473	NS5A	SSB	12963047	2

3. Click on "SRCAP" protein to retrieve interaction details and enriched functional biological information on both "NS5A" and "SRCAP" proteins as below:



Click on all cross-referenced links to familiarize yourself with the information they provide.

4. Click on "Details Molecule A" link to retrieve comprehensive information on "NS5A" For illustration view here:

http://apps.sanbi.ac.za/hcvpro/details_hcvprot.php?id=457&mol=a

5. Click on "Details Molecule B" to retrieve comprehensive information on "SRCAP"

For illustration view here: http://apps.sanbi.ac.za/hcvpro/details_humanprot.php?id=457

Explained data fields


Hepatocellular carcinoma associated genes are cross-referenced to the sources below:

- HCCNet: Hepatocellular carcinoma network database
- EHCO: Encyclopedia of hepatocellular carcinoma genes online
- **Oncodb.hcc**: Oncogenomic Database of hepatocellular carcinoma

NB: For details on EHCO gene expression levels consult: <u>http://ehco.iis.sinica.edu.tw/</u> You may also consult the frequently asked questions and HCVpro data statistics at: <u>http://apps.sanbi.ac.za/hcvpro/FAQ.php</u> and <u>http://apps.sanbi.ac.za/hcvpro/Statistics.php</u>/

Section C

Here, we demonstrate querying of the HCVpro via string search using the protein "vimentin"



1. Type "Vimentin" in the search area

2. Click on "search" to return a list of protein as shown below:

Home		Search	Manual	FAQ	Statistics	Links	Download	Contact	Interaction list
1 proteir	is fe	ound:							
	#	Corresponding	gene	Entrez gene ID	Human p	rotein name	HC	V interaction:	s
	1.	VIM		7431	Vimentin			&	
				_				1	
				В	ack to Search				
							Access the	protein in	teractions

3. Click on "HCV interactions" as indicated above to access the protein interactions

Home	Search	Manual	FAQ	Statistics	Links	Download	Contact	Interaction list
2 intera	ctions found:							
	# HCVpro ID	Molecule A	Molecu	le B Gene Symbo	ols	PubMed ID	Det	ails
	1. hcv0054	CORE	VIM			15846844	8	C
	2. hcv0397	NS3	VIM			18985028	8	2
							Click fo	r details

• Click on "details" as indicated above to retrieve detailed interaction data on vimentin:

Home	Search	Manual FAQ	Stat HCVpro ID
4	n details	Interaction Information	
Details Molecule A Details Molecule B Internion details 5		HCV Pr	a ID hcv0397
		Molecu	t ID le A NS3
		Molecule B Gene Sym Molecule B Gene Sym	
		PubMe	
			A., Agaugue, S., Naviali, Y., Haldread, L., Hiet, M. S., Addin-Oex, A., Agaugue, S., Meiffren, G., Pradezynski, F., Faria, B. F., Chantier, T., Le Breton, M., Pellet, J., Davoust, N., Mangeot, P. E., Chaboud, A., Penin, F., Jacob, Y., Vidalain, P. O., Vidal, M., Andre, P., Rabourdin-Combe, C., and Lotteau, V. (2008) Hepatitis C virus infection protein network, Mol Syst Biol 4, 230.
		Experimental evide	nce Two Hybrid Test
			Interaction detection method

• Click on all cross-referenced links to familiarize yourself with the information they provide.

4. Click on "Details Molecule A" link to retrieve comprehensive information on "NS3"


For illustration view here:

<u>http://apps.sanbi.ac.za/hcvpro/details_hcvprot.php?id=397&mol=a</u>
5. Click on "Details Molecule B" to retrieve comprehensive information on "vimentin"

For illustration view here:

http://apps.sanbi.ac.za/hcvpro/details_humanprot.php?id=397

• The diagram below shows a snapshot of data on vimentin and links to GO ontologies, hepatocellular carcinoma databases, canonical pathways and other essential databases.



Appendix VIII (Chapter 3)

Frequently asked questions

1. What is HCVpro?

HCVpro is a freely accessible online knowledgebase comprising of Hepatitis C Virus (HCV) and human protein interactions.

2. Why was HCVpro created?

Currently HCV protein interactions data are found in literature and other publicly available databases but there is no single database solely focused on HCV protein interactions. HCVpro was thus created to offer "a one stop" knowledgebase on HCV protein interactions. Data integrated in HCVpro may enhance understanding of HCV life cycle, molecular function of its proteins, pathways and infection, and thereby augment efforts towards discovery of drugs, drug targets and diagnostic biomarkers.

3. What are the data sources in HCVpro?

HCVpro comprises of both manually verified literature- and database-curated interactions. Protein interactions databases employed for the curations were: BIND, VirusMint and VirHostNet. Additionally, functional annotation data were obtained from publicly available annotation resources and published literature.

4. What is unique about HCVpro, which cannot be found in other databases?

HCVpro provides enriched comprehensive and integrated data on HCV and human protein interactions, functional annotations, hepatocellular carcinoma (HCC) related gene expression, drug development, pathways, and cross-referenced links to other external databases.

5. What type of interaction data can be obtained from HCVpro?

HCVpro provides two types of interactions:

- 1.HCV viral-viral protein interactions
- 2.HCV viral-human protein interactions

6. How can I query HCVpro?

The enhanced user query interface enables users to perform searches via the HCVpro by browsing the following sub query menus:

- Protein Select
 - HCV proteins: e.g. E2
 - Human proteins: e.g. CD81
 - H Cl 10
 - Human Chromosome number: e.g. 10
- Evidence
 - Experiment type: e.g. coimmunoprecipitation
 - PubMed ID: e.g. 10846074
- Identifier Search
 - HCVpro ID: e.g. hcv0128
 - BIND ID: e.g. 183964
 - MINT ID: e.g. MINT-14803

- String Search
 - Gene Name: e.g. Vimentin
 - Gene ID: e.g. 7431
 - Gene symbol: e.g. VIM

7. Are there any future updates or modification in the pipeline?

Yes, we would like to integrate Blast queries to enhance querying capabilities of HCVpro. Data on microRNA and siRNA would be integrated to augment efforts towards drug discovery. A complete HCV interactome would be provided in the background to enable users retrieve protein interaction sub-network and topological statistical features. Additionally, we will include features for computing druggability of protein interactions and also enable ligand and protein target screening online.

8. Can researchers submit interactions to HCVpro?

Yes, upon enquiries researchers may submit novel interactions either before or after publications in MIMIx compatible format. Data on interaction details such as domains, motif and residues involved in the interaction would be incorporated in the next update. Authors who have previously published HCV protein interactions would be called upon to submit interaction details or the developers involved in the HCVpro project will computationally infer as an alternative.

The basic format for submission of interactions has been adapted from VirHostNet and is found below:

Protein A id	Protein B id	PSI-MI 2.5 method id	PubMed id
--------------	--------------	----------------------	-----------

Users may use the following links to convert interaction detection methods to PSI-MI 2.5:

http://obo.cvs.sourceforge.net/*checkout*/obo/obo/ontology/genomic-

proteomic/protein/psi-mi.obo

or at

http://www.ebi.ac.uk/ontology-lookup/

Click the links below for more details on PSI-MI data format:

http://www.ncbi.nlm.nih.gov/pubmed/20078892

http://www.ncbi.nlm.nih.gov/pubmed/18936051

Click the links below for more details on MIMIx data formats:

http://www.ncbi.nlm.nih.gov/pubmed/17687370

9. Can I download interaction data from HCVpro?

Yes, users may download the full HCVpro interaction data in a tab-delimited format via the Download menu item.

WESTERN CAPE

10. Is there a user manual on HCVpro?

Yes, users can access the manual via the Manual menu item.

11. To whom can I report a bug or discrepancy?

Please report all queries via the Contact menu item.